,Interventions,count,enrolled
0,Biological: AlloRx Single Group Assignment    Treatment Group (AlloRx)       cultured allogeneic adult umbilical cord derived mesenchymal stem cells   AlloRx  Biological,16,290
1,nan,16,1201
2,Biological: AlloRx Single Group Assignment    Treatment Group       cultured allogeneic adult umbilical cord derived mesenchymal stem cells   AlloRx  Biological,11,200
3,Biological: COVI-MSC Drug: Placebo Parallel Assignment    COVI-MSC Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells Excipient solution   COVI-MSC Placebo  Biological Drug,3,160
4,Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs) Single Group Assignment    Injection of PMD-MSCs into the penis          Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs) Ovation Biological,2,13
5,Biological: Ex- vivo cultured adult allogeneic MSCs Biological: Plasmalyte-A Parallel Assignment  D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions Ex- vivo cultured adult allogeneic MSCs Plasmalyte-A All PhSol All Drugs and Chemicals Pharmaceutical Solutions CAB M9030 M85407 M21013 M11966 Hyaluronic Acid Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions low high low low Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan C000012499 Plasma-lyte 148 Ex- vivo cultured adult allogeneic MSCs Plasmalyte-A  Biological Biological,2,132
6,Biological: UMC119-06 Single Group Assignment    UMC119-06       Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06   UMC119-06  Biological,2,27
7,Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Other: Liberation therapy Single Group Assignment    AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells       Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)   Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Liberation therapy  Biological Other,2,138
8,Biological: autologous adipose derived mesenchymal stem cells Single Group Assignment    Treatment Group       cultured autologous adult adipose derived mesenchymal stem cells   autologous adipose derived mesenchymal stem cells  Biological,2,30
9,"Biological: Autologous BM MSC Single Group Assignment As the primary objective of the study is to assess safety of MSC infusion, a single arm non-blinded study design has been adopted.   Treatment Arm Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.   Autologous BM MSC  Biological",2,720
10,Hope Biosciences autologous adipose-derived mesenchymal stem cells   HB-adMSCs  Biological,2,0
11,"Single Group Assignment           Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).   Allogeneic Mesenchymal Stem Cells (AlloMSC)  Biological",2,40
12,"HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.   HB-adMSCs  Biological",2,0
13,Biological: Umbilical cord mesenchymal stem cells Single Group Assignment    Umbilical cord mesenchymal stem cells          Umbilical cord mesenchymal stem cells  Biological,2,40
14,"Biological: Mesenchymal stem cell transplantation Parallel Assignment    Mesenchymal stem cell transplantation Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.   Mesenchymal stem cell transplantation  Biological",1,40
15,Biological: UCMSCs Biological: Percutaneous Parallel Assignment    UCMSCs Placebo       Transplatation of umbilical cord mesenchymal stem cells Percutaneous injection   UCMSCs Percutaneous  Biological Biological,1,40
16,"Drug: Wharton's jelly derived Mesenchymal stem cells. Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) Parallel Assignment  D000017320 D000084762 D000011480 D000004791 D000045504 D000019380 D000044966 D000000998 D000000890 D000065692 D000065607 D000000900 D000000962 D000000981 D000000977 D000018501 HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Anti-Bacterial Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents Antirheumatic Agents Mesenchymal stem cell Control group Infe All ARhu Anti-Infective Agents All Drugs and Chemicals Antirheumatic Agents Moderate Derived Resonance Cetuximab M20547 M9092 M19284 M28990 M13495 M18761 M20503 M24581 M3466 M3366 M29717 M29690 M3374 M3432 M3450 M3446 M19757 Ritonavir Hydroxychloroquine Azithromycin Lopinavir Protease Inhibitors HIV Protease Inhibitors Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Anti-Bacterial Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents Antirheumatic Agents high high high high low low low low low low low low low low low low low IV Wharton's jelly derived Mesenchymal stem cells, two doses Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo D000019438 D000061466 D000017963 D000006886 Ritonavir Lopinavir Azithromycin Hydroxychloroquine Wharton's jelly derived Mesenchymal stem cells. Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)  Drug Drug",1,40
17,Drug: Mesenchymal stem cells Other: Placebo Crossover Assignment    Mesenchymal stem cells Placebo       Allogeneic bone marrow derived mesenchymal stem cells Normal Saline   Mesenchymal stem cells Placebo  Drug Other,1,40
18,"Biological: Mesenchymal Stem Cells Biological: Mesenchymal Stem Cells Parallel Assignment    MSC Kidney Transplantation MSC Liver Transplantation Infe ANeo All Hemat Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Hematinics  M11280 M9336 M3377 M3374 M10262 M18102 M9364 Mycophenolic Acid Immunoglobulins Antibodies Anti-Bacterial Agents Liver Extracts Tacrolimus Immunosuppressive Agents low low low low low low low Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.   Mesenchymal Stem Cells MSC Biological",1,40
19,"Procedure: BOLD-fMRI drived DTI scanning Biological: stem cell transplantation Procedure: BOLD-fMRI drived DTI scanning Parallel Assignment    BOLD-fMRI and DTI correlate the imaging results evaluation       the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal. All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.   stem cell transplantation BOLD-fMRI drived DTI scanning  Biological Procedure",1,40
20,"Biological: hUC-MSC + DMARDs Drug: DMARDs Parallel Assignment  D000000020 D000000019 D000012102 D000045505 D000000964 D000000963 D000045504 D000000970 D000003879 D000004791 D000005493 D000007166 D000007155 D000019384 Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Nucleic Acid Synthesis Inhibitors hUC-MSC + DMARDs DMARDs ANeo ARhu Derm Repr All Micro Hemat Vi Antineoplastic Agents Antirheumatic Agents Dermatologic Agents Reproductive Control Agents All Drugs and Chemicals Micronutrients Hematinics Vitamins Into Home exercise program M10855 M19757 M3433 M6226 M7770 M16698 M7771 M9364 M9353 T447 T446 T448 T475 Methotrexate Antirheumatic Agents Antimetabolites Dermatologic Agents Folic Acid Vitamin B Complex Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Folinic Acid Folic Acid Folate Vitamin B9 high high low low low low low low low low low low low Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times. Patients will be treated by conventional drugs (DMARDs) for alleviating disease. D000008727 D000018501 Methotrexate Antirheumatic Agents hUC-MSC + DMARDs DMARDs Human Umbilical Cord-Mesenchymal Stem Cells NSAIDs Methotrexate Biological Drug",1,40
21,Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution Other: Placebo Crossover Assignment    Stem Cells Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Intravenous administration Intravenous administration   Human Mesenchymal Stem Cells and Lactated Riunger's Solution Placebo  Drug Other,1,40
22,"Drug: Filgrastim Single Group Assignment  D000000276 D000007155 D000045505 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Melanoma, head and neck All All Drugs and Chemicals Long- M1945 M2780 M9353 Lenograstim Adjuvants, Immunologic Immunologic Factors high low low Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule D000078224 Lenograstim Filgrastim Neupogen Drug",1,40
23,Biological: Mesenchymal stem cell injection Biological: Placebo Parallel Assignment    Mesenchymal stem cell receipients Placebo       Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .   Mesenchymal stem cell injection Placebo stem cell transplantation Biological Biological,1,40
24,"Biological: Autologous mesenchymal cells transplantation Parallel Assignment    Treated group       Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.   Autologous mesenchymal cells transplantation  Biological",1,40
25,Drug: Mesenchymal Stem Cells Other: Placebo Crossover Assignment    Mesenchymal Stem Cells Placebo       Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease. Normal Saline   Mesenchymal Stem Cells Placebo  Drug Other,1,40
26,Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion Parallel Assignment    Dose Arm 2 Dose Arm 1       Single MSC infusion of 150x10^6 cells at time zero; intravenous delivery Two MSC infusions of 75x10^6 cells at time zero and three months; intravenous delivery   Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions  Drug Drug,1,40
27,Biological: Allogeneic umbilical cord mesenchymal stem cells Biological: Control group Parallel Assignment    UMSC01 Placebo       UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment. Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.   Allogeneic umbilical cord mesenchymal stem cells Control group  Biological Biological,1,41
28,"Drug: Mesenchymal Stem Cells Other: Placebo Crossover Assignment    Mesenchymal Stem Cells Placebo       Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s) Normal saline   Mesenchymal Stem Cells Placebo  Drug Other",1,40
29,Drug: Oseltamivir Drug: Azithromycin Drug: Oseltamivir Drug: Azithromycin Biological: Umbilical Cord Mesenchymal Stem Cells Parallel Assignment  D000000900 D000000890 D000000998 D000004791 D000045504 Anti-Bacterial Agents Anti-Infective Agents Antiviral Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Control Group Experiment Group Control Group Experiment Group Experiment Group Infe All Anti-Infective Agents All Drugs and Chemicals Resonance Oxidative M19284 M26299 M3374 M3366 M3466 Azithromycin Oseltamivir Anti-Bacterial Agents Anti-Infective Agents Antiviral Agents high high low low low Current standardized treatment for Covid-19 Current standardized treatment for Covid-19 Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin) D000017963 D000053139 Azithromycin Oseltamivir Oseltamivir Azithromycin Umbilical Cord Mesenchymal Stem Cells  Drug Drug Biological,1,40
30,"Biological: Mesenchymal stem cells Biological: Non-mesenchymal stem cells Parallel Assignment    Mesenchymal stem cells Non-mesenchymal stem cells       Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) each week, four times for a cycle. Other second line drugs are taken.   Mesenchymal stem cells Non-mesenchymal stem cells Mscs Non-MSCs Biological Biological",1,40
31,"Procedure: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation Procedure: Control group incision Parallel Assignment Prospective, Randomized, Single Blind Clinical Trial   Bone Marrow Aspiration Group Control       Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group 0.5cm sham incision over the iliac crest   Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation Control group incision  Procedure Procedure",1,40
32,Biological: UCMSC group Parallel Assignment    UCMSC group       Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10^7)   UCMSC group  Biological,1,40
33,Drug: Stem Cell Product Single Group Assignment    stem cell product Infl ANeo ARhu Analg All Coag Lipd Ot Anti-Inflammatory Agents Antineoplastic Agents Antirheumatic Agents Analgesics All Drugs and Chemicals Coagulants Lipid Regulating Agents Other Dietary Supplements  M5837 M25081 T377 Curcumin Chitosan Chitosan low low low Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate   Stem Cell Product mesenchymal stem cells Drug,1,40
34,"Biological: Peripheral Intravenous (IV) infusion of LMSCs Biological: Peripheral Intravenous (IV) infusion of LMSCs Biological: Peripheral Intravenous (IV) infusion of LMSCs Biological: Peripheral Intravenous (IV) infusion of LMSCs Parallel Assignment    LMSCs 10 million IV LMSCs 20 million IV LMSCs100 million IV Placebo (Plasmalyte A,HSA) IV PhSol All ANeo Pharmaceutical Solutions All Drugs and Chemicals Antineoplastic Agents  M85407 M8814 Plasma-lyte 148 Altretamine low low Peripheral Intravenous (IV) infusion of LMSCs   Peripheral Intravenous (IV) infusion of LMSCs LMSCs Biological Biological",1,40
35,Biological: hMSC Biological: hMSC Parallel Assignment    Lactated Ringer's Solution hMSCs PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low IV administration   hMSC allogeneic mesenchymal bone marrow cells Biological,1,40
36,"Biological: Umbilical Cord Mesenchymal Stem Cells transplantation Drug: drug therapy according to Vietnamese MOHS procedure Drug: drug therapy according to Vietnamese MOHS procedure Parallel Assignment    Treatment (UC-MSC trasnplatation) Treatment (UC-MSC trasnplatation) control arm Repr Resp All Reproductive Control Agents Respiratory System Agents All Drugs and Chemicals  M2919 M15648 Albuterol Terbutaline low low Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval Salbutamol, Terbutaline   Umbilical Cord Mesenchymal Stem Cells transplantation drug therapy according to Vietnamese MOHS procedure  Biological Drug",1,40
37,"Drug: Placebos Drug: Semaglutide Parallel Assignment    Group B Active Group A Placebo Hypo All Hypoglycemic Agents All Drugs and Chemicals  M10819 M26150 Metformin Glucagon-Like Peptide 1 low low 0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks Placebo injection   Semaglutide Placebos  Drug Drug",1,40
38,Biological: Symptoms and Objective Examination Parallel Assignment    Symptoms and Objective Examination       5.0*108~5.0*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection   Symptoms and Objective Examination transplant Biological,1,40
39,"Biological: Wharton's jelly-derived mesenchymal cells Biological: Wharton's jelly-derived mesenchymal cells Parallel Assignment A randomized clinical trial will be conducted as a proof of concept in 40 patients with previous myocardial infarction and a viable myocardial zone with indications for coronary artery bypass grafts. Twenty patients will be included in each treatment arm over 36 months. One group will undergo revascularization surgery, extracellular matrix patch placement and injection of cell culture medium; the other group will undergo revascularization surgery, extracellular matrix patch placement on the epicardial surface with cultured WJ-MSCs and injection of WJ-MSCs around the infarcted zone.  The allocation of treatments will be defined by block sizes of 2, 4 and 6, randomly determined by a random number generator (ralloc, Stata Co. 8,2). This assignment will only be known by the tissue bank that will deliver the syringes with the solution to be administered and the epicardium patches to the study participants.   Comparison/control group Experimental group       Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.   Wharton's jelly-derived mesenchymal cells  Biological",1,40
40,"Biological: Autologous, Adipose Derived Mesenchymal Stem Cells Other: Best Medical Management: Occupational and Physical Therapy Biological: Autologous, Adipose Derived Mesenchymal Stem Cells Crossover Assignment    Treatment Group 2: Best Medical Management Treatment Group 1: AD-MSC Injection Treatment Group 2: Best Medical Management ANeo All Antineoplastic Agents All Drugs and Chemicals  M7343 M341694 Etoposide Etoposide phosphate low low Observation while undergoing Occupational and Physical Therapy for 6 months The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.   Best Medical Management: Occupational and Physical Therapy Autologous, Adipose Derived Mesenchymal Stem Cells  Other Biological",1,40
41,Drug: MSC Drug: MSC Parallel Assignment Quasi experimental   Fat graft enriched with MSCs Fat graft only       Adipose tissue enriched with mesenchymal stem cells   MSC  Drug,1,40
42,"Procedure: Routine treatment Biological: Human umbilical cord mesenchymal stem cells Procedure: Routine treatment Parallel Assignment    HUC-MSCs adjuvant Group HUC-MSCs adjuvant Group Routine treatment group       Definitive Human umbilical cord mesenchymal stem cells selected by immunomodulatory assay through coculture with BV2 cell According to""Influenza diagnosis and treatment plan (2019 version)""   Human umbilical cord mesenchymal stem cells Routine treatment  Biological Procedure",1,40
43,"Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.   Application of exosomes in a whole blood assay  Biological",1,40
44,"Biological: UC-MSC Biological: Control Group Parallel Assignment    UC-MSC Control Group       0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability>80%, and endotoxin<0.1 EU， at the concentration of 2x10(7) cells/ml. Routine treatment without catheter infusion   UC-MSC Control Group Transplantation Group Biological Biological",1,40
45,Biological: Injection of secretome - mesenchymal stem cell Drug: Standard treatment of Covid-19 Other: Placebo Drug: Standard treatment of Covid-19 Parallel Assignment    Secretome - mesenchymal stem cell group (n = 20) Control ( n= 20) Control ( n= 20) Secretome - mesenchymal stem cell group (n = 20)       Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes. Normal saline Standard treatment of Covid-19 based on national protocol.   Injection of secretome - mesenchymal stem cell Placebo Standard treatment of Covid-19  Biological Other Drug,1,40
46,"Drug: ASCs Drug: Cryostor CS10 Parallel Assignment    Adipose tissue-derived mesenchymal stem cells (ASCs) Placebo (vehicle, Cryostor CS10)       ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml. CryoStor® CS10 freeze medium   ASCs Cryostor CS10 Allogeneic adipose-derived mesenchymal stem cells Drug Drug",1,40
47,"Biological: Allogeneic umbilical cord mesenchymal stem cell Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium Parallel Assignment  D000077264 D000045505 D000000894 D000018712 D000000700 D000018689 D000018373 D000000893 D000018501 D000005343 D000050299 D000045504 D000010975 D000016861 D000004791 D000058633 D000000924 D000000960 D000000963 D000057847 D000019161 Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Experimental group Control group Experimental group All Antipy Infl ARhu FiAg Analg PlAggInh Lipd BDCA All Drugs and Chemicals Antipyretics Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Analgesics Platelet Aggregation Inhibitors Lipid Regulating Agents Bone Density Conservation Agents Diabetes Dietary Supplement THA M4533 M3700 M351 M4550 M8941 M3369 M3370 M3184 M19939 M19757 M7625 M13017 M18361 M28329 M3395 M3430 M3433 M28036 M20308 Calcium Aspirin Atorvastatin Calcium, Dietary Hormones Anti-Inflammatory Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics Analgesics, Non-Narcotic Antirheumatic Agents Fibrinolytic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Antipyretics Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors high high high low low low low low low low low low low low low low low low low Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#) Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth. D000001241 D000069059 D000002118 Aspirin Atorvastatin Calcium Allogeneic umbilical cord mesenchymal stem cell Aspirin Enteric-coated Tablets & Atorvastatin Calcium  Biological Drug",1,40
48,Biological: human umbilical cord derived MSC transplantation for SLE Single Group Assignment    human umbilical cord derived MSC          human umbilical cord derived MSC transplantation for SLE Allogenic MSC derived from umbilical cord Biological,1,40
49,Biological: Infusion of Autologous Bone Marrow Mononuclear Cells Single Group Assignment    Stem Cell Injection       Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.   Infusion of Autologous Bone Marrow Mononuclear Cells  Biological,1,40
50,"Biological: Autologous MSCs Biological: Autologous MSCs Biological: Autologous MSCs Sequential Assignment    MSC dose level 1 MSC dose level 2 MSC dose level 3       Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting. Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting. Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.   Autologous MSCs Autologous MSCs Autologous MSCs  Biological Biological Biological",1,0
51,Biological: Mesenchymal stem cells Biological: Normal saline Parallel Assignment    Mesenchymal stem cells Normal saline       Intramuscular injection Intramuscular injection   Mesenchymal stem cells Normal saline  Biological Biological,1,40
52,Device: Echotip ProCoreⓇ HD Ultrasound Biopsy Needle Single Group Assignment    Arm who will undergo EUS-FNB          Echotip ProCoreⓇ HD Ultrasound Biopsy Needle  Device,1,39
53,Biological: Platelet Rich plasma (PRGF) Biological: 100 million Bone marrow mesenchimal stem cells Biological: Platelet Rich plasma (PRGF) Parallel Assignment    BMMSC with Platelet Rich Plasma (PRGF) BMMSC with Platelet Rich Plasma (PRGF) Platelet Rich Plasma (PRGF)       100 million Bone marrow mesenchimal stem cells with PRGF 3 injections of PRGF   100 million Bone marrow mesenchimal stem cells Platelet Rich plasma (PRGF)  Biological Biological,1,38
54,Biological: Lomecel-B medicinal signaling cells Parallel Assignment    Lomecel B Group       A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.   Lomecel-B medicinal signaling cells  Biological,1,38
55,Biological: Allogeneic adult mesenchymal bone marrow stem cells Single Group Assignment    Stem cells       Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells   Allogeneic adult mesenchymal bone marrow stem cells  Biological,1,38
56,"Drug: Conditioned Media Single Group Assignment Experimental clinical trial with open label   Conditioned Medium Group       Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.   Conditioned Media  Drug",1,38
57,"Drug: UC-MSCs Drug: Placebo Parallel Assignment    UC-MSCs treatment group Placebo control group       3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3). 3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).   UC-MSCs Placebo UC-MSCs treatment group Placebo control group Drug Drug",1,38
58,Biological: human cord blood mononuclear cells Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells Parallel Assignment    Rehabilitation plus hCB-MNCs treatment Rehabilitation plus hCB-MNCs and hUC-MSCs therapy       Participants will be given rehabilitation therapy plus hCB-MNCs transplantation. Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.   human cord blood mononuclear cells human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells Group 1 Group 2 Biological Biological,1,37
59,Biological: Autologous hMSCs Biological: Allogeneic hMSCs Parallel Assignment    Autologous hMSCs Allogeneic hMSCs       Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:  Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:  Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.   Autologous hMSCs Allogeneic hMSCs Biosense Webster MyoStar NOGA Injection Catheter System. Biosense Webster MyoStar NOGA Injection Catheter System. Biological Biological,1,37
60,Biological: Conventional therapy plus low dose UCMSCs treatment Biological: Conventional therapy plus medium dose UCMSCs treatment Biological: Conventional therapy plus high dose UCMSCs treatment Sequential Assignment    Low dose umbilical cord mesenchymal stem cells (UCMSCs) Medium dose UCMSCs High dose UCMSCs       Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10^6 UCMSCs/kg body) Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10^6 UCMSCs/kg body) Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10^6 UCMSCs/kg body)   Conventional therapy plus low dose UCMSCs treatment Conventional therapy plus medium dose UCMSCs treatment Conventional therapy plus high dose UCMSCs treatment  Biological Biological Biological,1,36
61,"Biological: Oncolytic Adenovirus Ad5-DNX-2401 Biological: Oncolytic Adenovirus Ad5-DNX-2401 Procedure: Therapeutic Conventional Surgery Sequential Assignment    Part I (oncolytic adenovirus Ad5-DNX-2401) Part II (oncolytic adenovirus Ad5-DNX-2401, surgery) Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)       Given IA Undergo surgery   Oncolytic Adenovirus Ad5-DNX-2401 Therapeutic Conventional Surgery Ad5-Delta24RGD DNX-2401 DNX2401 Oncolytic Ad5-Delta 24RGD Oncolytic Adenovirus Ad5-Delta 24RGD Biological Procedure",1,36
62,Procedure: Intraportal islet transplantation Procedure: Kidney transplantation Procedure: Intramuscular islet transplantation Procedure: Kidney transplantation Procedure: Intramuscular transpl with stemcells Procedure: Kidney transplantation Procedure: Kidney transplantation Parallel Assignment    Intraportal islet transplantation Intramuscular islet transplantation Intramuscular transpl with stemcells Intramuscular islet transplantation Intramuscular transpl with stemcells Intraportal islet transplantation Kidney transplantation only       All patients will undergo kidney transplantation regardless of arm   Intraportal islet transplantation Intramuscular islet transplantation Intramuscular transpl with stemcells Kidney transplantation  Procedure Procedure Procedure Procedure,1,36
63,Drug: Mesenchymal Stem Cells (MSCs) Drug: Mesenchymal Stem Cells (MSCs) Drug: Mesenchymal Stem Cells (MSCs) Parallel Assignment Participants are assigned to one of three groups in parallel for the duration of the study   Group 1 Group 2 Group 3       The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.   Mesenchymal Stem Cells (MSCs)  Drug,1,36
64,Procedure: Autologous mesenchymal stem cell transplantation Procedure: Autologous mesenchymal stem cell transplantation Parallel Assignment    A B       Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein   Autologous mesenchymal stem cell transplantation  Procedure,1,36
65,"Procedure: Regenerative Endodontic Procedure Procedure: Conventional Root Canal Treatment Parallel Assignment 2 interventions:  Endodontic regenerative treatment with Biological product of umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial. Endodontic treatment with inert product gutapercha.   Regenerative Endodontic Procedure (REP) Conventional Root Canal Treatment All BDCA Infe All Drugs and Chemicals Bone Density Conservation Agents Anti-Infective Agents  M4533 M4550 M14927 M43815 Calcium Calcium, Dietary Sodium Hypochlorite Eusol low low low low Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells. Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.   Regenerative Endodontic Procedure Conventional Root Canal Treatment REP Tissue engineering procedure Gold standard treatment Procedure Procedure",1,36
66,Biological: BM-MSC Single Group Assignment    Bone marrow-derived mesenchymal stromal cell (BM-MSC)       Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.   BM-MSC  Biological,1,36
67,"Biological: ASC Drug: Fibringlue Parallel Assignment    ASC (test arm) Fibringlue       Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.  The ASC injection dose is about 1x10^7 cells of ASC per 1cm^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu. Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.   ASC Fibringlue (Autologous Adipose-derived Mesenchymal Stem Cells) standard control Biological Drug",1,36
68,"Drug: Mesenchymal stromal cells (MSC) Drug: Placebo Parallel Assignment Control arm (placebo) and experimental arm (mesenchymal stromal cells)   Mesenchymal stromal cells (MSC) Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Endovenous injection of MSV in saline Endovenous injection of saline without cells   Mesenchymal stromal cells (MSC) Placebo MSV, GMP-compliant MSC manufactured by IBGM in Valladolid Saline Drug Drug",1,36
69,"Drug: AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION Drug: Placebo Parallel Assignment    ADSVF group Placebo group       Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.   AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION Placebo  Drug Drug",1,36
70,Biological: MSC treatment Drug: Standard of Care Drug: Standard of Care Drug: Placebo Parallel Assignment Superiority trial comparing MSCs versus Placebo in SLE patients with severe renal disease receiving Standard of Care treatment.   MSC treatment MSC treatment Placebo Placebo Infe ANeo All Infl AnEm NeuroAg Gast ARhu Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Anti-Inflammatory Agents Antiemetics Neuroprotective Agents Gastrointestinal Agents Antirheumatic Agents  M11280 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M5879 M13273 Mycophenolic Acid Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Cyclophosphamide Prednisone low low low low low low low low low low Umbilical cord-derived Mesenchymal Stromal Cell Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate MSC infusion vehicle   MSC treatment Standard of Care Placebo Cellistem ® Lupus Standard of Care for Lupus Nephritis Placebo (for MSC) Biological Drug Drug,1,39
71,"Biological: Human umbilical cord mesenchymal stem cells + best supportive care Biological: Human umbilical cord mesenchymal stem cells + best supportive care Biological: Human umbilical cord mesenchymal stem cells + best supportive care Biological: Human umbilical cord mesenchymal stem cells + best supportive care Other: Placebo control + best supportive care Sequential Assignment In phase 1, eligible subjects will be divided into low, medium and high-dose groups with 3 patients/group. If there is no safety concerns for each group, the dose will be escalated from lower dose to the next higher dose. In phase 2a, a total of 30 subjects will be randomized into the treatment and control groups with a ratio of 3:2.   Phase 1 High-dose Group Phase 1 Low-dose Group Phase 1 Middle-dose Group Phase 2a Treatment Group Phase 2a Control Group       hUC-MSC product will be administered intravenously in addition to the standard of care treatment. Placebo control will be administered intravenously in addition to the standard of care treatment.   Human umbilical cord mesenchymal stem cells + best supportive care Placebo control + best supportive care  Biological Other",1,39
72,"Other: Bio ACL Other: Control Parallel Assignment ACL harvested for autograft reconstruction of the ACL with either hamstring or patellar tendon grafts. The graft will be wrapped in a collagen wrap and injection with aspirate from the patient's bone marrow.  The control group will have standard ACL reconstruction with either hamstring or patellar tendon grafts.   Bio-ACL (Amion) Control       Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex Normal ACL reconstruction technique with either patella or hamstring autograft   Bio ACL Control Amnion Standard ACLr Other Other",1,40
73,Biological: Mesenchymal stem cells Other: Isotonic solution Parallel Assignment    Mensenchymal Stem Cells Placebo ANeo All PhSol Antineoplastic Agents All Drugs and Chemicals Pharmaceutical Solutions  M283219 M21013 M225481 Fludarabine Pharmaceutical Solutions Fludarabine phosphate low low low Mesenchymal stem cell injection Isotonic solution injection   Mesenchymal stem cells Isotonic solution  Biological Other,1,39
74,"Biological: Conventional therapy Biological: Injectable Collagen Scaffold + HUC-MSCs Parallel Assignment    Conventional therapy Injectable Collagen Scaffold + HUC-MSCs       Patients will receive the conventional therapy. Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5*10^8.   Conventional therapy Injectable Collagen Scaffold + HUC-MSCs  Biological Biological",1,40
75,"Biological: Normoxic Allogenic UCMSC Other: Normal saline solution Parallel Assignment    Treatment Control PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6) Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)   Normoxic Allogenic UCMSC Normal saline solution  Biological Other",1,42
76,Biological: MSC Parallel Assignment    MSC Treatment       infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells   MSC  Biological,1,40
77,Biological: Umbilical cord derived mesenchymal stem cell Other: Placebo Parallel Assignment    Group A Group B       Umbilical cord derived mesenchymal stem cell Normal saline   Umbilical cord derived mesenchymal stem cell Placebo Cyto-MSC Biological Other,1,40
78,Biological: Allogeneic Mesenchymal Stem Cells Biological: Allogeneic Mesenchymal Stem Cells Biological: Allogeneic Mesenchymal Stem Cells Parallel Assignment    Stem cells high dose Stem cells intermediate dose Stem cells low dose Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery   Allogeneic Mesenchymal Stem Cells Allogeneic Mesenchymal Stem Cells Allogeneic Mesenchymal Stem Cells  Biological Biological Biological,1,40
79,"Biological: PrimePro Other: Placebo Biological: PrimePro Other: Placebo Single Group Assignment This study is a randomized assignment, double-blind, placebo-controlled, multi-arm, multi-site study located at Southern California Hospitals at Culver City and Hollywood.   COVID-19 Patients Experimental Healthcare Providers Experimental COVID-19 Patients Placebo Healthcare Providers Placebo       Intravenous Injection Intravenous Injection   PrimePro Placebo  Biological Other",1,40
80,"Biological: Allogeneic umbilical cord mesenchymal stem cells Drug: Decitabine Drug: Decitabine Parallel Assignment  D000000964 D000000963 D000045504 D000000970 D000004791 Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors Experimental group Control group Experimental group ANeo All Antineoplastic Agents All Drugs and Chemicals Learning M1697 M3433 Decitabine Antimetabolites high low Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#) Decitabine，20mg/m^2/d D000077209 Decitabine Allogeneic umbilical cord mesenchymal stem cells Decitabine  Biological Drug",1,40
81,Biological: mesenchymal stem cell Biological: Placebo Parallel Assignment    mesenchymal stem cell placebo       intra articular injection of mesenchymal stem cell Patients with knee joint osteoarthritis who underwent intra articular placebo injection   mesenchymal stem cell Placebo stem cell transplantation Biological Biological,1,40
82,"Drug: Cyclophosphamide Biological: Mesenchymal stromal cells Single Group Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists MSC+CY MSC+CY ANeo ARhu All Antineoplastic Agents Antirheumatic Agents All Drugs and Chemicals Tablet M5879 M9364 M9353 M19757 M20095 M2972 Cyclophosphamide Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents high low low low low low Dose 50 mg/kg at day +3,+4 once daily Dose 1 million per kg, at day of recovery once D000003520 Cyclophosphamide Cyclophosphamide Mesenchymal stromal cells  Drug Biological",1,40
83,Biological: Human Umbilical Cord Mesenchymal Stem Cells Single Group Assignment    MSCs local treatment group/combined treatment group       MSCs treatment by intestinal submucosal injection/MSCs treatment by intravenous drip + MSCs treatment by intestinal submucosal injection   Human Umbilical Cord Mesenchymal Stem Cells  Biological,1,40
84,Biological: human umbilical cord mesenchymal stem cells Other: human serum albumin Parallel Assignment    experimental group control group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group. Saline solution containing 1 percent human serum albumin will be infused to the control group.   human umbilical cord mesenchymal stem cells human serum albumin  Biological Other,1,40
85,"Procedure: Non cultured epidermal cell suspension Procedure: Non cultured epidermal cell suspension Procedure: Non cultured dermal cell suspension Parallel Assignment    Non cultured dermal cell suspension Non cultured epidermal cell suspension Non cultured dermal cell suspension PhSol All Infe Pharmaceutical Solutions All Drugs and Chemicals Anti-Infective Agents  M21013 M3374 M12469 M3376 M15249 Pharmaceutical Solutions Anti-Bacterial Agents Penicillins Antibiotics, Antitubercular Streptomycin low low low low low Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells. Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.   Non cultured epidermal cell suspension Non cultured dermal cell suspension  Procedure Procedure",1,40
86,Genetic: Intravenous stem cell transplantation Parallel Assignment    Intravenous stem cell transplantation       Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation   Intravenous stem cell transplantation  Genetic,1,40
87,"Biological: UC-MSCs Biological: Secretomes Biological: UC-MSCs and Secretomes Biological: Control Parallel Assignment    WJ-MSCs Secretomes WJ-MSCs and Secretomes Control Hypo All Hypoglycemic Agents All Drugs and Chemicals  M10819 M9517 M172956 Metformin Insulin Insulin, Globin Zinc low low low Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days. Treatment with tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days. Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days. Treatment with Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.   UC-MSCs Secretomes UC-MSCs and Secretomes Control  Biological Biological Biological Biological",1,40
88,"Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) Drug: Aspirin Tablet Drug: Aspirin Tablet Parallel Assignment  D000000894 D000018712 D000000700 D000018689 D000018373 D000045505 D000000893 D000018501 D000005343 D000050299 D000045504 D000010975 D000016861 D000004791 D000058633 Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Group 1 Group 1 Group 2 Antipy Infl ARhu FiAg Analg PlAggInh All Antipyretics Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Analgesics Platelet Aggregation Inhibitors All Drugs and Chemicals Dietary Supplement M3700 M3369 M3370 M3184 M19939 M19757 M7625 M13017 M18361 M28329 Aspirin Anti-Inflammatory Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics Analgesics, Non-Narcotic Antirheumatic Agents Fibrinolytic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Antipyretics high low low low low low low low low low Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times. Drug: Aspirin Tablet, 100 mg/d D000001241 Aspirin Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) Aspirin Tablet  Biological Drug",1,40
89,Device: shockwave therapy Other: PT Other: PT Other: placebo Parallel Assignment    shockwave therapy placebo shockwave therapy placebo       Intervention with shockwave therapy Physical therapy 3 times per week for 3 weeks sham shockwave therapy   shockwave therapy PT placebo  Device Other Other,1,40
90,"Biological: human umbilical cord mesenchymal stem cells Biological: hUCMSCs and hCBMNCs Biological: human cord blood mononuclear cells Drug: Hormone Replacement Therapy Parallel Assignment  D000006730 D000045505 Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Group1 : HRT plus hUCMSCs treatment: Group 2: HRT plus hCBMNCs and hUCMSCs therapy Group3 : HRT plus hCBMNCs treatment: Group 4:Hormone Replacement Therapy All All Drugs and Chemicals Include M8941 M8940 Hormones Hormone Antagonists high low  D000006728 Hormones human umbilical cord mesenchymal stem cells hUCMSCs and hCBMNCs human cord blood mononuclear cells Hormone Replacement Therapy  Biological Biological Biological Drug",1,40
91,"Biological: UCMSC group Other: Control group(Normal saline) Parallel Assignment    UCMSC group Control group(Normal saline)       Human umbilical cord MSCs are transplanted by intravenous injection(5×10^5/kg) ，once a day,a total of three times. Normal saline in same volume as MSCs are transplanted to patients.   UCMSC group Control group(Normal saline)  Biological Other",1,40
92,"Biological: HUC-MSCs Biological: Lipoic Acid Parallel Assignment  D000000975 D000045504 D000020011 D000045505 D000014803 D000014815 D000018977 Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Vitamin B Complex Vitamins Micronutrients Experimental Comparator Micro All Hemat Ot Vi Micronutrients All Drugs and Chemicals Hematinics Other Dietary Supplements Vitamins Equal to Equal to M10215 M3444 M21022 M7770 M16710 M16698 M20162 M16037 T359 T446 T448 T475 Thioctic Acid Antioxidants Protective Agents Folic Acid Vitamins Vitamin B Complex Micronutrients Trace Elements Alpha-lipoic Acid Folic Acid Folate Vitamin B9 high low low low low low low low high low low low 5 × 10^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb Lipoic Acid Injection，600 mg/d for 15 consecutive days D000008063 Thioctic Acid HUC-MSCs Lipoic Acid  Biological Biological",1,42
93,Drug: Mesenchymal stem cell Drug: Mesenchymal stem cell Procedure: Mesenchymal stem cell delivery with stent placement Parallel Assignment    Mesenchymal stem cell delivery Mesenchymal stem cell delivery with stent placement Mesenchymal stem cell delivery with stent placement       Intra-arterial infusion of the single-dose MSC Intra-arterial stent placement after Mesenchymal stem cell infusion   Mesenchymal stem cell Mesenchymal stem cell delivery with stent placement Mesenchymal stem cell delivery Drug Procedure,1,42
94,Biological: Stem Cells Single Group Assignment    Stem Cells       Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.   Stem Cells  Biological,1,50
95,Biological: Autologous mesenchymal stem cells Other: Placebo Parallel Assignment    Study group control group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Autologous mesenchymal stem cells Saline solution   Autologous mesenchymal stem cells Placebo  Biological Other,1,50
96,"Biological: The pleiotropic factor derived from mesenchymal stem cells Parallel Assignment    experimental group       The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.   The pleiotropic factor derived from mesenchymal stem cells  Biological",1,50
97,Biological: umbilical cord mesenchymal stem cells Single Group Assignment    umbilical cord mesenchymal stem cells       Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.   umbilical cord mesenchymal stem cells mesenchymal stem cells Biological,1,50
98,"Other: Standard medical care Other: Standard medical care Biological: Autologous bone marrow-derived mesenchymal stem cells Parallel Assignment    BM-MSCs Standard medical care BM-MSCs       Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment. Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.   Standard medical care Autologous bone marrow-derived mesenchymal stem cells  Other Biological",1,50
99,Biological: MSCs Single Group Assignment    MSCs treated       mesenchymal stem cells therapy   MSCs  Biological,1,50
100,"Biological: umbilical cord mesenchymal stem cells Drug: Standard Therapy Parallel Assignment    umbilical cord mesenchymal stem cells Standard Therapy PlAggInh All FiAg AnCoag Platelet Aggregation Inhibitors All Drugs and Chemicals Fibrinolytic Agents Anticoagulants  M13017 M8731 M45326 Platelet Aggregation Inhibitors Heparin Calcium heparin low low low 5*10/7 per ischemic limb Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc   umbilical cord mesenchymal stem cells Standard Therapy mesenchymal stem cells Drug therapy Biological Drug",1,50
101,Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) Procedure: Marrow cellution Parallel Assignment    Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) Marrow cellution (standard treatment)       Human umbilical cord-derived mesenchymal stem cells Patients will undergo marrow cellution surgical procedure.   Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) Marrow cellution Chondrocell-EX Biological Procedure,1,50
102,"Biological: conventional therapy plus MenSC transplantation Drug: Conventional therapy plus placebo treatment Single Group Assignment  D000000970 D000000998 D000000890 D000002756 D000005765 Antineoplastic Agents Antiviral Agents Anti-Infective Agents Cholagogues and Choleretics Gastrointestinal Agents Intervention No intervention Infe All Hemat ANeo Gast Anti-Infective Agents All Drugs and Chemicals Hematinics Antineoplastic Agents Gastrointestinal Agents Inhibitor Ester M3466 M10262 M9559 M16481 M3366 M8033 Antiviral Agents Liver Extracts Interferons Ursodeoxycholic Acid Anti-Infective Agents Gastrointestinal Agents low low high high low low patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.  MenSCs transplantation: taken i.v., twice per week, at a dose of 1*10E6 MSC/kg body for 2 weeks. 25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine. D000007372 D000014580 Interferons Ursodeoxycholic Acid conventional therapy plus MenSC transplantation Conventional therapy plus placebo treatment Interferon Bifendatatum Ursodeoxycholic Acid Menstrual blood-derived stem cells(MenSCs) Interferon Bifendatatum Ursodeoxycholic Acid Biological Drug",1,50
103,"Biological: Umbilical Cord Mesenchymal Stem Cells Single Group Assignment    umbilical cord mesenchymal stem cells       Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1*10/7).   Umbilical Cord Mesenchymal Stem Cells Mesenchymal Stem Cells Biological",1,50
104,Other: physiological saline Biological: MSCs Derived Pleiotropic Factors Parallel Assignment    experimental group control group       The pleiotropic factor derived from mesenchymal stem cells was injected on the wound The physiological saline was injected on the wound   MSCs Derived Pleiotropic Factors physiological saline  Biological Other,1,50
105,"Single Group Assignment           Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure   Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis mesenchymal stem cells Knee Arthrosis Knee osteochondral defect Procedure",1,50
106,Biological: Adipose-cord mesenchymal stromal cells (A-MSCs) Other: Conventional drugs Other: Conventional drugs Parallel Assignment    Intervention group Control group Intervention group All Infe Derm HB All Drugs and Chemicals Anti-Infective Agents Dermatologic Agents Herbal and Botanical  M8199 M21142 T120 Glucocorticoids Salicylic Acid Cola low low low A-MSCs 5 x 10~7 diluted on 100 mL of normal saline 5-amino-salicylic acid or glucocorticoid   Adipose-cord mesenchymal stromal cells (A-MSCs) Conventional drugs  Biological Other,1,50
107,Biological: Human umbilical cord mesenchymal stem cells Single Group Assignment    Human umbilical cord mesenchymal stem cells       Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.   Human umbilical cord mesenchymal stem cells  Biological,1,50
108,"Biological: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa Biological: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa Parallel Assignment Group 1: Five (5) subjects will be treated by injecting UMSCs in sub-tenon space of eye.  Group 2: Five (5) subjects will be treated by suprachoroidal injection of UMSCs .  From two subjects in group 1 & 2 will not be treated 24 hrs apart. Patients will be randomized in a 1:1 ratio (Sub-tenon injection of UMSCs : Suprachoroidal injection of UMSCs).  Note: In total, twenty five patients will be subjected to cell injection for each of group 1 & 2.   Sub-tenon injection group Suprachoroidal injection group       Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360. Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.   Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa  Biological Biological",1,50
109,"Single Group Assignment           Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.   Chirurgical procedure  Procedure",1,50
110,Procedure: autologous mitochondria transplantation Combination Product: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI) Drug: intracytoplasmic sperm injection (ICSI) Parallel Assignment    autologous mitochondria transplantation autologous mitochondria transplantation ICSI       inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte autologous mitochondria transplantation intracytoplasmic sperm injection (ICSI)   autologous mitochondria transplantation autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI) intracytoplasmic sperm injection (ICSI)  Procedure Combination Product Drug,1,50
111,Biological: Stem Cell Transplantation Single Group Assignment    Stem Cell Transplantation       intervention with transplantation of autologous purified stem cells   Stem Cell Transplantation  Biological,1,50
112,Biological: hUC-MSCs+Injectable collagen scaffold+CABG Biological: hUC-MSCs+CABG Procedure: CABG Parallel Assignment    hUC-MSCs+Injectable collagen scaffold+CABG hUC-MSCs+CABG CABG       Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region. Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region. Patients underwent CABG alone.   hUC-MSCs+Injectable collagen scaffold+CABG hUC-MSCs+CABG CABG  Biological Biological Procedure,1,50
113,Biological: UCB Mesenchymal Stem Cells treatment Single Group Assignment    UCB Mesenchymal Stem Cells       reduce skin injury   UCB Mesenchymal Stem Cells treatment  Biological,1,50
114,Biological: Stem Cell Transplantation Biological: Stem Cell Transplantation Single Group Assignment    Stem Cell Transplantation Stem Cells       Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.   Stem Cell Transplantation  Biological,1,50
115,"Biological: Stem Cells,Mesenchymal Procedure: surgery (TVT) Parallel Assignment    Stem cells,Mesenchymal surgery (TVT) CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site. A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra & through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted & the remaining tape cut off at the level of the skin.   Stem Cells,Mesenchymal surgery (TVT)  Biological Procedure",1,50
116,"Drug: Hyaluronic Acid Biological: Autologous bone marrow-derived mesenchymal stem cells Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Hyaluronic acid Bone marrow mesenchymal stem cells All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Intra-articular injection; 30mg/2ml; three-weekly injection regimen Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid ""Orthovisc"" (3rd injection in a three-weekly injection regimen) D000006820 Hyaluronic Acid Hyaluronic Acid Autologous bone marrow-derived mesenchymal stem cells Orthovisc Drug Biological",1,50
117,"Procedure: Core decompression procedure Single Group Assignment    Hip avascular necrosis       Core Decompression with Bone Chips Allograft adjuvanted by Fibrin Platelet Rich-plasma (PRP) and Concentrated Autologous Mesenchymal Stromal Cells (MSCS), isolated from Bone Marrow   Core decompression procedure  Procedure",1,52
118,"Drug: Autologous BM-MSC Procedure: Sham Parallel Assignment Patients will be randomized in 2 arms of 26 patients and followed up for 24 months.   Active Arm Sham Procedure CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low intradiscal injection of autologous bone marrow mesenchymal stromal cells local anaesthesia, no disc injection, no placebo injection   Autologous BM-MSC Sham Treated Untreated Drug Procedure",1,52
119,"Procedure: Mesenchymal Stem Cell injection Procedure: Mesenchymal Stem Cell injection Procedure: Mesenchymal Stem Cell injection     Allogenic mesenchymal stem cells Autologous mesenchymal stem cells Stromal Vascular fraction       curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)   Mesenchymal Stem Cell injection  Procedure",1,52
120,Other: dac-MSCs Drug: Fitostimoline Other: MSCs Drug: Fitostimoline Drug: Fitostimoline Parallel Assignment    dac-MSCs and Fitostimoline MSCs and Fitostimoline Fitostimoline MSCs and Fitostimoline dac-MSCs and Fitostimoline       Cell-free therapy Cell-based therapy Triticum vulgare   dac-MSCs MSCs Fitostimoline Cell-free therapy Cell-based therapy Triticum vulgare Other Other Drug,1,51
121,"Biological: bone marrow derived mesenchymal stem cells Parallel Assignment    MSC       Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks   bone marrow derived mesenchymal stem cells Mesenchymal Stem Cells Multipotent Mesenchymal Stem Cells Multipotent Mesenchymal Stromal Cells Biological",1,50
122,Procedure: PCI and Stem Cells or Placebo injections Procedure: PCI and Stem Cells or Placebo injections Parallel Assignment    Group 1 (PCI+SC implantation) Group 2 (PCI+Placebo)       Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.   PCI and Stem Cells or Placebo injections  Procedure,1,50
123,"Biological: Intrathecal MSC-NP injection Other: Intrathecal saline injection Crossover Assignment    Intrathecal MSC-NP injection Intrathecal saline injection       MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable. Placebo   Intrathecal MSC-NP injection Intrathecal saline injection  Biological Other",1,50
124,Biological: Mononuclear and mesenchymal stem cells Biological: Mononuclear cells Parallel Assignment    Mononuclear and mesenchymal stem cells Mononuclear cells only       Intramuscular administration into the ischemic limb Intramuscular administration into the ischemic limb   Mononuclear and mesenchymal stem cells Mononuclear cells BM-MNC and BM-MSC BM-MNC Biological Biological,1,50
125,"Drug: exogenous indulin injection daily Biological: MenSCs transplantation Parallel Assignment    Stem cell infusion Traditional therapy control Hypo All Hypoglycemic Agents All Drugs and Chemicals  M9517 M172956 Insulin Insulin, Globin Zinc low low 1×10^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies. traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.   MenSCs transplantation exogenous indulin injection daily  Biological Drug",1,50
126,Single Group Assignment           Normal full-term deliveries by standard procedures according to institutional guidelines   Normal full-term deliveries  Procedure,1,50
127,"Drug: Conventional plus UC-MSC Drug: Conventional plus placebo Parallel Assignment  D000007155 D000045505 Immunologic Factors Physiological Effects of Drugs Conventional plus UC-MSC Conventional plus placebo Hemat All Hematinics All Drugs and Chemicals Granuloma M10262 M9364 M9353 Liver Extracts Immunosuppressive Agents Immunologic Factors low high low Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks. Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks. D000007166 Immunosuppressive Agents Conventional plus UC-MSC Conventional plus placebo Immunosuppressive agents plus umbilical cord stem cells Immunosuppressive agents plus saline Drug Drug",1,50
128,Biological: mesenchymal stem cells Procedure: without mesenchymal stem cells Parallel Assignment    mesenchymal stem cells without mesenchymal stem cells       mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery rotator cuff surgery without mesenchymal stem cells   mesenchymal stem cells without mesenchymal stem cells  Biological Procedure,1,50
129,"Procedure: stem cells Procedure: Chondrocytes Other: Rehabilitation program Parallel Assignment    Stem cells Stem cells Rehabilitation       Stem cells or chondrocytes under a commercial available membrane Implantation of chondrocytes Strength exercises, neuromuscular exercises   stem cells Chondrocytes Rehabilitation program  Procedure Procedure Other",1,50
130,Single Group Assignment           Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed   MSC (hPPL) Mesenchymal Stem Cells Biological,1,50
131,Biological: Stem cells Other: Placebo Parallel Assignment    Stem Cells Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant Lactated Ringer's Solution   Stem cells Placebo Allogeneic Low Oxygen mesenchymal stem cells Biological Other,1,50
132,Biological: Stem Cell Therapy Single Group Assignment    Stem Cells       Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.   Stem Cell Therapy  Biological,1,50
133,"Procedure: Conserved Therapy Procedure: Hepatic artery infusion Parallel Assignment    Interventional Therapy Conserved Therapy Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy. Conserved Therapy   Hepatic artery infusion Conserved Therapy interventional therapy interventional hepatic infusion Procedure Procedure",1,50
134,"Biological: umbilical cord Mesenchymal Stem Cells Drug: Conserved therapy Parallel Assignment    umbilical cord mesenchymal stem cells Conserved therapy Infe All Hemat Anti-Infective Agents All Drugs and Chemicals Hematinics  M3466 M10262 Antiviral Agents Liver Extracts low low Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes. Oral or intravenous administration   umbilical cord Mesenchymal Stem Cells Conserved therapy Mesenchymal Stem Cells Drug therapy Biological Drug",1,50
135,"Drug: CardioCell Drug: Placebos Parallel Assignment The N-O CLI trial will enroll 105 patients with randomization into active and sham therapy with 2:1 ratio.  Additional 5-10 subjects meeting inclusion/exclusion criteria will receive, in a non-blinded fashion, labelled CardioCell to determine the early uptake and retention of IMP in the target ischemic tissues.   Active Group Control Group       Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.  IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion. Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.  Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.   CardioCell Placebos CardioCell administration Placebo administration Drug Drug",1,50
136,"Other: Stem cell transplantation Other: Stem cell transplantation Other: Stem cell transplantation Other: Stem cell transplantation Other: Stem cell transplantation Other: Stem cell transplantation Other: Stem cell transplantation Parallel Assignment participants are assigned to one of two or more groups in parallel for the duration of the study   Rehabilitation control group hUC-MSCs intravenous administration group hUC-MSCs local administration group hUC-MSCs lumbar administration group hUCB-MSCs intravenous administration group hUCB-MSCs local administration group hUCB-MSCs lumbar administration group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.   Stem cell transplantation  Other",1,42
137,"Biological: Umbilical mesenchymal stem cell (UC-MSCs) infusion Drug: traditional therapy Parallel Assignment    Stem Cell Infusion traditional therapy control Hypo All Hypoglycemic Agents All Drugs and Chemicals  M9517 M172956 Insulin Insulin, Globin Zinc low low 1×10^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention. exogenous insulin injection daily   Umbilical mesenchymal stem cell (UC-MSCs) infusion traditional therapy  Biological Drug",1,44
138,"Biological: Placenta-derived MMSCs Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe Biological: Bone marrow-derived MMSCs Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe Parallel Assignment Experimental: HA + stem cells therapy Experimental Group 1: three intra-articular injection of allogeneic P-MMSCs with up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients Experimental Group 2: three intra-articular injection of autologous BM-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients Control Group: three intra-articular injection of 20 mg Hyaluronic Acid, no cell therapy - 15 patients D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Hyaluronic Acid (HA) + P-MMSCs Hyaluronic Acid (HA) + BM-MMSCs Hyaluronic Acid (HA) Hyaluronic Acid (HA) + BM-MMSCs Hyaluronic Acid (HA) + P-MMSCs All All Drugs and Chemicals Community mental health M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells Hyaluronic Acid 20 mg D000006820 Hyaluronic Acid Placenta-derived MMSCs Bone marrow-derived MMSCs Hyalgan 20 mg in 2 ML Prefilled Syringe P-MMSCs BM-MMSCs HA Biological Biological Drug",1,45
139,"Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells Sequential Assignment This study uses a rolling 6 dose escalation design with two independently accruing expansion cohorts: adults and pediatrics. Accrual in the pediatric tier will commence after the maximum dose tolerated has been determined in adults. D000000970 D000000998 D000000890 Antineoplastic Agents Antiviral Agents Anti-Infective Agents Adult Population Pediatric Population Infe ANeo All Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Inhibitor Details M9559 M9558 M3466 M3366 Interferons Interferon-gamma Antiviral Agents Anti-Infective Agents high high low low To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.  Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.  Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume. D000007372 D000007371 Interferons Interferon-gamma Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells  Drug",1,45
140,Drug: MSC+placebo Drug: MSC Drug: Placebo Parallel Assignment    MSC+placebo MSC Placebo       2 infusions of 10 X 10^6 MSC/kg and 1 placebo every 3 months. 3 infusions of 10 X 10^6 MSC/kg every 3 months. 3 infusions of placebo every 3 months. Placebo will be identical to the investigational product but will not contain MSCs.   MSC+placebo MSC Placebo allogeneic mesenchymal stem cell or similar placebo allogeneic mesenchymal stem cell Similar placebo Drug Drug Drug,1,45
141,"Biological: Mesenchymal Stem Cell Parallel Assignment    Mesenchymal Stem Cell Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks   Mesenchymal Stem Cell  Biological",1,45
142,"Procedure: Intravenous infusion Biological: umbilical cord mesenchymal stem cell Procedure: Intrathecal injection Biological: umbilical cord mesenchymal stem cell Parallel Assignment    Intravenous infusion group Intrathecal injection group Intrathecal injection group Intravenous infusion group       Intravenous infusion of mesenchymal stem cells: 2 * 10^7 cells (30ml) Intrathecal injection of mesenchymal stem cells: 2 * 10^7 cells (1ml) Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure   Intravenous infusion Intrathecal injection umbilical cord mesenchymal stem cell  Procedure Procedure Biological",1,45
143,"Drug: Prednisolone (Steroids) Drug: Sildenafil (Phosphodiesterase inhibitors) Procedure: Mesenchymal stem cell transplantation Parallel Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000018931 D000000970 D000000932 D000001337 D000018373 D000005765 D000018696 D000020011 D000014665 D000058986 D000004791 D000045504 D000064804 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents Vasodilator Agents Phosphodiesterase 5 Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents Phosphodiestrase inhibitors Steroid Mesenchymal stem cell transplantation Infl ANeo All AnEm NeuroAg Gast VaDiAg Urol AnCoag Ot Anti-Inflammatory Agents Antineoplastic Agents All Drugs and Chemicals Antiemetics Neuroprotective Agents Gastrointestinal Agents Vasodilator Agents Urological Agents Anticoagulants Other Dietary Supplements IV infusion IV infusion IV infusion IV infusion IV infusion IV infusion IV infusion 15 minutes Solanezumab M13272 M1833 M10901 M10902 M229437 M211896 M248768 M292 M12781 M20473 M1837 M3369 M8199 M8941 M8940 M20119 M3403 M8033 M19926 M21022 M16564 M28485 T382 Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Sildenafil Citrate Phosphodiesterase Inhibitors Citric Acid Sodium Citrate Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Antineoplastic Agents, Hormonal Antiemetics Gastrointestinal Agents Neuroprotective Agents Protective Agents Vasodilator Agents Phosphodiesterase 5 Inhibitors Citrate high high high high high high high high high low low low low low low low low low low low low low low tablet 25mg tablet 20 mg stem cell transplantation intramuscular D000011239 D000077555 D000008775 D000008776 C000009935 D000068677 C000021322 C000009022 D000010726 Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Sildenafil Citrate Prednisolone hemisuccinate Prednisolone phosphate Phosphodiesterase Inhibitors Sildenafil (Phosphodiesterase inhibitors) Prednisolone (Steroids) Mesenchymal stem cell transplantation sildenafil viagra Prednisolone 20 mg Drug Drug Procedure",1,45
144,Biological: Mesenchymal stem cell Procedure: Rotator cuff repair Procedure: Rotator cuff repair Parallel Assignment Randomized controlled trial   Mesenchymal stem cell group Control group Mesenchymal stem cell group       Mesenchymal stem cells applies at the end of rotator cuff repair in de active group Rotator cuff repair   Mesenchymal stem cell Rotator cuff repair  Biological Procedure,1,44
145,"Biological: Umbilical Cord Mesenchymal Stem Cells transplantation Drug: standard frailty treatment and supplementary medication Drug: standard frailty treatment and supplementary medication Parallel Assignment    Treatment (UC-MSC trasnplatation) Treatment (UC-MSC trasnplatation) control arm All BDCA All Drugs and Chemicals Bone Density Conservation Agents  M4533 M4550 Calcium Calcium, Dietary low low Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)   Umbilical Cord Mesenchymal Stem Cells transplantation standard frailty treatment and supplementary medication  Biological Drug",1,44
146,"Other: Control group Procedure: UC-MSCs Procedure: UC-MSCs Procedure: UC-MSCs Parallel Assignment    Control group Intranasal UC-MSCs group Intrathecal UC-MSCs group Intravenous UC-MSCs group       The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy. Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.   Control group UC-MSCs  Other Procedure",1,44
147,Biological: Infusion of one MPC expanded cord unit and one unexpanded cord unit Biological: Infusion of two unexpanded cord blood units. Parallel Assignment    Active Control       Infusion of one MPC expanded cord unit and one unexpanded cord unit. Umbilical Cord Blood.   Infusion of one MPC expanded cord unit and one unexpanded cord unit Infusion of two unexpanded cord blood units.  Biological Biological,1,49
148,"Biological: exosomes derived from mesenchymal stem cells (MSC-Exo) Parallel Assignment    Experimental group       After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .   exosomes derived from mesenchymal stem cells (MSC-Exo)  Biological",1,44
149,"Biological: UC-MSC Biological: Saline solution Parallel Assignment    Experimental Comparator PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Usage: The stem cell preparation in this study is used intravenously in the elbow.  Dose: The dose of stem cell injection in this clinical study is set at 1×10^6/Kg/time per injection, and the injection frequency is 2 weeks/time.  Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10^6/Kg/person. Usage: The saline solution in this study is used intravenously in the elbow.  Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.  Duration: 2 injections per person for the entire duration of the course   UC-MSC Saline solution  Biological Biological",1,44
150,"Other: Single dose experiments Other: Multi-dose experiments Single Group Assignment    Single dose experiments Multi-dose experiments       In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time. In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.   Single dose experiments Multi-dose experiments  Other Other",1,43
151,"Drug: Umbilical Cord Mesenchymal Stem Cells Single Group Assignment    Umbilical Cord Mesenchymal Stem Cells       Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months   Umbilical Cord Mesenchymal Stem Cells UC-MSC Drug",1,43
152,"Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell) Single Group Assignment    ASC (Adipose-derived Stem/Stroma Cells)       After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.   Autologous ASC (for Adipose-derived Stem/Stroma Cell)  Drug",1,43
153,"Biological: Bone marrow mesenchymal stem cells transfer Drug: Best medical treatment Procedure: Percutaneous coronary intervention Drug: Best medical treatment Procedure: Percutaneous coronary intervention Parallel Assignment    BM-MSCs group BM-MSCs group Control group BM-MSCs group Control group       Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 ~ 8 times Refer to the latest medication guidelines and give the best medication to the patients Percutaneous coronary intervention   Bone marrow mesenchymal stem cells transfer Best medical treatment Percutaneous coronary intervention  Biological Drug Procedure",1,43
154,Single Group Assignment           harvest of a small bone marrow sample during open chest surgery   harvest of a small bone marrow sample  Procedure,1,35
155,"Biological: Bone marrow-derived mesenchymal stem cells Biological: Bone marrow-derived mesenchymal stem cells Other: Placebo Parallel Assignment This will be a randomized, controlled clinical trial in which non-diabetic CP patients scheduled for TP-IAT who meet the study criteria and consented will be randomized into three groups. One group will receive islet transplantation alone (n=14). The other two groups will receive islets plus BM-MSCs at two different doses (20x10^6/patient, or 50x10^6/patient, n=14 in each group).   BM-MSCs at 20x10^6 BM-MSCs at 50x10^6 Placebo       MSC transplantation Standard of Care   Bone marrow-derived mesenchymal stem cells Placebo  Biological Other",1,42
156,"Biological: human umbilical cord blood derived mesenchymal stem cells Biological: human umbilical cord blood derived mesenchymal stem cells Other: Normal saline 2mL Parallel Assignment    NEUROSTEM® (hUCB-MSCs) - high dose NEUROSTEM® (hUCB-MSCs)- low dose Placebo       Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals  High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations   human umbilical cord blood derived mesenchymal stem cells Normal saline 2mL NEUROSTEM® Biological Other",1,45
157,Biological: Cultured Mesenchymal Stem Cells Biological: Cultured Mesenchymal Stem Cells Procedure: Autologous iliac crest graft Parallel Assignment    hBM-MSCs-High Dose hBM-MSCs-Low Dose Autologous iliac crest graft       Cultured Mesenchymal Stem Cells obtained from expanded bone marrow Autologous iliac crest grafting   Cultured Mesenchymal Stem Cells Autologous iliac crest graft  Biological Procedure,1,46
158,Biological: bone marrow-derived MSC and HRT Other: hormonal replacement therapy Parallel Assignment    bone marrow-derived MSC and HRT hormonal replacement therapy       Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells Three cycles of HRT following MSC transplantation; Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle; Frozen/thawed embryo transfer 3-6 months after transplantation. standard treatment of hypoplastic endometrium or Asherman's syndrome:  Three cycles of HRT preceding frozen/thawed embryo transfer; Frozen/thawed embryo transfer.   bone marrow-derived MSC and HRT hormonal replacement therapy  Biological Other,1,46
159,Biological: Application of allogeneic ADSC stem cells in fibrin gel Procedure: Standard care in diabetic foot ulcer Parallel Assignment    Allogeneic ADSC cells in fibrin solution Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface. PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control. Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.   Application of allogeneic ADSC stem cells in fibrin gel Standard care in diabetic foot ulcer  Biological Procedure,1,46
160,"Single Group Assignment     Infe ARhu Derm All Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals  M18113 M5882 Cyclosporine Cyclosporins low low Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes. Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells. Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells. Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells. Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells. Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes. Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.   graft versus host disease prophylaxis/therapy fluorescence in situ hybridization immunoenzyme technique immunohistochemistry staining method laboratory biomarker analysis in vitro-treated bone marrow transplantation management of therapy complications  Biological Genetic Other Other Other Procedure Procedure",1,49
161,Biological: Injection of Secretome-MSCs Drug: Standard treatment of Covid-19 Drug: Standard treatment of Covid-19 Parallel Assignment    Secretome-MSCs (n=24) Control (n=24) Secretome-MSCs (n=24)       Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :  Day 1: 1 cc every 12 hours  Day 2: 1 cc every 12 hours  Day 3: 1 cc every 12 hours Patients will be given Standard treatment of Covid-19 which accordance with National protocol   Injection of Secretome-MSCs Standard treatment of Covid-19  Biological Drug,1,48
162,Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC) Other: Placebo Parallel Assignment    Allogeneic Wharton's jelly-MSCs (WJ-MSC) Placebo All ANeo All Drugs and Chemicals Antineoplastic Agents  M6457 M8814 Dimethyl Sulfoxide Altretamine low low The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.  Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes. Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group   Allogeneic Wharton's jelly-MSCs (WJ-MSC) Placebo Protrans Biological Other,1,48
163,Biological: Microfragmented Adipose Tissue Transplant Drug: Corticosteroid injection Parallel Assignment    Lipogems Steroid       Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit intra-articular knee injection of corticosteroid   Microfragmented Adipose Tissue Transplant Corticosteroid injection aMAT steroid Biological Drug,1,48
164,"Biological: Mesenchymal Stromal Cells Other: Placebo Parallel Assignment    Bone marrow-derived Mesenchymal Stromal Cells Cryostor CS10       Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml Volume total of fluid infused: 40 ml   Mesenchymal Stromal Cells Placebo Allogeneic Cellular Therapy (NEPHSTROM ORBCEL-M) Cryostor CS10 Biological Other",1,48
165,Drug: Allogeneic Mesenchymal Precursor Cells Drug: Normal Saline Parallel Assignment    Normal Saline Placebo Allogeneic Mesenchymal Precursor Cells          Allogeneic Mesenchymal Precursor Cells Normal Saline  Drug Drug,1,48
166,Biological: Autologous MSC-NTF cells Biological: Placebo Parallel Assignment    Autologous MSC-NTF cells Excipient       Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration Excipient administration by combined intramuscular and intrathecal administration   Autologous MSC-NTF cells Placebo NurOwn Biological Biological,1,48
167,"Biological: Mesenchymal stem cells Biological: Mesenchymal stem cells Biological: Mesenchymal stem cells Crossover Assignment Patients were randomised into three groups and treated intrathecally (IT) or intravenously (IV) with autologous MSCs or placebo. At 6-months, treatment groups were crossed over and patients re-treated with either MSC or placebo   IT- Treated IV - Treated Placebo       A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.   Mesenchymal stem cells Autologous MSC Biological",1,48
168,"Biological: UC-MSCs Drug: Placebo Parallel Assignment Parallel Assignment   UC-MSCs Treatment Group Conventional Control Group       4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7). 4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).   UC-MSCs Placebo  Biological Drug",1,48
169,Biological: UC-MSC infusion via intravenous route Other: standard stroke treatment and rehabilitation therapy Biological: UC-MSC infusion via intrathecal route Other: standard stroke treatment and rehabilitation therapy Other: standard stroke treatment and rehabilitation therapy Parallel Assignment    UC-MSC infusion via intravenous route UC-MSC infusion via intrathecal route UC-MSC infusion via intrathecal route UC-MSC infusion via intravenous route control arm       Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval Each patient can receive up to 30 days of rehabilitation therapy   UC-MSC infusion via intravenous route UC-MSC infusion via intrathecal route standard stroke treatment and rehabilitation therapy  Biological Biological Other,1,48
170,"Drug: FAB117-HC Other: Control group Drug: FAB117-HC Parallel Assignment    FAB117-HC (Ph 1) Control group (Ph 2) FAB117-HC (Ph 2) Infe All Anti-Infective Agents All Drugs and Chemicals  M9070 Hydrogen Peroxide low (Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells) (Ph 2) No treatment will be administered (Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)   FAB117-HC Control group FAB117-HC  Drug Other Drug",1,48
171,"Biological: UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC) Single Group Assignment    Umbilical Cord Mesenchymal stromal cells (UC-MSC) ANeo All Antineoplastic Agents All Drugs and Chemicals  M17393 Pentostatin low pentostatin, dose 1 mg/m2  § MSC doses:  3 patients → 3 infusions of 1x106 cells /kg 3 patients → 3 infusions of 2x106 cells /kg 3 patients → 3 infusions of 3x106 cells /kg   UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)  Biological",1,47
172,"Biological: Umbilical cord Wharton's jelly-derived human Other: NaCl 0.9% Parallel Assignment    MSC NaCl       Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5. NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5   Umbilical cord Wharton's jelly-derived human NaCl 0.9%  Biological Other",1,47
173,Biological: Allo-MSCs Biological: Placebo Parallel Assignment    Allo-MSCs Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low 20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure) 20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)   Allo-MSCs Placebo Allogeneic Mesenchymal Stem Cells Buminate solution Biological Biological,1,46
174,"Genetic: MSCTRAIL Genetic: MSCTRAIL Drug: Placebo Sequential Assignment Phase I:  Single centre, accelerated dose dose de-escalation design with a modified Bayesian continual reassessment method (mCRM) to estimate the recommended Phase II dose (RP2D) of MSCTRAIL in combination with pemetrexed/cisplatin chemotherapy.  Phase II:  Multicentre, randomised double blind placebo controlled trial comparing MSCTRAIL at the RP2D and pemetrexed/cisplatin chemotherapy versus pemetrexed/cisplatin chemotherapy alone.   Phase 1 - RP2D finding study Phase 2 Intervention Arm Phase 2 Control Arm ANeo All Antineoplastic Agents All Drugs and Chemicals  M5334 M264 Cisplatin Pemetrexed low low 3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).  After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL. Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product   MSCTRAIL Placebo Mesenchymal stromal cells genetically modified to express TRAIL Genetic Drug",1,46
175,"Biological: human umbilical cord blood derived mesenchymal stem cells Biological: human umbilical cord blood derived mesenchymal stem cells Other: Normal saline 2mL Parallel Assignment Stage 1: 9 subjects (3 subjects for low dose and 6 subjects for high dose) Stage 2: 36 subjects ( 24 subjects for high dose and 12 subjects for placebo) A total of 45 subjects to be enrolled   NEUROSTEM (hUCB-MSCs) - high dose NEUROSTEM (hUCB-MSCs)- low dose Placebo       Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals  High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations   human umbilical cord blood derived mesenchymal stem cells Normal saline 2mL NEUROSTEM Biological Other",1,46
176,Biological: stem cell transplantation Biological: stem cell transplantation Parallel Assignment    Allogeneic umbilical cord MSC group Autologous bone marrow-derived MNC group       Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation   stem cell transplantation  Biological,1,46
177,"Procedure: arthroplasty Single Group Assignment    Surgical intervention       Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings   arthroplasty  Procedure",1,35
178,"Procedure: Laparoscopic surgery Device: NeuroRegen scaffold transplantation Biological: NeuroRegen scaffold/BMMCs transplantation Biological: NeuroRegen scaffold/HUC-MSCs transplantation Parallel Assignment    Laparoscopic surgery NeuroRegen scaffold transplantation NeuroRegen scaffold/BMMCs transplantation NeuroRegen scaffold/HUC-MSCs transplantation       Completely resected rectal tumor. After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve. Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve. Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.   Laparoscopic surgery NeuroRegen scaffold transplantation NeuroRegen scaffold/BMMCs transplantation NeuroRegen scaffold/HUC-MSCs transplantation  Procedure Device Biological Biological",1,34
179,"Procedure: Unilateral Bone Marrow Procurement Procedure: Bilateral Bone Marrow Procurement Parallel Assignment    Unilateral Procurement of Bone Marrow Bilateral Bone Marrow Procurement       A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes. 30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.   Unilateral Bone Marrow Procurement Bilateral Bone Marrow Procurement  Procedure Procedure",1,35
180,"Biological: UC-MSCs Single Group Assignment    Treat Psoriasis Vulgaris with UC-MSCs       Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.   UC-MSCs umbilical cord derived mesenchymal stem cells Biological",1,30
181,Procedure: Autologous Mesenchymal Stem Cells Single Group Assignment    Mesenchymal Stem cells       Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation   Autologous Mesenchymal Stem Cells  Procedure,1,30
182,Biological: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients Single Group Assignment    Autologous ADRC injection       3 injections of ADRC: 1 intraspinal and 2 intrathecal   Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients  Biological,1,30
183,"Other: Human umbilical cord-derived MSCs Other: cyclosporine A (CsA) Parallel Assignment  D000004791 D000045504 D000007166 D000007155 D000045505 D000000935 D000000890 D000003879 D000018501 D000065095 Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Human umbilical cord-derived MSCs cyclosporine A (CsA) Infe ARhu Derm All Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Impact Impact M18113 M5882 M9364 M9353 M3406 M5404 M10948 M3366 M6226 M19757 M29605 Cyclosporine Cyclosporins Immunosuppressive Agents Immunologic Factors Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors high high low low low low low low low low low 1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle CsA 5mg/kg po for 6 months D000016572 D000003524 Cyclosporine Cyclosporins Human umbilical cord-derived MSCs cyclosporine A (CsA)  Other Other",1,30
184,Biological: Descartes 30 Single Group Assignment    Descartes 30       Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.   Descartes 30  Biological,1,30
185,"Drug: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) Procedure: core decompression Procedure: core decompression Parallel Assignment    Group 1 Group 1 Group 2       Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2*10^7 cells, The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.   Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) core decompression  Drug Procedure",1,30
186,Procedure: Mesenchymal stem cell infusion Single Group Assignment    1       Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.   Mesenchymal stem cell infusion Mesenchymal stem cells Procedure,1,30
187,"Other: Alogenic adipose tissue-derived stem cells Drug: Placebo solution Parallel Assignment Two different treatment grupos; intravenous alogenic adipose tissue-derived mesenchymal stem cells or intravenous placebo solution   Treatment group Placebo group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Concentration of the cells: 10 million cells / ml Placebo intravenous solution, same appearance stem cells solution   Alogenic adipose tissue-derived stem cells Placebo solution  Other Drug",1,30
188,Biological: ucMSC Other: Controls Parallel Assignment    ucMSC Controls PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low 1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma Autologous Serum will administrated as placebo   ucMSC Controls Umbilical Cord Mesenchymal Stem Cells Biological Other,1,30
189,Procedure: Implantation of bone substitute plus autologous cultured mesenchymal cells Single Group Assignment    Implantation surgery       Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded   Implantation of bone substitute plus autologous cultured mesenchymal cells  Procedure,1,30
190,"Biological: autologous bone marrow mesenchymal stem cells transplantation Biological: autologous bone marrow msenchymal stem cells transplantation Biological: autologous bone marrow mesenchymal stem cells transplantation Biological: autologous bone marrow msenchymal stem cells transplantation Biological: autologous bone marrow mesenchymal stem cells transplantation Biological: autologous bone marrow msenchymal stem cells transplantation Single Group Assignment    autologous bone marrow mesenchymal stem cells transplantation mesenchymal stem cells transplantation stem cells transplantation autologous bone marrow mesenchymal stem cells transplantation mesenchymal stem cells transplantation stem cells transplantation Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.   autologous bone marrow mesenchymal stem cells transplantation autologous bone marrow msenchymal stem cells transplantation  Biological Biological",1,30
191,"Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells Drug: Antibiotics Drug: Hormones Drug: Anticoagulant Therapy Device: Оxygen therapy Drug: Antibiotics Drug: Hormones Drug: Anticoagulant Therapy Device: Оxygen therapy Parallel Assignment Experimental: stem cells therapy + treatment in according with approved by Ukrainian Health Ministry COVID-19 clinical protocol Experimental Group 1: Subjects with severe COVID-19 pneumonia shall be received three infusions of cryopreserved allogeneic P-MMSCs (1 million cells/kg body weight) at 2-days intervals: Day ""1"", Day ""4"", Day ""7"".  Control Group: treatment in according with approved by Ukrainian MoH COVID-19 clinical protocol. D000000893 D000000932 D000001337 D000018373 D000045505 D000005765 D000005938 D000006730 D000018931 D000000970 D000045504 D000000890 D000005343 D000050299 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Molecular Mechanisms of Pharmacological Action Anti-Infective Agents Fibrinolytic Agents Fibrin Modulating Agents Experimental group Control Group Experimental group Control Group Experimental group Control Group Experimental group Control Group Experimental group Infl ANeo AnEm Gast All Infe FiAg AnCoag Anti-Inflammatory Agents Antineoplastic Agents Antiemetics Gastrointestinal Agents All Drugs and Chemicals Anti-Infective Agents Fibrinolytic Agents Anticoagulants Test Include Position Choice Colony Resonance Chemoradiation M6254 M8941 M3374 M235540 M19304 M3396 M3376 M136812 M19284 M4845 M3369 M3403 M8033 M8199 M8940 M20119 M3366 M7625 Dexamethasone Hormones Anti-Bacterial Agents Dexamethasone acetate Enoxaparin Anticoagulants Antibiotics, Antitubercular Enoxaparin sodium Azithromycin Ceftriaxone Anti-Inflammatory Agents Antiemetics Gastrointestinal Agents Glucocorticoids Hormone Antagonists Antineoplastic Agents, Hormonal Anti-Infective Agents Fibrinolytic Agents high high high low high high low low high high low low low low low low low low i/v infusions per os a moderate amount of dexamethasone i/v Sub-Q Оxygen therapy, mechanical ventilation and other supportive therapies D000000900 D000017963 D000002443 D000003907 D000017984 D000000925 D000006728 Anti-Bacterial Agents Azithromycin Ceftriaxone Dexamethasone Enoxaparin Anticoagulants Hormones Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells Antibiotics Hormones Anticoagulant Therapy Оxygen therapy P-MMSCs ceftriaxone and azithromycin capsules dexamethasone Еnoxaparin Оxygen insufflation Procedure Drug Drug Drug Device",1,30
192,"Biological: umbilical cord mesenchymal stem cells and hyaluronic acid Drug: hyaluronic acid Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents UCMSCs-HA Control All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low  D000006820 Hyaluronic Acid umbilical cord mesenchymal stem cells and hyaluronic acid hyaluronic acid  Biological Drug",1,30
193,"Drug: ExoFlo Drug: ExoFlo Drug: ExoFlo Parallel Assignment    10ml ExoFlo 15ml ExoFlo Placebo       Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1   ExoFlo  Drug",1,30
194,"Biological: NeuroRegen scaffold with BMMCs or MSCs transplantation Single Group Assignment    NeuroRegen Scaffold with BMMCs or MSCs transplantation       Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.   NeuroRegen scaffold with BMMCs or MSCs transplantation  Biological",1,30
195,Procedure: Fat graft enriched with ex vivo expanded stem cells Procedure: Fat graft not enriched with ex vivo expanded stem cells Parallel Assignment    Stem cell enriched Non stem cell enriched       Fat graft will be enriched with ex vivo expanded stem cells Fat graft will not be enriched with ex vivo expanded stem cells   Fat graft enriched with ex vivo expanded stem cells Fat graft not enriched with ex vivo expanded stem cells  Procedure Procedure,1,30
196,Drug: Mesenchymal stem cell Drug: Isotonic NaCl Parallel Assignment    Stemcells injected into submandibularis Saltwater injected into submandibularis CNSDep All Analg Central Nervous System Depressants All Drugs and Chemicals Analgesics  M3259 M3184 Anesthetics Analgesics low low Stemcells injected into submandibularis   Mesenchymal stem cell Isotonic NaCl  Drug Drug,1,30
197,"Biological: Allogeneic Mesenchymal Bone Marrow Cells Single Group Assignment    Allogeneic Mesenchymal Bone Marrow Cells       Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.   Allogeneic Mesenchymal Bone Marrow Cells  Biological",1,29
198,Other: Two intrathecal MSC injections Single Group Assignment    MSC injection          Two intrathecal MSC injections  Other,1,28
199,Biological: UC-MSCs Other: Placebo Parallel Assignment    UC-MSCs treatment group Control group       1*10E6 UC-MSCs /kg body weight suspended in 100mL saline 100mL saline intravenously   UC-MSCs Placebo  Biological Other,1,30
200,Biological: MSC Single Group Assignment    Conventional plus MSC treatment       conventional plus MSC or placebo treatment   MSC  Biological,1,30
201,"Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell Single Group Assignment    Stem cell transplantation CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 M3261 Anesthetics Anesthetics, Local low low Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure   Expanded autologous bone marrow-derived mesenchymal stem cell  Combination Product",1,30
202,"Other: Autologous Adipose-derived Mesenchymal Stem Cell Gel Procedure: Extraction of abdominal fat Drug: Sodium Hyaluronate Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Autologous Adipose-derived Mesenchymal Stem Cell Gel sodium hyaluronate Autologous Adipose-derived Mesenchymal Stem Cell Gel All All Drugs and Chemicals PCOS M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation. The control group received intra-articular injection of sodium hyaluronate one month after operation. In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel. D000006820 Hyaluronic Acid Autologous Adipose-derived Mesenchymal Stem Cell Gel Sodium Hyaluronate Extraction of abdominal fat hyaluronic acid Fat extraction Other Drug Procedure",1,30
203,Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) Biological: Placebo Parallel Assignment    Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Placebo       Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)   Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) Placebo  Biological Biological,1,30
204,"Biological: Autologous tolerogenic dendritic cells Other: Standard treatment according to the clinical protocols Other: Standard treatment according to the clinical protocols Parallel Assignment    Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells Patients with Type 1 Diabetes Mellitus receiving standard treatment Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells BDCA Micro All Vi Bone Density Conservation Agents Micronutrients All Drugs and Chemicals Vitamins  M16702 M5155 M16710 T479 T440 T442 Vitamin D Cholecalciferol Vitamins Vitamin D3 Calciferol Cholecalciferol low low low low low low Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous. Standard treatment of type 1 diabetes mellitus according to the clinical protocols   Autologous tolerogenic dendritic cells Standard treatment according to the clinical protocols  Biological Other",1,30
205,Biological: allogeneic umbilical cord-derived mesenchymal stem cells Biological: allogeneic umbilical cord-derived mesenchymal stem cells Biological: Placebo (NaCl) Parallel Assignment    double dose simple dose placebo       Injection of mesenchymal stem cells Placebo injection   allogeneic umbilical cord-derived mesenchymal stem cells Placebo (NaCl)  Biological Biological,1,30
206,"Other: Human umbilical cord-derived MSCs and cyclosporin A Other: cyclosporin A Parallel Assignment  D000004791 D000045504 D000007166 D000007155 D000045505 D000000935 D000000890 D000003879 D000018501 D000065095 Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Human umbilical cord-derived MSCs and cyclosporin cyclosporine A Infe ARhu Derm All Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Impact Impact M18113 M5882 M9364 M9353 M3406 M5404 M10948 M3366 M6226 M19757 M29605 Cyclosporine Cyclosporins Immunosuppressive Agents Immunologic Factors Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors high high low low low low low low low low low 1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months cyclosporin A 5mg/kg po for 12 months D000016572 D000003524 Cyclosporine Cyclosporins Human umbilical cord-derived MSCs and cyclosporin A cyclosporin A  Other Other",1,30
207,"Device: Marrow Cellution System Single Group Assignment    Bone Marrow aspirate       The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.   Marrow Cellution System  Device",1,30
208,Procedure: umbilical cord mesenchymal stem cell Single Group Assignment    umbilical cord mesenchymal stem cell       allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection   umbilical cord mesenchymal stem cell  Procedure,1,30
209,"Biological: Umbilical cord derived mesenchymal stem cells Biological: Placebo Parallel Assignment It will be included 30 patients, randomly assigned by centralized electronic sequence of assignation, for the application of a single dosis of 1*10^6 cells/Kg or placebo   Experimental Control       One dosis of 1*10^6 cells/Kg Placebo   Umbilical cord derived mesenchymal stem cells Placebo  Biological Biological",1,30
210,Biological: umbilical cord mesenchymal stem cells Single Group Assignment    umbilical cord mesenchymal stem cells       Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.   umbilical cord mesenchymal stem cells mesenchymal stem cells Biological,1,30
211,Drug: GXCPC1 Device: HA Parallel Assignment    GXCPC1 hyaluronic acid All All Drugs and Chemicals  M9030 Hyaluronic Acid low The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10^6 or 4×10^7 ADSCs in 3 mL saline. (allogeneic injection) Hya Joint Plus synovial fluid supplement 3mL   GXCPC1 HA  Drug Device,1,30
212,"Drug: Triamcinolone acetonide Biological: CELLISTEM-OA Parallel Assignment Controlled, randomized, double-blind clinical trial comparing CELLISTEM-OA and active comparator (triamcinolone acetonide). D000000893 D000005938 D000006728 D000006730 D000045505 D000007166 D000007155 D000004791 D000045504 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Group 2 (experimental- CELLISTEM-OA) Group 1 (control-Triamcinolone acetonide) PhSol All Infl Pharmaceutical Solutions All Drugs and Chemicals Anti-Inflammatory Agents Pulse Periodontal Periodontal Periodontal M21013 M16126 M16127 M237968 M209570 M3369 M8199 M8941 M8940 M9364 M9353 Pharmaceutical Solutions Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Immunosuppressive Agents Immunologic Factors low high high high high low low low low low low The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice. The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice. D000014221 D000014222 C000005900 C000030262 Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate CELLISTEM-OA Triamcinolone acetonide Mesenchymal stem cells Kenacort-A Biological Drug",1,30
213,"Biological: SLE group Biological: LN group Other: the control group Parallel Assignment    SLE group LN group the control group       The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation. The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation. The patients will be assigned to the control group.   SLE group LN group the control group  Biological Biological Other",1,30
214,"Combination Product: adipose-derived mesenchymal stem cells Combination Product: adipose-derived mesenchymal stem cells Single Group Assignment 30 patients with sexual hormone deficiency will be injected AD-MSCs   Stem cell Administration for female patients Stem cell Administration for male patients All All Drugs and Chemicals  M8941 Hormones low Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure   adipose-derived mesenchymal stem cells  Combination Product",1,30
215,Drug: transplantation of hUC-MSCs Single Group Assignment    Mesenchymal Stem Cell       Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.   transplantation of hUC-MSCs intravenous infusion of hUC-MSCs Drug,1,30
216,Biological: Autologous Mesenchymal Stem Cells Biological: Autologous Mesenchymal Stem Cells Biological: Autologous Mesenchymal Stem Cells Biological: Autologous Mesenchymal Stem Cells Biological: Autologous Mesenchymal Stem Cells Sequential Assignment    1 dose of 1 × 10(7) MSCs 2 doses of 5 × 10(7) MSCs 2 doses of 1 × 10(8) MSCs 10 doses of 5 x 10(7) (±20%) MSCs 10 doses of 2.5 x 10(7) (±20%) MSCs       single dose of 1 × 10(7) cells intrathecally 2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart 2 doses of 1 × 10(8) cells intrathecally each 1 month apart Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart   Autologous Mesenchymal Stem Cells Autologous Mesenchymal Stem Cells Autologous Mesenchymal Stem Cells Autologous Mesenchymal Stem Cells Autologous Mesenchymal Stem Cells  Biological Biological Biological Biological Biological,1,30
217,"Procedure: ACL reconstruction only Biological: Cartistem(TM) Procedure: ACL reconstruction only Biological: hyaluronic acid Procedure: ACL reconstruction only Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents ACL reconstruction + Cartistem(TM) ACL reconstruction + Hyaluronic acid ACL reconstruction + Cartistem(TM) ACL reconstruction + Hyaluronic acid ACL reconstruction only All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy. ACL reconstruction and injection of hyaluronic acid under arthroscopy. ACL reconstruction only without any injection under arthroscopy D000006820 Hyaluronic Acid Cartistem(TM) hyaluronic acid ACL reconstruction only  Biological Biological Procedure",1,30
218,"Procedure: stem cell transplantation Single Group Assignment    stem cell transplantation       after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.   stem cell transplantation the stem cell treatment of ALS Procedure",1,30
219,"Other: Implantation of autologous cells Other: Implantation of autologous cells Parallel Assignment    Autologous ASC implantation Autologous Chondrocytes implantation       Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane   Implantation of autologous cells ACI Other",1,30
220,Drug: allogeneic human mesenchymal stem cells (allo-hMSCs) Drug: Placebo Parallel Assignment    allogeneic human mesenchymal stem cells (allo-hMSCs) Placebo Infe CNSDep All PhSol Anti-Infective Agents Central Nervous System Depressants All Drugs and Chemicals Pharmaceutical Solutions  M2929 M85407 Ethanol Plasma-lyte 148 low low Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion. Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.   allogeneic human mesenchymal stem cells (allo-hMSCs) Placebo  Drug Drug,1,28
221,Biological: MSCs Drug: Placebo Biological: MSCs Drug: Placebo Biological: MSCs Drug: Placebo Parallel Assignment  D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions Intravenous infusion of 1 million allogenic MSC's/Kg Intravenous infusion of 3 million allogeneic MSCs/kg Intravenous infusion of Plasmalyte A (placebo) Intravenous infusion of 1 million allogenic MSC's/Kg Intravenous infusion of 3 million allogeneic MSCs/kg Intravenous infusion of Plasmalyte A (placebo) Intravenous infusion of 1 million allogenic MSC's/Kg Intravenous infusion of 3 million allogeneic MSCs/kg Intravenous infusion of Plasmalyte A (placebo) Infl All AAll AnEm CNSDep Gast Derm PhSol Anti-Inflammatory Agents All Drugs and Chemicals Anti-Allergic Agents Antiemetics Central Nervous System Depressants Gastrointestinal Agents Dermatologic Agents Pharmaceutical Solutions CAB M9064 M155022 M228602 M263157 M6490 M13420 M85407 M21013 M11966 Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Diphenhydramine Promethazine Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions low low low low low low high low low Intravenous infusion of 1 million allogeneic MSCs/kg. Intravenous infusion of 3 million allogeneic MSCs/kg Intravenous infusion of Plasmalyte A (placebo) C000012499 Plasma-lyte 148 MSCs MSCs Placebo Plasmalyte A Biological Biological Drug,1,28
222,"Genetic: Cell therapy Genetic: Cell therapy Genetic: Cell therapy Sequential Assignment Patients will be subjected into 3 groups, with a low (0.2×107), medium (0.5×107) and high dosage (1.0×107) of cells transplantation for each ovary. The investigator will first carry out the low dosage group, and then the medium dosage group, based on the safety evaluation of the previous group, the high dosage group will be executed in the same way.   High dosage Low dosage Medium dosage       Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.   Cell therapy  Genetic",1,28
223,"Drug: HCR040 (Phase 1) Drug: Placebo (Phase 2) Drug: HCR040 (Phase 2) Parallel Assignment  D000000891 D000000890 Anti-Infective Agents, Local Anti-Infective Agents HCR040 (Phase 1) Control group (Phase 2) HCR040 (Phase 2) Infe All PhSol Anti-Infective Agents All Drugs and Chemicals Pharmaceutical Solutions BeneFIX M9070 M21013 M3366 M3367 Hydrogen Peroxide Pharmaceutical Solutions Anti-Infective Agents Anti-Infective Agents, Local high low low low (Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg) (Phase 2) Intravenous administration of vehicle solution (Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg) D000006861 Hydrogen Peroxide HCR040 (Phase 1) Placebo (Phase 2) HCR040 (Phase 2) Allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2 Saline solution Allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2 Drug Drug Drug",1,26
224,Drug: REcycled CartiLage Auto/Allo IMplantation Single Group Assignment    RECLAIM       Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).   REcycled CartiLage Auto/Allo IMplantation RECLAIM Drug,1,25
225,"Biological: stem cell therapy Biological: stem cell therapy Crossover Assignment    delayed stem cell therapy immediate stem cell therapy CNSDep All PhSol Central Nervous System Depressants All Drugs and Chemicals Pharmaceutical Solutions  M3259 M21013 Anesthetics Pharmaceutical Solutions low low Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.   stem cell therapy  Biological",1,25
226,"Biological: Anti-Thymocyte Globulin Drug: Busulfan Drug: Clofarabine Biological: Filgrastim-sndz Drug: Fludarabine Drug: Mycophenolate Mofetil Biological: Rituximab Drug: Tacrolimus Radiation: Total-Body Irradiation Procedure: Umbilical Cord Blood Transplantation Biological: Anti-Thymocyte Globulin Biological: Filgrastim-sndz Drug: Fludarabine Drug: Melphalan Drug: Mycophenolate Mofetil Drug: Tacrolimus Procedure: Umbilical Cord Blood Transplantation Biological: Anti-Thymocyte Globulin Drug: Cyclophosphamide Biological: Filgrastim-sndz Drug: Fludarabine Drug: Mycophenolate Mofetil Drug: Tacrolimus Radiation: Total-Body Irradiation Procedure: Umbilical Cord Blood Transplantation Parallel Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 D000000964 D000000963 D000065095 D000004791 D000000276 D000000903 D000000904 D000000995 D000000900 D000000890 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antimetabolites, Antineoplastic Antimetabolites Calcineurin Inhibitors Enzyme Inhibitors Adjuvants, Immunologic Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Group I (chemotherapy, TBI, cord blood) Group II (chemotherapy, cord blood) Group III (chemotherapy, TBI, cord blood) Group I (chemotherapy, TBI, cord blood) Group I (chemotherapy, TBI, cord blood) Group III (chemotherapy, TBI, cord blood) Group I (chemotherapy, TBI, cord blood) Group II (chemotherapy, cord blood) Group III (chemotherapy, TBI, cord blood) Group I (chemotherapy, TBI, cord blood) Group II (chemotherapy, cord blood) Group III (chemotherapy, TBI, cord blood) Group II (chemotherapy, cord blood) Group I (chemotherapy, TBI, cord blood) Group II (chemotherapy, cord blood) Group III (chemotherapy, TBI, cord blood) Group I (chemotherapy, TBI, cord blood) Group I (chemotherapy, TBI, cord blood) Group II (chemotherapy, cord blood) Group III (chemotherapy, TBI, cord blood) Group I (chemotherapy, TBI, cord blood) Group III (chemotherapy, TBI, cord blood) Group I (chemotherapy, TBI, cord blood) Group II (chemotherapy, cord blood) Group III (chemotherapy, TBI, cord blood) Infe ANeo All ARhu AA Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Antirheumatic Agents Amino Acids Bolus Controlled Under Off Androgen Followed by Tablet Compliance Controlled Two Cardiac Long- Orientation Orientation Inhaler Training program Followed by Ejection Fraction Confirmed M11280 M9336 M283219 M4488 M1921 M3382 M5879 M10693 M3377 M373 M225481 M18102 M1945 M10601 M11677 M255749 M3431 M1346 M18269 M9364 M9353 M19757 M20095 M2972 M3433 M29605 M2780 M3374 M3376 M3463 M3366 T0 T14 Mycophenolic Acid Immunoglobulins Fludarabine Busulfan Clofarabine Antibodies, Monoclonal Cyclophosphamide Melphalan Antibodies Rituximab Fludarabine phosphate Tacrolimus Lenograstim Mechlorethamine Nitrogen Mustard Compounds Thymoglobulin Antilymphocyte Serum Antineoplastic Agents, Immunological Immunoglobulins, Intravenous Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Antimetabolites Calcineurin Inhibitors Adjuvants, Immunologic Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Infective Agents Alanine Phenylalanine high high high high high high high high high high low high high high high high high high low low low low low low low low low low low low low high high Given IV Given IV Given IV Given IV Given SC Given IV Given IV Given IV or PO Given IV Given IV Undergo total body irradiation Undergo cord blood transplant D000009173 D000003520 D000008558 D000002066 D000008466 D000009588 D000069283 C000024352 D000077866 D000074322 D000016559 C000512542 D000000961 D000000906 D000007136 D000000911 D000078224 Mycophenolic Acid Cyclophosphamide Melphalan Busulfan Mechlorethamine Nitrogen Mustard Compounds Rituximab Fludarabine Clofarabine Antineoplastic Agents, Immunological Tacrolimus Thymoglobulin Antilymphocyte Serum Antibodies Immunoglobulins Antibodies, Monoclonal Lenograstim Anti-Thymocyte Globulin Busulfan Clofarabine Cyclophosphamide Filgrastim-sndz Fludarabine Melphalan Mycophenolate Mofetil Rituximab Tacrolimus Total-Body Irradiation Umbilical Cord Blood Transplantation Antithymocyte Globulin Antithymocyte Serum ATG ATGAM ATS Thymoglobulin 1, 4-Bis[methanesulfonoxy]butane BUS Bussulfam Busulfanum Busulfex Busulphan CB 2041 CB-2041 Glyzophrol GT 41 GT-41 Joacamine Methanesulfonic Acid Tetramethylene Ester Methanesulfonic acid, tetramethylene ester Mielucin Misulban Misulfan Mitosan Myeleukon Myeloleukon Myelosan Mylecytan Myleran Sulfabutin Tetramethylene Bis(methanesulfonate) Tetramethylene bis[methanesulfonate] WR-19508 Clofarex Clolar (-)-Cyclophosphamide 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate Carloxan Ciclofosfamida Ciclofosfamide Cicloxal Clafen Claphene CP monohydrate CTX CYCLO-cell Cycloblastin Cycloblastine Cyclophospham Cyclophosphamid monohydrate Cyclophosphamidum Cyclophosphan Cyclophosphane Cyclophosphanum Cyclostin Cyclostine Cytophosphan Cytophosphane Cytoxan Fosfaseron Genoxal Genuxal Ledoxina Mitoxan Neosar Revimmune Syklofosfamid WR- 138719 Filgrastim Biosimilar Filgrastim-sndz Zarxio Fluradosa Alanine Nitrogen Mustard CB-3025 L-PAM L-Phenylalanine Mustard L-sarcolysin L-Sarcolysin Phenylalanine mustard L-Sarcolysine Melphalanum Phenylalanine Mustard Phenylalanine nitrogen mustard Sarcoclorin Sarkolysin WR-19813 Cellcept MMF ABP 798 BI 695500 C2B8 Monoclonal Antibody Chimeric Anti-CD20 Antibody CT-P10 IDEC-102 IDEC-C2B8 IDEC-C2B8 Monoclonal Antibody MabThera Monoclonal Antibody IDEC-C2B8 PF-05280586 Rituxan Rituximab Biosimilar ABP 798 Rituximab Biosimilar BI 695500 Rituximab Biosimilar CT-P10 Rituximab Biosimilar GB241 Rituximab Biosimilar IBI301 Rituximab Biosimilar PF-05280586 Rituximab Biosimilar RTXM83 Rituximab Biosimilar SAIT101 RTXM83 FK 506 Fujimycin Hecoria Prograf Protopic Total Body Irradiation Whole-Body Irradiation Cord Blood Transplantation UCB transplantation Biological Drug Drug Drug Biological Drug Drug Drug Biological Drug Radiation Procedure",1,25
227,"Biological: Allogenic Mesenchymal Stromal Cells Drug: Mepivacaine Parallel Assignment  D000000779 D000000777 D000002492 D000045505 D000018689 D000018373 Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Allogenic Mesenchymal Stromal Cells Mepivacaine CNSDep All Central Nervous System Depressants All Drugs and Chemicals Lumbar spine M10752 M3259 M3261 Mepivacaine Anesthetics Anesthetics, Local high low low  D000008619 Mepivacaine Allogenic Mesenchymal Stromal Cells Mepivacaine Mesenchymal stem cells (MSC) MSC injection MSV (MSV=MSC prepared following Valladolid IBGM procedure) Sham-treated comparator Mepivacaine is also known as Carbocaine Mepivacaine is also known as Polocaine Biological Drug",1,25
228,Biological: Subchondral and intra-articular injection of BMC Single Group Assignment    Bone Marrow Concentrate       Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis   Subchondral and intra-articular injection of BMC  Biological,1,25
229,Procedure: PTA Biological: PTA + Infusion of MSC_Apceth Parallel Assignment    Group A Group B       percutaneous transluminal angioplasty followed by infusion of MSC_Apceth percutaneous transluminal angioplasty only   PTA + Infusion of MSC_Apceth PTA  Biological Procedure,1,25
230,Procedure: Bone Marrow Aspiration Procedure: Bone marrow mesenchymal stem cell implantation Single Group Assignment    Single Single CNSDep All Coag Central Nervous System Depressants All Drugs and Chemicals Coagulants  M3259 M17443 Anesthetics Fibrin Tissue Adhesive low low Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place   Bone Marrow Aspiration Bone marrow mesenchymal stem cell implantation Bone marrow Biopsy Autologous stem cell implantation for cartilage repair Procedure Procedure,1,25
231,"Gast All Gastrointestinal Agents All Drugs and Chemicals  M5317 Cimetidine low The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.   BioCue Concentration Kit  Device",1,25
232,Single Group Assignment              Mesenchymal Stem Cell Infusion  Drug,1,25
233,"Drug: Autologous Bone Marrow Aspirate Concentrate Drug: Sterile saline Single Group Assignment    Autologous bone marrow concentrate Placebo       Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees. Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.   Autologous Bone Marrow Aspirate Concentrate Sterile saline  Drug Drug",1,25
234,"Procedure: Adipose tissue collection Biological: Transdermal injection Procedure: Transdermal injection Parallel Assignment    Test Test Control All CNSDep All Drugs and Chemicals Central Nervous System Depressants  M9030 M3259 Hyaluronic Acid Anesthetics low low Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.  The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia. Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid. Transdermal injection of hyaluronic acid only.   Adipose tissue collection Transdermal injection Transdermal injection  Procedure Biological Procedure",1,25
235,"Biological: Human Umbilical Cord derived MSCs Drug: Cyclophosphamide Parallel Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Human Umbilical Cord derived MSCs Cyclophosphamide ANeo ARhu All Antineoplastic Agents Antirheumatic Agents All Drugs and Chemicals Tablet M5879 M9364 M9353 M19757 M20095 M2972 Cyclophosphamide Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents high low low low low low Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis D000003520 Cyclophosphamide Human Umbilical Cord derived MSCs Cyclophosphamide Allogeneic stem cells derived from umbilical cord Immunosupressive agent Biological Drug",1,25
236,no intervention   no intervention  Other,1,25
237,Genetic: autologous mesenchymal stem cell transplantation Single Group Assignment    autologous mesenchymal stem cell transplantation Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Every patient is given 1x106 MSCs per kg infused via peripheral vein.   autologous mesenchymal stem cell transplantation  Genetic,1,25
238,Genetic: Allogeneic Mesenchymal Precursor Cells (MPCs) Procedure: Standard-of-care treatment with NOGA® mapping and staged injections. Genetic: Allogeneic Mesenchymal Precursor Cells (MPCs) Procedure: Standard-of-care treatment with NOGA® mapping and staged injections. Genetic: Allogeneic Mesenchymal Precursor Cells (MPCs) Procedure: Standard-of-care treatment with NOGA® mapping and staged injections. Parallel Assignment    A1 A2 B1 B2 C1 C2       25 M allogeneic MPCs by transendocardial injection Standard-of-care treatment with NOGA® mapping and staged injections. 75 M allogeneic MPCs by transendocardial injection Standard-of-care treatment with NOGA® mapping and staged injections. 150 M allogeneic MPCs by transendocardial injection Standard-of-care treatment with NOGA® mapping and staged injections.   Allogeneic Mesenchymal Precursor Cells (MPCs) Standard-of-care treatment with NOGA® mapping and staged injections. Allogeneic Mesenchymal Precursor Cells (MPCs) Standard-of-care treatment with NOGA® mapping and staged injections. Allogeneic Mesenchymal Precursor Cells (MPCs) Standard-of-care treatment with NOGA® mapping and staged injections.  Genetic Procedure Genetic Procedure Genetic Procedure,1,25
239,"Biological: JOINTSTEM Drug: Saline solution Parallel Assignment    Jointstem Saline solution PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Jointstem (Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml), 1 time injection Saline solution (Sodium chloride 9mg/ml), 1 time injection   JOINTSTEM Saline solution Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml Sodium chloride 9mg/ml Biological Drug",1,24
240,Biological: Autologous mesenchymal stem cell transplantation Single Group Assignment    Autologous MSC transplantation       A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion   Autologous mesenchymal stem cell transplantation  Biological,1,24
241,Biological: mesenchymal stem cells Other: standard treatment Biological: limbal stem cells Other: standard treatment Other: standard treatment Parallel Assignment    mesenchymal stem cells limbal stem cells control limbal stem cells mesenchymal stem cells All PhSol All Drugs and Chemicals Pharmaceutical Solutions  M9030 M21013 Hyaluronic Acid Pharmaceutical Solutions low low Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution Standard treatment according to the Clinical protocols   mesenchymal stem cells limbal stem cells standard treatment  Biological Biological Other,1,25
242,Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml Parallel Assignment    Autologous Adipose Tissue derived MSCs PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low biological : Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml drug: saline solution   Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml JOINTSTEM Biological,1,26
243,Drug: JointStem Drug: Synvisc-One Parallel Assignment  D000055675 D000020011 D000045505 Viscosupplements Protective Agents Physiological Effects of Drugs JointStem Synvisc-One All All Drugs and Chemicals Hepatitis A M9030 M250495 M27448 M21022 Hyaluronic Acid Hylan Viscosupplements Protective Agents low high low low  C000049816 Hylan JointStem Synvisc-One Active Comparator Drug Drug,1,28
244,Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS Parallel Assignment    Experimental       Two doses of 80 million adipose-tissue derived mesenchymal stem cells   ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS  Drug,1,26
245,"Biological: ReJoinTM Drug: Sodium Hyaluronate Crossover Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents ReJoinTM Group Sodium Hyaluronate Group All All Drugs and Chemicals PCOS M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low adipose derived mesenchymal progeinitor cells Sodium Hyaluronate Injection D000006820 Hyaluronic Acid ReJoinTM Sodium Hyaluronate adipose derived mesenchymal progenitor cells Artz Biological Drug",1,28
246,Biological: Cartistem Biological: Cartistem Parallel Assignment    Cartistem standard treatment HB All Herbal and Botanical All Drugs and Chemicals  T63 Astragalus low Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.   Cartistem  Biological,1,28
247,Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA Single Group Assignment    Treatment (iExosomes) Gast All Gastrointestinal Agents All Drugs and Chemicals  M21707 M12266 Pancrelipase Pancreatin low low Given IV   Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA MSC-derived Exosomes with KrasG12D siRNA (SY); KrasG12D siRNA-loaded Mesenchymal Stromal Cells-derived Exosomes (SY) Drug,1,28
248,"Biological: autologous mesenchymal stem cells Single Group Assignment    Autologous Mesenchymal Stem Cells       There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:  Group 1: single intrathecal dose of 1 x 107 cells Group 2: single intrathecal dose of 5 x 107 cells Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells Group 4: single intrathecal dose of 1 x 108 cells Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells   autologous mesenchymal stem cells  Biological",1,27
249,Biological: Mesenchymal stem cell Single Group Assignment    Mesenchymal stem cell Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.  Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1.   Mesenchymal stem cell  Biological,1,27
250,"Biological: normal saline Biological: autologous mesenchymal stem cells Parallel Assignment    autologous mesenchymal stem cells normal saline       4*107 stem cell (100ml) Intra arterial infusion/ one time, then 4*107 stem cell(100ml)Intravenous infusion 3 times/monthly  -> Total four times saline   autologous mesenchymal stem cells normal saline  Biological Biological",1,27
251,"Drug: Umbilical Mesenchymal Stem Cells derived Exosomes Single Group Assignment    UMSC-exo treatment PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M29659 Lubricant Eye Drops low Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.   Umbilical Mesenchymal Stem Cells derived Exosomes UMSC-exo Drug",1,27
252,Procedure: Injection of autologous adipose tissue in anal fistula Single Group Assignment    Injection with adipose tissue          Injection of autologous adipose tissue in anal fistula  Procedure,1,27
253,Procedure: Stem Cell with Amniotic Membrane Transplant Procedure: Stem Cell with Amniotic Membrane Transplant Parallel Assignment    Allogenic limbal stem cell Transplant Bone Marrow mesenchymal stem cell       Single stem cell expansion in amniotic membrane transplant   Stem Cell with Amniotic Membrane Transplant  Procedure,1,27
254,Biological: mesenchymal stem cells Other: standard treatment Other: standard treatment Parallel Assignment    mesenchymal stem cells control mesenchymal stem cells       autologous mesenchymal stem cells standard treatment according to clinical protocols   mesenchymal stem cells standard treatment  Biological Other,1,27
255,"Other: CONVENTIONAL PHYSICAL THERAPY Other: MUSCLE ENERGY TECHNIQUE Parallel Assignment    CONVENTIONAL PHYSICAL THERAPY MUSCLE ENERGY TECHNIQUE       High frequency TENS for 10 mins, 3 days/week Ankle pumps for blood circulation 10 repetitions x1 set, 3 days/week. Heel slides10 repetitions x1 set, 3 days/week. Open chain knee flexion and extension 10 repetitions x1 set, 3 days/week. SLR (straight leg raise) 10 repetitions x1 set, 3 days/week. Calf stretch 10 repetitions x1 set, 3 days/week. Quad set 10 repetitions x1 set, 3 days/week.  Total 6 sessions each consisting of 30-45 minutes Experimental group treated by applying Muscle energy technique along conventional physical therapy.  For MET patient is positioned at maximal comfort and lengthening while engaging the barrier and then patient is asked to perform isometric contraction with 6-10 sec hold and then release and lengthen the muscle 4-5 repetition x 1 set, 3days/week Total 6 sessions each consisting of 30-45 minutes   CONVENTIONAL PHYSICAL THERAPY MUSCLE ENERGY TECHNIQUE  Other Other",1,26
256,"Other: Bone marrow mesenchymal stem cells autologous Other: Placebo comparator Crossover Assignment    Experimental Placebo Comparator PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg Lactated Ringer's solution, 2.5% glucose and 1% human albumin.   Bone marrow mesenchymal stem cells autologous Placebo comparator  Other Other",1,26
257,Biological: AlloRx Stem Cells® Other: Placebo control Parallel Assignment Randomized Placebo Controlled Double Blinded   Intervention Arm 1 Intervention Arm 2       Umbilical cord-derived allogeneic mesenchymal stem cells Placebo infusion without mesenchymal stem cells   AlloRx Stem Cells® Placebo control  Biological Other,1,26
258,"Biological: Cultured autologous Mesenchymal Cells Single Group Assignment    Cultured autologous Mesenchymal Cells       Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.   Cultured autologous Mesenchymal Cells  Biological",1,26
259,"Procedure: UC-MSCs therapy Single Group Assignment treatment of infertility caused by recurrent intrauterine adhesions by collagen scaffold loaded with UC-MSCs   UC-MSCs therapy All Repr All Drugs and Chemicals Reproductive Control Agents  M13397 M7260 M266205 M266206 M234941 Progesterone Estradiol Estradiol 17 beta-cypionate Estradiol 3-benzoate Polyestradiol phosphate low low low low low Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.   UC-MSCs therapy  Procedure",1,26
260,Biological: Suspension of human autologous MSC 3P in 1.5 ml Single Group Assignment    Autologous Multipotent MSC       Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension   Suspension of human autologous MSC 3P in 1.5 ml  Biological,1,26
261,Biological: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension Biological: normal saline Single Group Assignment A package of 100ml normal saline with 10^6/kg umbilical cord derived MSCs suspension will infused from central venous catheter.   UCMSCs group UCMSCs group       Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours. A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.   umbilical cord derived mesenchymal stem cells (UCMSCs) suspension normal saline  Biological Biological,1,26
262,Biological: High concentration of Allo-ASC Drug: Fibrin glue Biological: Low concentration of Allo-ASC Drug: Fibrin glue Drug: Fibrin glue Drug: Normal saline Parallel Assignment  D000006490 D000003029 Hemostatics Coagulants High concentration of Allo-ASC group Low concentration of Allo-ASC group High concentration of Allo-ASC group Low concentration of Allo-ASC group Placebo Comparator (Fibrin) group Placebo Comparator (Fibrin) group PhSol All Coag Pharmaceutical Solutions All Drugs and Chemicals Coagulants Isoflurane M21013 M17443 M8728 M5411 Pharmaceutical Solutions Fibrin Tissue Adhesive Hemostatics Coagulants low high low low 10 million cells of Allo-ASC 0.5cc 1 million cells of Allo-ASC 0.5cc Fibrin glue 0.5cc Normal saline 0.5cc D000015718 Fibrin Tissue Adhesive High concentration of Allo-ASC Low concentration of Allo-ASC Fibrin glue Normal saline Fibrin sealant 0.9% Sodium Chloride Solution Biological Biological Drug Drug,1,30
263,Biological: Human umbilical cord mesenchymal stem cells（HUC-MSCs） Biological: Placebo Parallel Assignment    HUC-MSCs Group Control Group       Human umbilical cord mesenchymal stem cells（HUC-MSCs） Placebo   Human umbilical cord mesenchymal stem cells（HUC-MSCs） Placebo  Biological Biological,1,30
264,"Biological: carrier plus in vitro expanded autologous BMSCs Biological: carrier plus in vitro expanded autologous BMSCs Parallel Assignment    carrier alone (control). carrier plus BMSCs       The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container   carrier plus in vitro expanded autologous BMSCs  Biological",1,35
265,Device: Medical Collagen Membrane with MSC Device: Medical Collagen Membrane Parallel Assignment    Medical Collagen Membrane with MSC Medical Collagen Membrane          Medical Collagen Membrane with MSC Medical Collagen Membrane  Device Device,1,30
266,"Biological: Mesenchymal Stem Cells Biological: Mesenchymal Stem Cells Crossover Assignment    Autologous Mesenchymal Stem Cells Suspension media All PhSol All Drugs and Chemicals Pharmaceutical Solutions  M6457 M85407 Dimethyl Sulfoxide Plasma-lyte 148 low low Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.  Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product).   Mesenchymal Stem Cells  Biological",1,31
267,"Biological: allo-APZ2-CVU Single Group Assignment Interventional, single arm, multicenter, phase I/IIa clinical trial   allo-APZ2-CVU       Suspension of ABCB5-positive mesenchymal stem cells   allo-APZ2-CVU  Biological",1,31
268,"Biological: SVF Containg Autologous Non Expanded ADSC Single Group Assignment Participants will be placed in a single group. Those having a harvested total ""Adipose Derived Stem Cell (ADSC)"" count (in 5 ml SVF solution) above 1 x 10^6 will be included in the study and they will be studied for Phase I/ Phase II trial by the proposed outcome measures over the stipulated time frame.  Those having a harvested total ""Adipose Derived Stem Cell (ADSC)"" count (in 5 ml SVF solution) less than 1 x 10^6 will be excluded from the study.   Group A PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low 5 ml of SVF containing Autologous Non Expanded ADSC will be injected intravenously and outcome will be observed over the period of 1(one) year.   SVF Containg Autologous Non Expanded ADSC  Biological",1,31
269,"Biological: NeuroRegen scaffold/mesenchymal stem cells transplantation Biological: NeuroRegen scaffold/neural stem cells transplantation Parallel Assignment    NeuroRegen scaffold/mesenchymal stem cells transplantation NeuroRegen scaffold/neural stem cells transplantation       Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures. Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.   NeuroRegen scaffold/mesenchymal stem cells transplantation NeuroRegen scaffold/neural stem cells transplantation  Biological Biological",1,30
270,"Drug: Hyaluronic acid Drug: Hyaluronic acid Biological: 10 million Bone marrow mesenchimal stem cells Drug: Hyaluronic acid Biological: 100 million Bone marrow mesenchimal stem cells Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Hialuronic acid Hyaluronic acid AND MSC 100 Hyaluronic acid and MSC 10 Hyaluronic acid and MSC 10 Hyaluronic acid AND MSC 100 All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million of Bone marrow mesenchimal stem cells 100 million of Bone marrow mesenchimal stem cells D000006820 Hyaluronic Acid Hyaluronic acid 10 million Bone marrow mesenchimal stem cells 100 million Bone marrow mesenchimal stem cells HyalOne Drug Biological Biological",1,30
271,"Biological: BM-MSCs/fibrin glue/collagen fleece Other: Fibrin glue/collagen fleece Procedure: Open flap debridement Parallel Assignment  D000006490 D000003029 Hemostatics Coagulants Group A Group B Group C Coag All Coagulants All Drugs and Chemicals Isoflurane M17443 M11052 M8728 M5411 Fibrin Tissue Adhesive Mitogens Hemostatics Coagulants high low low low Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece. The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials D000015718 Fibrin Tissue Adhesive BM-MSCs/fibrin glue/collagen fleece Fibrin glue/collagen fleece Open flap debridement Procedure/Surgery/Growth factors Biological Other Procedure",1,30
272,"Biological: Human Umbilical Cord Derived MSC Single Group Assignment    Human Umbilical Cord Derived MSC       1×10^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days   Human Umbilical Cord Derived MSC UC-MSC Biological",1,30
273,Other: Biological: Cell-based therapy Single Group Assignment    Autologous BM-MSCs injection       Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.   Biological: Cell-based therapy  Other,1,30
274,"Other: Allogenic mesenchymal stromal cells injection Drug: Hyaluronic Acid Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Allogenic mesenchymal stromal cells injection Hyaluronic acid (Durolane) All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml) D000006820 Hyaluronic Acid Allogenic mesenchymal stromal cells injection Hyaluronic Acid MSV Mesenchymal Stem Cells MSC Hyaluronic acid, durolane, CE mark:516407 Other Drug",1,30
275,Procedure: Micro-fragmented adipose tissue injection Single Group Assignment Interventional pilot study   MF-AT injection       Intra-articular ultrasound-guided injection of MF-AT   Micro-fragmented adipose tissue injection  Procedure,1,30
276,Biological: Mesenchymal Precursor Cells (MPCs) Biological: Mesenchymal Precursor Cells (MPCs) Parallel Assignment    Cohort 1 Cohort 2       Single Intravenous Infusion of MPCs Dose 1 or Placebo Single Intravenous Infusion of MPCs Dose 2 or Placebo   Mesenchymal Precursor Cells (MPCs) Mesenchymal Precursor Cells (MPCs)  Biological Biological,1,30
277,Biological: Adipose Tissue derived Total-Stromal-Cells (TOST) Parallel Assignment    Adipose Tissue derived Total-Stromal-Cells (TOST)       Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.   Adipose Tissue derived Total-Stromal-Cells (TOST)  Biological,1,30
278,"Biological: UCMSC group Other: Control group(Normal saline) Parallel Assignment    UCMSC group Control group(Normal saline)       Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10^6/kg) ,once every week，a total of three times. Normal saline in same volume as MSCs are transplanted to patients.   UCMSC group Control group(Normal saline)  Biological Other",1,30
279,"Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation Parallel Assignment Patients with recent onset type 1 diabetes wil receive an dose of allogenic adipose tissue-derived stem/stromal cells (ASCs) and oral Cholecalciferol UI/day for 24 months. D000077264 D000045505 D000014815 D000018977 D000050071 Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Vitamins Micronutrients Bone Density Conservation Agents Adipose tissue-derived stem/stromal cells Daily 2000 UI of daily oral cholecalciferol All BDCA Micro Hypo Vi All Drugs and Chemicals Bone Density Conservation Agents Micronutrients Hypoglycemic Agents Vitamins Cell lymphoma Cell lymphoma Cell lymphoma Cell lymphoma Cell lymphoma M4533 M9336 M16702 M8941 M9517 M172956 M3377 M4550 M5155 M16710 M9093 M4527 M20162 M16037 T479 T440 T442 Calcium Immunoglobulins Vitamin D Hormones Insulin Insulin, Globin Zinc Antibodies Calcium, Dietary Cholecalciferol Vitamins Hydroxycholecalciferols Calcifediol Micronutrients Trace Elements Vitamin D3 Calciferol Cholecalciferol low low high low low low low low high low low low low low high high high The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 [T3], 6 [T6], 12 [T12], 18 [T18], and 24 [T24] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D. D000002762 D000014807 Cholecalciferol Vitamin D Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation  Biological",1,30
280,Biological: BM-MSC transplantation Single Group Assignment    BM-MSC       Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.   BM-MSC transplantation  Biological,1,30
281,"Genetic: Allogeneic MSC Drug: Placebo Genetic: Allogeneic MSC Drug: Placebo Parallel Assignment Randomisation (2:1) will allocate 30 patients to two treatment groups. The first group will receive either 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv or placebo (consisting of a 5% DMSO-solution in isotonic solution) at week 4 and 3 before the second LVRS. The second group will receive either the same dose of 2 x 10^6/kg body weight MSC iv or placebo at week 12 and 11 before the second LVRS.   MSC week 12 and 11 before LVRS2 MSC week 4 and 3 before LVRS2 Placebo week 12 and 11 before LVRS2 Placebo week 4 and 3 before LVRS2 PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low These MSCs will originate from bone marrow that will be aspirated from healthy volunteer donors screened by a trained physician of the center for stem cell therapy of LUMC The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%   Allogeneic MSC Placebo  Genetic Drug",1,30
282,"Genetic: intracerebral stem cell transplantation Parallel Assignment    intracerebral stem cell transplantation       Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient   intracerebral stem cell transplantation  Genetic",1,30
283,Drug: Group 2: Dasatinib Drug: Group 2: Quercetin Parallel Assignment  D000000970 D000047428 D000004791 D000045504 D000000975 D000020011 D000045505 Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antioxidants Protective Agents Physiological Effects of Drugs Group 2: Dasatinib & Quercetin Group 2: Dasatinib & Quercetin ANeo All Fl Antineoplastic Agents All Drugs and Chemicals Flavonoid Inhaled IRI IRI M410 M13796 M24973 M3444 M21022 T41 Dasatinib Quercetin Protein Kinase Inhibitors Antioxidants Protective Agents Quercetin high high low low low high Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days. Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days. D000069439 D000011794 Dasatinib Quercetin Group 2: Dasatinib Group 2: Quercetin Sprycel Drug Drug,1,30
284,Genetic: Autologous mesenchymal stem cells Genetic: Autologous mesenchymal stem cells Parallel Assignment    2 3 PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume<100ml) less than 6 weeks after stroke   Autologous mesenchymal stem cells  Genetic,1,31
285,"Biological: Auto-hMSCs Biological: Allo-hMSCs Parallel Assignment    Auto-hMSCs Allo-hMSCs       Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter. Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.   Auto-hMSCs Allo-hMSCs  Biological Biological",1,31
286,Biological: stem cell Single Group Assignment    Mesenchymal stromal cell       mesenchymal stromal cell   stem cell  Biological,1,31
287,"Drug: Prochymal® - 2 Million cells/kg Drug: Methylprednisolone Drug: Prednisone Drug: Cyclosporine Drug: Tacrolimus Drug: Mycophenolate Mofetil Drug: Prochymal®- 8 Million cells/kg Drug: Methylprednisolone Drug: Prednisone Drug: Cyclosporine Drug: Tacrolimus Drug: Mycophenolate Mofetil Parallel Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000018931 D000000970 D000007166 D000007155 D000065095 D000004791 D000045504 D000000935 D000000890 D000003879 D000018501 D000000903 D000000904 D000000995 D000000900 D000000932 D000001337 D000018373 D000005765 D000018696 D000020011 D000000998 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Calcineurin Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents Antiviral Agents Prochymal® - 2 Million cells/kg Prochymal® - 8 Million cells/kg Prochymal® - 2 Million cells/kg Prochymal® - 8 Million cells/kg Prochymal® - 2 Million cells/kg Prochymal® - 8 Million cells/kg Prochymal® - 2 Million cells/kg Prochymal® - 8 Million cells/kg Prochymal® - 2 Million cells/kg Prochymal® - 8 Million cells/kg Prochymal® - 2 Million cells/kg Prochymal® - 8 Million cells/kg Infe ARhu Derm All ANeo Infl AnEm NeuroAg Gast Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Antineoplastic Agents Anti-Inflammatory Agents Antiemetics Neuroprotective Agents Gastrointestinal Agents Impact Impact Bolus Neck Cardiac Until 1440 M18113 M5882 M11280 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M18102 M13273 M186752 M3369 M8199 M8941 M8940 M20119 M9364 M9353 M29605 M3406 M5404 M10948 M3366 M6226 M19757 M3374 M3376 M3463 M3403 M8033 M19926 M21022 M3466 Cyclosporine Cyclosporins Mycophenolic Acid Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Tacrolimus Prednisone Remestemcel-l Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Antineoplastic Agents, Hormonal Immunosuppressive Agents Immunologic Factors Calcineurin Inhibitors Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents Antiemetics Gastrointestinal Agents Neuroprotective Agents Protective Agents Antiviral Agents high high high low low high low low low low high high high low low low low low low low low low low low low low low low low low low low low low low 2 million hMSCs/kg actual body weight, IV on study Days 1 and 4 8 million hMSCs/kg actual body weight IV on study Days 1 and 4 Methylprednisolone 2 mg/kg administered intravenously. Prednisone 2.5 mg/kg administered orally. Administered as prescribed by the caregiver. Administered as prescribed by the caregiver. Administered as prescribed by the caregiver. D000016572 D000009173 C000711674 D000011241 D000008775 D000016559 D000003524 Cyclosporine Mycophenolic Acid Remestemcel-l Prednisone Methylprednisolone Tacrolimus Cyclosporins Prochymal® - 2 Million cells/kg Prochymal®- 8 Million cells/kg Methylprednisolone Prednisone Cyclosporine Tacrolimus Mycophenolate Mofetil Remestemcel-L ex-vivo cultured adult human mesenchymal stem cells hMSCs Remestemcel-L ex-vivo cultured adult human mesenchymal stem cells hMSCs Drug Drug Drug Drug Drug Drug Drug",1,32
288,"Other: Cartilage repair surgery Single Group Assignment First in man surgery: autologous chondrons are mixed with allogeneic MSCs and implanted in a fibrin glue carrier in a one-stage surgical procedure.   Cartilage repair surgery Coag All Coagulants All Drugs and Chemicals  M17443 Fibrin Tissue Adhesive low Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs   Cartilage repair surgery Single-stage Cartilage repair IMPACT Other",1,35
289,Procedure: blood samples Procedure: blood samples     liver transplant patients Liver resection patients Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low liver transplant patients will have (5) 3cc blood samples drawn at specific time points. liver resection patients will have (3) 3cc. blood samples drawn at specific time points   blood samples blood samples  Procedure Procedure,1,35
290,"Drug: Prednisone and cyclosporine or primary therapies Biological: Mesenchymal stem cell (MSC) Parallel Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000018931 D000000970 D000004791 D000045504 D000007166 D000007155 D000000935 D000000890 D000003879 D000018501 D000065095 D000000903 D000000904 D000000995 D000000900 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Mesenchymal stem cell (MSC) Control group Infe ARhu Derm All ANeo Infl AnEm NeuroAg Gast Repr Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Antineoplastic Agents Anti-Inflammatory Agents Antiemetics Neuroprotective Agents Gastrointestinal Agents Reproductive Control Agents Bavencio Bavencio Approved Oxaliplatin Until M18113 M5882 M11280 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M18102 M10855 M13273 M9364 M3369 M8199 M8941 M8940 M20119 M9353 M3406 M5404 M10948 M3366 M6226 M19757 M29605 M3374 M3376 M3463 Cyclosporine Cyclosporins Mycophenolic Acid Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Tacrolimus Methotrexate Prednisone Immunosuppressive Agents Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Antineoplastic Agents, Hormonal Immunologic Factors Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents high high high low low low low low low low high low high low low low low low low low low low low low low low low low low low Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).  Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus  Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.) D000016572 D000009173 D000011241 D000003524 D000016559 Cyclosporine Mycophenolic Acid Prednisone Cyclosporins Tacrolimus Mesenchymal stem cell (MSC) Prednisone and cyclosporine or primary therapies Medrol Sandimmun Neoral FK506,prograf Cellcept MTX Medral Sandimmun Neoral FK506,Prograf Cellcept,MMF MTX Biological Drug",1,52
291,"Device: Zephyr Endobronchial Valve Biological: Marrow-derived mesenchymal stromal cell Device: Zephyr Endobronchial Valve Parallel Assignment    Endobronchial valve Endobronchial valve + marrow-derived mesenchymal stromal cell Endobronchial valve + marrow-derived mesenchymal stromal cell Infl All Infe Anti-Inflammatory Agents All Drugs and Chemicals Anti-Infective Agents  M3369 M3366 Anti-Inflammatory Agents Anti-Infective Agents low low Endoscopic lung volume reduction therapy. Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.   Zephyr Endobronchial Valve Marrow-derived mesenchymal stromal cell  Device Biological",1,34
292,Biological: Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation Parallel Assignment A Matched Control Prospective Study   Umbilical cord blood - derived mesenchymal stem cells Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia   Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation  Biological,1,34
293,Other: total or subtotal gastrectomy     prognostic factors of gastrointestinal stromal tumors       resection of the gastric tumor   total or subtotal gastrectomy  Other,1,34
294,Biological: Longeveron Mesenchymal Stem Cells Biological: Longeveron Mesenchymal Stem Cells Biological: Placebo Parallel Assignment    Cohort 1 Cohort 2 Cohort 3 PhSol All ANeo Pharmaceutical Solutions All Drugs and Chemicals Antineoplastic Agents  M85407 M8814 Plasma-lyte 148 Altretamine low low via peripheral intravenous infusion via peripheral intravenous infusion   Longeveron Mesenchymal Stem Cells Placebo  Biological Biological,1,33
295,Biological: FURESTEM-RA Inj Other: sterile saline Parallel Assignment    FURESTEM-RA Inj. Placebo Comparator: Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.  Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.  Dose level 1: 5.0 x 10^7 cells /body 3 repeated intravenous injection at 4 week intervals Dose level 2: 1.0 x 10^8 cells /body 3 repeated intravenous injection at 4 week intervals sterile saline 3 repeated intravenous injection at 4 week intervals  Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.  Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.   FURESTEM-RA Inj sterile saline  Biological Other,1,33
296,Other: Mesenchymal stem cells from adipose tissue Other: Mesenchymal stem cells from adipose tissue Parallel Assignment    High dose Low dose       - Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.   Mesenchymal stem cells from adipose tissue  Other,1,33
297,"Drug: Autologous adipose derived mesenchymal stem cells Drug: Autologous adipose derived mesenchymal stem cells Parallel Assignment    Mesenchymal stem cells 0,5 million * weight (kg) Mesenchymal stem cells 1 million * weight (kg)       Intra-arterial administration through a selective cannulation of target common femoral artery   Autologous adipose derived mesenchymal stem cells  Drug",1,33
298,Procedure: Non-cultured Autologous Keratinocyte Suspension Procedure: Adipose-Derived Stem cell-Keratinocyte Suspension Procedure: Split skin graft Parallel Assignment    study group 1 study group 2 Control group       New method for treatment of post-burn raw area New method for treatment of post-burn raw area Traditional method for treatment of post-burn raw area   Non-cultured Autologous Keratinocyte Suspension Adipose-Derived Stem cell-Keratinocyte Suspension Split skin graft  Procedure Procedure Procedure,1,33
299,Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells Other: Standard treatment according to the Clinical protocols Other: Standard treatment according to the Clinical protocols Parallel Assignment    mesenchymal stem cells control mesenchymal stem cells       Allogenic pooled olfactory mucosa-derived mesenchymal stem cells Standard treatment according to the Clinical protocols   Allogenic pooled olfactory mucosa-derived mesenchymal stem cells Standard treatment according to the Clinical protocols  Biological Other,1,32
300,"Other: Intravenous infusion of cells Other: Intravenous infusion of cells Other: Intravenous infusion of cells Other: Intravenous infusion of cells Parallel Assignment    First arm Fourth arm Second arm Third arm PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low The treatment administration will be infused intravenously to the subjects after randomization:  An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator.   Intravenous infusion of cells  Other",1,32
301,Biological: ASC enriched lipofilling Biological: Standard Lipofilling Parallel Assignment    ASC Control       Fat grafts enriched with ex vivo expanded ASC Non-ASC enriched fat grafts   ASC enriched lipofilling Standard Lipofilling  Biological Biological,1,32
302,"Drug: Cyclophosphamide Drug: Fludarabine Drug: Anti-thymocyte globulin Drug: Cyclosporine A Drug: Mycophenolate mofetil Procedure: Mesenchymal stem cell transplantation Radiation: Total body irradiation Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation Single Group Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 D000004791 D000000935 D000000890 D000003879 D000065095 D000000903 D000000904 D000000995 D000000900 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Enzyme Inhibitors Antifungal Agents Anti-Infective Agents Dermatologic Agents Calcineurin Inhibitors Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Transplant in Epidermolysis Bullosa Transplant in Epidermolysis Bullosa Transplant in Epidermolysis Bullosa Transplant in Epidermolysis Bullosa Transplant in Epidermolysis Bullosa Transplant in Epidermolysis Bullosa Transplant in Epidermolysis Bullosa Transplant in Epidermolysis Bullosa Infe ARhu Derm All ANeo CNSDep Ot Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Antineoplastic Agents Central Nervous System Depressants Other Dietary Supplements Impact Impact Bolus Under Tablet Training program M18113 M5882 M11280 M283219 M5879 M4006 M225481 M3431 M9364 M9353 M19757 M20095 M2972 M3406 M5404 M10948 M3366 M6226 M29605 M3374 M3376 M3463 T433 Cyclosporine Cyclosporins Mycophenolic Acid Fludarabine Cyclophosphamide Benzocaine Fludarabine phosphate Antilymphocyte Serum Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Calcineurin Inhibitors Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents Tannic Acid high high high high high low low high low low low low low low low low low low low low low low low Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6. 40 mg/m^2/day intravenously on Days -6, -5, -4, -3 and -2. 30 mg/kg on Days -4, -3 and -2. Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children. 15 mg/kg intravenous twice per day on days -3 through 30. infused via intravenous drip on Day 0 300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus. Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip. D000016572 D000009173 D000003520 C000024352 D000003524 D000000961 Cyclosporine Mycophenolic Acid Cyclophosphamide Fludarabine Cyclosporins Antilymphocyte Serum Cyclophosphamide Fludarabine Anti-thymocyte globulin Cyclosporine A Mycophenolate mofetil Mesenchymal stem cell transplantation Total body irradiation Bone marrow or umbilical cord blood (UCG) stem cell transplantation Cytoxan Fludara ATG CSA CellCept(R) MSCT UCBSCT Drug Drug Drug Drug Drug Procedure Radiation Procedure",1,32
303,"Biological: BMAC injection Biological: PRP injection Device: Gel-One® hyaluronate injection Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents BMAC injection and PRP injection BMAC injection and PRP injection Gel-One® hyaluronate injection All PhSol All Drugs and Chemicals Pharmaceutical Solutions Interdigital M9030 M21013 M2780 M9353 M27448 M21022 Hyaluronic Acid Pharmaceutical Solutions Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low low 60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician. 60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician. Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution [10 mg/mL], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance. D000006820 Hyaluronic Acid BMAC injection PRP injection Gel-One® hyaluronate injection  Biological Biological Device",1,32
304,"Biological: Wharton's jelly derived mesenchymal stem cell Biological: Wharton's jelly derived mesenchymal stem cell Sequential Assignment Prospective, open-label clinical trial; The statistical comparisons were made primarily between the baseline and final values from the same eye. The parametric results for visual functions and structural changes were analyzed.   After application Before application PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .   Wharton's jelly derived mesenchymal stem cell  Biological",1,32
305,Biological: human derived umbilical cord derived mesenchymal stem cells Parallel Assignment    hUC-MSCs treatment       intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells   human derived umbilical cord derived mesenchymal stem cells  Biological,1,30
306,"Biological: MSC Biological: MSC Biological: MSC Parallel Assignment    MSC and insulins MSC and the combination of drugs and insulins MSC and the oral hypoglycemic drugs Hypo All Hypoglycemic Agents All Drugs and Chemicals  M9206 M9517 M172956 M21797 M225598 Hypoglycemic Agents Insulin Insulin, Globin Zinc Acarbose Gliquidone low low low low low 1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.   MSC  Biological",1,30
307,Biological: Allogeneic hMSCs Biological: Allogeneic hMSCs Parallel Assignment    Group 1: 20 million Allogeneic hMSCs Group 2: 100 million Allogeneic hMSCs       Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection   Allogeneic hMSCs Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) Biological,1,30
308,"Drug: Standard therapy of septic shock Genetic: Mesenchymal stromal cells Drug: Standard therapy of septic shock Parallel Assignment    Mesenchymal stromal cells+ standard therapy of septic shock Mesenchymal stromal cells+ standard therapy of septic shock Standard therapy of septic shock Infe All VaCoAg Anti-Infective Agents All Drugs and Chemicals Vasoconstrictor Agents  M3374 M3376 M16561 Anti-Bacterial Agents Antibiotics, Antitubercular Vasoconstrictor Agents low low low MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l). Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids   Mesenchymal stromal cells Standard therapy of septic shock  Genetic Drug",1,30
309,Biological: Mesenchymal stem cells Parallel Assignment    Patients received MSCs       Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.   Mesenchymal stem cells  Biological,1,30
310,Biological: Allogenic mesenchymal stem cells Other: Placebo Parallel Assignment    Allogenic Mesenchymal stem cells Placebo PhSol All Hemat Pharmaceutical Solutions All Drugs and Chemicals Hematinics  M21013 M10262 Pharmaceutical Solutions Liver Extracts low low Cell therapy Serum without stem cells   Allogenic mesenchymal stem cells Placebo  Biological Other,1,30
311,Dietary Supplement: Fisetin Drug: Placebo oral capsule Parallel Assignment    Treatment Placebo Fl All Flavonoid All Drugs and Chemicals Pibrentasvir T28 Fisetin high Flavonoid family Placebo   Fisetin Placebo oral capsule Placebo Dietary Supplement Drug,1,30
312,Drug: XCEL-UMC-BETA Other: Placebo Parallel Assignment    Treatment A Treatment B       Administration on top of the standard administered treatment Administration on top of the standard administered treatment   XCEL-UMC-BETA Placebo WJ-MSC Drug Other,1,30
313,"Procedure: Endoscopic ultrasound guided radiofrequency ablation Single Group Assignment A non-blinded, single center, non-randomized prospective feasibility trial.   EUS guided RFA Hemat All AA Hematinics All Drugs and Chemicals Amino Acids  M10262 T22 Liver Extracts Tyrosine low low Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.   Endoscopic ultrasound guided radiofrequency ablation  Procedure",1,30
314,Other: Autologous mesenchymal stem cells from adipose tissue. Other: Autologous mesenchymal stem cells from adipose tissue. Parallel Assignment    High dose Low dose autologous mesenchymal cells       Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg. Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.   Autologous mesenchymal stem cells from adipose tissue. Autologous mesenchymal stem cells from adipose tissue.  Other Other,1,30
315,Biological: Umbilical Cord Mesenchymal Stem Cells Biological: saline Parallel Assignment    experimental group control group       human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group saline containing human albumin will be infused to the control group   Umbilical Cord Mesenchymal Stem Cells saline  Biological Biological,1,30
316,Drug: 100 million Allogeneic Mesenchymal Human Stem Cells Other: Placebo Parallel Assignment    Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group Group 2: Placebo Group PhSol All ANeo Pharmaceutical Solutions All Drugs and Chemicals Antineoplastic Agents  M85407 M8814 Plasma-lyte 148 Altretamine low low 1 single intravenous infusion Placebo delivered via peripheral intravenous infusion   100 million Allogeneic Mesenchymal Human Stem Cells Placebo allo-human Mesenchymal Stem Cells (hMSCs) stem cells Drug Other,1,30
317,Biological: MSC and Tregs Single Group Assignment    Conventional plus MSC and Tregs treatment Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low conventional plus MSC and Tregs or placebo treatment   MSC and Tregs  Biological,1,30
318,Drug: adipose derived mesenchymal stromal cells Drug: adipose derived mesenchymal stromal cells Drug: Saline Parallel Assignment Double-blind placebo-controlled dose titrating study   Infusion of 100 million ASC Infusion of 200 million ASC Infusion of placebo       Intravenous infusion of cells Intravenous infusion of saline   adipose derived mesenchymal stromal cells Saline CSCC_ASC Drug Drug,1,30
319,Drug: UCMSCC Drug: conventional treatment Drug: conventional treatment Parallel Assignment    MSC MSC conventional       infusion of aUCMSC and conventional therapy conventional treatment   UCMSCC conventional treatment  Drug Drug,1,30
320,"Single Group Assignment           1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.   Human umbilical cord blood-derived mesenchymal stem cells PROMOSTEM® Biological",1,30
321,"Biological: umbilical-cord mesenchymal stromal cells Drug: Hyaluronic Acid Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Umbilical-cord mesenchymal stromal cells Hyaluronic Acid (HA) All PhSol All Drugs and Chemicals Pharmaceutical Solutions Compression M9030 M21013 M2780 M9353 M27448 M21022 Hyaluronic Acid Pharmaceutical Solutions Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low low Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months D000006820 Hyaluronic Acid umbilical-cord mesenchymal stromal cells Hyaluronic Acid UC-MSCs Durolane Biological Drug",1,30
322,"Biological: fibroblast growth factor Biological: Stem cell-derived derived pleiotropic factor Parallel Assignment  D000050258 D000045504 Mitosis Modulators Molecular Mechanisms of Pharmacological Action experimental group control group All All Drugs and Chemicals Due M11052 Mitogens high After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days. After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days. D000008934 Mitogens Stem cell-derived derived pleiotropic factor fibroblast growth factor  Biological Biological",1,30
323,"Biological: mesenchymal stem cell transplantation Other: control Biological: MNC's TRANSPLANTATION Parallel Assignment    mesenchymal stem cell transplantation Control MNC's TRANSPLANTATION Hypo All Micro Hemat Gast Vi Hypoglycemic Agents All Drugs and Chemicals Micronutrients Hematinics Gastrointestinal Agents Vitamins  M10819 M7770 M9517 M172956 M16710 M8195 M26150 M16698 M1693 M1857 T446 T448 T475 Metformin Folic Acid Insulin Insulin, Globin Zinc Vitamins Glucagon Glucagon-Like Peptide 1 Vitamin B Complex Pioglitazone Vildagliptin Folic Acid Folate Vitamin B9 low low low low low low low low low low low low low 20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months . 5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months . 20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .   mesenchymal stem cell transplantation control MNC's TRANSPLANTATION  Biological Other Biological",1,30
324,"Biological: umbilical cord mesenchymal stem cells Single Group Assignment    umbilical cord mesenchymal stem cells       patients were divided into 3 dose treatment groups (6.29 × 107,9.43 × 107 and 14.15 × 107 cells/m2). After 4 and 8 weeks, patients were injected the same number of cells.   umbilical cord mesenchymal stem cells  Biological",1,30
325,Single Group Assignment     Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low    injection of progenitor of hepatocyte drived from Mesenchymal stem cell  Procedure,1,30
326,Biological: cotransplantation of islet and mesenchymal stem cell Single Group Assignment    1       islet of allograft and MSCs of autograft   cotransplantation of islet and mesenchymal stem cell  Biological,1,30
327,Biological: GMSCs and collagen scaffolds Biological: Collagen scaffolds Procedure: Open flap debridement Parallel Assignment    Group A: GMSCs and collagen scaffolds Group B: collagen scaffolds Group C: comparator       Patients in this group were given GMSCs and collagen scaffolds. Patients in this group were given collagen scaffolds. The patients in this group will only receive the treatment of open flap debridement.   GMSCs and collagen scaffolds Collagen scaffolds Open flap debridement  Biological Biological Procedure,1,30
328,"Drug: SF-MSC-EX Drug: SF-MSC Parallel Assignment The study was planned as three arms. One arm will be the control group, and the other two arms will be the experimental group. The control group defines the group that did not receive treatment. Those in the experimental group, who are the participants other than the control group, will occur in both experimental groups. SF-MSC (synovial fluid-derived mesenchymal stem cells) will be applied intraarticularly to the experimental group's right knee, and the experimental group's right knee will be included in the SF-MSC treatment group. SF-MSC-EX (synovial fluid-derived mesenchymal stem cells-derived exosomes) will be applied intraarticularly to the experimental group's left knee, and the experimental group's left knee will be included in the SF-MSC-EX treatment group.   SF-MSC-EX Treatment Group (Experimental group's left knees) SF-MSC Treatment Group (Experimental group's right knees)       Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes Intra-articular administration of synovial fluid-derived mesenchymal stem cells   SF-MSC-EX SF-MSC Intraarticular Exosome Treatment Intraarticular Stem Cell Treatment Drug Drug",1,30
329,"Device: Fractional CO₂ Laser Device: Microneedle Parallel Assignment Each participant will receive fractional CO₂ laser treatment on one side of the face and microneedle treatment on the other half. The allocation of which side receive a particular treatment will be determined by an independent operator.   Secretome + Fractional CO₂ Laser Secretome + Microneedle CNSDep All Derm AnArAg ChanBlk ANeo Central Nervous System Depressants All Drugs and Chemicals Dermatologic Agents Anti-Arrhythmia Agents Channel Blockers Antineoplastic Agents  M3259 M15407 M10166 M16117 M13343 Anesthetics Sunscreening Agents Lidocaine Tretinoin Prilocaine low low low low low Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.6 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables. Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.6 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.   Fractional CO₂ Laser Microneedle  Device Device",1,30
330,"Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose Parallel Assignment    Lower Dose MSC Higher Dose MSC       Two MSC infusions of 2.5x10^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery Two MSC infusions of 5.0x10^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery   Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose  Biological Biological",1,30
331,Biological: HUC-MSCs Biological: Injectable Collagen Scaffold + HUC-MSCs Parallel Assignment    HUC-MSCs Injectable Collagen Scaffold + HUC-MSCs       The subjects will receive intracavernous injection of HUCMSC. The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.   HUC-MSCs Injectable Collagen Scaffold + HUC-MSCs  Biological Biological,1,30
332,"Procedure: Stereotactic Hematoma Evacuation Biological: MSCs Transplantation Biological: Injectable Collagen Scaffold with MSCs Transplantation Parallel Assignment    Stereotactic Hematoma Evacuation MSCs Transplantation Injectable Collagen Scaffold with MSCs Transplantation       Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out. Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out. Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.   Stereotactic Hematoma Evacuation MSCs Transplantation Injectable Collagen Scaffold with MSCs Transplantation  Procedure Biological Biological",1,30
333,"Infl All Anti-Inflammatory Agents All Drugs and Chemicals  M3369 M11052 M17833 Anti-Inflammatory Agents Mitogens Endothelial Growth Factors low low low ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.  This tudy is a follow-up study without intervention.  Other Names:  Allogenic adipose-derived mesenchymal stem cells   ALLO-ASC-DFU  Biological",1,30
334,"Dietary Supplement: Personalized Nutritional Intervention Factorial Assignment    Nutritional Intervention (NI)       Those with malnutrition criteria will also receive a nutritional supplement (e.g. fortimel cubitan, advanced or extra, Nutricia) or another of similar composition, in case of intolerance to the first option. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing.   Personalized Nutritional Intervention  Dietary Supplement",1,30
335,"Biological: epidermal growth factor Biological: mesenchymal stem cell conditioned medium-derived pleiotropic factor Parallel Assignment  D000050258 D000045504 Mitosis Modulators Molecular Mechanisms of Pharmacological Action control group experimental group All All Drugs and Chemicals Due M11052 Mitogens high Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days. Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days. D000008934 Mitogens epidermal growth factor mesenchymal stem cell conditioned medium-derived pleiotropic factor  Biological Biological",1,30
336,"Biological: Autologous adipose-derived mesenchymal stem/stromal cells Other: Placebo Parallel Assignment Long-term follow-up of Randomized controlled trial MESRIX   Autologous Adipose-derived mesenchymal stem cells Placebo       Autologous adipose-derived mesenchymal stem/stromal cells Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%   Autologous adipose-derived mesenchymal stem/stromal cells Placebo  Biological Other",1,30
337,"Biological: Allogeneic adipose-derived stem cells Biological: Allogeneic adipose-derived stem cells Parallel Assignment The Phase 2 study is a randomized, double blind and placebo control study conducted initially in a single clinic facility.   Control Group Study Group       Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue   Allogeneic adipose-derived stem cells Celltex-AdMSCs Biological",1,30
338,"Biological: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells Biological: Placebo Parallel Assignment Phase IIa double-blind randomized controlled trial   MSC Arm Placebo Arm PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.  day 0: 1.10^6 MSC/kg day 3: 0.5. 10^6 MSC/kg day 5: 0.5 . 10^6 MSC/kg Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).   Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells Placebo  Biological Biological",1,30
339,Other: Biological: Cell-based therapy Single Group Assignment    Allogeneic WJ-MSCs injection       Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.   Biological: Cell-based therapy  Other,1,30
340,Drug: UC-MSC infusion Single Group Assignment    UC-MSC infusion       UC-MSC infusion by introvenus   UC-MSC infusion  Drug,1,30
341,Biological: IMS001 Biological: IMS001 Biological: IMS001 Sequential Assignment    High Dose Low Dose Optional Dose       IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).   IMS001  Biological,1,30
342,Biological: bone marrow stem cells (BMC) Biological: tissue repair cells (TRC) Biological: tissue repair cells (TRC) Biological: bone marrow stem cells (BMC) Parallel Assignment    tissue repair cells intraarterial tissue repair cells intramuscular bone marrow stem cells intraarterial bone marrow stem cells intramuscular       expanded bone marrow cells enriched in CD90+ mesenchymal stem cells bone marrow stem cells   tissue repair cells (TRC) bone marrow stem cells (BMC)  Biological Biological,1,30
343,Biological: Mesenchymal Stem Cells Transplantation Biological: Mesenchymal Stem Cells Transplantation Parallel Assignment    Conventional Therapy Conventional Therapy with Add-On MSC therapy       Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals   Mesenchymal Stem Cells Transplantation  Biological,1,30
344,Biological: Human Umbilical Cord Derived MSC Single Group Assignment    Human Umbilical Cord Derived MSC       20 million cells per subject（0.5×10^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months   Human Umbilical Cord Derived MSC Other Name: UC-MSC Biological,1,30
345,"Drug: EXO 1 inhalation Drug: EXO 2 inhalation Drug: Placebo inhalation Parallel Assignment The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.   EXO-1 EXO-2 Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type. Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type. Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).   EXO 1 inhalation EXO 2 inhalation Placebo inhalation  Drug Drug Drug",1,30
346,"Drug: WJ-MSC Drug: Teriparatide Drug: Teriparatide Parallel Assignment  D000077264 D000045505 D000050071 Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Bone Density Conservation Agents WJ-MSC group Teriparatide group WJ-MSC group All BDCA All Drugs and Chemicals Bone Density Conservation Agents Simultaneous M8941 M12346 M20502 M4533 M4550 Hormones Parathyroid Hormone Teriparatide Calcium Calcium, Dietary low low high low low Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.  Other: intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months. subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months. D000019379 Teriparatide WJ-MSC Teriparatide teriparatide Drug Drug",1,30
347,"Drug: Autologous BM-MSC Other: Sham Procedure Parallel Assignment Patients will be randomized in 2 arms of 26 patients and followed up for 12 months.   Autologous BM-MSC injection Sham Procedure CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells anaesthesia, no disc injection, no placebo injection   Autologous BM-MSC Sham Procedure Treated Sham Drug Other",1,52
348,Biological: human umbilical cord mesenchymal stem cells Other: saline Parallel Assignment    experimental group control group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group Saline solution containing human serum albumin will be infused to the control group   human umbilical cord mesenchymal stem cells saline  Biological Other,1,54
349,Other: Intravenous administration of placebo Drug: Intravenous administration of 1 million of MSC Drug: Intravenous administration of 2 million of MSC Drug: Intravenous administration of 4 million of MSC Single Group Assignment    Placebo 1 million of MSC 2 million of MSC 4 million of MSC          Intravenous administration of placebo Intravenous administration of 1 million of MSC Intravenous administration of 2 million of MSC Intravenous administration of 4 million of MSC  Other Drug Drug Drug,1,52
350,"Other: SVFderived MSC transplantations Drug: Basiliximab Parallel Assignment  D000007166 D000007155 D000045505 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs SVF(Stromal Vascular Fraction) derived MSC transprlantation Basiliximab All All Drugs and Chemicals Genotype 1 M1830 M9364 M9353 Basiliximab Immunosuppressive Agents Immunologic Factors high low low infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.  Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab. induction with Basiliximab before kidney transplantation and on POD 4 D000077552 Basiliximab SVFderived MSC transplantations Basiliximab  Other Drug",1,120
351,Drug: Atorvastatin Drug: Atorvastatin Drug: Low dose BMMSC Drug: Atorvastatin Drug: Middle dose BMMSC Drug: Atorvastatin Drug: High dose BMMSC Drug: Atorvastatin Drug: Atorvastatin Drug: Transplantation Drug: Intensive Atorvastatin Drug: Intensive Atorvastatin Drug: Transplantation Factorial Assignment  D000000924 D000000960 D000000963 D000045504 D000057847 D000019161 D000004791 Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors Phase A: Atorvastatin Phase A: High dose BMMSC Phase A: Low dose BMMSC Phase A: Middle dose BMMSC Phase B: Atorvastatin Phase B: Atorvastatin+Transplantation Phase B: Intensive Atorvastatin Phase B: Intensive Atorvastatin+Transplantation Phase A: Low dose BMMSC Phase A: Middle dose BMMSC Phase A: High dose BMMSC Phase B: Atorvastatin+Transplantation Phase B: Intensive Atorvastatin+Transplantation Lipd All Lipid Regulating Agents All Drugs and Chemicals Failure M351 M20308 M3395 M3430 M3433 M28036 Atorvastatin Hydroxymethylglutaryl-CoA Reductase Inhibitors Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Lipid Regulating Agents high low low low low low Routine dose of Atorvastatin therapy Intensive dose of Atorvastatin therapy Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation D000069059 Atorvastatin Atorvastatin Intensive Atorvastatin Low dose BMMSC Middle dose BMMSC High dose BMMSC Transplantation Statin Drug Drug Drug Drug Drug Drug,1,124
352,Biological: PBSC Biological: MSCs Biological: MSCs Parallel Assignment    MSCs&PBSC MSCs MSCs&PBSC          PBSC MSCs  Biological Biological,1,120
353,Biological: neural progenitor cell Biological: Paracrine factors Biological: progenitor cell and paracrine factors Parallel Assignment    Neural progenitor cell Paracrine factors Progenitor cell and paracrine factors       Neural progenitor cells are derived from the same aborted human fetal forebrain. The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times Neural progenitor cells will be received after paracrine factors therapy   neural progenitor cell Paracrine factors progenitor cell and paracrine factors paracrine factor of human mesenchymal stem cells Biological Biological Biological,1,120
354,"Biological: Stem cells Biological: Placebo Parallel Assignment The study is a prospective, double-blinded, randomized, placebo-controlled trial   Stem cell group Placebo group All All Drugs and Chemicals  M6457 Dimethyl Sulfoxide low Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO). Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).   Stem cells Placebo  Biological Biological",1,120
355,"Combination Product: CSWT+BMMSCs Device: CSWT+Sham operation Parallel Assignment S-CURE study has a two-stage design. Stage 1 is an open-labled, lead-in study. 20 participants will be enrolled in this stage. It is conducted to assess the feasibility and safety of the study procedures as well as the bioactivity of the products. Stage 2 is an randomized, placebo controlled study, 100 participants will be enrolled in this stage.   CSWT+BMMSCs CSWT+Sham operation       All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary. Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.   CSWT+BMMSCs CSWT+Sham operation  Combination Product Device",1,120
356,"Other: Conventional treatment Other: Conventional plus UC-MSC treatment Other: Conventional plus PE treatment Other: Conventional plus UC-MSC and PE therapy Parallel Assignment    Conventional plus UC-MSC treatment Conventional plus PE treatment Conventional plus UC-MSC and PE therapy Conventional treatment Infe All Hemat Anti-Infective Agents All Drugs and Chemicals Hematinics  M3466 M10262 Antiviral Agents Liver Extracts low low Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times). Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange. Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.   Conventional plus UC-MSC treatment Conventional plus PE treatment Conventional plus UC-MSC and PE therapy Conventional treatment  Other Other Other Other",1,120
357,"Other: Intravenous normal saline Biological: DB-001 Biological: DB-001 Parallel Assignment Multi-center, double-blinded, placebo-controlled, randomized controlled trial.   Experimental Dose 1 Experimental Dose 2 Placebo       Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles Placebo   DB-001 Intravenous normal saline  Biological Other",1,120
358,Biological: Cotransplant with MSCs Parallel Assignment    MSC+HSC       Co-transplantation of MSCs during allogeneic HSCT   Cotransplant with MSCs  Biological,1,120
359,"Other: Group 1 Other: Group 2 Other: Group 3 Parallel Assignment    Group A Group A Group A Infe All Hemat Anti-Infective Agents All Drugs and Chemicals Hematinics  M3466 M10262 Antiviral Agents Liver Extracts low low Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times). Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times). Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).   Group 1 Group 2 Group 3  Other Other Other",1,120
360,Behavioral: Types of Exercise Behavioral: Types of Exercise Behavioral: Types of Exercise Parallel Assignment comparing 3 exercise interventions to a control (non-exercise) group   Aerobic Type of Exercise Combination Type of Exercise Resistance Type of Exercise       moderate intensity exercise   Types of Exercise  Behavioral,1,160
361,Biological: PBSC Biological: MSCs Single Group Assignment    PBSC & MSCs PBSC & MSCs          PBSC MSCs  Biological Biological,1,120
362,Other: Umbilical cord MSCs Other: 0.9% Saline Parallel Assignment    Umbilical cord MSCs Group Placebo-Controlled Group       Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision. Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.   Umbilical cord MSCs 0.9% Saline  Other Other,1,120
363,Other: BM-MSCs Other: Saline Parallel Assignment    MSCs group Control group       BM-MSCs are from third-party healthy volunteer donors. Saline is the placebo of MSCs in this study.   BM-MSCs Saline allogeneic bone marrow-derived MSCs Other Other,1,120
364,"Biological: Human Mesenchymal Stromal Cells Biological: Cell Reconstitution Media Parallel Assignment For this Phase 2b trial, after informed consent is given, an assignment will be made by computer-generated randomization to administer either hMSCs therapy or placebo with a 1:1 allocation to the hMSCs:placebo arms.   Human Mesenchymal Stromal Cells Cell Reconstitution Media AnCoag BlSubst All Anticoagulants Blood Substitutes All Drugs and Chemicals  M6258 Dextrans low Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL. 300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)   Human Mesenchymal Stromal Cells Cell Reconstitution Media hMSCs Placebo Biological Biological",1,120
365,"Other: bone marrow-derived mesenchymal stem cells Drug: Induction therapy (ATG or Basiliximab) Drug: Maintenance therapy (Low-dose CNI + MPA + steroids) Other: Saline Drug: Induction therapy (ATG or Basiliximab) Drug: Maintenance therapy (Low-dose CNI + MPA + steroids) Parallel Assignment  D000007166 D000007155 D000045505 D000065095 D000004791 D000045504 D000000903 D000000970 D000000904 D000000995 D000000900 D000000890 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Calcineurin Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antibiotics, Antineoplastic Antineoplastic Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents MSCs group Control group Control group MSCs group Control group MSCs group Infe ANeo All Infl Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Anti-Inflammatory Agents POC Cardiac Genotype 1 M11280 M9336 M3377 M18102 M13273 M9364 M3431 M1830 M9353 M29605 M3374 M3376 M3463 M3366 Mycophenolic Acid Immunoglobulins Antibodies Tacrolimus Prednisone Immunosuppressive Agents Antilymphocyte Serum Basiliximab Immunologic Factors Calcineurin Inhibitors Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Infective Agents high low low high low low low high low low low low low low BM-MSCs is harvested from third-party health volunteer donors. Saline as placebo of MSCs ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group. Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group. D000009173 D000016559 D000077552 Mycophenolic Acid Tacrolimus Basiliximab bone marrow-derived mesenchymal stem cells Saline Induction therapy (ATG or Basiliximab) Maintenance therapy (Low-dose CNI + MPA + steroids) BM-MSCs ATG or Basiliximab Low-dose tacrolimus + Mycophenolic acid (MPA) + steroids Other Other Drug Drug",1,120
366,"Drug: Autologous MSCs Drug: Allogenic MSCs Drug: Hyaluronic Acid Parallel Assignment Randomized, Open-label, Clinical Trial comparing 3 active treatments. D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Autologous Mesenchymal Stromal Cells (MSC) Allogenic Mesenchymal Stromal Cells (MSC) Active Control All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Intra-articular injection 40 million/4 ml. Intra-articular injection 40 million/4 ml. Intra-articular injection 60mg / 3 ml . D000006820 Hyaluronic Acid Autologous MSCs Allogenic MSCs Hyaluronic Acid Hyaluronic Acid 20 mg/ml Drug Drug Drug",1,120
367,"Biological: MSC Drug: ""celecoxib"", ""Celebrex®"" Drug: ""celecoxib"", ""Celebrex®"" Parallel Assignment  D000000894 D000018712 D000000700 D000018689 D000018373 D000045505 D000000893 D000018501 D000052246 D000016861 D000004791 D000045504 Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action MSC plus NSAID MSC plus NSAID NSAID Infl ARhu Analg All AnObAg VaCoAg Resp Anti-Inflammatory Agents Antirheumatic Agents Analgesics All Drugs and Chemicals Anti-Obesity Agents Vasoconstrictor Agents Respiratory System Agents SARS- M277 M3369 M12722 M8390 M186171 M3370 M3184 M19939 M19757 M26162 M18361 Celecoxib Anti-Inflammatory Agents Phenylpropanolamine Guaifenesin Chlorpheniramine, phenylpropanolamine drug combination Anti-Inflammatory Agents, Non-Steroidal Analgesics Analgesics, Non-Narcotic Antirheumatic Agents Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors high low low low low low low low low low low human mesenchymal stem cells,1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.  a total of 24 weeks for follow up. non-steroid anti-inflammatory drugs (NSAID):""celecoxib"", ""Celebrex®"" 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up D000068579 Celecoxib MSC ""celecoxib"", ""Celebrex®""  Biological Drug",1,120
368,"Biological: human umbilical cord mesenchymal stem cells Other: standardized treatment Biological: Placebo Other: standardized treatment Parallel Assignment placebo controlled, randomized, double blinded   MSCs group control group MSCs group control group       The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose. Placebo standardized treatment   human umbilical cord mesenchymal stem cells Placebo standardized treatment  Biological Biological Other",1,120
369,Biological: Mesenchymal Stem Cells (MSC) Biological: c-kit+ cells Biological: Mesenchymal Stem Cells (MSC) Biological: c-kit+ cells Biological: Placebo (Plasmalyte A) Parallel Assignment  D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions Combination Cells (MSC and c-kit+ cells) Mesenchymal Stem Cells (MSC) Combination Cells (MSC and c-kit+ cells) c-kit+ cells Placebo (Plasmalyte A) PhSol All Pharmaceutical Solutions All Drugs and Chemicals CAB M85407 M21013 M11966 Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions high low low 15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure) 15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure) 15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure) C000012499 Plasma-lyte 148 Mesenchymal Stem Cells (MSC) c-kit+ cells Placebo (Plasmalyte A) Plasmalyte A Biological Biological Biological,1,125
370,Biological: JOINTSTEM Single Group Assignment    JOINTSTEM       Autologous Adipose Tissue derived MSCs   JOINTSTEM  Biological,1,129
371,"Biological: Human umbilical cord derived CD362 enriched MSCs Biological: Placebo (Plasma-Lyte 148) Parallel Assignment The phase 1 trial is an open label dose escalation pilot study in which cohorts of subjects with moderate to severe ARDS will receive increasing doses of a single infusion of Realist Orbcel-C in a 3+3 design. Initially 3 cohorts with 3 subjects/cohort.  In the completed Phase 1 REALIST trial, infusion of 400 million cells was achieved without any dose limiting toxicity at day 7 and has been approved by the DMEC as the intervention dose for this study.  The phase 2 trial is a randomised, double-blind, allocation concealed placebo-controlled study using the maximal tolerable dose as determined by the DMEC in patients with moderate to severe ARDS due to COVID-19 or other causes of ARDS. D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions Human umbilical cord derived CD362 enriched MSCs Placebo (Plasma-Lyte 148) infusion PhSol All Pharmaceutical Solutions All Drugs and Chemicals Ganoderma M85407 M21013 M11966 Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions high low low Infusion of Human umbilical cord derived CD362 enriched MSCs Infusion of placebo C000012499 Plasma-lyte 148 Human umbilical cord derived CD362 enriched MSCs Placebo (Plasma-Lyte 148)  Biological Biological",1,129
372,"Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency Crossover Assignment    AD-MSCs infusions, then Placebo Placebo, then AD-MSCs infusions All All Drugs and Chemicals  M8941 Hormones low Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14. Dose: 1.0 x 106 cells/kg patient bodyweight. Route: intravenous infusion  ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours   Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency  Biological",1,130
373,Biological: WJMSCs Vs. placebo Biological: Placebo Parallel Assignment    Intracoronary infusion WJMSCs Intravenous infusion WJMSCs       WJMSCs Vs. placebo WJMSCs Vs. placebo   WJMSCs Vs. placebo Placebo  Biological Biological,1,160
374,"Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency Crossover Assignment    Placebo, then Umbilical Cord-Derived Mesenchymal Stem Cell (group B) Umbilical Cord-Derived Mesenchymal Stem Cell, then Placebo (group A) All Infe All Drugs and Chemicals Anti-Infective Agents  M8941 M3374 M3376 Hormones Anti-Bacterial Agents Antibiotics, Antitubercular low low low Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.   Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency  Biological",1,158
375,Hemat All Lipd VaDiAg PlAggInh Urol Infl Ot Hematinics All Drugs and Chemicals Lipid Regulating Agents Vasodilator Agents Platelet Aggregation Inhibitors Urological Agents Anti-Inflammatory Agents Other Dietary Supplements  M10262 M34170 M3020 M20763 T404 Liver Extracts Polyene phosphatidylcholine Alprostadil Glycyrrhizic Acid Lecithin low low low low low      ,1,158
376,Biological: AC607 Biological: Vehicle Only Parallel Assignment    AC607 Placebo       AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight The dose will be calculated and recorded in the same way as for AC607.   AC607 Vehicle Only allogeneic bone marrow-derived human mesenchymal stem cells Biological Biological,1,156
377,"Biological: Mesenchymal stem cells Drug: Glucocorticoids Drug: cyclosporine Drug: Glucocorticoids Drug: cyclosporine Parallel Assignment  D000004791 D000045504 D000007166 D000007155 D000045505 D000000935 D000000890 D000003879 D000018501 D000065095 D000006728 D000006730 Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Hormones Hormones, Hormone Substitutes, and Hormone Antagonists MSCs group Control group MSCs group Control group MSCs group Infe ARhu Derm All Infl ANeo AnEm NeuroAg Gast Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Anti-Inflammatory Agents Antineoplastic Agents Antiemetics Neuroprotective Agents Gastrointestinal Agents Impact Impact Postprandial M18113 M5882 M8199 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M9364 M9353 M3406 M5404 M10948 M3366 M6226 M19757 M29605 M8941 M8940 Cyclosporine Cyclosporins Glucocorticoids Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Immunosuppressive Agents Immunologic Factors Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Hormones Hormone Antagonists high high high low low low low low low low low low low low low low low low low low low Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses. Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg. Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml. D000016572 D000003524 D000005938 Cyclosporine Cyclosporins Glucocorticoids Mesenchymal stem cells Glucocorticoids cyclosporine  Biological Drug Drug",1,152
378,"Application of Darvadstrocel locally, after fistula tract curettage and internal opening closure.   Stem Cell Therapy Darvadstrocel Procedure",1,150
379,"Other: Bone marrow analyses Other: Bone marrow analyses     Acute Myeloid Leukemia patients Healthy donors       This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.   Bone marrow analyses Cellular properties of mesenchymal stromal cells Other",1,150
380,Biological: PRP injection Biological: Placebo Parallel Assignment    platelet reach plasma placebo       Injection of PRP in patients with knee osteoarthritis.   PRP injection Placebo  Biological Biological,1,150
381,Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Other: Placebo Parallel Assignment    Study Group A Study Group B Study Group C Study Group D Study Group E       Intravenously delivered Intravenously delivered   Longeveron Mesenchymal Stem Cells (LMSCs) Placebo  Biological Other,1,150
382,"Procedure: Autologous bone graft Combination Product: Advanced medicinal Therapy (MSC combined with biomaterial) Parallel Assignment Randomized controlled trial with advanced therapy medicinal product   Test Control All BDCA All Drugs and Chemicals Bone Density Conservation Agents  M4533 M4550 Calcium Calcium, Dietary low low Augmentation of alveolar ridge with MSC and biomaterial Augmentation of the alveolar ridge with bone graft   Advanced medicinal Therapy (MSC combined with biomaterial) Autologous bone graft  Combination Product Procedure",1,150
383,Drug: JointStem Other: Placebo Control Parallel Assignment    JointStem Placebo       Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC) Normal Saline with autologous Serum   JointStem Placebo Control  Drug Other,1,140
384,"Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein Parallel Assignment    MSC group control       0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points   mesenchymal stem cell transplantation or placebo infusion via peripheral vein  Procedure",1,140
385,"Biological: Autologous adipose tissue derived stromal cells Single Group Assignment This is prospective, open label, single arm clinical study that will establish the safety and efficacy of adipose derived stromal cells in patients with osteoarthritis disease. Total 140 subjects were enrolled in the study. Each subject will receive intra-articular Autologous ADSC with PRP along with standard treatment for osteoarthritis disease.   Experimental       autologous adipose tissue derived stromal cells is recovered as pellet after non enzymatic processing with sonication using ultrasound . This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC,2-- 20%), plus a wide number of CD34+ hematopoietic cells (40%)   Autologous adipose tissue derived stromal cells  Biological",1,140
386,"Other: Placebo Biological: allogeneic human mesenchymal stem cells (hMSCs) Other: Placebo Biological: allogeneic human mesenchymal stem cells (hMSCs) Other: Placebo Biological: allogeneic human mesenchymal stem cells (hMSCs) Parallel Assignment    Genotype A administered with hMSC Group Genotype B administered with hMSC Group Genotype C administered with hMSC Group Genotype A administered with placebo Group Genotype B administered with placebo Group Genotype C administered with placebo Group PhSol All ANeo Pharmaceutical Solutions All Drugs and Chemicals Antineoplastic Agents  M85407 M8814 Plasma-lyte 148 Altretamine low low allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections   allogeneic human mesenchymal stem cells (hMSCs) Placebo  Biological Other",1,136
387,Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cells Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes Other: Placebo Parallel Assignment    Wharton jelly-derived mesenchymal stem cell Mesenchymal stem cell exosome (Wharton jelly-derived) Placebo       Single subtenon's injection for single eye Single subtenon's injection for single eye Single Subtenon injection of saline for a single eye   Subtenon injection of Wharton jelly derived mesenchymal stem cells Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes Placebo  Biological Biological Other,1,135
388,"Drug: UC-MSC Drug: Anti-CD25 mAb Drug: Anti-CD25 mAb Parallel Assignment  D000007166 D000007155 D000045505 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs UC-MSC and anti-CD25 mAb Anti-CD25 mAb UC-MSC and anti-CD25 mAb All All Drugs and Chemicals Genotype 1 M1830 M9364 M9353 Basiliximab Immunosuppressive Agents Immunologic Factors high low low UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks. D000077552 Basiliximab UC-MSC Anti-CD25 mAb Umbilical cord-derived mesenchymal stem cells Basiliximab Drug Drug",1,130
389,"Biological: Mesenchymal Stromal Cells Parallel Assignment    Mesenchymal stem cells (MSC) Infe ARhu Derm All ANeo Infl Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Antineoplastic Agents Anti-Inflammatory Agents  M18113 M5882 M11280 M18102 M13273 Cyclosporine Cyclosporins Mycophenolic Acid Tacrolimus Prednisone low low low low low Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).   Mesenchymal Stromal Cells MSC Biological",1,130
390,Procedure: Laparoscopic endoscopy combined surgery Procedure: laparoscopic and endoscopic cooperative surgery Procedure: Single-arch laparoscopic and endoscopic cooperative surgery Parallel Assignment    Laparoscopic surgery laparoscopic and endoscopic Single-arch laparoscopic and endoscopic          Laparoscopic endoscopy combined surgery laparoscopic and endoscopic cooperative surgery Single-arch laparoscopic and endoscopic cooperative surgery  Procedure Procedure Procedure,1,120
391,"Biological: Bone Marrow Derived MSCs Device: Bone Marrow Aspirate Biological: Bone Marrow Derived MSCs Device: Bone Marrow Aspirate Biological: Bone Marrow Derived MSCs Device: Bone Marrow Aspirate Drug: Corticosteroid Device: Bone Marrow Aspirate Parallel Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000007166 D000007155 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs) Subchondral injection with Bone Marrow Derived MSCs Corticosteroid injection Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs Corticosteroid injection Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs) Subchondral injection with Bone Marrow Derived MSCs Infl All Anti-Inflammatory Agents All Drugs and Chemicals Battery M16126 M16127 M237968 M209570 M3369 M8199 M8941 M8940 M9364 M9353 Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Immunosuppressive Agents Immunologic Factors low high low low low low low low low low Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance. The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog [40 mg/dL], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%. The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate. D000014222 Triamcinolone Acetonide Bone Marrow Derived MSCs Corticosteroid Bone Marrow Aspirate Bone Marrow Aspirate Marrow Cellutions Kenalog Biological Drug Device",1,120
392,"Procedure: SVF-MSC induction Drug: Basiliximab induction Parallel Assignment  D000007166 D000007155 D000045505 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs SVF-MSC induction Basiliximab induction All All Drugs and Chemicals Genotype 1 M1830 M9364 M9353 Basiliximab Immunosuppressive Agents Immunologic Factors high low low Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.  Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4 D000077552 Basiliximab SVF-MSC induction Basiliximab induction  Procedure Drug",1,120
393,"Biological: Mesenchymal stem cell augmentation in rotator cuff repair Procedure: Standard arthroscopic rotator cuff repair Procedure: Standard arthroscopic rotator cuff repair Parallel Assignment    Rotator cuff repair with stem cells Rotator cuff repair with stem cells Rotator cuff repair without stem cells CNSDep All Ot Central Nervous System Depressants All Drugs and Chemicals Other Dietary Supplements  M4006 T433 Benzocaine Tannic Acid low low Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint. All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.   Mesenchymal stem cell augmentation in rotator cuff repair Standard arthroscopic rotator cuff repair  Biological Procedure",1,100
394,"Biological: UC-MSCs Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs） Parallel Assignment Randomized, double-blind, placebo-controlled study   Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs) Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low 3 does of UC-MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6. 3 does of placebo（intravenously at Day 0, Day 3, Day 6）   UC-MSCs Saline containing 1% Human serum albumin（solution without UC-MSCs）  Biological Biological",1,100
395,Procedure: ACIC Device: implant with a collagen + fibrin gel mixture Procedure: MCIC Parallel Assignment    ACIC MCIC ACIC Infe All Anti-Infective Agents All Drugs and Chemicals  M2719 Acyclovir low Autologous Collagen Induced Chondrogenesis (ACIC):  ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation. Mesenchymal Cell Induced Chondrogenesis (MCIC):  MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.   ACIC MCIC implant with a collagen + fibrin gel mixture  Procedure Procedure Device,1,100
396,"Biological: Single Dose MPCs Injection Biological: Single Dose MPCs Injection Procedure: Single injection of saline solution Procedure: Single injection of hyaluronic acid Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents High Dose MPCs Low Dose MPCs Saline injection Hyaluronic acid injection High Dose MPCs Low Dose MPCs All PhSol All Drugs and Chemicals Pharmaceutical Solutions Compression M9030 M21013 M2780 M9353 M27448 M21022 Hyaluronic Acid Pharmaceutical Solutions Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low low Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus. Intradiscal control injection with saline solution Intradiscal control injection with hyaluronic acid Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus. D000006820 Hyaluronic Acid Single Dose MPCs Injection Single injection of saline solution Single injection of hyaluronic acid Single Dose MPCs Injection Direct MPCs Lumbar Disc Injection. Stem Cells Saline injection Sham control Hyaluronic acid injection Vehicle control Stem Cells Biological Procedure Procedure Biological",1,100
397,Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint Parallel Assignment    Enzymatic digestion group Mechanical fragmentation group       Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis   Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint Autologous mechanically fragmented adipose tissue injection into the knee joint using Lipogems device Procedure,1,100
398,Procedure: Laser therapy Biological: Autologous ADSC injection Procedure: Laser therapy Procedure: Normal saline injection Parallel Assignment Patients receive injections of autologous SVF or ADSC cells isolated in the laboratory from adipose tissue.   Autologous adipose derived stem cells Placebo - Normal saline injection Autologous adipose derived stem cells Placebo - Normal saline injection       non-ablative fractional laser therapy of skin Subcutaneous injection of autologous ADSC Subcutaneous Normal saline injection   Laser therapy Autologous ADSC injection Normal saline injection  Procedure Biological Procedure,1,100
399,Biological: Stem Cell Transplantation Single Group Assignment    Stem Cells       Intravenous administration of autologous bone marrow derived stem cells for immunomodulation. Transplantation of autologous bone marrow derived stem cells in joints.   Stem Cell Transplantation  Biological,1,100
400,Biological: human umbilical cord mesenchymal stem cells Biological: placebo Parallel Assignment    group 1 group 2       human UC-MSCs: 0.2ml(about 2*10^6 cells) subconjunctival injection Saline injection   human umbilical cord mesenchymal stem cells placebo  Biological Biological,1,100
401,"Other: conventional plus UC-MSC treatment Other: Conventional plus placebo treatment Parallel Assignment    Conventional plus UC-MSC treatment Conventional plus placebo treatment All Hemat All Drugs and Chemicals Hematinics  M9336 M3377 M10262 M18269 M9274 Immunoglobulins Antibodies Liver Extracts Immunoglobulins, Intravenous Immunoglobulin G low low low low low Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks. Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks   conventional plus UC-MSC treatment Conventional plus placebo treatment  Other Other",1,100
402,Biological: Intraarticular injection of WJMSC Biological: Intraarticular injection of WJMSC Biological: Intraarticular injection of WJMSC Parallel Assignment Parallel Assignment   osteoarthritis of the glenohumeral joint osteoarthritis of the hip osteoarthritis of the knee       ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure   Intraarticular injection of WJMSC  Biological,1,100
403,Drug: GLP-1 Biological: SC Other: Standard Medical Treatment Biological: SC Other: Standard Medical Treatment Drug: GLP-1 Other: Standard Medical Treatment Other: Standard Medical Treatment Factorial Assignment    GLP-1 SC-GLP-1 SC SC-GLP-1 Control GLP-1 SC SC-GLP-1 All Hypo All Drugs and Chemicals Hypoglycemic Agents  M26150 M419 Glucagon-Like Peptide 1 Liraglutide low low GLP-1 therapy Stem cell infusion Standard Medical Treatment   GLP-1 SC Standard Medical Treatment SMT Drug Biological Other,1,100
404,Drug: transplantation of mesenchymal stem cell Drug: no transplantation of mesenchymal stem cell Parallel Assignment    transplantation of mesenchymal stem cell no transplantation of mesenchymal stem cell       allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants MSC transplantation will be not given to preterm infants   transplantation of mesenchymal stem cell no transplantation of mesenchymal stem cell  Drug Drug,1,100
405,"Combination Product: Aspire Needle + Emcyte PureBMC Drug: Triamcinolone Parallel Assignment bone marrow aspirate concentrate versus triamcinolone D000000893 D000005938 D000006728 D000006730 D000045505 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Bone marrow aspirate concentrate Triamcinolone Infl All AnArAg ChanBlk CNSDep Anti-Inflammatory Agents All Drugs and Chemicals Anti-Arrhythmia Agents Channel Blockers Central Nervous System Depressants Pulse M16126 M16127 M237968 M209570 M10166 M3369 M8199 M8941 M8940 Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate Lidocaine Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists high low low low low low low low low The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip. 40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip. D000014221 Triamcinolone Aspire Needle + Emcyte PureBMC Triamcinolone  Combination Product Drug",1,100
406,Biological: Injection (2x106 ASC/5ml). Biological: Injection (10x106 ASC/5ml). Other: Placebo Parallel Assignment    2x106 ASC intra-articular injection 10x106 ASC intra-articular injection Placebo       Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24. Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24. Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.   Injection (2x106 ASC/5ml). Injection (10x106 ASC/5ml). Placebo  Biological Biological Other,1,100
407,Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis Parallel Assignment    BMSC group Control group          Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis  Biological,1,100
408,Biological: Mesenchymal stem cells Biological: Mesenchymal stem cells Biological: Mesenchymal stem cells Single Group Assignment    1 2 3       Mesenchymal Stem Cell infusion   Mesenchymal stem cells  Biological,1,100
409,Biological: Autologous adipose stem cell therapy Drug: Mecobalamin Drug: Mecobalamin Parallel Assignment    Stem cell therapy group Neurotrophic drugs treatment group Stem cell therapy group Vi All Vitamins All Drugs and Chemicals Pontine T451 Methylcobalamin high    Autologous adipose stem cell therapy Mecobalamin  Biological Drug,1,100
410,"Biological: Stem Cells Single Group Assignment    Laboratory and Clinical       60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.   Stem Cells Stem Cell Dose 3-5 Million Autologous MSCs Injected into rete testis. Biological",1,100
411,Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells Parallel Assignment    Treatment       Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg   Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells  Drug,1,100
412,"Biological: Intra-articular injection of ADMSC Biological: Intra-articular injection of ADMSC Biological: Intra-articular injection of ADMSC Parallel Assignment Parallel Assignment   osteoarthritis of the glenohumeral joint osteoarthritis of the hip osteoarthritis of the knee       Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million   Intra-articular injection of ADMSC  Biological",1,100
413,Biological: MSCs Single Group Assignment    MSCs          MSCs  Biological,1,120
414,Procedure: Autologous bone marrow stem cell graft Single Group Assignment    Autologous bone marrow stem cell graft       All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.   Autologous bone marrow stem cell graft  Procedure,1,100
415,"Drug: conventional therapy Drug: Rituximab Drug: Mesenchymal stem cells Parallel Assignment  D000074322 D000000970 D000007155 D000045505 D000018501 Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents experimental group parallel control of conventional therapy experimental group All FiAg AnCoag ANeo ARhu AnArAg AnAg ChanBlk VaDiAg Urol All Drugs and Chemicals Fibrinolytic Agents Anticoagulants Antineoplastic Agents Antirheumatic Agents Anti-Arrhythmia Agents Antihypertensive Agents Channel Blockers Vasodilator Agents Urological Agents Two M9336 M8733 M3382 M3377 M373 M8731 M45326 M19305 M10914 M1943 M18752 M301 M252819 M1346 M9353 M19757 Immunoglobulins Heparin, Low-Molecular-Weight Antibodies, Monoclonal Antibodies Rituximab Heparin Calcium heparin Dalteparin Metoprolol Tinzaparin Amlodipine Valsartan Terazosin Antineoplastic Agents, Immunological Immunologic Factors Antirheumatic Agents low low low low high low low low low low low low low low low low Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer. Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on. Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation. D000069283 Rituximab Rituximab conventional therapy Mesenchymal stem cells Mabthera RTX Rituxan MSCs Drug Drug Drug",1,116
416,"Drug: CardioCell Drug: Placebos Parallel Assignment The CIHF trial will enroll 105 patients with randomization into active and placebo therapy with 2:1 ratio.  Additional 5-10 subjects meeting inclusion/exclusion criteria will receive, in a non-blinded fashion, labelled CardioCell to determine the early myocardial uptake and retention of IMP.   Active Group Control Group       Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).  Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties. Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.   CardioCell Placebos CardioCell administration Placebo administration Drug Drug",1,115
417,"Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells Other: Placebo Parallel Assignment    Mesenchymal Stromal Cells (MSCs) Placebo       Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously. Placebo, with excipients, will be administered intravenously.   Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells Placebo  Biological Other",1,114
418,"Biological: Stem cell Single Group Assignment    Stem Cell therapy in POF       Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).   Stem cell - Edessy Stem cell Score. - Laparoscopic stem cell transplantation. - Hormonal Analysis - Ultrasonic evaluation Biological",1,112
419,Biological: mesenchymal stem cell application Biological: mesenchymal stem cell application Parallel Assignment Cases were divided into two groups. Group A included cases with skin graft only and group B included cases with skin graft and application of mesenchymal stem cells. Every odd patients were kept in group A and every Even patients were kept in group B.   skin grafting and stem cell group skin grafting only          mesenchymal stem cell application  Biological,1,110
420,"Biological: CD34+ autologous stem cell transplantation Drug: Bone Marrow Stimulation Biological: SC therapy Parallel Assignment    SC Group SC Group SC Group All All Drugs and Chemicals  M1945 Lenograstim low Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline). In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect   CD34+ autologous stem cell transplantation Bone Marrow Stimulation SC therapy G-CSF stimulation Biological Drug Biological",1,110
421,"Biological: MNC Biological: MSC Procedure: Control Biological: MNC Biological: MSC Parallel Assignment HLA typing were done for 150 cases of spastic CP with our inclusion criteria and 36 cases of class 6 matching of HLA selected for hematopoietic stem cells derived from allogenic umbilical cord and 72 cases were randomly divided to Mesenchymal cells derived from allogenic umbilical cord and control group .   MNC & MSC MNC & MSC with Control MNC & MSC MNC & MSC with Control MNC & MSC with Control       Hematopoietic stem cells derived from allogenic umbilical cord Mesenchymal cells derived from allogenic umbilical cord control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .   MNC MSC Control Hematopoietic stem cells Mesenchymal stem cells Biological Biological Procedure",1,108
422,Biological: Mesenchymal progenitor cells Biological: Mesenchymal progenitor cells Biological: No mesenchymal progenitor cells Parallel Assignment    Mesenchymal progenitor cells Dosage 1 Mesenchymal progenitor cells Dosage 2 No mesenchymal progenitor cells       Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use No mesenchymal progenitor cells for intra- articular use   Mesenchymal progenitor cells No mesenchymal progenitor cells  Biological Biological,1,108
423,Other: Placebo Biological: Mesenchymal Precursor Cells (MPC) 12.5 M Biological: Mesenchymal Precursor Cells (MPC) 25 M Parallel Assignment    Placebo Mesenchymal Precursor Cells (MPC) 12.5 M Mesenchymal Precursor Cells (MPC) 25 M PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Matching placebo solution for infusion. MPC 12.5 M solution for infusion. MPC 25 M solution for infusion.   Placebo Mesenchymal Precursor Cells (MPC) 12.5 M Mesenchymal Precursor Cells (MPC) 25 M  Other Biological Biological,1,106
424,"Biological: Trinity Evolution     Trinity Evolution       Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells   Trinity Evolution Allograft Mesenchymal Stem Cells Biological",1,106
425,"Drug: Cardiac Drug Drug: Placebos Parallel Assignment The AMI trial will enroll 105 patients with randomization into active vs. sham therapy with 2:1 ratio.  Additional 5-10 subjects meeting inclusion/exclusion criteria will receive, in a non-blinded fashion, labelled CardioCell to determine the early uptake and retention of IMP in the target ischemic tissues.   Active Group Control Group       Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.  Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group. Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.  Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.   Cardiac Drug Placebos CardioCell administration Placebo administration Drug Drug",1,105
426,Biological: Cartistem Procedure: Microfracture treatment Parallel Assignment    Cartistem Microfracture treatment       allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product   Cartistem Microfracture treatment  Biological Procedure,1,104
427,Biological: CARTISTEM Procedure: Microfracture Parallel Assignment    CARTISTEM Microfracture       A single dose of 500㎕/㎠ of cartilage defect Active control   CARTISTEM Microfracture hUCB-MSCs Conventional surgical treatment Biological Procedure,1,103
428,Biological: Umbilical cord mesenchymal stem cells Biological: Controlled suspension liquid Parallel Assignment UC-MSCs (1.5×106/kg) or the same volume of placebo (suspension liquid without UC-MSCs)   Umbilical cord mesenchymal stem cells Controlled suspension liquid       Infusion treatment Infusion treatment   Umbilical cord mesenchymal stem cells Controlled suspension liquid  Biological Biological,1,103
429,Biological: human umbilical cord mesenchymal stem cells (hUC-MSCs) Single Group Assignment    hUC-MSC Transplantation       Four times of intrathecal administrations of hUC-MSCs   human umbilical cord mesenchymal stem cells (hUC-MSCs) umbilical cord mesenchymal stem cells Biological,1,102
430,"Biological: CARTISTEM® Procedure: Microfracture Parallel Assignment A multicenter, Single-blinded, Stratified randomized   Microfracture + CARTISTEM® Microfracture HB All Herbal and Botanical All Drugs and Chemicals  T63 Astragalus low *Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠  Procedure: Microfracture Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product) *Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠  1. Procedure: Microfracture   CARTISTEM® Microfracture  Biological Procedure",1,102
431,"Other: conventional plus UC-MSC treatment Other: Conventional plus placebo treatment Parallel Assignment    Conventional plus UC-MSC treatment Conventional plus placebo treatment All All Drugs and Chemicals  M4101 Bilirubin low Received conventional treatment and taken i.v., once per 4 week, at a dose of 1*10E6 UC-MSC/kg body weight for 12 weeks. Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks   conventional plus UC-MSC treatment Conventional plus placebo treatment  Other Other",1,100
432,Genetic: intracoronary human umbilical WJ-MSC transfer Parallel Assignment    WJ-MSC       intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.   intracoronary human umbilical WJ-MSC transfer  Genetic,1,160
433,"Biological: Cord Tissue Mesenchymal Stromal Cells Other: Placebo Infusion Crossover Assignment This study is a phase II, prospective, randomized, blinded, cross over, clinical trial designed to assess the efficacy of intravenous dosing of hCT-MSC for improving social communication abilities in young children with ASD. All participants will ultimately be treated with hCT-MSC. Participants randomized to arm A will each receive a single intravenous dose of 6x106 hCT-MSC per kilogram at baseline, followed by a placebo infusion at six months. Participants randomized to arm B will each receive a placebo infusion at baseline, followed by an intravenous dose of 6x106 hCT-MSC per kilogram at six months.   MSC Placebo Infusion       Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously. Placebo comparative infusion   Cord Tissue Mesenchymal Stromal Cells Placebo Infusion  Biological Other",1,164
434,"Biological: Mesenchymal progenitor cells Biological: Sodium Hyaluronate Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Mesenchymal progenitor cells Sodium Hyaluronate All All Drugs and Chemicals PCOS M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Administrated for intra-articular injection D000006820 Hyaluronic Acid Mesenchymal progenitor cells Sodium Hyaluronate  Biological Biological",1,53
435,"Device: Cellular Matrix / A-CP HA Device: Ostenil® Plus Device: RegenKit-BCT-1 Parallel Assignment    Experimental group Control group 1 Control group 2 All PhSol AnCoag NaAg Ot All Drugs and Chemicals Pharmaceutical Solutions Anticoagulants Natriuretic Agents Other Dietary Supplements  M9030 M21013 M20473 M1837 M3396 M10494 T382 Hyaluronic Acid Pharmaceutical Solutions Citric Acid Sodium Citrate Anticoagulants Mannitol Citrate low low low low low low low Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation. Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint. Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.   Cellular Matrix / A-CP HA Ostenil® Plus RegenKit-BCT-1  Device Device Device",1,306
436,"Procedure: Therapeutic Plasma exchange Procedure: Therapeutic Plasma exchange Biological: Convalescent Plasma Drug: Tocilizumab Drug: Remdesivir Biological: Mesenchymal stem cell therapy Procedure: Therapeutic Plasma exchange Biological: Convalescent Plasma Drug: Tocilizumab Drug: Remdesivir Biological: Mesenchymal stem cell therapy Factorial Assignment It will be an interventional retrospective case control, single centre based cohort study in Pak Emirates Military Hospital Rawalpindi (PEMH), Pakistan from 1st April to 31st July 2020. This study will be carried out at the Department of Pulmonology and Critical care. PEMH is the largest Covid-19 designated hospital in the country. Data of all hospitalized patients is maintained by PEMH Covid-19 Research and evaluation cell. The study was approved by Institutional Review Board. D000000963 D000045504 D000000998 D000000890 Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Either alone or combination of MSC, Remdesivir and Tocilizumab TPE arm TPE in combination with other investigational treatments Either alone or combination of MSC, Remdesivir and Tocilizumab TPE in combination with other investigational treatments Either alone or combination of MSC, Remdesivir and Tocilizumab TPE in combination with other investigational treatments Either alone or combination of MSC, Remdesivir and Tocilizumab TPE in combination with other investigational treatments Either alone or combination of MSC, Remdesivir and Tocilizumab TPE in combination with other investigational treatments Infl ANeo AnEm Gast All NeuroAg PhSol Antipy ARhu FiAg Analg PlAggInh AnCoag Infe VaCoAg Resp Anti-Inflammatory Agents Antineoplastic Agents Antiemetics Gastrointestinal Agents All Drugs and Chemicals Neuroprotective Agents Pharmaceutical Solutions Antipyretics Antirheumatic Agents Fibrinolytic Agents Analgesics Platelet Aggregation Inhibitors Anticoagulants Anti-Infective Agents Vasoconstrictor Agents Respiratory System Agents Sibling M6254 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M21013 M3700 M235540 M3396 M341692 M228466 M3433 M3466 M3366 Dexamethasone Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Pharmaceutical Solutions Aspirin Dexamethasone acetate Anticoagulants Remdesivir Xylometazoline Antimetabolites Antiviral Agents Anti-Infective Agents low low low low low low low low low low low low high low low low low 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of > 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;  After 28 day of illness till 3 months Symptom free 2 weeks prior to donation Negative two consecutive PCRs any time between initial positivity and before donation Anti SARS-CoV2 IgG positive, IgM negative Fulfills healthy donor criteria as per WHO/AABB guidelines Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation A predefined number of patients having evidence of cytokine release storm with normal procalcitonin level for three consecutive days, a normal blood culture and IL-6 level > 3 times ULN will be given 1-2 doses of Tocilizumab (80mg IV) . Following contraindications to Tocilizumab will be considered (Allergy to any monoclonal Ab, ANC < 1000, Platelets < 50, ALT or AST > 5 times ULN, Pregnancy and breast feeding, Post TB lung). Some patients will receive it alone in addition to standard treatment whereas in few patients where indicated it will be given in combination with MSC or Remdesivir or both It will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. For adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on Day 1 followed by once daily maintenance doses of 100 mg IV for 9 days (days 2 through 10). For adults not requiring invasive mechanical ventilation 5 standard doses will be used. However, patients with known hypersensitivity to Remdesivir, multi organ failure, ALT > 5 times ULN and GFR < 30ml/minute will not be given Remdesivir. In some patients, where indicated other novel treatments including MSC therapy, Tocilizumab and therapeutic plasma exchange will be given. Single Dose of 2 x 106 cells/kg will be administered either alone or in combination with other novel therapies. At Armed Forces Bone Marrow Transplant Centre (AFBMTC), MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37Oc in 5% CO2. Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- EDTA solution. C000606551 Remdesivir Therapeutic Plasma exchange Convalescent Plasma Tocilizumab Remdesivir Mesenchymal stem cell therapy MSC Procedure Biological Drug Drug Biological",1,600
437,"Biological: Allogeneic Mesenchymal Precursor Cells (MPCs) Other: Sham Comparator Parallel Assignment    Allogeneic Mesenchymal Precursor Cells Control Treatment All All Drugs and Chemicals  M9336 M3377 Immunoglobulins Antibodies low low Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.   Allogeneic Mesenchymal Precursor Cells (MPCs) Sham Comparator MPCs rexlemestrocel-L Biological Other",1,566
438,"Biological: Bone Marrow Derived MSCs Biological: Adipose-derived MSCs Biological: Umbilical Cord Tissue (UCT) MSCs Drug: Corticosteroid injection Parallel Assignment The study will include a parallel design using a blocked central randomization scheme of 1:1:1:1. Participants will first be randomized to have MSCs derived from either bone marrow, adipose tissue, or umbilical cord tissue. Then they will be further randomized to receive either an injection of MSCs (from bone marrow, adipose, or umbilical cord tissue, depending on the first randomization) or a corticosteroid injection. D000000893 D000000932 D000001337 D000018373 D000045505 D000005765 D000005938 D000006728 D000006730 D000018696 D000020011 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Neuroprotective Agents Protective Agents Bone Marrow Derived MSCs Adipose-derived MSCs Umbilical Cord Tissue (UCT) MSCs Corticosteroid Injection Infl ANeo All AnEm NeuroAg Gast PhSol Anti-Inflammatory Agents Antineoplastic Agents All Drugs and Chemicals Antiemetics Neuroprotective Agents Gastrointestinal Agents Pharmaceutical Solutions Organic Neck M13272 M1833 M10901 M10902 M229437 M211896 M248768 M85407 M3369 M3403 M8033 M8199 M8941 M8940 M19926 M21022 Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Plasma-lyte 148 Anti-Inflammatory Agents Antiemetics Gastrointestinal Agents Glucocorticoids Hormones Hormone Antagonists Neuroprotective Agents Protective Agents low high high low low low low low low low low low low low low low Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis.The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach. Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach. Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach. The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach. D000008775 D000077555 Methylprednisolone Methylprednisolone Acetate Bone Marrow Derived MSCs Adipose-derived MSCs Umbilical Cord Tissue (UCT) MSCs Corticosteroid injection Depo-Medrol Methylprednisolone Biological Biological Biological Drug",1,480
439,Drug: EXOFLO Drug: EXOFLO Parallel Assignment    Treatment Arm 1 Treatment Arm 2       The intervention will be infused over 60 minutes on Day 1 and repeated on Day 4 provided that the patient has not recovered as defined by WHO ordinal scale category 4 or less. The intervention will be infused over 60 minutes on Day 1 and repeated on Day 4 provided that the patient has not recovered as defined by WHO ordinal scale category 4 or less.   EXOFLO  Drug,1,400
440,Drug: Placebo Drug: Prochymal® Drug: Prochymal® Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Prochymal® - High dose Prochymal® - Low dose Placebo Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals Unsuccessful M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low Prochymal® IV infusion Prochymal® Placebo-matching IV infusion C000711674 Remestemcel-l Prochymal® Placebo Adult Human Mesenchymal Stem Cells Drug Drug,1,330
441,"Biological: Conventional therapy Biological: mesenchymal stem cells Parallel Assignment    mesenchymal stem cells Conventional therapy Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year) Conventional therapy without cell therapy   mesenchymal stem cells Conventional therapy  Biological Biological",1,320
442,Biological: Placebo transplantation Biological: HUC-MSCs transplantation Parallel Assignment    Control group Experimental group All All Drugs and Chemicals  M8941 Hormones low Intraovarian injection of placebo through vagina under the guidance of ultrasonic. Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.   Placebo transplantation HUC-MSCs transplantation  Biological Biological,1,320
443,"Biological: Sham, no injection Biological: Injection of C3BS-CQR-1 Parallel Assignment    C3BS-CQR-1 Treated Control       Injection of the C3BS-CQR-1 using the C-Cath® injection catheter. Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed   Injection of C3BS-CQR-1 Sham, no injection  Biological Biological",1,315
444,"Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS Parallel Assignment Parallel Assignment Arms Placebo Comparator: WANICAD Trial are as a 3 arm trial comparing standard of care plus placebo to either standard of care plus WJMSC one or three times infusion with participants allocated to each study arm in a 1:1:1 ratio   Infusion WJMSCs multiple doses Placebo Infusion PBS Single dose Infusion WJMSCs All Infl All Drugs and Chemicals Anti-Inflammatory Agents  M16512 M3369 Vaccines Anti-Inflammatory Agents low low Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease   Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS Intravenous infusion WJMSCs or placebo Biological",1,300
445,Biological: ALLO-ASC-DFU Procedure: Vehicle sheet Parallel Assignment    ALLO-ASC-DFU Vehicle Sheet       Application of ALLO-ASC-DFU sheet to diabetic foot ulcer Application of Vehicle sheet to diabetic foot ulcer   ALLO-ASC-DFU Vehicle sheet Hydrogel sheet containing allogenic mesenchymal stem cells Hydrogel sheet without Allogenic mesenchymal stem cell Biological Procedure,1,164
446,"Biological: Celltex- AdMSCs Biological: Celltex- AdMSCs Biological: Celltex- AdMSCs Biological: Celltex- AdMSCs Biological: Celltex- AdMSCs Biological: Celltex- AdMSCs Parallel Assignment The Phase 2 study is an open-label, 6 arms, randomized, control group clinical study conducted in multiple clinical facilities.   Phase 2 Arm 1 - OA Knee Phase 2 Arm 2 OA Knee Phase 2 Arm 3 - OA Hip Phase 2 Arm 4 - OA Hip Phase 2 Arm 5 - OA Shoulder Phase 2 Arm 6 - OA Shoulder       Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue   Celltex- AdMSCs AdMSCs Biological",1,300
447,Biological: MesenCure Other: Placebo Parallel Assignment    treatment control       Enhanced mesenchymal cell-based product Saline   MesenCure Placebo  Biological Other,1,300
448,Other: rehabilitation Biological: cell therapy Parallel Assignment cell therapy or rehabitation treatment   cell therapy rehabilitation       Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture. Patients only receive rehabilitation of limb function.   cell therapy rehabilitation physical exercise rehabilitation Biological Other,1,300
449,"Other: DNA extraction of tumer tissue samples and high-throughput sequencing of small panels Other: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels Other: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels     The construction of Gene detection technology flow Establishment of non-invasive gene testing technology process Prospective cohort (double-blind recommended)       DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients   DNA extraction of tumer tissue samples and high-throughput sequencing of small panels DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels  Other Other Other",1,300
450,Other: rehabilitation Biological: stem cell injection Parallel Assignment    rehabilitation stem cell injection       Patients only receive rehabilitation of physical therapy and occupational therapy. Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.   rehabilitation stem cell injection phsical exercise rehabilitation Other Biological,1,300
451,"Biological: BMAC     BMAC Application       A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.   BMAC  Biological",1,300
452,Other: Cx601 Other: Saline solution Parallel Assignment    Treatment Arm Placebo-control group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low 120 million cells administered by intralesional injection. 24 mL saline solution by intralesional injection   Cx601 Saline solution  Other Other,1,278
453,"Drug: conventional plus MSC treatment Drug: conventional plus placebo treatment Parallel Assignment    conventional plus MSC treatment conventional plus placebo treatment Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 8 weeks. received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.   conventional plus MSC treatment conventional plus placebo treatment  Drug Drug",1,266
454,"Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Biological: PrimePro™/ PrimeMSK™ Parallel Assignment This is a multi-center, prospective, open label clinical trial. It will include 5000 patients suffering acute and chronic conditions under 10 different categories. Patients will undergo a single treatment with a biological tissue allograft and will be followed for 12 months.   Arm 10: Viral Illnesses Arm 1: Autoimmune Diseases Arm 2: Cardiovascular Disorders Arm 3: Diabetes Complications Arm 4: Integumentary Disease Arm 5: Musculoskeletal Disorders Arm 6: Neurodegenerative Disorders Arm 7: Pulmonary Disorders Arm 8: Sexual Dysfunction Arm 9: Urologic Disorders       Injection via condition specific route of administration.   PrimePro™/ PrimeMSK™  Biological",1,5000
455,D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents  Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals 1440 M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low Patients will be treated with Prochymal® twice per week at a dose of 2 x 10^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart. C000711674 Remestemcel-l remestemcel-L Prochymal® Ex-vivo Cultured Adult Human Mesenchymal Stem Cells Biological,1,0
456,D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents  Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals Unsuccessful M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart. C000711674 Remestemcel-l Prochymal® Ex-vivo Cultured Adult Human Mesenchymal Stem Cells Drug,1,0
457,Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.   total knee / hip replacement  Other,1,0
458,Adipose-Derived Mesenchymal Stem Cells  Drug,1,0
459,Hope Biosciences adipose derived Mesenchymal Stem Cells.   HB-adMSCs MSCs Biological,1,0
460,Hope Biosciences adipose derived Mesenchymal Stem Cells   HB-adMSCs MSC's Biological,1,0
461,Autologous adipose derived mesenchymal stem cells   HB-adMSCs  Biological,1,0
462,Hope Biosciences adipose derived autologous mesenchymal stem cell product   HB-adMSC  Biological,1,0
463,Intrathecal administration   NurOwn (MSC-NTF cells)  Biological,1,0
464,Intravenous Infusion over 60 minutes   Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment ExoFlo Biological,1,0
465,"HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.   HB-adMSC  Biological",1,0
466,"D000000893 D000068776 D000006993 D000002492 D000045505 D000000779 D000000777 D000018689 D000018373 D000000932 D000001337 D000005765 D000006634 D000006633 D000018494 D000018377 D000045504 D000018926 D000000982 D000003879 D000000998 D000000890 Anti-Inflammatory Agents Sleep Aids, Pharmaceutical Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Anesthetics, Local Anesthetics Sensory System Agents Peripheral Nervous System Agents Antiemetics Autonomic Agents Gastrointestinal Agents Histamine H1 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Allergic Agents Antipruritics Dermatologic Agents Antiviral Agents Anti-Infective Agents  Infl All AAll AnEm CNSDep Gast Derm Infe Anti-Inflammatory Agents All Drugs and Chemicals Anti-Allergic Agents Antiemetics Central Nervous System Depressants Gastrointestinal Agents Dermatologic Agents Anti-Infective Agents Pump Rivaroxaban Rivaroxaban 1440 M9064 M155022 M228602 M263157 M6490 M13420 M186752 M3369 M9195 M3259 M3261 M3403 M8033 M8862 M8860 M212140 M8861 M19657 M20115 M6226 M3466 M3366 Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Diphenhydramine Promethazine Remestemcel-l Anti-Inflammatory Agents Hypnotics and Sedatives Anesthetics Anesthetics, Local Antiemetics Gastrointestinal Agents Histamine H1 Antagonists Histamine Histamine phosphate Histamine Antagonists Neurotransmitter Agents Anti-Allergic Agents Dermatologic Agents Antiviral Agents Anti-Infective Agents high low low low high high high low low low low low low low low low low low low low low low Participants may receive up to 2 infusions of 2 x 10^6 remestemcel-L within a 5-day period. Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L. Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L. D000004155 D000011398 C000711674 D000006854 Diphenhydramine Promethazine Remestemcel-l Hydrocortisone Remestemcel-L Hydrocortisone Diphenhydramine Benadryl® Biological Drug Drug",1,0
467,Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly   Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly  Biological,1,0
468,"D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents  Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals 1440 M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low Participants will receive remestemcel-L in two infusions of 2 x 10^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV). C000711674 Remestemcel-l Remestemcel-L  Drug",1,0
469,"Gast All Gastrointestinal Agents All Drugs and Chemicals  M21707 M12266 Pancrelipase Pancreatin low low Culture-expanded, adipose-derived mesenchymal stem cells donated by first blood relative   HB-adMSCs  Biological",1,0
470,HB-adMSCs Hope Biosciences autologous adipose-derived mesenchymal stem cells Biological,1,0
471,intravenous infusion of Hope Biosciences autologous adipose-derived stem cells   HB-adMSCs  Biological,1,0
472,single infusion of HB-adMSCs   HB-adMSCs  Biological,1,0
473,Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.  10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart.   Intrathecal MSC-NP injection  Drug,1,0
474,"D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents  Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals 1440 M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter C000711674 Remestemcel-l PROCHYMAL (remestemcel-L)  Drug",1,0
475,"Biological: NurOwn® (MSC-NTF cells) Other: Bone Marrow aspiration Other: Placebo Other: Bone Marrow aspiration Parallel Assignment Randomized, Double-Blind, Placebo-Controlled Multicenter Study   NurOwn® (MSC-NTF cells) Placebo NurOwn® (MSC-NTF cells) Placebo       Autologous transplantation of bone marrow derived mesenchymal stem cells propagated ex vivo and induced to secrete neurotrophic factors Placebo Bone Marrow aspiration   NurOwn® (MSC-NTF cells) Placebo Bone Marrow aspiration  Biological Other Other",1,263
476,Drug: umbilical cord blood mesenchymal stem cells Drug: umbilical cord blood mesenchymal stem cells Parallel Assignment    Group MSC-1 Group MSC-2 Infe All Hemat Infl Anti-Infective Agents All Drugs and Chemicals Hematinics Anti-Inflammatory Agents  M3466 M10262 M20763 Antiviral Agents Liver Extracts Glycyrrhizic Acid low low low    umbilical cord blood mesenchymal stem cells  Drug,1,261
477,"Biological: Prochymal® Drug: Standard of Care for GVHD Drug: Placebo Drug: Standard of Care for GVHD Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Prochymal® Placebo Placebo Prochymal® Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals Unsuccessful M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low 2 infusions of 2 million cells/kg per week for 4 weeks 2 infusions per week for 4 weeks Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy) C000711674 Remestemcel-l Prochymal® Placebo Standard of Care for GVHD Mesenchymal Stem Cells excipients without adult human mesenchymal stem cells Biological Drug Drug",1,260
478,Biological: Cellgram-LC Parallel Assignment    Injection group: Cellgram-LC Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.   Cellgram-LC Autologous bone marrow-derived mesenchymal stem cell Biological,1,200
479,"Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein Parallel Assignment    MSC group control Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low 0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points   mesenchymal stem cell transplantation or placebo infusion via peripheral vein  Procedure",1,200
480,"Biological: umbilical cord-derived mesenchymal stem cell Other: Comprehensive treatment Parallel Assignment    Comprehensive treatment plus UC-MSC treatment Comprehensive treatment Infe All Hemat Lipd Gast Anti-Infective Agents All Drugs and Chemicals Hematinics Lipid Regulating Agents Gastrointestinal Agents  M3374 M10262 M296 M230376 M3376 M20308 M1946 M2823 Anti-Bacterial Agents Liver Extracts Tenofovir Entecavir Antibiotics, Antitubercular Hydroxymethylglutaryl-CoA Reductase Inhibitors Rifaximin Adrenergic beta-Antagonists low low low low low low low low Taken a dose of 1.0*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment. All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)). Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers).   umbilical cord-derived mesenchymal stem cell Comprehensive treatment  Biological Other",1,200
481,Drug: 0.9% sodium chloride Other: mesenchymal stem cells therapy Parallel Assignment    mesenchymal stem cells Placebo       mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group 0.9% sodium chloride in control group   mesenchymal stem cells therapy 0.9% sodium chloride  Other Drug,1,200
482,"Procedure: mesenchymal stem cell transplantation via peripheral vein Other: mesenchymal stem cell Parallel Assignment    MSC group MSC group Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low 1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China   mesenchymal stem cell transplantation via peripheral vein mesenchymal stem cell  Procedure Other",1,200
483,"Drug: MesoCellA-Ortho administration Drug: HA administration Drug: MesoCellA-Ortho administration Drug: HA administration Drug: MesoCellA-Ortho administration Drug: HA administration Parallel Assignment Randomized   MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity Control Patients with type 2 diabetes and obesity Control Patients without type 2 diabetes and with obesity Control Patients without type 2 diabetes and without obesity All PhSol All Drugs and Chemicals Pharmaceutical Solutions  M9030 M21013 Hyaluronic Acid Pharmaceutical Solutions low low Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in ""MesoCellA-Ortho- treated"" groups. Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in ""Control Patients"" groups.   MesoCellA-Ortho administration HA administration Experimental treatment Standard treatment (control) Drug Drug",1,200
484,Biological: BMMSCs Biological: BMMSCs Biological: BMMSCs Parallel Assignment    BMMSCs Controls pre-conditioned BMMSCs          BMMSCs  Biological,1,200
485,"Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) Biological: UC-MSC+DMARDS Single Group Assignment    UC-MSCs Treatment DMARDS UC-MSC+DMARDS ARhu All Antirheumatic Agents All Drugs and Chemicals Home exercise program M19757 Antirheumatic Agents high -The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion. -Patients will be treated by conventional drugs (DMARDS) for alleviating disease. The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated. D000018501 Antirheumatic Agents Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) UC-MSC+DMARDS  Biological Drug Biological",1,200
486,"Drug: CD25 monoclonal antibody Drug: calcineurin inhibitors Biological: MSCs Drug: CD25 monoclonal antibody Drug: calcineurin inhibitors Parallel Assignment  D000007155 D000045505 D000004791 D000045504 Immunologic Factors Physiological Effects of Drugs Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action CD25 Mc Ab & calcineurin inhibitors Mesenchymal stem cells CD25 Mc Ab & calcineurin inhibitors Mesenchymal stem cells Mesenchymal stem cells All All Drugs and Chemicals Followed by Controlled Preparing M9336 M3382 M3377 M29605 M9353 Immunoglobulins Antibodies, Monoclonal Antibodies Calcineurin Inhibitors Immunologic Factors low high high high low  D000000906 D000000911 D000065095 Antibodies Antibodies, Monoclonal Calcineurin Inhibitors CD25 monoclonal antibody calcineurin inhibitors MSCs  Drug Drug Biological",1,200
487,Biological: Umbilical Cord-derived Mesenchymal Stem Cells Drug: Placebo Parallel Assignment Two different treatment groups; intravenous umbilical cord-derived mesenchymal stem cells or intravenous placebo solution   Treatment group Placebo Comparator PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million. intravenous placebo solution with the same appearance as the treatment group.   Umbilical Cord-derived Mesenchymal Stem Cells Placebo  Biological Drug,1,200
488,"Biological: allo-APZ2-CVU Drug: Placebo Biological: allo-APZ2-CVU Biological: allo-APZ2-CVU Parallel Assignment Randomized, placebo-controlled, double-blind, dose-ranging, interventional, multicenter, phase IIb clinical trial   allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²) allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²) allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²) Placebo       Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe. One topical application with a syringe   allo-APZ2-CVU Placebo Skin-derived ABCB5-positive dermal mesenchymal stromal cells Biological Drug",1,200
489,"Biological: autologous adipose-derived stem cells Biological: autologous adipose-derived stem cells Parallel Assignment The Phase 2 study is a randomized, double-blind, placebo-control study conducted in multiple clinic facilities.   Phase 2 AdMSC group Phase 2 Placebo group       Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue   autologous adipose-derived stem cells Celltex-AdMSCs Biological",1,200
490,"Drug: Conserved Therapy Procedure: Hepatic artery infusion or Intravenous infusion Parallel Assignment    Conserved Therapy Interventional Therapy Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Conserved Therapy Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.   Conserved Therapy Hepatic artery infusion or Intravenous infusion  Drug Procedure",1,200
491,"Other: Placebo Other: Corticosteroid Drug: Prochymal® Other: Corticosteroid Parallel Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000018931 D000000970 D000000932 D000001337 D000018373 D000005765 D000018696 D000020011 D000000998 D000000890 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents Antiviral Agents Anti-Infective Agents Prochymal® 2x10^6 hMSC/kg Placebo Placebo Prochymal® 2x10^6 hMSC/kg Infl ANeo All AnEm NeuroAg Gast Infe Anti-Inflammatory Agents Antineoplastic Agents All Drugs and Chemicals Antiemetics Neuroprotective Agents Gastrointestinal Agents Anti-Infective Agents Neck Until 1440 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M13273 M186752 M3369 M8199 M8941 M8940 M20119 M3403 M8033 M19926 M21022 M3466 M3366 Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Prednisone Remestemcel-l Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Antineoplastic Agents, Hormonal Antiemetics Gastrointestinal Agents Neuroprotective Agents Protective Agents Antiviral Agents Anti-Infective Agents low low high low low low low high high low low low low low low low low low low low Prochymal® intravenous infusion. Placebo-matching Prochymal® intravenous infusion. Administration will be intravenously as prescribed by the caregiver. C000711674 D000011241 D000008775 Remestemcel-l Prednisone Methylprednisolone Prochymal® Placebo Corticosteroid Remestemcel-L Methylprednisolone Prednisone Drug Other Other",1,192
492,"Other: hUC-MSCs Other: glucocorticoids Parallel Assignment  D000006728 D000006730 D000045505 Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs hUC-MSCs combined with glucocorticoids group. glucocorticoids group All All Drugs and Chemicals Postprandial M8199 M8941 M8940 Glucocorticoids Hormones Hormone Antagonists high low low Participants will be treated with hUC-MSCs at a dose of 1×10^6 /kilogram (kg) actual body weight at Screening for twice per week in 1-2 weeks and once a week in 3-4 weeks after being rolled into this study. At the same time, patients will be treated with glucocorticoids according to patients' condition. Participants were treated with glucocorticoids only. D000005938 Glucocorticoids hUC-MSCs glucocorticoids  Other Other",1,182
493,Drug: Human Umbilical Cord-derived Mesenchymal stem cell Drug: placebo Parallel Assignment    Mesenchymal stem cell placebo       The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube saline   Human Umbilical Cord-derived Mesenchymal stem cell placebo  Drug Drug,1,180
494,"Biological: low dose hMSC-Exos Biological: medium dose hMSC-Exos Biological: high dose hMSC-Exos Biological: Dosage 1of hMSC-Exos Biological: Dosage 2 of hMSC-Exos Biological: No hMSC-derived exosomes Parallel Assignment    Phase 1: hMSC-Exos low dose Phase 1: hMSC-Exos medium dose Phase 1: hMSC-Exos high dose Phase 2: hMSC-Exos dosage 1 Phase 2: hMSC-Exos dosage 2 Phase 2: control group       basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7) basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7) basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7) basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7) basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7) basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)   low dose hMSC-Exos medium dose hMSC-Exos high dose hMSC-Exos Dosage 1of hMSC-Exos Dosage 2 of hMSC-Exos No hMSC-derived exosomes  Biological Biological Biological Biological Biological Biological",1,169
495,"Procedure: Kidney transplantation with MSCs infusion Procedure: Kidney transplantation with MSCs infusion Procedure: kidney transplantation without MSC infusion Parallel Assignment    A B C All ANeo Analg All Drugs and Chemicals Antineoplastic Agents Analgesics  M8199 M9336 M9563 M3377 M29605 M9364 M1830 Glucocorticoids Immunoglobulins Interleukin-2 Antibodies Calcineurin Inhibitors Immunosuppressive Agents Basiliximab low low low low low low low Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later. kidney transplantation with standard immunosuppressive treatment regime   Kidney transplantation with MSCs infusion kidney transplantation without MSC infusion MSCs induction plus a standard or a lower dose of CNI Anti-IL2R induction therapy with standard dose of CNI Procedure Procedure",1,165
496,"Biological: Autologous adipose-derived MSCs Drug: Compound betamethasone Parallel Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000018927 D000019141 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Autologous adipose-derived MSCs Compound betamethasone Infl ANeo AnEm Gast All Resp Anti-Inflammatory Agents Antineoplastic Agents Antiemetics Gastrointestinal Agents All Drugs and Chemicals Respiratory System Agents At 3 M6254 M235540 M4061 M4062 M229281 M259082 M248671 M3369 M8199 M8941 M8940 M20116 M20290 Dexamethasone Dexamethasone acetate Betamethasone Betamethasone Valerate Betamethasone-17,21-dipropionate Betamethasone benzoate Betamethasone sodium phosphate Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Anti-Asthmatic Agents Respiratory System Agents low low high low low low low low low low low low low The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times. 1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times. D000001623 Betamethasone Autologous adipose-derived MSCs Compound betamethasone  Biological Drug",1,200
497,Biological: Intravenous infusion placebo Biological: Intravenous infusion WJMSCs Biological: Intravenous infusion placebo Biological: Intravenous infusion WJMSCs Parallel Assignment Placebo Comparator: Intravenous infusion WJMSCs +standard therapy Vs placebo+ standard therapy in patients with acute myocardial infarction   Placebo PBS WJMScs Placebo PBS WJMScs Infl All Anti-Inflammatory Agents All Drugs and Chemicals  M3369 Anti-Inflammatory Agents low Intravenous infusion placebo or WJMSCs in patients with AMI Intravenous infusion WJMSCs or placebo in patients with AMI   Intravenous infusion placebo Intravenous infusion WJMSCs PBS WJMSCs Biological Biological,1,200
498,"Biological: JOINTSTEM Drug: saline Parallel Assignment    JOINTSTEM saline       JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10^8cells/(saline), 1 time injection saline, 1 time injection   JOINTSTEM saline Autologous Adipose Tissue derived MSCs Biological Drug",1,260
499,"Drug: Conventional treatment Genetic: Conventional plus BM-MSC treatment Genetic: Conventional plus UC-MSC treatment Parallel Assignment  D000000890 Anti-Infective Agents Conventional plus BM-MSC treatment Conventional plus UC-MSC treatment Conventional treatment Infe All Hemat Lipd Ot Anti-Infective Agents All Drugs and Chemicals Hematinics Lipid Regulating Agents Other Dietary Supplements An 11- M3466 M10262 M230376 M20396 M34170 M219479 M341471 M3366 T404 Antiviral Agents Liver Extracts Entecavir Lamivudine Polyene phosphatidylcholine Adefovir Adefovir dipivoxil Anti-Infective Agents Lecithin high low low low low low low low low Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times). Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times) Received conventional treatment including:  A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma. D000000998 Antiviral Agents Conventional plus BM-MSC treatment Conventional plus UC-MSC treatment Conventional treatment Antiviral drugs Hepatoprotective drugs Plasma Genetic Genetic Drug",1,210
500,"Biological: mesenchymal stem cell Biological: mesenchymal stem cell Biological: mesenchymal stem cell Biological: mesenchymal stem cell Parallel Assignment    Routine AMR treatment plus MSC to prevent AMR Routine CMR treatment plus MSC to prevent CMR ia and iv of MSC to prevent rejection iv of BMSC to prevent rejection All All Drugs and Chemicals  M9336 M3382 M3377 Immunoglobulins Antibodies, Monoclonal Antibodies low low low    mesenchymal stem cell  Biological",1,260
501,Genetic: autologous peripheral blood mesenchymal stem cell Procedure: Microfracture Combination Product: Microfracture + collagen membrane Procedure: Autologous osteochondral transplantation Parallel Assignment    test group control group 1 control group 2 control group 3       Transplantation of autologous peripheral blood mesenchymal stem cell Microfracture Microfracture plus collagen membrane transplantation Autologous osteochondral transplantation   autologous peripheral blood mesenchymal stem cell Microfracture Microfracture + collagen membrane Autologous osteochondral transplantation  Genetic Procedure Combination Product Procedure,1,252
502,"Biological: UC-MSC Biological: UC-MSC Biological: UC-MSC Parallel Assignment Patients with decompensated liver cirrhosis are going to be assigned to receive standard medical care plus UC-MSC treatment with two different protocol (group 1 and group 2) or standard medical care (control). Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1（once every 4 days), and two times of MSC infusion once every 7 days to group 2.   Control group MSC group 1 MSC group 2 Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.   UC-MSC Human umbilical cord mesenchymal stem cells Biological",1,252
503,Biological: UC-MSCs Parallel Assignment    UC-MSCs treatment       The UC-MSCs will be administrated by intravenous injection at the dose of 1×10^6 cells/kg.   UC-MSCs placebo Biological,1,250
504,"Biological: Intravenous infusion of MSCs Drug: Etanercept Parallel Assignment  D000000894 D000018712 D000000700 D000018689 D000018373 D000045505 D000000893 D000018501 D000005765 D000007166 D000007155 Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Gastrointestinal Agents Immunosuppressive Agents Immunologic Factors Intravenous infusion of MSCs Etanercept Infl ARhu Analg Gast All Anti-Inflammatory Agents Antirheumatic Agents Analgesics Gastrointestinal Agents All Drugs and Chemicals SARS-CoV- M311 M3369 M3370 M3184 M19939 M19757 M8033 M9364 M9353 Etanercept Anti-Inflammatory Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics Analgesics, Non-Narcotic Antirheumatic Agents Gastrointestinal Agents Immunosuppressive Agents Immunologic Factors high low low low low low low low low Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop 50mg,hypodermic injection,once per week, for 12 weeks D000068800 Etanercept Intravenous infusion of MSCs Etanercept TNF alpha receptor inhibitor Biological Drug",1,250
505,Biological: human umbilical cord mesenchymal stem cell Parallel Assignment    treatment group A （with mesenchymal stem cell intervention）       2*10^7   human umbilical cord mesenchymal stem cell  Biological,1,242
506,"Biological: UC-MSCs Biological: Placebo(solution without UC-MSCs) Parallel Assignment Randomized, double-blind, placebo-controlled, multicenter study   Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs) Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low 3 doses of UC-MSCs intravenously at week 0, week 4, week 8. 3 doses of placebo intravenously at week 0, week 4, week 8.   UC-MSCs Placebo(solution without UC-MSCs)  Biological Biological",1,240
507,Device: KIT BMAC AND at-SVF FIDIA Device: KIT BMAC AND at-SVF FIDIA Device: KIT BMAC AND at-SVF FIDIA Device: KIT BMAC AND at-SVF FIDIA Parallel Assignment    intra-articular injection of BMAC intra-articular injection of at- SVF intra-osseous and intra-articular injection of BMAC intraosseous and intra-articular injection of at-SVF       intra-articular infiltration or intra-articular and intra-osseous infiltration   KIT BMAC AND at-SVF FIDIA  Device,1,240
508,"Biological: Umbilical Cord Mesenchymal Stem Cells Biological: saline Parallel Assignment    Umbilical Cord Mesenchymal Stem Cells saline       stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells   Umbilical Cord Mesenchymal Stem Cells saline  Biological Biological",1,240
509,"Other: conventional treatment Other: UC-MSC transplantation Parallel Assignment    UC-MSC transplantation conventional Infe All Hemat Anti-Infective Agents All Drugs and Chemicals Hematinics  M3466 M10262 Antiviral Agents Liver Extracts low low After enrolled, Participant will receive umbilical cord MSC transplantation of 1*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit Participants will receive conventional treatment and antiviral treatment.   UC-MSC transplantation conventional treatment  Other Other",1,240
510,"Biological: mesenchymal stem cells Biological: saline Parallel Assignment    Autologous Bone Marrow Stem Cell saline       stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell saline injections   mesenchymal stem cells saline  Biological Biological",1,240
511,"Biological: UC-MSCs Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs） Parallel Assignment Randomized, double-blind, placebo-controlled, multicenter study   Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs) Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low 3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8. 3 does of placebo intravenously at week 0, week 4, week 8.   UC-MSCs Saline containing 1% Human serum albumin（solution without UC-MSCs）  Biological Biological",1,240
512,"Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) Other: Conventional Treatment Other: Conventional Treatment Parallel Assignment A single-blinded, randomized, multicenter trial.   Cohort 1 Cohort 1 Cohort 2 (Control Group) Antipy Infl ARhu FiAg Analg PlAggInh All VaDiAg Lipd Antipyretics Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Analgesics Platelet Aggregation Inhibitors All Drugs and Chemicals Vasodilator Agents Lipid Regulating Agents  M3700 M1812 M8254 M20308 M2823 Aspirin Ticagrelor Nitroglycerin Hydroxymethylglutaryl-CoA Reductase Inhibitors Adrenergic beta-Antagonists low low low low low Cell Tech Pharmed Company (Tehran, Iran) will provide us with cGMP grade WJ-MSCs. 10^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions. Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.   Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) Conventional Treatment  Biological Other",1,240
513,"Other: Mesenchymal stem cells Drug: Placebo of Mycophenolate Mofetil Drug: Mycophenolate Mofetil Other: Placebo of Mesenchymal stem cells Parallel Assignment  D000000903 D000000970 D000000904 D000000995 D000000900 D000000890 D000004791 D000045504 Antibiotics, Antineoplastic Antineoplastic Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Mesenchymal stem cells Mycophenolate Mofetil Mycophenolate Mofetil Mesenchymal stem cells Infl ANeo AnEm Gast All Infe Anti-Inflammatory Agents Antineoplastic Agents Antiemetics Gastrointestinal Agents All Drugs and Chemicals Anti-Infective Agents Bolus M6254 M11280 M235540 M3374 M3376 M3463 M3366 Dexamethasone Mycophenolic Acid Dexamethasone acetate Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Infective Agents low high low low low low low The group receive pulse infusion of MSCs once of 2 x 10^6/kg body weight This group receive oral MMF of 2.0 g / d. The group receive placebo of Mesenchymal stem cells. The group receive placebo of oral mycophenolate mofetil. D000009173 Mycophenolic Acid Mesenchymal stem cells Mycophenolate Mofetil Placebo of Mesenchymal stem cells Placebo of Mycophenolate Mofetil  Other Drug Other Drug",1,230
514,"Biological: Remestemcel-L Drug: Placebo Parallel Assignment This will be a randomized (1:1 ratio), double blind, parallel design, placebo controlled trial. D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Remestemcel-L Plus Standard of Care Placebo Plus Standard of Care PhSol All Infe Infl Pharmaceutical Solutions All Drugs and Chemicals Anti-Infective Agents Anti-Inflammatory Agents 1440 M85407 M186752 M3369 M3466 M3366 Plasma-lyte 148 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents low high low low low administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day) administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day) C000711674 Remestemcel-l Remestemcel-L Placebo  Biological Drug",1,223
515,Drug: Prochymal® Drug: Placebo Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Prochymal® Placebo Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals 1440 M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells Intravenous infusion of excipients of Prochymal® C000711674 Remestemcel-l Prochymal® Placebo Remestemcel-L Drug Drug,1,220
516,"Biological: MC0518 Biological: BAT Parallel Assignment    MC0518 Best Available Therapy (BAT) Infe ANeo All Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals  M11280 M255 M3431 Mycophenolic Acid Everolimus Antilymphocyte Serum low low low MC0518 will be intravenously infused immediately after thawing. BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.   MC0518 BAT  Biological Biological",1,210
517,"Biological: Biological: mesenchymal stem cell Drug: Cyclosporine and Glucocorticoid Parallel Assignment  D000004791 D000045504 D000007166 D000007155 D000045505 D000000935 D000000890 D000003879 D000018501 D000065095 D000006728 D000006730 Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Hormones Hormones, Hormone Substitutes, and Hormone Antagonists allogenic mesenchymal stem cells (MSCs) Control group Infe ARhu Derm All Infl ANeo AnEm NeuroAg Gast Hemat Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Anti-Inflammatory Agents Antineoplastic Agents Antiemetics Neuroprotective Agents Gastrointestinal Agents Hematinics Impact Impact Postprandial M18113 M5882 M8199 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M5879 M10262 M9364 M9353 M3406 M5404 M10948 M3366 M6226 M19757 M29605 M8941 M8940 Cyclosporine Cyclosporins Glucocorticoids Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Cyclophosphamide Liver Extracts Immunosuppressive Agents Immunologic Factors Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Hormones Hormone Antagonists high high high low low low low low low low low low low low low low low low low low low low low Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms. Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study. D000016572 D000003524 D000005938 Cyclosporine Cyclosporins Glucocorticoids Biological: mesenchymal stem cell Cyclosporine and Glucocorticoid Regenerative medicine: MSCs Calmodulin inhibitors combined with Glucocorticoid Biological Drug",1,100
518,Device: Autologous Bone Marrow Derived Mesenchymal Stem Cells Other: Sham incision Parallel Assignment Randomized Control Trial   Mesenchymal Stem Cell Recipient Control Sham Incision       Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation. Small incision over the site where bone marrow aspirate would have been obtained   Autologous Bone Marrow Derived Mesenchymal Stem Cells Sham incision Sham Incision Device Other,1,100
519,Biological: Chondrogen Biological: Placebo Parallel Assignment 100 patients will be selected from 2 different study sites. Each study site comprises 50 patients.   Active Participant of Phase 2B Clinical Study Chondrogen Placebo Participant of Phase 2B Clinical Study Chondrogen All All Drugs and Chemicals  M9030 Hyaluronic Acid low Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid Consist of saline and hyaluronic acid   Chondrogen Placebo Mesenchymal Stem Cell Biological Biological,1,100
520,"Biological: Stem Cell Preparation and Injection Single Group Assignment    Stem Cell Preparation and Injection       Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.  Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .  Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue.   Stem Cell Preparation and Injection  Biological",1,60
521,Drug: Conserved therapy Procedure: Autologous BMSCs transplantation Parallel Assignment    Group B (BMSC Transplantion) Group A(conserved therapy ) Infe All Hemat Anti-Infective Agents All Drugs and Chemicals Hematinics  M3466 M10262 Antiviral Agents Liver Extracts low low 10 ml autologous BMSCs(7~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B. Oral or intravenous administration   Autologous BMSCs transplantation Conserved therapy  Procedure Drug,1,60
522,"Biological: Non-mesenchymal stem cells Biological: Mesenchymal stem cells Parallel Assignment    Mesenchymal stem cells Non-mesenchymal stem cells       Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) every two weeks, four times for a cycle. Other second line drugs are taken.   Mesenchymal stem cells Non-mesenchymal stem cells MSCs Non-MSCs Biological Biological",1,60
523,"Drug: Allogeneic Mesenchymal Stromal Cell Other: Placebo Parallel Assignment    Allogeneic Mesenchymal Stromal Cell Placebo AdjAn CNSDep PsychDr All Analg Adjuvants, Anesthesia Central Nervous System Depressants Psychotropic Drugs All Drugs and Chemicals Analgesics  M10997 M7570 Midazolam Fentanyl low low Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5*10^6 MSC per site; total 150*10^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary. Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.   Allogeneic Mesenchymal Stromal Cell Placebo Allogeneic bone marrow-derived mesenchymal stromal cells Allogeneic bone marrow-derived mesenchymal stem cells Allogeneic BM-MSC Drug Other",1,60
524,Drug: Conserved therapy Procedure: Allogenic bone marrow stem cells transplantation Parallel Assignment    Group B (BMSC Transplantion) Group A(conserved therapy ) Infe All Hemat Anti-Infective Agents All Drugs and Chemicals Hematinics  M3466 M10262 Antiviral Agents Liver Extracts low low 30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy Oral or intravenous administration   Allogenic bone marrow stem cells transplantation Conserved therapy  Procedure Drug,1,60
525,"Biological: COVI-MSC Biological: Placebo Parallel Assignment    COVI-MSC Placebo       2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.  Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4  Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4  Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2  Group D: 2 MSC vials infused on D0, D2 and D4 6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.   COVI-MSC Placebo  Biological Biological",1,60
526,"Biological: MSCs Drug: AZM Drug: Glucocorticoid Drug: AZM Drug: Glucocorticoid Parallel Assignment  D000006728 D000006730 D000045505 Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs MSCs MSCs Non-MSCs MSCs Non-MSCs All Infe All Drugs and Chemicals Anti-Infective Agents Postprandial M8199 M19284 M8941 M8940 Glucocorticoids Azithromycin Hormones Hormone Antagonists high low low low MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 weeks as one cycle treatment. AZM will be given （0.25g qd）for 4 weeks as one cycle treatment. Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment. D000005938 Glucocorticoids MSCs AZM Glucocorticoid  Biological Drug Drug",1,60
527,"Drug: Oseltamivir Drug: hormones Device: oxygen therapy Drug: Oseltamivir Drug: hormones Device: oxygen therapy Procedure: mesenchymal stem cells Parallel Assignment Control group: conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies; Experimental group: On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106 / Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission. D000006730 D000045505 D000000998 D000000890 D000004791 D000045504 Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Control group Experimental group Control group Experimental group Control group Experimental group Experimental group All Infe All Drugs and Chemicals Anti-Infective Agents Include Oxidative M8941 M3466 M26299 M8940 M3366 Hormones Antiviral Agents Oseltamivir Hormone Antagonists Anti-Infective Agents high low high low low Oseltamivir capsules a moderate amount of hormone oxygen therapy,mechanical ventilation and other supportive therapies mesenchymal stem cells D000053139 D000006728 Oseltamivir Hormones Oseltamivir hormones oxygen therapy mesenchymal stem cells  Drug Drug Device Procedure",1,60
528,"Biological: Mesenchymal stem cells Biological: Mesenchymal stem cells and cord blood Parallel Assignment    Mesenchymal stem cells Mesenchymal stem cells and cord blood       Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given. Mesenchymal stem cells will be given (at a dose of 1×10^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.   Mesenchymal stem cells Mesenchymal stem cells and cord blood  Biological Biological",1,60
529,Procedure: rehabilitation of limb function Procedure: Stem Cells Transplantation Factorial Assignment    rehabilitation Stem Cell Transplantation       only receive rehabilitation of limb function mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture   rehabilitation of limb function Stem Cells Transplantation phsical exercise rehabilitation Procedure Procedure,1,60
530,"Drug: AstroStem Drug: Placebo Parallel Assignment    Treatment Placebo Control       Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36. Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.   AstroStem Placebo AstroStem Placebo Drug Drug",1,100
531,"Biological: Auotologous BMSCs plus autologous PRP Biological: Auotologous PRP Parallel Assignment    BMSCs plus PRP group PRP group       30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP. 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.   Auotologous BMSCs plus autologous PRP Auotologous PRP  Biological Biological",1,60
532,Biological: BM-MNC and UC-MSC Other: Control Parallel Assignment    BM-MNC and UC-MSC Stand medicines       Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.  UC-MSC: 1-2 x 10^6 cells/kg Standard medicine   BM-MNC and UC-MSC Control  Biological Other,1,60
533,Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells Biological: Plasma-Lyte A Parallel Assignment  D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions Human Mesenchymal Stromal Cells (hMSCs) Plasma-Lyte A (placebo) PhSol All Pharmaceutical Solutions All Drugs and Chemicals Chronic Lung Disease M85407 M21013 M11966 Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions high low low Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes. Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes. C000012499 Plasma-lyte 148 Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells Plasma-Lyte A  Biological Biological,1,60
534,"Biological: Low Dose of Mesenchymal stem cell Biological: High Dose of Mesenchymal stem cell Drug: Sodium Hyaluronate Parallel Assignment low dose of dental pulp mesenchymal stem cells high dose of dental pulp mesenchymal stem cells Sodium hyaluronate D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Low Dose of Mesenchymal stem cell High Dose of Mesenchymal stem cell Sodium Hyaluronate All All Drugs and Chemicals PCOS M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Mesenchymal stem cell injection Mesenchymal stem cell injection Sodium Hyaluronate injection D000006820 Hyaluronic Acid Low Dose of Mesenchymal stem cell High Dose of Mesenchymal stem cell Sodium Hyaluronate 1 2 3 Biological Biological Drug",1,60
535,"Biological: Umbilical cord derived Mesenchymal Stem Cells Biological: Umbilical cord derived Mesenchymal Stem Cells Other: Supervised physical therapy Other: Supervised physical therapy Parallel Assignment    Injection of Umbilical cord derived UC- MSCs injection of UC- MSCs and SPT Supervised Physical Therapy (SPT) injection of UC- MSCs and SPT       Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients A combined physical therapy program of Balance, strengthening and endurance exercises   Umbilical cord derived Mesenchymal Stem Cells Supervised physical therapy UC-MSCs SPT Biological Other",1,60
536,"Biological: Mesenchymal stem cells Single Group Assignment    Mesenchymal stem cells       Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.   Mesenchymal stem cells  Biological",1,60
537,"Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) Drug: conventional treatment Drug: conventional treatment Parallel Assignment    Treatment group Control group Treatment group NaAg All CaAg VaDiAg PlAggInh Natriuretic Agents All Drugs and Chemicals Cardiotonic Agents Vasodilator Agents Platelet Aggregation Inhibitors  M7936 M21096 M3286 M28069 M2823 Furosemide Milrinone Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists Adrenergic beta-Antagonists low low low low low Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation. The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.   Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) conventional treatment  Biological Drug",1,60
538,Biological: PNEUMOSTEM Other: Placebo Parallel Assignment    PNEUMOSTEM Placebo       human umbilical cord blood-derived mesenchymal stem cells normal saline   PNEUMOSTEM Placebo  Biological Other,1,60
539,"Procedure: HAM and HUMCWJ Injections Parallel Assignment    HAM and HUMCWJ Injections (Group 1)       SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.   HAM and HUMCWJ Injections  Procedure",1,60
540,"Biological: it-hMSC Biological: it-hMSC Biological: it-hMSC Biological: it-hMSC Biological: it-hMSC Biological: it-hMSC Parallel Assignment 3 arms for phase 1, and 3 arms for pashe 2   High dose group Highest dose cell group Low dose group Middle dose group Sub high dose cell group placebo group       Different doses of it-hMSC   it-hMSC  Biological",1,60
541,"Procedure: Coronary bypass operation Procedure: Bone marrow aspiration (crista iliaca) Biological: Intramyocardial mesenchymal stem cell transplantation Procedure: Coronary bypass operation Procedure: Bone marrow aspiration (crista iliaca) Biological: Intramyocardial injection of autologous serum Factorial Assignment    A B A B A B       Coronary bypass operation is performed via sternotomy during cardiac arrest. The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark). During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml) Intramyocardial injection of autologous serum is injected during cardiac arrest   Coronary bypass operation Bone marrow aspiration (crista iliaca) Intramyocardial mesenchymal stem cell transplantation Intramyocardial injection of autologous serum CABG Stem cell harvest Stem cell therapy Stem cell control therapy Procedure Procedure Biological Biological",1,60
542,Biological: Olfactory mucosa-derived mesenchymal stem cells Other: Standard treatment of type Allergic Rhinitis according to the clinical protocols Biological: Olfactory mucosa-derived mesenchymal stem cells Other: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols Other: Standard treatment of type Allergic Rhinitis according to the clinical protocols Other: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols Parallel Assignment    Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells Patients with allergic rhinitis receiving standard treatment Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells Patients with chronic polypous rhinosinusitis receiving standard treatment Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells       Olfactory mucosa-derived mesenchymal stem cells Standard treatment of type Allergic Rhinitis according to the clinical protocols Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols   Olfactory mucosa-derived mesenchymal stem cells Standard treatment of type Allergic Rhinitis according to the clinical protocols Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols  Biological Other Other,1,60
543,Drug: Mesenchymal Precursor Cells (MPCs) Drug: Mesenchymal Precursor Cells (MPCs) Drug: Mesenchymal Precursor Cells (MPCs) Parallel Assignment    Cohort 1 Cohort 2 Cohort 3 Hypo All Hypoglycemic Agents All Drugs and Chemicals  M10819 Metformin low Single intravenous infusion of MPCs Dose 1 Single intravenous infusion of MPCs Dose 2 Single intravenous infusion of MPCs Dose 3   Mesenchymal Precursor Cells (MPCs) Mesenchymal Precursor Cells (MPCs) Mesenchymal Precursor Cells (MPCs)  Drug Drug Drug,1,61
544,"Biological: Mesenchymal Stromal Cells Single Group Assignment Non-controlled, non-randomized, open label study   Mesenchymal Stromal Cells       Suspension of mesenchymal stromal cells for intratissular injection   Mesenchymal Stromal Cells  Biological",1,60
545,"Drug: Quercetin Cap/Tab ,Fisetin Cap/Tab Drug: Quercetin Cap/Tab,Fisetin Cap/tab,Glycyrrhizin capsules Other: Placebo Parallel Assignment  D000000975 D000045504 D000020011 D000045505 D000000893 Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Anti-Inflammatory Agents (Quercetin +Fisetin) Quercetin +Fisetin +Glycyrrhizin) Placebo All Infl Fl HB All Drugs and Chemicals Anti-Inflammatory Agents Flavonoid Herbal and Botanical IRI Restylane Perlane IRI Pibrentasvir M13796 M20763 M3444 M21022 M3369 T41 T28 T208 Quercetin Glycyrrhizic Acid Antioxidants Protective Agents Anti-Inflammatory Agents Quercetin Fisetin Licorice high high low low low high high low Quercetin and Fisetin areNatural senolytic agents . Quercetin and Fisetin are Natural senolytic agents, Glycyrrhizin is Licorice extract These are capsules without active ingredients for control group D000019695 D000011794 Glycyrrhizic Acid Quercetin Quercetin Cap/Tab ,Fisetin Cap/Tab Quercetin Cap/Tab,Fisetin Cap/tab,Glycyrrhizin capsules Placebo  Drug Drug Other",1,60
546,Drug: Exosome-MSC Intravenous injection Drug: COVID-19 Standard Treatment Drug: Placebo Intravenous Injection Drug: COVID-19 Standard Treatment Parallel Assignment    Intervention group Control group Control group Intervention group       Intravenous injection of Exosome-MSC Intravenous injection of Placebo Specific drugs considered standard treatment for COVID-10 by each location may vary   Exosome-MSC Intravenous injection Placebo Intravenous Injection COVID-19 Standard Treatment Dermama Exosome-MSC Placebo Drugs accepted as cures for COVID-19 Drug Drug Drug,1,60
547,Biological: placebo Biological: mesenchymal cell transplantation Parallel Assignment    mesencymal stem cell placebo       Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.   mesenchymal cell transplantation placebo  Biological Biological,1,60
548,"Procedure: Cardiac catheterization Biological: Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells Procedure: Cardiac catheterization Parallel Assignment    Control Group Main Group Main Group FiAg AnCoag All Fibrinolytic Agents Anticoagulants All Drugs and Chemicals  M8731 M45326 M15911 Heparin Calcium heparin Tin Fluorides low low low Catheterization of the right and left heart cavities After performing cardiac catheterization, selective coronary angiography will be performed abruptly to assess the condition of the coronary canal by access through the right radial or common femoral artery on the right after 70 U/kg of heparin iv. Then 20 ml of the finished suspension (1×10(7) umbilical cord-derived mesenchymal stromal cells diluted in 20 ml of heparinized saline) will be administrated into the mouth of the left coronary artery (LCA) without occlusion of the vessel with a balloon catheter and without stopping the coronary blood flow. Cell injection will be carried out using a standard 6 Fr catheter for selective coronary angiography with perfusion for 10 minutes at a volume rate of 2 ml/min, thereby introducing 1×10(6) cells per minute   Cardiac catheterization Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells  Procedure Biological",1,60
549,"Biological: urine collection Biological: urine collection Biological: urine collection Biological: urine collection     Non-obese patients with impaired renal function Non-obese patients with normal renal function (control group) Obese patients with impaired renal function Obese patients with normal renal function       To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.   urine collection  Biological",1,60
550,"Biological: Mesenchymal stem cell Other: Placebo Parallel Assignment    Treatment Placebo PhSol All FiAg AnCoag Pharmaceutical Solutions All Drugs and Chemicals Fibrinolytic Agents Anticoagulants  M21013 M8731 M45326 Pharmaceutical Solutions Heparin Calcium heparin low low low Administration of advanced cell product Ringer's lactate, albumin and heparin solution   Mesenchymal stem cell Placebo  Biological Other",1,60
551,Biological: Autologous Stromal Vascular Fraction (SVF) Biological: Autologous Adipose Derieved MSCs Other: Control Parallel Assignment    Autologous Stromal Vascular Fraction Autologous Adipose Derived MSCs Control       Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly   Autologous Stromal Vascular Fraction (SVF) Autologous Adipose Derieved MSCs Control Autologous Stromal Vascular Fraction Biological Biological Other,1,60
552,"Biological: Biological/Vaccine: Allogeneic HB-adMSCs Other: Placebo Biological: Biological/Vaccine: Allogeneic HB-adMSCs Other: Placebo Parallel Assignment A parallel study is a type of clinical study where two groups of treatments, A (allogeneic HB-adMSCs) and B (Placebo), are given so that one group receives only A while another group receives only B.   Allogeneic HB-adMSCs. Placebo Allogeneic HB-adMSCs. Placebo All PhSol All Drugs and Chemicals Pharmaceutical Solutions  M16512 M21013 Vaccines Pharmaceutical Solutions low low HB-adMSCs will be administered intravenously to study participants who qualify. Sterile Saline Solution 0.9%   Biological/Vaccine: Allogeneic HB-adMSCs Placebo Allogeneic Hope Biosciences adipose derived mesenchymal stem cells. Placebo will be administered intravenously to study participants who qualify. Biological Other",1,60
553,Other: Cord Blood Mononuclear Cells (UCB-MNCs) Other: normal saline Parallel Assignment    control group stem cell treating group       Intra-articular injection of normal saline Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)   normal saline Cord Blood Mononuclear Cells (UCB-MNCs)  Other Other,1,60
554,"Biological: Cell therapy protocol 1 Biological: Cell therapy protocol 2 Parallel Assignment    Two MSC infusion Two MSC infusion Plus two EVs infusion       Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment. Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.   Cell therapy protocol 1 Cell therapy protocol 2  Biological Biological",1,60
555,Biological: Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter Biological: Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter. Parallel Assignment    Differentiated stem cell therapy group undifferentiated stem cell therapy group          Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.  Biological Biological,1,60
556,Other: Saline Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Parallel Assignment    Treatment Arm 2 Treatment Arm 1       Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Placebo Saline   Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Saline  Biological Other,1,60
557,"Biological: Auotologous AMSCs plus autologous PRP Biological: Auotologous PRP Parallel Assignment    AMSCs plus PRP group PRP group       150 mL subcutaneous abdominal adipose tissue will be harvested via liposuction . AMSCs will be isolated and cultured from adipose tissue. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.Cultured AMSCs will be collected and suspended by 3ml autologous PRP. 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.   Auotologous AMSCs plus autologous PRP Auotologous PRP  Biological Biological",1,60
558,"Biological: Umbilical-cord mesenchymal stromal cells (UC-MSCs) Other: Hyaluronic acid Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Intervention group Control group All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Allogeneic UC-MSCs 1 x 10~7 diluted on 5 mL of Platelet Rich Plasma intra-articular injection of Hyaluronic Acid D000006820 Hyaluronic Acid Umbilical-cord mesenchymal stromal cells (UC-MSCs) Hyaluronic acid  Biological Other",1,60
559,Drug: it-hMSC Drug: Placebo Parallel Assignment    Experimental: it-hMSC Placebo-controlled: Placebo       Single intravenous infusion of it-hMSC for ischemic stroke patients Single intravenous infusion of 1 ml/kg placebo   it-hMSC Placebo  Drug Drug,1,60
560,"Biological: Autologous mesenchymal stem cells Parallel Assignment    study group ChanBlk Analg AntiConv CNSDep PsychDr All Hypo Channel Blockers Analgesics Anticonvulsants Central Nervous System Depressants Psychotropic Drugs All Drugs and Chemicals Hypoglycemic Agents  M4632 M1701 M1711 M3398 M16535 M12692 Carbamazepine Lamotrigine Topiramate Anticonvulsants Valproic Acid Phenobarbital low low low low low low Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.   Autologous mesenchymal stem cells  Biological",1,60
561,"Other: placebo Biological: MESENDO Single Group Assignment    MESENDO Placebo       For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin. For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe   MESENDO placebo  Biological Other",1,60
562,"Biological: MSC Parallel Assignment Part 1: totally 30 patient will be enrolled, and 15 patients will be given MSC immediately after ascending aortic replacement combined with open placement of triple-branched stent graft for ATAAD.  Part 2: totally 30 patient will be enrolled, and 15 patients will be given MSC after onset of multiple organ dysfuntion syndrome after ascending aortic replacement combined with open placement of triple-branched stent graft for ATAAD.   Mesenchymal stem cell       MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times   MSC  Biological",1,60
563,Drug: Transplantation of mesenchymal stem cell Drug: No Transplantation of Mesenchymal Stem Cell Parallel Assignment    Transplantation of Mesenchymal Stem Cell No Transplantation of Mesenchymal Stem Cell       Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.  Dose A - 1 million cells per kg Dose B - 5 million cells per kg Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.   Transplantation of mesenchymal stem cell No Transplantation of Mesenchymal Stem Cell  Drug Drug,1,57
564,"Biological: Low-dose UC-MSCs Biological: High-dose UC-MSCs Drug: Methotrexate Crossover Assignment  D000000020 D000000019 D000012102 D000045505 D000000964 D000000963 D000045504 D000000970 D000003879 D000004791 D000005493 D000007166 D000007155 D000018501 D000019384 Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Nucleic Acid Synthesis Inhibitors Low-Dose UC-MSCs High-Dose UC-MSCs Methotrexate ANeo ARhu Derm Repr All Micro Hemat Vi Antineoplastic Agents Antirheumatic Agents Dermatologic Agents Reproductive Control Agents All Drugs and Chemicals Micronutrients Hematinics Vitamins Into M10855 M3433 M6226 M7770 M16698 M7771 M9364 M9353 M19757 T447 T446 T448 T475 Methotrexate Antimetabolites Dermatologic Agents Folic Acid Vitamin B Complex Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Folinic Acid Folic Acid Folate Vitamin B9 high low low low low low low low low low low low low Participants will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）. Participants will receive 6 times UC-MSCs infusions (each time 3×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）. Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15). D000008727 Methotrexate Low-dose UC-MSCs High-dose UC-MSCs Methotrexate regenskin regenskin Biological Biological Drug",1,57
565,Biological: ALLO-ASC-DFU Procedure: Hydrogel SHEET(Vehicle control) Parallel Assignment    ALLO-ASC-DFU Hydrogel SHEET(Vehicle control)       Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer Application of Hydrogel SHEET to diabetic foot ulcer   ALLO-ASC-DFU Hydrogel SHEET(Vehicle control) Hydrogel sheet containing Allogenic Mesenchymal Stem Cells Hydrogel sheet without Allogenic Mesenchymal Stem Cells Biological Procedure,1,56
566,"Biological: HB-adMSCs Single Group Assignment    HB-adMSCs       Five IV infusion of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2,6,10,14,18,22,26.   HB-adMSCs  Biological",1,56
567,Biological: Orbcel-C Biological: Orbcel-C Parallel Assignment    AiH patients PSC patients Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Selected Mesenchymal Stromal Cells derived from human ubmical cord   Orbcel-C  Biological,1,56
568,Drug: remestemcel-L Single Group Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Remestemcel-L 2×10^6 MSCs/kg Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals 1440 M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low Participants were treated with IV remestemcel-L at a dose of 2 x 10^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion. C000711674 Remestemcel-l remestemcel-L  Drug,1,55
569,Biological: HB-adMSCs Biological: HB-adMSCs Biological: HB-adMSCs Other: Placebos Parallel Assignment    Allogeneic HB-adMSCs 100MM Allogeneic HB-adMSCs 200MM Allogeneic HB-adMSCs 50MM Placebo       Hope Biosciences allogeneic adipose-derived mesenchymal stem cells Saline   HB-adMSCs Placebos  Biological Other,1,55
570,"Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix Other: Untreated contemporaneous cohort Parallel Assignment Treatment arm subjects receiving PMSC-ECM (Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix). Additionally, we will follow a contemporaneous cohort of patients undergoing routine fetal or postnatal MMC repair without PMSC-ECM (non-PMSC untreated contemporaneous cohort). 35 participants will be enrolled under the treatment arm and 20 participants will be enrolled under the untreated contemporaneous cohort.  The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.   Treatment with PMSC-ECM non-PMSC untreated contemporaneous cohort Infe All Analg Anti-Infective Agents All Drugs and Chemicals Analgesics  M3374 M3184 M3376 Anti-Bacterial Agents Analgesics Antibiotics, Antitubercular low low low As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion. The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.   Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix Untreated contemporaneous cohort PMSC-ECM non-PMSC-ECM Biological Other",1,55
571,"Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8) Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8) Drug: MSC-exosomes delivered intravenously every other day (8:8:8) Drug: MSC-exosomes delivered intravenously every other day (8:8:8) Sequential Assignment Nested Cohort with Escalating Dose. The trial has three cohorts of 5 patients each. The subsequent cohort will receive an escalating dose of exosomes via intravenous infusion. The final group of 40 participants will be randomized 1:3 (placebo:intervention).   Escalating Dose First Cohort Escalating Dose Second Cohort Escalating Dose Third Cohort Treatment Dose Fourth Cohort Randomized control ratio 1:3       Escalating dose 2 X 10^9, 4 X 10^9, 8 X 10^9/mL Escalating dose 8 X 10^9, 4 X 10^9, 8 X 10^9 mL Dosed 8 X 10^9, 8 X 10^9, 8 X 10^9 mL   MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8) MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8) MSC-exosomes delivered intravenously every other day (8:8:8) Ardoxso Ardoxso Ardoxso Drug Drug Drug",1,55
572,Biological: UC-MSCs Biological: Placebo Parallel Assignment Randomized (2:1) placebo-controlled trial   MSCs Arm Placebo Arm PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M85407 Plasma-lyte 148 low 3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs) PlasmaLyte A and 5% Human Albumin   UC-MSCs Placebo  Biological Biological,1,54
573,"Biological: autologous adipose derived stem cells Biological: autologous adipose derived stem cells Biological: autologous adipose derived stem cells Sequential Assignment Combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients who failed disease-modifying antirheumatic drug (DMARDs).   Phase 1 ARM 0 Phase 2 ARM 1 Phase 2 ARM 2       Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue   autologous adipose derived stem cells Celltex-AdMSCs Biological",1,54
574,"Biological: bone marrow mesenchymal stem cells Biological: Adipose Mesenchymal stem cells Biological: bone marrow & adipose mesenchymal stem cells injection Parallel Assignment A total of 54 patients with the diagnosis of knee OA grade II and III will be recruited to receive a single intra-articular injection of MSC: Group 1 (n 18 patients) will receive BM-MSC, Group 2 (n 18 patients) will receive AD-MSC. Group 3 (18 patients) will receive a combination of BM-MSC and AD-MSC.   bone marrow mesenchymal stem cell adipose mesenchymal stem cells Bone marrow and Adipose mesenchymal stem cells       intrarticular bone marrow mesenchymal stem cells injection intrarticular adipose mesenchymal stem cells injection intrarticular bone marrow and adipose stem cells injection.   bone marrow mesenchymal stem cells Adipose Mesenchymal stem cells bone marrow & adipose mesenchymal stem cells injection  Biological Biological Biological",1,54
575,Biological: Cellgram-ED Parallel Assignment    Injection group: Cellgram-ED All All Drugs and Chemicals  M28485 Phosphodiesterase 5 Inhibitors low Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.   Cellgram-ED Autologous bone marrow derived mesenchymal stem cell Biological,1,54
576,Biological: ALLO-ASC-DFU Other: Standard therapy     ALLO-ASC-DFU Standard therapy       Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention. Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.   ALLO-ASC-DFU Standard therapy Allogeneic mesenchymal stem cells Biological Other,1,54
577,"Biological: XSTEM-OA Single Group Assignment    XSTEM-OA       XSTEM-OA is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of osteoarthritis.   XSTEM-OA  Biological",1,54
578,Biological: Mesenchymal Stromal Cells Other: Placebo Parallel Assignment    Experimental Placebo       Intravenous injection of 1 million MSV cells/Kg diluted in 100 ml saline Intravenous injection of 100 ml saline containing no cells   Mesenchymal Stromal Cells Placebo MSV Biological Other,1,24
579,Biological: HB-adMSC Other: Placebo Parallel Assignment    HB-adMSCs Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Hope Biosciences allogeneic adipose-derived mesenchymal stem cells Saline   HB-adMSC Placebo  Biological Other,1,53
580,"Genetic: Stem cells Genetic: Placebo Parallel Assignment    Treatment Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low first cohort: 1 million stem cells/kg administered at days 1, 8 and 15 second cohort: 2 million stem cells / kg administered at days 1, 8 and 15 third cohort: 4 million stem cells / kg administered at days 1, 8 and 15 first cohort: 20 ml administered at days 1, 8 and 15 second cohort: 40 ml administered at days 1, 8 and 15 third cohort: 80 ml administered at days 1, 8 and 15   Stem cells Placebo  Genetic Genetic",1,53
581,Other: Laboratory Biomarker Analysis Procedure: Mesenchymal Stem Cell Transplantation Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Single Group Assignment    Treatment (MV-NIS infected mesenchymal stem cells) Treatment (MV-NIS infected mesenchymal stem cells) Treatment (MV-NIS infected mesenchymal stem cells) Micro Infe All Micronutrients Anti-Infective Agents All Drugs and Chemicals  M9640 Iodine low Correlative studies Given IP Given IP   Laboratory Biomarker Analysis Mesenchymal Stem Cell Transplantation Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter MV-NIS Other Procedure Biological,1,57
582,Biological: Mesenchymal stromal cell Biological: Saline Parallel Assignment    1 2       Mesenchymal stromal cells 20 - 40 mill. 12 injection with 0.2 ml saline   Mesenchymal stromal cell Saline  Biological Biological,1,59
583,Biological: Provacel Biological: Provacel Biological: Provacel Biological: Provacel Biological: Placebo Parallel Assignment    Provacel: Cohort 1 Provacel: Cohort 2 Provacel: Cohort 3 Provacel: Cohort 4 Placebo       ex vivo cultured adult mesenchymal stem cells Placebo   Provacel Placebo  Biological Biological,1,60
584,Biological: ALLO-ASC-DFU Other: Standard therapy Parallel Assignment    ALLO-ASC-DFU Standard therapy       Application of ALLO-ASC-DFU sheet to diabetic foot ulcer Standard therapy conducted for patients with diabetic foot ulcer   ALLO-ASC-DFU Standard therapy Allogeneic mesenchymal stem cells Biological Other,1,59
585,"Biological: adipose derived mesenchymal stem cells Drug: Conventional drug therapy（expectorant，bronchodilator） Drug: Conventional drug therapy（expectorant，bronchodilator） Parallel Assignment  D000001337 D000018373 D000045505 D000018927 D000019141 Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Intervention group Control group Intervention group Resp All Respiratory System Agents All Drugs and Chemicals NCI Schema Therapy M4421 M7395 M20116 M20290 Bronchodilator Agents Expectorants Anti-Asthmatic Agents Respiratory System Agents high high low low The MSCs of 1×10*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg. Conventional drug therapy（expectorant，bronchodilator） D000001993 D000005100 Bronchodilator Agents Expectorants adipose derived mesenchymal stem cells Conventional drug therapy（expectorant，bronchodilator）  Biological Drug",1,60
586,"Other: BM-MSCs Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib) Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib) Parallel Assignment  D000074322 D000000970 D000007155 D000045505 D000018501 Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents MSCs group Control group MSCs group ANeo All ARhu Antineoplastic Agents All Drugs and Chemicals Antirheumatic Agents Peripheral Two M376 M9336 M3377 M373 M18269 M7988 M19343 M1346 M9353 M19757 Bortezomib Immunoglobulins Antibodies Rituximab Immunoglobulins, Intravenous gamma-Globulins Rho(D) Immune Globulin Antineoplastic Agents, Immunological Immunologic Factors Antirheumatic Agents high low low high low low low low low low BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients. At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition. D000069283 D000069286 Rituximab Bortezomib BM-MSCs Desensitization therapy (PP, IVIG, rituximab or Bortezomib) allogeneic bone marrow-derived MSCs Other Other",1,60
587,Procedure: Seton Placement Drug: AVB-114 Procedure: Seton Placement Parallel Assignment    Standard of Care Treatment Standard of Care Treatment + AVB-114 Standard of Care Treatment + AVB-114       This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable. AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.   Seton Placement AVB-114  Procedure Drug,1,60
588,"Biological: Exosome of MSC Parallel Assignment Part 1: totally 30 patient will be enrolled, and 15 patients will be given Exosomes of MSCs immediately after ascending aortic replacement combined with open placement of triple-branched stent graft for ATAAD.  Part 2: totally 30 patient will be enrolled, and 15 patients will be given Exosomes of MSC after onset of multiple organ dysfuntion syndrome after ascending aortic replacement combined with open placement of triple-branched stent graft for ATAAD.   The exosome of MSC arm       Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.   Exosome of MSC  Biological",1,60
589,Biological: MSC Biological: Saline Parallel Assignment    MSC Saline       No of cells after culture expansion 3 cc saline   MSC Saline Adipose derived stem cells Mesenchymal stromal cells Mesenchymal stem cells Biological Biological,1,60
590,Biological: PNEUMOSTEM® Biological: normal saline Parallel Assignment    PNEUMOSTEM® normal saline       A single intratracheal administration of PNEUMOSTEM® (1.0 x 10^7 cells/kg) A single intratracheal administration of normal saline   PNEUMOSTEM® normal saline Human umbilical cord blood-derived mesenchymal stem cells Biological Biological,1,60
591,Other: Mesenchymal stem cell Parallel Assignment    Mesenchymal stem cell treatment       intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum   Mesenchymal stem cell  Other,1,60
592,Biological: Mesenchymal Stem Cells (MSCs) Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin) Parallel Assignment  D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions Group A Treatment Group B Placebo All PhSol All Drugs and Chemicals Pharmaceutical Solutions CAB M3777 M85407 M21013 M11966 Autoantibodies Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions low high low low Patients in Group A will receive a single MSCs infusion Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin) C000012499 Plasma-lyte 148 Mesenchymal Stem Cells (MSCs) Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)  Biological Other,1,60
593,"Procedure: autologous bone marrow aspirate concentrate by centrifugation Procedure: autologous bone marrow aspirate concentrate by centrifugation Parallel Assignment double blind   control treatment with autologous bone marrow aspirate concentrate CNSDep All Analg Central Nervous System Depressants All Drugs and Chemicals Analgesics  M3259 M3184 Anesthetics Analgesics low low 50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.  Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.  Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.  The separated MNCs is administered intra-articularly immediately after centrifugation.   autologous bone marrow aspirate concentrate by centrifugation  Procedure",1,60
594,"Drug: Autologous Adipose-derived Mesenchymal Stromal Cells Single Group Assignment    Mesenchymal Stromal Cells       The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.   Autologous Adipose-derived Mesenchymal Stromal Cells  Drug",1,60
595,"Biological: Low dose mesenchymal stem cells Procedure: Intraarticular injection Biological: High dose mesenchymal stem cells Procedure: Intraarticular injection Parallel Assignment    Low dose mesenchymal stem cells High dose mesenchymal stem cells High dose mesenchymal stem cells Low dose mesenchymal stem cells       Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 * 10^7 cells (5ml); Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 * 10^7 cells (5ml) Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group   Low dose mesenchymal stem cells High dose mesenchymal stem cells Intraarticular injection  Biological Biological Procedure",1,60
596,Biological: Mesenchymal Precursor Cells (MPCs) Procedure: standard-of-care treatment with mock mapping and injection procedures. Biological: Mesenchymal Precursor Cells (MPCs) Procedure: standard-of-care treatment with mock mapping and injection procedures. Biological: Mesenchymal Precursor Cells (MPCs) Procedure: standard-of-care treatment with mock mapping and injection procedures. Factorial Assignment    A1 B1 C1 A2 B2 C2       25 M allogeneic MPCs by transendocardial injection and mapping. 75 M allogeneic MPCs by transendocardial injection and mapping. 150 M allogeneic MPCs by transendocardial injection Mock Mock Mock   Mesenchymal Precursor Cells (MPCs) Mesenchymal Precursor Cells (MPCs) Mesenchymal Precursor Cells (MPCs) standard-of-care treatment with mock mapping and injection procedures. standard-of-care treatment with mock mapping and injection procedures. standard-of-care treatment with mock mapping and injection procedures. Revascor Revascor Revascor Biological Biological Biological Procedure Procedure Procedure,1,60
597,Biological: Autologous Stromal Vascular Fraction (SVF) Biological: Autologous Adipose Derived MSCs (ADMSCs) Other: Control Parallel Assignment    Autologous Stromal Vascular Fraction Autologous Adipose Derived MSCs Control Infl ANeo All AnEm NeuroAg Gast ARhu Infe Resp Analg Anti-Inflammatory Agents Antineoplastic Agents All Drugs and Chemicals Antiemetics Neuroprotective Agents Gastrointestinal Agents Antirheumatic Agents Anti-Infective Agents Respiratory System Agents Analgesics  M13272 M1833 M10901 M10902 M229437 M211896 M248768 M5879 M2627 M244015 M3830 M194716 M9364 M3444 Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Cyclophosphamide Acetylcysteine N-monoacetylcystine Azathioprine Pirfenidone Immunosuppressive Agents Antioxidants low low low low low low low low low low low low low low Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously. Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals. Standard Therapy   Autologous Stromal Vascular Fraction (SVF) Autologous Adipose Derived MSCs (ADMSCs) Control Autologous Stromal Vascular Fraction Autologous Adipose Derived MSCs Biological Biological Other,1,60
598,Device: Lipogems Single Group Assignment    injection       harvest and inject micro-fragment adipose tissue   Lipogems  Device,1,60
599,Biological: Percutaneous injection Other: Percutaneous injection Parallel Assignment    MSC recipients Placebo       percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture. Percutaneous implantation of placebo in patients with nonunion fracture.   Percutaneous injection Percutaneous injection  Biological Other,1,60
600,"Biological: PRG combined with BMMSCs transplantation Biological: PRG combined with BMMSCs transplantation Parallel Assignment diabetic foot ulcer which Wagner classification at 2-3 grade.   PRG combined with BMMSCs transplantation Traditional treatment Hypo All Hypoglycemic Agents All Drugs and Chemicals  M9517 M172956 Insulin Insulin, Globin Zinc low low PRG combined with BMMSCs transplantation   PRG combined with BMMSCs transplantation PRG Biological",1,60
601,"Biological: Dosage 1 of MPCs-derived exosomes Biological: Dosage 2 of MPCs-derived exosomes Biological: No MPCs-derived exosomes Parallel Assignment    MPCs-derived exosomes Dosage 1 MPCs-derived exosomes Dosage 2 No exosomes       7 times aerosol inhalation of MPCs-derived exosomes (8.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7). 7 times aerosol inhalation of MPCs-derived exosomes (16.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7). No aerosol inhalation of MPCs-derived exosomes   Dosage 1 of MPCs-derived exosomes Dosage 2 of MPCs-derived exosomes No MPCs-derived exosomes  Biological Biological Biological",1,60
602,Drug: Prochymal™ Drug: Placebo Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Prochymal™ Placebo Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals Unsuccessful M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low IV infusion of ex- vivo cultured adult human mesenchymal stem cells. IV infusion of excipient of Prochymal™. C000711674 Remestemcel-l Prochymal™ Placebo  Drug Drug,1,62
603,Combination Product: Mesenchymal stem cells associated with biomaterials Combination Product: Iliac crest autogenous bone graft Parallel Assignment    Mesenchymal stem cells associated with biomaterials Iliac crest autogenous bone graft       Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen. Autogenous bone will be obtained from iliac crest.   Mesenchymal stem cells associated with biomaterials Iliac crest autogenous bone graft  Combination Product Combination Product,1,62
604,Biological: Pneumostem® Biological: normal saline Parallel Assignment    Pneumostem® normal saline          Pneumostem® normal saline Human umbilical cord blood-derived mesenchymal stem cells Biological Biological,1,62
605,"Drug: Placebos Drug: Low dose allogeneic mesenchymal stromal cells Drug: High dose allogeneic mesenchymal stromal cells Parallel Assignment    High dose treatment arm Low dose treatment arm Control arm       Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly 0,9% physiological saline   High dose allogeneic mesenchymal stromal cells Low dose allogeneic mesenchymal stromal cells Placebos  Drug Drug Drug",1,90
606,Product in a Institute of Bio-Stem Cell rehabilitation UAB - sponsored clinical trial who agree to participate in this study   Observational  Other,1,86
607,"Drug: Thymoglobulin Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation Procedure: Bone marrow infusion Drug: Tacrolimus Drug: Mycophenolate Mofetil Drug: Thymoglobulin Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation Procedure: Bone marrow infusion Drug: Tacrolimus Drug: Mycophenolate Mofetil Biological: Donor mesenchymal stem cell infusions Drug: Thymoglobulin Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation Procedure: Bone marrow infusion Drug: Tacrolimus Drug: Mycophenolate Mofetil Biological: Donor mesenchymal stem cell infusions Drug: Thymoglobulin Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation Procedure: Bone marrow infusion Drug: Mycophenolate Mofetil Drug: Thymoglobulin Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation Procedure: Bone marrow infusion Drug: Mycophenolate Mofetil Biological: Donor mesenchymal stem cell infusions Drug: Thymoglobulin Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation Procedure: Bone marrow infusion Drug: Tacrolimus Drug: Mycophenolate Mofetil Drug: Busulfan Drug: Thymoglobulin Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation Procedure: Bone marrow infusion Drug: Tacrolimus Drug: Mycophenolate Mofetil Biological: Donor mesenchymal stem cell infusions Drug: Busulfan Parallel Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 D000000964 D000000963 D000000998 D000000890 D000065095 D000004791 D000000903 D000000904 D000000995 D000000900 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antimetabolites, Antineoplastic Antimetabolites Antiviral Agents Anti-Infective Agents Calcineurin Inhibitors Enzyme Inhibitors Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Arm C: Re-Transplant with 300 cGy of TBI Arm D: HCT with 200 cGy BID of TBI Arm E: HCT plus MSC, 200 cGy BID of TBI Arm F: HCT Alone, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI Arm C: Re-Transplant with 300 cGy of TBI Arm D: HCT with 200 cGy BID of TBI Arm E: HCT plus MSC, 200 cGy BID of TBI Arm F: HCT Alone, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI Arm C: Re-Transplant with 300 cGy of TBI Arm D: HCT with 200 cGy BID of TBI Arm E: HCT plus MSC, 200 cGy BID of TBI Arm F: HCT Alone, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI Arm C: Re-Transplant with 300 cGy of TBI Arm D: HCT with 200 cGy BID of TBI Arm E: HCT plus MSC, 200 cGy BID of TBI Arm F: HCT Alone, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI Arm C: Re-Transplant with 300 cGy of TBI Arm D: HCT with 200 cGy BID of TBI Arm E: HCT plus MSC, 200 cGy BID of TBI Arm F: HCT Alone, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI Arm C: Re-Transplant with 300 cGy of TBI Arm F: HCT Alone, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI Arm C: Re-Transplant with 300 cGy of TBI Arm D: HCT with 200 cGy BID of TBI Arm E: HCT plus MSC, 200 cGy BID of TBI Arm F: HCT Alone, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI Arm C: Re-Transplant with 300 cGy of TBI Arm E: HCT plus MSC, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI Arm F: HCT Alone, 200 cGy BID of TBI Arm G: HCT plus MSC, 200 cGy Infe ANeo All Infl AnEm NeuroAg Gast ARhu Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Anti-Inflammatory Agents Antiemetics Neuroprotective Agents Gastrointestinal Agents Antirheumatic Agents Bolus Under Off Tablet Under Cardiac Inhaler Training program Under M11280 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M283219 M4488 M5879 M225481 M18102 M255749 M3431 M16963 M16637 M9364 M9353 M19757 M20095 M2972 M3433 M3466 M3366 M29605 M3374 M3376 M3463 Mycophenolic Acid Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Fludarabine Busulfan Cyclophosphamide Fludarabine phosphate Tacrolimus Thymoglobulin Antilymphocyte Serum Mesna Vidarabine Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Antimetabolites Antiviral Agents Anti-Infective Agents Calcineurin Inhibitors Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents high low low low low low low low high high high high high high high low high low low low low low low low low low low low low 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3 30 mg/m2 IV over 60 minutes days -6 through day -2 See arm description for dosing. Bone marrow infusion on Day 0 Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors) 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35 Day 60, 100 and 180 (collected during donor BM harvest for graft) busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G) D000014740 D000009173 D000003520 D000002066 C000024352 C000042382 D000016559 C000512542 D000000961 Vidarabine Mycophenolic Acid Cyclophosphamide Busulfan Fludarabine Fludarabine phosphate Tacrolimus Thymoglobulin Antilymphocyte Serum Thymoglobulin Cyclophosphamide Fludarabine Total Body Irradiation Bone marrow infusion Tacrolimus Mycophenolate Mofetil Donor mesenchymal stem cell infusions Busulfan ATG anti-thymocyte globulin Cytoxan fludarabine phosphate Fludara TBI HCT Prograf MMF Drug Drug Drug Radiation Procedure Drug Drug Biological Drug",1,84
608,Drug: Umbilical Cord Mesenchymal Stem Cells Drug: Placebo Parallel Assignment A 2:1 ratio of randomization (intervention group:control group) was used.   Umbilical Cord Mesenchymal Stem Cells Control       Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells Saline，Sham operation   Umbilical Cord Mesenchymal Stem Cells Placebo UC-MSC Sham operation Drug Drug,1,84
609,Other: conditioned media of umbilical cord blood-derived stem cells Other: Placebo Parallel Assignment Product group / Control(placebo) group   NGF-574H placebo       Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells   conditioned media of umbilical cord blood-derived stem cells Placebo NGF-574H Other Other,1,84
610,"Other: UC-MSCs by peripheral intravenous infusion Drug: received hormone maintenance therapy Parallel Assignment  D000006730 D000045505 Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs UC-MSCs control All All Drugs and Chemicals Include M8941 M8940 Hormones Hormone Antagonists high low  D000006728 Hormones UC-MSCs by peripheral intravenous infusion received hormone maintenance therapy  Other Drug",1,82
611,Drug: Core decompression/PREOB® implantation Drug: Core decompression/BMC implantation Parallel Assignment    Core decompression/PREOB® implantation Core decompression/BMC implantation CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration). All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).   Core decompression/PREOB® implantation Core decompression/BMC implantation  Drug Drug,1,82
612,"Drug: Bone-marrow derived MSCs Drug: Placebo Parallel Assignment    Bone-marrow derived MSCs Placebo       Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells Placebo product visually very similar to mesenchymal stromal cells   Bone-marrow derived MSCs Placebo MSC Drug Drug",1,82
613,"Drug: Low Dose Mesenchymal Stem Cells (MSCs) Drug: High Dose Mesenchymal Stem Cells (MSCs) Drug: Placebo Infusion Parallel Assignment    Low Dose Mesenchymal Stem Cells (MSCs) High Dose Mesenchymal Stem Cells (MSCs) Plasma Lyte A Solution PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 M85407 Pharmaceutical Solutions Plasma-lyte 148 low low Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution. Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.   Low Dose Mesenchymal Stem Cells (MSCs) High Dose Mesenchymal Stem Cells (MSCs) Placebo Infusion  Drug Drug Drug",1,81
614,Other: Saline Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Crossover Assignment    10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles 15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Placebo Saline       Injectable Placebo Saline   Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Saline ExoFlo Drug Other,1,81
615,"Procedure: laparoscopic surgery Procedure: laparoscopic and endoscopic cooperative surgery Parallel Assignment    laparoscopic and endoscopic combined surgery laparoscopic surgery       compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery the traditional surgery   laparoscopic and endoscopic cooperative surgery laparoscopic surgery  Procedure Procedure",1,80
616,"Other: placenal MSC derived exosomes Other: placenal MSC derived exosomes Parallel Assignment This study includes two arms. The first one is the cases that are treated with MSC-derived exosomes and the controls do not receive exosomes and are treated with placebo   exosome therapy placebo Infl All Anti-Inflammatory Agents All Drugs and Chemicals  M3369 Anti-Inflammatory Agents low placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial   placenal MSC derived exosomes  Other",1,80
617,Drug: Mesenchymal stem cell Drug: Control group Parallel Assignment    Mesenchymal stem cell treatment group Control group Antipy Infl ARhu FiAg Analg PlAggInh All Antipyretics Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Analgesics Platelet Aggregation Inhibitors All Drugs and Chemicals  M3700 M1669 Aspirin Clopidogrel low low Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention No additional treatment of mesenchymal stem cells   Mesenchymal stem cell Control group Hearticellgram-AMI Drug Drug,1,80
618,"Procedure: large volume whole-lung lavage (WLL) Procedure: large volume whole-lung lavage (WLL) Biological: clinical grade umbilical cord mesenchymal stem cells Parallel Assignment    Control Group Experimental Group Experimental Group       Generally 1000 ~ 2000ml each time, 14 ~ 10 times totally, each side of the lung to 20 ~ 15 liters, until the lavage fluid from the black into a colorless clear clarification 10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage   large volume whole-lung lavage (WLL) clinical grade umbilical cord mesenchymal stem cells  Procedure Biological",1,80
619,Procedure: Autologous bone marrow transplant Procedure: Physical therapy Procedure: Physical therapy Parallel Assignment    BM transplant with physiotherapy BM transplant with physiotherapy Physiotherapy only          Autologous bone marrow transplant Physical therapy  Procedure Procedure,1,80
620,"Biological: Mesenchymal stem cells Other: Saline Parallel Assignment    Mesenchymal stem cells cohort Saline cohort       In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7 In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7   Mesenchymal stem cells Saline  Biological Other",1,80
621,"Other: placenta-MSCs derived exosomes Other: placenta-MSCs derived exosomes Parallel Assignment    Controls exosome cases Infl All Anti-Inflammatory Agents All Drugs and Chemicals  M3369 Anti-Inflammatory Agents low Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.   placenta-MSCs derived exosomes  Other",1,80
622,Biological: Autologous transplantation Single Group Assignment    mesenchymal stem cells       Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously   Autologous transplantation SWH2010A19 Biological,1,80
623,"Drug: Placebo comparator Drug: Autologous MSC from bone marrow Parallel Assignment    Autologous MSC from bone marrow Placebo comparator       After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system. injections of human albumin   Autologous MSC from bone marrow Placebo comparator mesenchymal stem cells Human Albumin Drug Drug",1,90
624,"Drug: Rabbit antithymoglobulin (ATG) Drug: Rabbit antithymoglobulin (ATG) Procedure: Adipose derived mesenchymal stem cells ( AD-MSCs) Drug: Rabbit antithymoglobulin (ATG) Procedure: AD-MSC transdifferentiated HSCs (AD-HSCs) Parallel Assignment  D000007155 D000045505 D000007166 Immunologic Factors Physiological Effects of Drugs Immunosuppressive Agents Rabbit ATG & AD-HSCs Rabbit ATG & AD-MSCs Rabbit antithymoglobulin （ATG） Rabbit ATG & AD-MSCs Rabbit ATG & AD-HSCs All All Drugs and Chemicals FLX475 M255749 M3431 M9353 M9364 Thymoglobulin Antilymphocyte Serum Immunologic Factors Immunosuppressive Agents low high low low Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2. Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3. Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4. D000000961 Antilymphocyte Serum Rabbit antithymoglobulin (ATG) Adipose derived mesenchymal stem cells ( AD-MSCs) AD-MSC transdifferentiated HSCs (AD-HSCs) ATG AD-MSCs AD-HSCs Drug Procedure Procedure",1,90
625,Other: BM-MSCs Parallel Assignment    Maximal medical therapy and BM-MSCs       Intracoronary implantation of bone marrow-derived mesencymal stem cells   BM-MSCs Bone marrow-derived mesenchymal stem cells implantation Other,1,80
626,"Drug: conventional treatment Biological: mesenchymal stem cells Crossover Assignment  D000003879 D000005765 D000018501 D000007166 D000007155 D000045505 Dermatologic Agents Gastrointestinal Agents Antirheumatic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs mesenchymal stem cells conventional treatment ARhu Derm Gast All Antirheumatic Agents Dermatologic Agents Gastrointestinal Agents All Drugs and Chemicals Outpatient Genotype 1 M375 M1830 M6226 M8033 M19757 M9364 M9353 Infliximab Basiliximab Dermatologic Agents Gastrointestinal Agents Antirheumatic Agents Immunosuppressive Agents Immunologic Factors high high low low low low low MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR. D000069285 D000077552 Infliximab Basiliximab mesenchymal stem cells conventional treatment mesenchymal stomal cells Basiliximab and/or Infliximab Biological Drug",1,90
627,Procedure: stereotactic surgery Biological: hUMSCs Procedure: stereotactic surgery Biological: hUMSCs Biological: placebo Parallel Assignment    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 2       stereotactic aspiration surgery single intracavitary infusion 1 day after stereotactic aspiration surgery single intracavitary infusion 1 day after stereotactic aspiration surgery   stereotactic surgery hUMSCs placebo  Procedure Biological Biological,1,100
628,"Biological: clonal fetal MSCs Single Group Assignment    Single arm, cfMSC to treat immune disorders          clonal fetal MSCs  Biological",1,100
629,"Biological: human Mesenchymal Stem Cell (MSC) infusion therapy Single Group Assignment Prospective, Unblinded, non-randomized   Treatment Population       Subjects will be infused with 100million human MSCs   human Mesenchymal Stem Cell (MSC) infusion therapy  Biological",1,100
630,"Biological: mesenchymal stem cells Single Group Assignment    Mesenchymal stem cells Mesenchymal stem cells       Intravenous administration of up to 1~2x10^6 MSCs per kg,for 2 times,d0 and d14 bone marrow derived mesenchymal stem cells from related donors.   mesenchymal stem cells mesenchymal stem cells Multipotent Mesenchymal Stromal Cells Biological Biological",1,100
631,Drug: Treatment group Drug: Control group Parallel Assignment    Treatment group Control group       Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment. Conventional treatment were used to treat patients with chronic renal failure.   Treatment group Control group Stem cells treatment group Conventional treatment group Drug Drug,1,100
632,Biological: BRTX-100 Drug: Saline Parallel Assignment All subjects will be randomized (2:1) to receive either intradiscal BRTX-100 or saline.   Active Treatment- BRTX-100 Saline PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution   BRTX-100 Saline  Biological Drug,1,99
633,"Procedure: Cord Blood Infusion Drug: Busulfan Drug: Fludarabine Drug: Rituximab Other: ATG Drug: Cyclophosphamide Drug: Clofarabine Radiation: Total Body Irradiation (TBI) Drug: Melphalan Drug: Tacrolimus Drug: Mycophenolate Mofetil Drug: G-CSF Single Group Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 D000074322 D000000964 D000000963 D000000890 D000065095 D000004791 D000000903 D000000904 D000000995 D000000900 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antineoplastic Agents, Immunological Antimetabolites, Antineoplastic Antimetabolites Anti-Infective Agents Calcineurin Inhibitors Enzyme Inhibitors Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Cord Blood Infusion Infe ANeo All ARhu Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Antirheumatic Agents Bolus Under Off Androgen Tablet Solid Tumors Two Under Cardiac Inhaler Depot M11280 M283219 M4488 M1921 M5879 M10693 M373 M225481 M18102 M1945 M255749 M3431 M9364 M9353 M19757 M20095 M2972 M1346 M3433 M3366 M29605 M3374 M3376 M3463 Mycophenolic Acid Fludarabine Busulfan Clofarabine Cyclophosphamide Melphalan Rituximab Fludarabine phosphate Tacrolimus Lenograstim Thymoglobulin Antilymphocyte Serum Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Antineoplastic Agents, Immunological Antimetabolites Anti-Infective Agents Calcineurin Inhibitors Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents high high high high high high high high high low high high low low low low low low low low low low low low Cord blood transplantation performed on day 0. 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s). 10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).  40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.  40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3. 375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy. 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.  1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3. 50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy. 30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s). 200 cGy at 25 cGy/minute delivered on Day -3. 140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3. 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present. 1 gram by vein twice a day Days -3 through Day 100. 5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is > 2.5 x 109/L. D000009173 D000003520 D000008558 D000002066 D000069283 C000024352 C000042382 D000077866 D000016559 C000512542 D000000961 Mycophenolic Acid Cyclophosphamide Melphalan Busulfan Rituximab Fludarabine Fludarabine phosphate Clofarabine Tacrolimus Thymoglobulin Antilymphocyte Serum Cord Blood Infusion Busulfan Fludarabine Rituximab ATG Cyclophosphamide Clofarabine Total Body Irradiation (TBI) Melphalan Tacrolimus Mycophenolate Mofetil G-CSF Busulfex Myleran Fludarabine Phosphate Fludara Rituxan Antithymocyte Globulin Thymoglobulin Cytoxan Neosar Clofarex Clolar TBI XRT Alkeran Prograf MMF CellCept Filgrastim Neupogen Procedure Drug Drug Drug Other Drug Drug Radiation Drug Drug Drug Drug",1,98
634,Drug: Placebo Drug: PROCHYMAL adult human mesenchymal stem cells Drug: PROCHYMAL adult human mesenchymal stem cells Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Placebo PROCHYMAL High dose PROCHYMAL Low dose Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals Unsuccessful M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low Placebo intravenous infusion four times over two weeks; possibly repeated once C000711674 Remestemcel-l Placebo PROCHYMAL adult human mesenchymal stem cells  Drug Drug,1,98
635,Procedure: Human biological samples Single Group Assignment    Patients with and without sepsis       Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)   Human biological samples  Procedure,1,93
636,"Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study   Long term follow up LONG TERM FOLLOW UP Other",1,91
637,"Biological: Infusion of allogeneic umbilical cord blood Biological: Infusion of MSCs Biological: Infusion of allogeneic umbilical cord blood Parallel Assignment    Allogeneic Umbilical Cord Blood Natural History Cord Tissue Mesenchymal Stromal Cells       Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit. Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).   Infusion of allogeneic umbilical cord blood Infusion of MSCs  Biological Biological",1,91
638,"Biological: SMUP-IA-01(low dose) Biological: SMUP-IA-01(mid dose) Drug: Active Control Group Sodium chloride Parallel Assignment    Study Group 1: SMUP-IA-01 (low dose) Study Group 2:SMUP-IA-01 (mid dose) Active Control Group All All Drugs and Chemicals  M9030 Hyaluronic Acid low A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL) A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL) A single knee administration of Sodium chloride   SMUP-IA-01(low dose) SMUP-IA-01(mid dose) Active Control Group Sodium chloride SMUP allogenic cord blood-derived mesenchymal stem cell (SMUP-Cell) SMUP allogenic cord blood-derived mesenchymal stem cell (SMUP-Cell) Sodium chloride Biological Biological Drug",1,90
639,"Biological: NestaCell® Biological: Placebo Parallel Assignment Patients will be randomized (1:1) to receive NestaCell (n=45) or Placebo (n=45).   NestaCell® Placebo       A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects. Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.   NestaCell® Placebo Mesenchymal Stem Cell Biological Biological",1,90
640,"Diagnostic Test: Intestinal microbiome new generation sequencing Diagnostic Test: Intestinal microbiome new generation sequencing Diagnostic Test: Intestinal microbiome new generation sequencing Diagnostic Test: Intestinal microbiome new generation sequencing     HSCT-recipients Kidney transplant recipients Liver transplant recipients MSCT-recipients Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.   Intestinal microbiome new generation sequencing  Diagnostic Test",1,90
641,"Drug: EXO 1 inhalation Drug: EXO 2 inhalation Drug: Placebo inhalation Parallel Assignment The trial has three groups, each with 30 subjects (n=90). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.   EXO-1 EXO-2 Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type. Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type. Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).   EXO 1 inhalation EXO 2 inhalation Placebo inhalation  Drug Drug Drug",1,90
642,Biological: Allogeneic Mesenchymal Stem Cells Biological: Allogeneic Mesenchymal Stem Cells Parallel Assignment    Low dose Intermediate dose       Single intramuscular administration of low dose of stem cells Single intramuscular administration of intermediate dose of stem cells   Allogeneic Mesenchymal Stem Cells Allogeneic Mesenchymal Stem Cells Stempeucel - CLI Stempeucel - CLI Biological Biological,1,90
643,"Biological: Hearticellgram-AMI Parallel Assignment    Single dose of Hearticellgram-AMI FiAg AnCoag All Antipy Infl ARhu Analg PlAggInh Lipd Infe ANeo Fibrinolytic Agents Anticoagulants All Drugs and Chemicals Antipyretics Anti-Inflammatory Agents Antirheumatic Agents Analgesics Platelet Aggregation Inhibitors Lipid Regulating Agents Anti-Infective Agents Antineoplastic Agents  M8733 M3700 M1669 M8731 M45326 M19305 M1943 M6563 M20308 M3286 M28069 M2823 M273811 M15898 Heparin, Low-Molecular-Weight Aspirin Clopidogrel Heparin Calcium heparin Dalteparin Tinzaparin Diuretics Hydroxymethylglutaryl-CoA Reductase Inhibitors Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists Adrenergic beta-Antagonists polysaccharide-K Ticlopidine low low low low low low low low low low low low low low    Hearticellgram-AMI (Autologous bone marrow derived mesenchymal stem cells) Biological",1,90
644,Biological: HB-adMSCs (allogeneic) Other: Placebo Parallel Assignment Randomized Double-Blind   Treatment Placebo       HB-adMSCs allogenic Placebo comarator   HB-adMSCs (allogeneic) Placebo Hope Biosciences adipose derived mesenchymal stem cells Sterile Normal Saline Biological Other,1,80
645,"Device: Lipogems Drug: Normal Saline Parallel Assignment    Micro-Fragmented Adipose Tissue Saline PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications. Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small ""tunnels"" are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions.   Lipogems Normal Saline Micro-fragmented Adipose Tissue Percutaneous Trephination with Saline Device Drug",1,80
646,"Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Biological: Fluzone High Dose Vaccine Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Biological: Fluzone High Dose Vaccine Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Biological: Fluzone High Dose Vaccine Parallel Assignment    Double-Blind,Randomized,Placebo Phase Pilot Phase Cohort B & C Pilot Phase- Cohort A Double-Blind,Randomized,Placebo Phase Pilot Phase Cohort B & C Pilot Phase- Cohort A All All Drugs and Chemicals  M16512 M9336 M3377 Vaccines Immunoglobulins Antibodies low low low Intravenously delivered Intramuscular injection   Longeveron Mesenchymal Stem Cells (LMSCs) Fluzone High Dose Vaccine Lomecel-B Biological Biological",1,62
647,Biological: Mesenchymal stem cells Parallel Assignment    With MSC       Mesenchymal stem cells infusion   Mesenchymal stem cells Mesenchymal stem cells infusion Biological,1,70
648,"Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Other: Placebo Biological: Longeveron Mesenchymal Stem Cells (LMSCs) Other: Placebo Parallel Assignment Double-blinded, randomized, placebo-controlled study with 2 cohorts.  Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs. Arm 2: 10 subjects treated with up to 3 doses of Placebo.  Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs. Arm 4: 10 subjects treated with up to 3 doses of Placebo.  Each subject will be intravenously infused with 100 million LMSCs or placebo on Day 0. If no treatment-related AEs are seen after the infusion, a second infusion will be given on Day 3. If no treatment-related AEs are seen after the second infusion, a third infusion will be given Day 6.  Follow-up visits will be conducted: daily until hospital discharge; at Week 4 after treatment (with LMSCs or placebo) for patients already discharged; and at Month 6 after treatment (with LMSCs or placebo).   Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs) Cohort 2 (Flu): Arm 3 (LMSCs) Cohort (SARS-CoV-2): Arm 2 (Placebo) Cohort 2 (Flu): Arm 4 (Placebo)       Longeveron Mesenchymal Stem Cells (LMSCs) Placebo   Longeveron Mesenchymal Stem Cells (LMSCs) Placebo  Biological Other",1,70
649,"Biological: XCEL-MT-OSTEO-ALPHA Procedure: Standard treatment Parallel Assignment    XCEL-MT-OSTEO-ALPHA Standard treatment       Isolation and ""ex-vivo"" expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion. Instrumented spinal fusion together with patient's bone iliac crest   XCEL-MT-OSTEO-ALPHA Standard treatment  Biological Procedure",1,69
650,Biological: Pneumostem® Other: Normal Saline Parallel Assignment    Pneumostem® normal saline          Pneumostem® Normal Saline Human umbilical cord blood-derived mesenchymal stem cells Biological Other,1,69
651,Drug: Core decompression/PREOB® implantation Drug: Core decompression/placebo implantation Parallel Assignment    Core decompression/PREOB® implantation Core decompression/placebo implantation CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration). All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).   Core decompression/PREOB® implantation Core decompression/placebo implantation  Drug Drug,1,68
652,Biological: Mesenchymal Stromal Cells Other: Supportive Care Parallel Assignment    Mesenchymal stromal cells Control Group       Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10^8 MSCs. Patients will receive supportive care per their treating physician   Mesenchymal Stromal Cells Supportive Care MSCs Biological Other,1,66
653,"Biological: PLX-PAD Biological: PLX-PAD Biological: Placebo Biological: PLX-PAD Biological: Placebo Parallel Assignment    PLX-PAD high dose PLX-PAD interval high dose PLX-PAD low dose Control Group A Control Group B PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells Placebo solution for injection   PLX-PAD Placebo  Biological Biological",1,66
654,Biological: Injection of mesenchymal stem cells Biological: Injection of albumin alone Parallel Assignment    MSC Placebo       Injection of mesenchymal stem cells Injection of albumin alone   Injection of mesenchymal stem cells Injection of albumin alone  Biological Biological,1,66
655,"Biological: Mesenchymal stromal cell therapy Biological: Mesenchymal stromal cell therapy Parallel Assignment  D000000893 D000000932 D000001337 D000018373 D000045505 D000005765 D000005938 D000006728 D000006730 D000018696 D000020011 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Neuroprotective Agents Protective Agents Corticosteroid therapy Mesenchymal stromal cell therapy Infl ANeo All AnEm NeuroAg Gast Anti-Inflammatory Agents Antineoplastic Agents All Drugs and Chemicals Antiemetics Neuroprotective Agents Gastrointestinal Agents Neck M13272 M1833 M10901 M10902 M229437 M211896 M248768 M3369 M3403 M8033 M8199 M8941 M8940 M19926 M21022 Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Anti-Inflammatory Agents Antiemetics Gastrointestinal Agents Glucocorticoids Hormones Hormone Antagonists Neuroprotective Agents Protective Agents low low high low low low low low low low low low low low low One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy D000008775 Methylprednisolone Mesenchymal stromal cell therapy Methylprednisolone Mesenchymal stem cells Biological",1,66
656,Drug: Umbilical Cord Mesenchymal Stem Cells Drug: Placebos Parallel Assignment A 2:1 ratio of randomization (intervention group:control group) was used.   Umbilical Cord Mesenchymal Stem Cells Control       Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells Placebos: Saline，Sham operation   Umbilical Cord Mesenchymal Stem Cells Placebos UC-MSC Sham operation Drug Drug,1,66
657,Biological: the ATMP Protrans Biological: the ATMP Protrans Parallel Assignment    Placebo Wharton's jelly derived mesenchymal stromal cells (Protrans)       Protrans consists of Wharton's jelly derived mesenchymal stromal cells   the ATMP Protrans  Biological,1,66
658,"Drug: huc-MSCs Drug: Placebo Parallel Assignment    Conventional treatment, huc-MSCs Conventional plus placebo PhSol All Hemat Pharmaceutical Solutions All Drugs and Chemicals Hematinics  M21013 M10262 Pharmaceutical Solutions Liver Extracts low low Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight. Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).   huc-MSCs Placebo Umbilical Cord-Derived Mesenchymal Stem Cells saline solution Drug Drug",1,66
659,"Procedure: transplantation of human UC-MSCs into ovaries of POI patients Drug: hormone replacement treatment Drug: hormone replacement treatment Parallel Assignment  D000006730 D000045505 Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs UC-MSCs+hormone replacement group UC-MSCs+hormone replacement group hormone replacement group All PhSol All Drugs and Chemicals Pharmaceutical Solutions Include M7268 M21013 M8941 M13397 M8940 Estrogens Pharmaceutical Solutions Hormones Progesterone Hormone Antagonists low low high low low UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance. Routine estrogen progesterone replacement periodic therapy D000006728 Hormones transplantation of human UC-MSCs into ovaries of POI patients hormone replacement treatment HRT Procedure Drug",1,66
660,"Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Biological: Placebo Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Parallel Assignment  D000000900 D000000890 D000011500 D000004791 D000045504 Anti-Bacterial Agents Anti-Infective Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Addendum B - Antibiotic free cell Group Pilot Phase - Group 2 Pilot Phase - Group 3 Pilot phase - Group 1 Randomized Phase - Group A Randomized Phase - Group C Randomized phase - Group B Randomized Phase - Group C Addendum B - Antibiotic free cell Group Infe All Anti-Infective Agents All Drugs and Chemicals Hip Replacement Surface electromyography M3374 M12469 M3376 M15249 M3366 Anti-Bacterial Agents Penicillins Antibiotics, Antitubercular Streptomycin Anti-Infective Agents low high low high low Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion Placebo administered by peripheral intravenous infusion. Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion. D000010406 D000013307 Penicillins Streptomycin Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) Placebo Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)  Biological Biological Biological",1,65
661,Biological: Autologous human mesenchymal cells (hMSCs) Biological: Autologous human bone marrow cells (hBMCs) Biological: Placebo Parallel Assignment    1 2 3 Infl All Anti-Inflammatory Agents All Drugs and Chemicals  M16126 M16127 M237968 M209570 Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate low low low low Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter. Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter. Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.   Autologous human mesenchymal cells (hMSCs) Autologous human bone marrow cells (hBMCs) Placebo  Biological Biological Biological,1,65
662,Biological: ALLO-ASC-SHEET Biological: ALLO-ASC-SHEET Parallel Assignment    ALLO-ASC-SHEET Hydrogel SHEET(Vehicle control)       Hydrogel sheet containing Allogenic Mesenchymal Stem Cells   ALLO-ASC-SHEET Hydrogel sheet containing Allogenic Mesenchymal Stem Cells Biological,1,64
663,Biological: umbilical cord mesenchymal stem cells Parallel Assignment    UCMSCs          umbilical cord mesenchymal stem cells  Biological,1,64
664,"Drug: PROCHYMAL® Drug: Placebo Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Prochymal Placebo Hypo All Infe Infl Hypoglycemic Agents All Drugs and Chemicals Anti-Infective Agents Anti-Inflammatory Agents Unsuccessful M9517 M172956 M186752 M3369 M3466 M3366 Insulin Insulin, Globin Zinc Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents low low high low low low Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells Intravenous infusion of excipients of PROCHYMAL® C000711674 Remestemcel-l PROCHYMAL® Placebo ex vivo cultured adult human mesenchymal stem cells Prochymal Drug Drug",1,63
665,"Drug: Conventional plus MSC treatment Drug: Conventional plus pacebo treatment Parallel Assignment    Conventional plus MSC treatment Conventional plus pacebo treatment Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 12 weeks. Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.   Conventional plus MSC treatment Conventional plus pacebo treatment  Drug Drug",1,70
666,"Drug: Mesenchymal Stromal Cells Parallel Assignment    Mesenchymal Stromal Cells + Everolimus ANeo All Antineoplastic Agents All Drugs and Chemicals  M255 M18102 Everolimus Tacrolimus low low Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight   Mesenchymal Stromal Cells Bone marrow derived mesenchymal stromal cells Drug",1,70
667,"Biological: bone allogaft with bone marrow concentrate Parallel Assignment    bone marrow concentrate       In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.   bone allogaft with bone marrow concentrate  Biological",1,80
668,Other: placebo intervention Other: bone marrow-derived MSCs injection Parallel Assignment    bone marrow-derived MSCs injection placebo comparator PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle. placebo administration   bone marrow-derived MSCs injection placebo intervention  Other Other,1,70
669,"Drug: Tranexamic Acid Drug: Tranexamic Acid Drug: Tranexamic Acid Parallel Assignment  D000000933 D000050299 D000045504 D000006490 D000003029 Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants Group A, Tranexamic acid Group B, autologous transfusion Group C, alogenous transfusion Coag All Coagulants All Drugs and Chemicals Intramuscular M16054 M3404 M8728 M5411 Tranexamic Acid Antifibrinolytic Agents Hemostatics Coagulants high low low low Imunomodulatory effect D000014148 Tranexamic Acid Tranexamic Acid Medsamic Drug",1,80
670,Drug: ◦Drug: ASCs. + fibrin glue Drug: fibrin glue Parallel Assignment  D000006490 D000003029 Hemostatics Coagulants ASC + fibrin glue Fibrin glue Coag All Coagulants All Drugs and Chemicals Isoflurane M17443 M8728 M5411 Fibrin Tissue Adhesive Hemostatics Coagulants high low low Experimental group •Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive D000015718 Fibrin Tissue Adhesive ◦Drug: ASCs. + fibrin glue fibrin glue Experimental Drug: ASCs + fibrin glue Drug Drug,1,80
671,"Biological: Umbilical Cord Mesenchymal Stem Cells Biological: Conditioned Medium Biological: Umbilical Cord Mesenchymal Stem Cells Other: Standard Therapy Factorial Assignment    UCMSCs UCMSCs + CM UCMSCs + CM Standard Therapy       The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product. Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product. Standard therapy for cerebral palsy such as physiotherapy   Umbilical Cord Mesenchymal Stem Cells Conditioned Medium Standard Therapy Allogeneic Mesenchymal Stem Cells Umbilical Cord Mesenchymal Stem Cells derived Conditioned Medium Physiotheraphy Biological Biological Other",1,78
672,"Procedure: silver ion dressing Other: stem cell preparation combined with silver ion dressing Parallel Assignment    control group experimental group       The dosage range of each cm2 ulcer wound is (1～5)×10^6. The dosage of human umbilical cord mesenchymal stem cells for the second treatment is determined according to the severity of the ulcer. Each patient is treated for 2 consecutive times, and the interval between each treatment is 3 days. fter wound debridement, a silver ion dressing suitable for the size of the wound was cut and covered on the wound bed. Sterile gauze was covered on the silver ion dressing and fixed with adhesive tape.   stem cell preparation combined with silver ion dressing silver ion dressing  Other Procedure",1,76
673,Biological: Autologous Mesenchymal Stem Cells Biological: Autologous Mesenchymal Stem Cells Other: Placebo Other: Placebo Parallel Assignment Randomized Double-Blind Placebo-Controlled Adaptive Design Trial   Arm 1 Arm 2 Arm 2 Arm 3       Autologous Mesenchymal Stem Cells administered intrathecally Placebo administered intrathecally   Autologous Mesenchymal Stem Cells Placebo  Biological Other,1,76
674,"Drug: Saline Drug: Corticosteroid injection Device: Microfragmented Adipose Tissue (Lipogems) Parallel Assignment This study will be conducted as a randomized, placebo-controlled clinical trial. Patients will be randomized to receive either Lipogems, intra-articular corticosteroids, or a placebo injection of saline. Lipogems is cleared for use by the FDA in orthopaedics and arthroscopy and is offered as a treatment option for knee osteoarthritis. This study will be evaluating the effectiveness (not safety) of Lipogems when compared to corticosteroids and placebo. Thus, no information will be submitted to the FDA.   Lipogems Injection Corticosteroid Injection Placebo Injection PhSol All AnArAg ChanBlk CNSDep Infl Pharmaceutical Solutions All Drugs and Chemicals Anti-Arrhythmia Agents Channel Blockers Central Nervous System Depressants Anti-Inflammatory Agents  M21013 M10166 M5721 Pharmaceutical Solutions Lidocaine Cortisone low low low Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections. Cortisone is a standard of care injection to reduce joint inflammation. Sterile saline injection will act as a placebo group.   Microfragmented Adipose Tissue (Lipogems) Corticosteroid injection Saline  Device Drug Drug",1,75
675,Biological: Allogeneic umbilical cord mesenchymal stem cells Biological: Controlled normal saline Parallel Assignment    UMSC01 Placebo       UMSC01 cells will be IV infusion with 12 months of follow up after treatment. Normal saline will be IV infusion with 12 months of follow up after treatment.   Allogeneic umbilical cord mesenchymal stem cells Controlled normal saline  Biological Biological,1,75
676,Hypo All Hypoglycemic Agents All Drugs and Chemicals  M10819 Metformin low      ,1,75
677,Drug: allo-APZ2-OTS Drug: Placebo Crossover Assignment    Verum Placebo       Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) Placebo   allo-APZ2-OTS Placebo  Drug Drug,1,74
678,Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC) Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC) Biological: Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC) Drug: Placebo Parallel Assignment    Single dose AMSC treatment at first stage of brachiobasilic arteriovenous fistula Single dose AMSC treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula Placebo treatment in brachiobasilic arteriovenous fistula AMSC treatment at first and second stage of brachiobasilic arteriovenous fistula PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period. 5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period. Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery   Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC) Placebo Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)  Biological Drug Biological,1,74
679,"Drug: adult human mesenchymal stem cells Single Group Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Prochymal Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals 1440 M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603. C000711674 Remestemcel-l adult human mesenchymal stem cells Prochymal remestemcel-L Drug",1,73
680,Other: Best Practice Other: Laboratory Biomarker Analysis Drug: Mesenchymal Stem Cell Transplantation Other: Best Practice Other: Laboratory Biomarker Analysis Drug: Mesenchymal Stem Cell Transplantation Other: Best Practice Other: Laboratory Biomarker Analysis Parallel Assignment    Arm I (hMSCs IV) Arm II (hMSCs transendocardially) Arm III (standard of care) Arm I (hMSCs IV) Arm II (hMSCs transendocardially) Arm III (standard of care) Arm I (hMSCs IV) Arm II (hMSCs transendocardially)       Given standard of care Correlative studies Given IV Given transendocardially   Best Practice Laboratory Biomarker Analysis Mesenchymal Stem Cell Transplantation Mesenchymal Stem Cell Transplantation standard of care standard therapy Other Other Drug Drug,1,72
681,"Drug: high dose of MSC Drug: low dose of MSC treatment Parallel Assignment    Drug: high dose of MSC treatment low dose of MSC treatment Infe All Anti-Infective Agents All Drugs and Chemicals  M3466 Antiviral Agents low Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5*10E6/kg for 48 weeks. Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5*10E6/kg for 48 weeks.   high dose of MSC low dose of MSC treatment MSC treatment dose MSC low dose Drug Drug",1,72
682,"Biological: Livercellgram Biological: Livercellgram Parallel Assignment    1-time injection group: Livercellgram 2-time injection group: Livercellgram CNSSti All Hemat Ot Central Nervous System Stimulants All Drugs and Chemicals Hematinics Other Dietary Supplements  M4525 M10262 T370 Caffeine Liver Extracts Caffeine low low low Livercellgram  Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20~25℃  Injection Method: Directly inject into liver through hepatic artery   Livercellgram Autologous bone marrow-derived mesenchymal stem cell Biological",1,72
683,Biological: Mesenchymal Stem Cell Other: Best Practice Biological: Mesenchymal Stem Cell Parallel Assignment    Phase II Arm II (standard of care) Phase II Arm I (mesenchymal stem cells) Pilot study (mesenchymal stem cells)       Receive standard of care Given IV   Best Practice Mesenchymal Stem Cell standard of care standard therapy Mesenchymal Progenitor Cell MPC Other Biological,1,70
684,Biological: Allogenic stromal mesenchymal cells derived from the umbilical cord Procedure: Debridement and microfracture Procedure: Debridement and microfracture Parallel Assignment    Debridement and microfracture in LOC + Cells Debridement and microfracture in LOC Debridement and microfracture in LOC + Cells HB All Herbal and Botanical All Drugs and Chemicals  T63 Astragalus low Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus   Allogenic stromal mesenchymal cells derived from the umbilical cord Debridement and microfracture  Biological Procedure,1,70
685,"Drug: Bone marrow mesenchymal stem cells Drug: hyaluronic acid Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Chondrochymal® group Hya-Joint Plus Synovial Fluid Supplement All PhSol All Drugs and Chemicals Pharmaceutical Solutions Compression M9030 M21013 M2780 M9353 M27448 M21022 Hyaluronic Acid Pharmaceutical Solutions Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low low The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product. (60 mg/3 mL hyaluronic acid [HA]) D000006820 Hyaluronic Acid Bone marrow mesenchymal stem cells hyaluronic acid Chondrochymal® Hya-Joint Plus Synovial Fluid Supplement Drug Drug",1,70
686,"Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells Parallel Assignment    M100 M50 S100 S50       Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).   Autologous Adipose-Derived Mesenchymal Stromal Cells AMSCs Drug",1,24
687,"Single Group Assignment     Hypo All Gast Hypoglycemic Agents All Drugs and Chemicals Gastrointestinal Agents  M9517 M172956 M21707 M12266 Insulin Insulin, Globin Zinc Pancrelipase Pancreatin low low low low 1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.   mesenchymal stem cells  Biological",1,24
688,"Biological: HB-adMSCs Drug: Placebo Parallel Assignment Randomized, Double-Blind   Treatment Placebo       Autologous product Normal Saline   HB-adMSCs Placebo Hope Biosciences adipose derived mesenchymal stem cells 0.9% NS Biological Drug",1,24
689,Drug: pneumostem Single Group Assignment    pneumostem group       human umbilical cord blood derived mesenchymal stem cells   pneumostem  Drug,1,9
690,Drug: XCEL-UMC-BETA Drug: Placebo Drug: XCEL-UMC-BETA Drug: Placebo Crossover Assignment    Placebo/XCEL-UMC-BETA XCEL-UMC-BETA/placebo Placebo/XCEL-UMC-BETA XCEL-UMC-BETA/placebo       Intrathecal allogeneic cell therapy in a blinded syringe Placebo in a blinded syringe   XCEL-UMC-BETA Placebo Expanded MSC from Wharton Jelly Drug Drug,1,10
691,Biological: Wharton Jelly derived mesenchymal stem cell Single Group Assignment    Wharton Jelly mesenchymal stem cell       Intra-articular Wharton Jelly derived mesenchymal stem cell injection.   Wharton Jelly derived mesenchymal stem cell  Biological,1,10
692,"Other: Autologous bone marrow transplantation Single Group Assignment    Autologous bone marrow transplantation FiAg AnCoag All Fibrinolytic Agents Anticoagulants All Drugs and Chemicals  M8731 M45326 Heparin Calcium heparin low low Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.   Autologous bone marrow transplantation  Other",1,10
693,Procedure: Bone Marrow Harvest     Healthy Volunteer       Healthy volunteer bone marrow harvest   Bone Marrow Harvest  Procedure,1,10
694,Drug: Adipose-derived stem cells without expanded Single Group Assignment    Autologous SVF       Administration will be intralesional injection of cells suspension. They will be placed into fistula walls   Adipose-derived stem cells without expanded Adipose-Derived Mesenchymal Stem Cells Drug,1,10
695,Procedure: sham transplantation of mesenchymal stem cells Biological: autologous mesenchymal stem cell transplantation Parallel Assignment    autologous mesenchymal stem cell transplantation sham transplantation of mesenchymal stem cells       Placebo control for transplantation of mesenchymal stem cells   autologous mesenchymal stem cell transplantation sham transplantation of mesenchymal stem cells  Biological Procedure,1,10
696,Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords Single Group Assignment    COVID-19 patients       Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.   Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords UCMSC Biological,1,9
697,"Biological: ALLO-ASC-CD     ALLO-ASC-CD injection       ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.   ALLO-ASC-CD Allogenic adipose-derived mesenchymal stem cell Biological",1,9
698,"Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells Single Group Assignment    NEUROSTEM®-AD       DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain   Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells NEUROSTEM®-AD Biological",1,9
699,Combination Product: stem cell transplantation Single Group Assignment    Stem cell transplantation       Transplantation of umbilical cord mesenchymal stem cells   stem cell transplantation  Combination Product,1,10
700,Biological: Lower dose mesenchymal stem cell (MSC) injection Biological: Higher dose MSC injection Genetic: Placebo Parallel Assignment    Lower dose mesenchymal stem cell (MSC) injection (3) Placebo Higher dose MSC injection ANeo All Antineoplastic Agents All Drugs and Chemicals  M8814 Altretamine low Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10^7 cells. The injections will be administered following completion of CABG surgery. Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA). Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10^8 cells. The injections will be administered following completion of CABG surgery.   Lower dose mesenchymal stem cell (MSC) injection Placebo Higher dose MSC injection  Biological Genetic Biological,1,9
701,Biological: human umbilical cord blood derived mesenchymal stem cells Single Group Assignment    NEUROSTEM (hUCB-MSCs) - high dose       High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals   human umbilical cord blood derived mesenchymal stem cells NEUROSTEM Biological,1,9
702,"Single Group Assignment     Infe ARhu Derm All Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals  M18113 M5882 M9364 M255749 M3431 Cyclosporine Cyclosporins Immunosuppressive Agents Thymoglobulin Antilymphocyte Serum low low low low low After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.   Intravenous bone marrow mesenchymal stem cells infusion  Biological",1,9
703,Biological: mesenchymal stem cells Single Group Assignment    Autologous mesenchymal stem cells       autologous transplantation of mesenchymal stem cells in spinal cord injury patients   mesenchymal stem cells MSC Biological,1,9
704,Biological: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells Single Group Assignment    Mesenchymal Stromal Cell Therapy       Cryopreserved allogeneic umbilical cord tissue-derived mesenchymal stromal cells are thawed and administered intravenously.   Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells  Biological,1,9
705,Biological: MSC Biological: MSC Biological: MSC Biological: MSC Sequential Assignment Dose escalation study   Group 1 MSC dose .5 x 10^6/kg IV Group 2 MSC dose 1 x 10^6/kg IV Group 3 MSC dose 2 x 10^6/kg IV Group 4 MSC dose 0.5 x 10^6/kg I       bone marrow derived cultured MSC (mesenchymal stem cell)   MSC  Biological,1,9
706,"Biological: Aadipose-Derived Mesenchymal Stem Cells Sequential Assignment This study plans to enroll approximately 4 subjects to obtain 3 evaluable subjects successfully receiving 3×10^7 cells/hemisphere (total 6×10^7 cells, Cohort 1) and approximately 8 subjects to obtain 6 evaluable subjects for 1×10^8 cells/hemisphere (total 2×10^8 cells, Cohort 2)   Single Arm Study       Stereotactic intrastriatal implantation of 3×10^7 per hemisphere (total 6×10^7 cells) or 1×10^8 per hemisphere (total 2×10^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).   Aadipose-Derived Mesenchymal Stem Cells MitoCell Biological",1,9
707,Drug: Suspension of human autologous MSC 3P Single Group Assignment    Suspension of human autologous MSC 3P       Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon   Suspension of human autologous MSC 3P hAMSC Drug,1,9
708,"Diagnostic Test: progenitor potential of Gingival Mesenchymal cells Diagnostic Test: progenitor potential of Gingival Mesenchymal cells Parallel Assignment    Progenitor Potential at Molar site Progenitor Potential at Premolar site       tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.   progenitor potential of Gingival Mesenchymal cells  Diagnostic Test",1,10
709,Biological: mesenchymal stem cells Single Group Assignment    mesenchymal stem cells       Procedure: Selected patients were randomly divided into a cell therapy group and a control group.  Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million.   mesenchymal stem cells  Biological,1,10
710,"Other: AD-SVF Single Group Assignment    Deployment of AD-SVF       Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.   AD-SVF Mesenchymal Stem Cells Other",1,10
711,Biological: Allogeneic adipose derived stem/stromal cells Single Group Assignment    Allogeneic mesenchymal stem/stromal cell therapy       Culture expanded allogeneic adipose derived stem/stromal cells   Allogeneic adipose derived stem/stromal cells  Biological,1,10
712,Biological: Adipose derived mesenchymal stem cell Single Group Assignment    Adipose derived Mesenchymal Stem cell       Allogeneic Adipose derived Mesenchymal Stem cell transplant   Adipose derived mesenchymal stem cell Cell Therapy Biological,1,10
713,Biological: Intravenous Mesenchymal stem cell infusion Single Group Assignment    Intravenous mesenchymal stem cell       Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart   Intravenous Mesenchymal stem cell infusion  Biological,1,10
714,Biological: Adipose tissue derived mesenchymal stem cell Single Group Assignment    adipose tissue mesenchymal stem cell       Intra-articular adipose tissue derived mesenchymal stem cell injection.   Adipose tissue derived mesenchymal stem cell  Biological,1,10
715,"Drug: AGLE 102 Single Group Assignment This is a phase 1/2A, non-randomized, multicenter, ascending dose, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.   AGLE 102       Exosomes from MSCs   AGLE 102  Drug",1,10
716,Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) Single Group Assignment    Interstitial Lung Disease with Connective Tissue Disorder       Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.   Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)  Biological,1,10
717,Biological: Allogeneic adipose derived stem cells (CSCC_ASC) Single Group Assignment    Stem cell therapy       Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)   Allogeneic adipose derived stem cells (CSCC_ASC)  Biological,1,10
718,"Biological: mesenchymal stem cells Single Group Assignment    mesenchymal stem cells       SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.   mesenchymal stem cells  Biological",1,10
719,"Biological: CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) Single Group Assignment    Assigned interventions       Two intravenous infusions of CS20AT04 (2.0×10^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.   CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)  Biological",1,10
720,Biological: Mesenchymal Stem Cell (MSC) therapy Single Group Assignment    Mesenchymal Stem Cell (MSC) therapy       3 doses of 5 million MSC will be administered   Mesenchymal Stem Cell (MSC) therapy  Biological,1,10
721,Biological: Mesenchymal Stromal Cells infusion Single Group Assignment    Intervention       Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion   Mesenchymal Stromal Cells infusion  Biological,1,10
722,Biological: Bone Marrow Aspirate Concentrate Device: Angel Concentrated Platelet Rich Plasma (cPRP) System Single Group Assignment    Bone marrow aspiration concentrate using the Angel System Bone marrow aspiration concentrate using the Angel System       Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System. Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.   Bone Marrow Aspirate Concentrate Angel Concentrated Platelet Rich Plasma (cPRP) System BMAC The Angel System Biological Device,1,10
723,"Drug: Prochymal™ adult human mesenchymal stem cells Drug: adult human mesenchymal stem cells Drug: Prochymal™ adult human mesenchymal stem cells Drug: adult human mesenchymal stem cells Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents High dose Low dose High dose Low dose All PhSol Infe Infl All Drugs and Chemicals Pharmaceutical Solutions Anti-Infective Agents Anti-Inflammatory Agents Unsuccessful M6457 M9364 M85407 M186752 M3369 M3466 M3366 Dimethyl Sulfoxide Immunosuppressive Agents Plasma-lyte 148 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents low low low high low low low Cells in plasmalyte and containing dimethylsulfoxide two infusions, one week apart, each comprising adult human mesenchymal stem cells C000711674 Remestemcel-l Prochymal™ adult human mesenchymal stem cells adult human mesenchymal stem cells PROCHYMAL PROCHYMAL Drug Drug",1,10
724,Device: PBM+ACB Device: ABB+ACB Parallel Assignment    PBM+ACB ABB+ACB       Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone   PBM+ACB ABB+ACB  Device Device,1,10
725,"Drug: MSC11FCD Single Group Assignment    The investigational drug into the Intratumoral administration Infe All Anti-Infective Agents All Drugs and Chemicals  M7717 Flucytosine low Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10^7, 3x10^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.  Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day  Directions:  Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.  Route of administration: Oral administration   MSC11FCD Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD) Drug",1,10
726,Drug: Mesenchymal stem cells Single Group Assignment    Mesenchymal stem cells       Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed   Mesenchymal stem cells  Drug,1,10
727,Other: Umbilical cord MSCs Single Group Assignment    Umbilical cord MSCs Group       Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.   Umbilical cord MSCs  Other,1,10
728,"Drug: Mesenchymal stromal cells Single Group Assignment    Intervention arm All All Drugs and Chemicals  M11052 Mitogens low TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.   Mesenchymal stromal cells TC-MSC Drug",1,10
729,"Biological: autologous mesenchymal stem cells Crossover Assignment    autologous mesenchymal stem cell       A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS   autologous mesenchymal stem cells  Biological",1,9
730,Biological: Human Umbilical Cord Derived-Mesenchymal Stem Cells Single Group Assignment    UMC119-01       Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg   Human Umbilical Cord Derived-Mesenchymal Stem Cells  Biological,1,9
731,"Drug: mesenchymal stem cells Drug: mesenchymal stem cells Drug: mesenchymal stem cells Parallel Assignment    high dose of mesenchymal stem cells low dose of mesenchymal stem cells medium dose of mesenchymal stem cells       we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature [5]. The low-dose is 1 × 10^7cells / 3mL, the medium-dose is 5 × 10^7cells / 3mL and the high dose is 1 × 10^8cells / 3mL   mesenchymal stem cells  Drug",1,9
732,"Drug: allogeneic mesenchymal stem cell Drug: allogeneic mesenchymal stem cell Other: Placebo Parallel Assignment Randomized, Double-blind, and Placebo-controlled Clinical Trial   High-dose group Low-dose group Control group (placebo)       Assignment of Administration Group allogeneic mesenchymal stem cell:  Low-dose group (5 x 10^7cells) High-dose group (1 x 10^8 cells) Control group (placebo)   allogeneic mesenchymal stem cell Placebo Investigational product Drug Other",1,9
733,Biological: Wharton Jelly Mesenchymal stem cells Single Group Assignment    Dose I       Intracavernous injection of Wharton Jelly Mesenchymal stem cells.   Wharton Jelly Mesenchymal stem cells  Biological,1,9
734,Biological: Wharton Jelly Mesenchymal stem cells Single Group Assignment    Dose 1       Intracavernous injection of Wharton Jelly Mesenchymal stem cells.   Wharton Jelly Mesenchymal stem cells  Biological,1,9
735,"Biological: low dosage MSCs-Exos administrated for nasal drip Biological: mild dosage MSCs-Exos administrated for nasal drip Biological: high dosage MSCs-Exos administrated for nasal drip Sequential Assignment    MSCs-Exos Dosage 1 MSCs-Exos Dosage 2 MSCs-Exos Dosage 3       Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks   low dosage MSCs-Exos administrated for nasal drip mild dosage MSCs-Exos administrated for nasal drip high dosage MSCs-Exos administrated for nasal drip  Biological Biological Biological",1,9
736,Drug: Allogeneic adipose tissue-derived mesenchymal stem cells Single Group Assignment    allogeneic ASCs PhSol All HB Pharmaceutical Solutions All Drugs and Chemicals Herbal and Botanical  M21013 T120 Pharmaceutical Solutions Cola low low The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.   Allogeneic adipose tissue-derived mesenchymal stem cells Cx-601 (company code) Drug,1,8
737,Single Group Assignment           Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells   Autologous Adipose Derived Mesenchymal Stem Cells Astrostem® Other,1,8
738,Biological: PNEUMOSTEM     Pneumostem®       A single intratracheal administration  Low Dose Group (3 patients): 1.0 x 10^7 cells/kg High Dose Group (6 patients): 2.0 x 10^7 cells/kg  * The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study.   PNEUMOSTEM human umbilical cord blood-derived mesenchymal stem cells Biological,1,8
739,Drug: XCEL-MC-ALPHA Drug: Placebo Drug: XCEL-MC-ALPHA Drug: Placebo Crossover Assignment    Treatment A: XCEL-MC-ALPHA/Placebo Treatment B: Placebo/XCEL-MC-ALPHA Treatment A: XCEL-MC-ALPHA/Placebo Treatment B: Placebo/XCEL-MC-ALPHA       Single infusion Single infusion   XCEL-MC-ALPHA Placebo Bone-marrow mesenchymal stromal cells Drug Drug,1,8
740,"Procedure: Cellularized composite graft augmentation Procedure: Acellular composite graft augmentation Parallel Assignment  D000006490 D000003029 Hemostatics Coagulants cellularized composite graft augmentation Control acellular composite graft augmentation Coag All Derm Coagulants All Drugs and Chemicals Dermatologic Agents Length of stay M17443 M5415 M8728 M5411 Fibrin Tissue Adhesive Coal Tar Hemostatics Coagulants high low low low liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite D000015718 Fibrin Tissue Adhesive Cellularized composite graft augmentation Acellular composite graft augmentation Cellution/CR800, Cytori, US Tisseel, Baxter, Germany Actifuse Microgranules, Apatech, Germany Tisseel, Baxter, Germany Actifuse Microgranules, Apatech, Germany Procedure Procedure",1,8
741,Device: Biphasic phycogenic biomaterial Device: Xenograft bovine hydroxyapatite Parallel Assignment    Biphasic phycogenic biomaterial Xenograft bovine hydroxyapatite       Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone   Biphasic phycogenic biomaterial Xenograft bovine hydroxyapatite  Device Device,1,8
742,"Drug: Calcipotriol ointment Biological: adipose-derived multipotent mesenchymal stem cells Single Group Assignment  D000003879 Dermatologic Agents AD-MSCs plus Calcipotriol ointment group AD-MSCs plus Calcipotriol ointment group Derm All Dermatologic Agents All Drugs and Chemicals Dyslipidemia M347448 M6226 Calcipotriene Dermatologic Agents high low The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks. AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg. C000055085 Calcipotriene Calcipotriol ointment adipose-derived multipotent mesenchymal stem cells AD-MSCs Drug Biological",1,8
743,"Drug: Autologous adipose-derived mesenchymal stem cells Procedure: abdominal liposuction Single Group Assignment    Autologous adipose-derived mesenchymal stem cells Autologous adipose-derived mesenchymal stem cells       Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device. 50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells   Autologous adipose-derived mesenchymal stem cells abdominal liposuction  Drug Procedure",1,8
744,"Other: Placental MSC Other: Placental MSC Single Group Assignment    1*10^6 MSC / kg 2*10^6 MSC / kg       MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.   Placental MSC  Other",1,8
745,"Drug: Calcipotriol ointment Drug: PSORI-CM01 Granule Biological: adipose-derived multipotent mesenchymal stem cells Single Group Assignment  D000003879 Dermatologic Agents Experimental group Experimental group Experimental group Derm All Dermatologic Agents All Drugs and Chemicals Dyslipidemia M347448 M6226 Calcipotriene Dermatologic Agents high low The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks. PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks. AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg C000055085 Calcipotriene Calcipotriol ointment PSORI-CM01 Granule adipose-derived multipotent mesenchymal stem cells Dovonex Chinese Herbal Medicine Drug Drug Biological",1,8
746,Biological: intrathecal injection Single Group Assignment    stem cell reciepient       Intrathecal injection of mesenchymal stem cells in patients with ALS   intrathecal injection  Biological,1,8
747,Other: micro injection of SVF in vocal cords Single Group Assignment    micro injection of SVF in vocal cords          micro injection of SVF in vocal cords  Other,1,8
748,"Biological: Marrow stromal cell infusion Single Group Assignment    1       This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.  As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.  Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10^6 MSC/kg and the second dose of cells will be 5x10^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion.   Marrow stromal cell infusion Gene marking mesenchymal cells Biological",1,8
749,"Other: flow cytometry Other: flow cytometry Other: flow cytometry Parallel Assignment    aggressive periodontitis (AP) chronic periodontitis controls All All Drugs and Chemicals  M9336 M3377 M9270 Immunoglobulins Antibodies Immunoglobulin A low low low These populations will be identified by different combinations of antibodies to identify:  T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56). Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR) Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)   flow cytometry proportion of lymphocytes, myeloid and mesenchymal populations in the samples, as determined by flow cytometry. Other",1,8
750,Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs) Biological: matched placebo Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs) Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs) Parallel Assignment    100 million hMSCs 20 million hMSCs 200 million hMSCs Placebo CNSDep All PhSol ANeo Central Nervous System Depressants All Drugs and Chemicals Pharmaceutical Solutions Antineoplastic Agents  M7286 M85407 M8814 Ether Plasma-lyte 148 Altretamine low low low The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.   Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs) matched placebo  Biological Biological,1,9
751,Biological: Human Umbilical Cord-derived Mesenchymal Stem Cells Single Group Assignment    Human Umbilical Cord-derived Mesenchymal Stem Cells       Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.   Human Umbilical Cord-derived Mesenchymal Stem Cells  Biological,1,9
752,"Biological: infusion of ADR-001 (Mesenchymal stem cell) Single Group Assignment 3 + 3 dose escalation study design   ADR-001 All All Drugs and Chemicals  M9336 M3377 M18269 M9270 Immunoglobulins Antibodies Immunoglobulins, Intravenous Immunoglobulin A low low low low Once or twice with two week interval at a dose of 100 x 10 ^ 6 cells.   infusion of ADR-001 (Mesenchymal stem cell)  Biological",1,9
753,Biological: Allogeneic mesenchymal stromal cells Single Group Assignment    allogeneic mesenchymal stromal cells       The allogeneic mesenchymal stromal cells will be administered intravenously.   Allogeneic mesenchymal stromal cells  Biological,1,9
754,Biological: MSC Single Group Assignment    implantation group       subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose   MSC  Biological,1,9
755,Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells Single Group Assignment    Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells       Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.   Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells  Biological,1,9
756,"Other: Bone Marrow Cell Transplantation Drug: Cyclophosphamide Drug: Cyclosporin Procedure: Mesenchymal Stem Cell Transplantation Drug: Busulfan Other: Bone Marrow Cell Transplantation Radiation: Irradiation, Total Body Drug: Cyclophosphamide Procedure: Mesenchymal Stem Cell Transplantation Drug: Busulfan Single Group Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 D000004791 D000000935 D000000890 D000003879 D000065095 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Enzyme Inhibitors Antifungal Agents Anti-Infective Agents Dermatologic Agents Calcineurin Inhibitors 1 2 2 1 2 1 1 2 1 2 Infe ARhu Derm All ANeo Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Antineoplastic Agents Impact Impact Off Tablet M18113 M5882 M4488 M5879 M9364 M9353 M19757 M20095 M2972 M3406 M5404 M10948 M3366 M6226 M29605 Cyclosporine Cyclosporins Busulfan Cyclophosphamide Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Calcineurin Inhibitors high high high high low low low low low low low low low low low  D000016572 D000003520 D000002066 D000003524 Cyclosporine Cyclophosphamide Busulfan Cyclosporins Bone Marrow Cell Transplantation Irradiation, Total Body Cyclophosphamide Cyclosporin Mesenchymal Stem Cell Transplantation Busulfan  Other Radiation Drug Drug Procedure Drug",1,9
757,Biological: ALLO-ASC Single Group Assignment    ALLO-ASC       Infusion for Crohn's disease   ALLO-ASC ALLO-ASC-CD Biological,1,9
758,Biological: CS10BR05 Single Group Assignment    CS10BR05       The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.   CS10BR05  Biological,1,9
759,"Drug: mesenchymal stem cells from umbilical cord Single Group Assignment    mesenchymal stem cells       inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.   mesenchymal stem cells from umbilical cord  Drug",1,9
760,Biological: intravenous delivery of allogeneic bone marrow-derived MSCs Biological: intravenous delivery of allogeneic bone marrow-derived MSCs Biological: intravenous delivery of allogeneic bone marrow-derived MSCs Sequential Assignment Dose finding study   High dose Low dose Medium dose       MSCs   intravenous delivery of allogeneic bone marrow-derived MSCs allogeneic NK1R+MSC Biological,1,9
761,Biological: Bone marrow autologous mesenchymal stem cells transplantation Biological: Bone marrow autologous mesenchymal stem cells transplantation Crossover Assignment    Arm 1 Arm 2          Bone marrow autologous mesenchymal stem cells transplantation  Biological,1,9
762,Biological: Mesenchymal stromal cells Other: Placebo Parallel Assignment This is a randomized (2:1 ratio) placebo controlled trial.   Mesenchymal Stromal Cells Placebo AnCoag BlSubst All Anticoagulants Blood Substitutes All Drugs and Chemicals  M6258 Dextrans low Thawed product containing MSC(300x10^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin [total volume 60 mL] Dextran 40 + 5% human serum albumin [total volume 60 mL]   Mesenchymal stromal cells Placebo MSC Biological Other,1,9
763,"Drug: Hyaluronic Acid Drug: Hyaluronic Acid Biological: Umbilical Cord Mesenchymal Stem Cell Biological: Recombinant Human Somatropin Drug: Hyaluronic Acid Biological: Umbilical Cord Mesenchymal Stem Cell Drug: Hyaluronic Acid Biological: Recombinant Human Somatropin Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Control Intervention 1 Intervention 2 Intervention 3 Intervention 1 Intervention 2 Intervention 1 Intervention 3 All All Drugs and Chemicals Compression M9030 M250495 M2780 M9353 M27448 M21022 Hyaluronic Acid Hylan Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low low  D000006820 Hyaluronic Acid Hyaluronic Acid Umbilical Cord Mesenchymal Stem Cell Recombinant Human Somatropin Hyaluronan Drug Biological Biological",1,9
764,Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs) Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs) Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs) Parallel Assignment    10 million MSC 15 million MSC 5 million MSC       Intra-ovarian injection of Adipose derived mesenchymal stem cells.   Intraovarian injection of Adipose derived Stromal cells (ADSCs) stem cell transplantation Biological,1,9
765,"Drug: hUC-MSC infusion (BC-U001) Sequential Assignment    hUC-MSC infusion (BC-U001)       The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10^6 cells/kg body weight, 1.0x10^6 cells/kg body weight, 1.5x10^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.   hUC-MSC infusion (BC-U001)  Drug",1,9
766,"Biological: ProTrans® Single Group Assignment This is an open, dose escalating Phase IB Clinical Trial   Treatment       Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells   ProTrans®  Biological",1,9
767,"Biological: Pneumostem®     Pneumostem®       A single intratracheal administration  Low Dose Group (3 patients): 1.0 x 10^7 cells/kg, High Dose Group (6 patients): 2 x 10^7 cells/kg  * The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study.   Pneumostem® Human umbilical cord blood-derived mesenchymal stem cells Biological",1,9
768,Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells Single Group Assignment    PNEUMOSTEM®       Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration   Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells PNEUMOSTEM® Biological,1,9
769,Biological: UMC119-06 Single Group Assignment    UMC119-06       Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06   UMC119-06  Biological,1,9
770,Biological: mesenchymal stem cells derived from bone marrow (BM-MSCs) Single Group Assignment    Haploidentical MSCs derived from bone marrow       Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg   mesenchymal stem cells derived from bone marrow (BM-MSCs)  Biological,1,9
771,"Procedure: intrauterine injection Biological: human umbilical cord mesenchymal stem cell Single Group Assignment    hUC-MSC intrauterine injection group hUC-MSC intrauterine injection group       intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times 2 * 10^7 cells (2ml)   intrauterine injection human umbilical cord mesenchymal stem cell  Procedure Biological",1,10
772,"Biological: MSCs Single Group Assignment    DMT1+MSCs Hypo All Hypoglycemic Agents All Drugs and Chemicals  M9517 M172956 Insulin Insulin, Globin Zinc low low origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single   MSCs mesenchymal stem cells Biological",1,10
773,"Biological: Human umbilical cord mesenchymal stem cells Single Group Assignment    hUC-MSC treatment       A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.   Human umbilical cord mesenchymal stem cells hUC-MSC Biological",1,10
774,"Other: mesenchymal stem cell Single Group Assignment    mesenchymal stem cell ANeo All Antineoplastic Agents All Drugs and Chemicals  M10601 Mechlorethamine low There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers   mesenchymal stem cell  Other",1,10
775,Biological: ucMSCs Other: Normal saline Parallel Assignment    Mesenchymal stem cells Control       the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube   ucMSCs Normal saline  Biological Other,1,10
776,Procedure: Liposuction with Local Anesthesia Biological: Intra articular infusion of AD-SVF Single Group Assignment  D000002492 D000045505 Central Nervous System Depressants Physiological Effects of Drugs Autologous Adipose-derived Stromal Vascular Fraction infusion Autologous Adipose-derived Stromal Vascular Fraction infusion CNSDep All Central Nervous System Depressants All Drugs and Chemicals Ultrasound M3259 M11052 Anesthetics Mitogens high low Liposuction under tumescent anesthesia for adipose tissue harvesting. Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.  AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment. Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing. D000000777 Anesthetics Liposuction with Local Anesthesia Intra articular infusion of AD-SVF Lipoplasty Liposculpture Suction-assisted fat removal Procedure Biological,1,10
777,"Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate Parallel Assignment    15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46 15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46       ExoFlo 15ml, IV   Bone Marrow MSC Derived Extracellular Vesicle Isolate  Drug",1,10
778,"Biological: Autologous Mesenchymal Bone Marrow Cell Single Group Assignment    Autologous Mesenchymal Bone Marrow Cell       Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.  Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration   Autologous Mesenchymal Bone Marrow Cell  Biological",1,10
779,"Biological: mesenchymal stem cells Single Group Assignment    mesenchymal stem cells       Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:  1.10^6 CSM / kg 2.10^6 CSM / kg 4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion   mesenchymal stem cells  Biological",1,10
780,Biological: Mesenchymal Stem Cell Single Group Assignment    Mesenchymal Stem Cell Infusion       Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.   Mesenchymal Stem Cell Lungcellgram Biological,1,10
781,Drug: mesenchymal stromal cells Single Group Assignment    mesenchymal stromal cells       2 doses of 1-2x10^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation   mesenchymal stromal cells MSC bone marrow derived mesenchymal stromal cells Drug,1,10
782,Biological: Autologous mesenchymal stem cells Other: standard treatment Other: standard treatment Parallel Assignment    mesenchymal stem cells control mesenchymal stem cells       Autologous adipose tissue-derived mesenchymal stem cells standard treatment according to clinical protocols   Autologous mesenchymal stem cells standard treatment  Biological Other,1,10
783,"Other: autologous adipose derived mesenchymal stem cell Single Group Assignment    a single, open clinical trial All All Drugs and Chemicals  M9030 Hyaluronic Acid low autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe   autologous adipose derived mesenchymal stem cell  Other",1,10
784,"Drug: Mesenchymal Stem Cell + NaCl 0,9% 2ml Single Group Assignment    Mesenchymal Stem Cell       Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.   Mesenchymal Stem Cell + NaCl 0,9% 2ml  Drug",1,10
785,Biological: Autologous adipose-derived mesenchymal stem cells Other: Standard treatment according to the Clinical protocols Other: Standard treatment according to the Clinical protocols Parallel Assignment    mesenchymal stem cells control mesenchymal stem cells PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space Standard treatment according to the Clinical protocols   Autologous adipose-derived mesenchymal stem cells Standard treatment according to the Clinical protocols  Biological Other,1,10
786,"Biological: expanded autologous bone marrow derived MSC Single Group Assignment    Arm 1       Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary   expanded autologous bone marrow derived MSC BM-MSc Biological",1,10
787,Biological: Mesenchymal Stem Cells (MSCs) Biological: OrthADAPT Parallel Assignment    Mesenchymal stem cells (MSCs) OrthADAPT       20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.   Mesenchymal Stem Cells (MSCs) OrthADAPT  Biological Biological,1,10
788,Drug: Allogenic Mesenchymal stem cells Single Group Assignment    osseointegration using Allogenic MSC's       Allogenic mesenchymal stem cells are introduced during placement of dental implants.   Allogenic Mesenchymal stem cells Transchymal Drug,1,10
789,Biological: Allogeneic umbilical cord mesenchymal stem cells Single Group Assignment    UMSC01       UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.   Allogeneic umbilical cord mesenchymal stem cells  Biological,1,10
790,Drug: stem cells + hydroxy apatite Other: autograft taken from iliac crest Parallel Assignment    stem cells autograft       patient will be transplanted with stem cells and hydroxyapatite patient will be transplanted with autograft   stem cells + hydroxy apatite autograft taken from iliac crest  Drug Other,1,10
791,Biological: clinical grade umbilical cord mesenchymal stem cells Single Group Assignment    treatment group       10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions   clinical grade umbilical cord mesenchymal stem cells  Biological,1,10
792,"Biological: Fucosylated MSC for Osteoporosis Single Group Assignment    Fucosylated MSC for Osteoporosis       Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).  Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access.   Fucosylated MSC for Osteoporosis  Biological",1,10
793,"Biological: Allogeneic Mesenchymal Stromal Cells Single Group Assignment Open label, single group, Phase 1 study   Allogeneic Mesenchymal Stromal Cell infusion       Intravenous MSCs 1.2-1.5 x 10^6 cells/kg on Days 1 and 3 after study enrollment   Allogeneic Mesenchymal Stromal Cells  Biological",1,10
794,Single Group Assignment              surgical operation of cell transplantation  Procedure,1,10
795,"Drug: Linagliptin Drug: Linagliptin Parallel Assignment  D000007004 D000045505 D000054795 D000006728 D000006730 D000054873 D000011480 D000004791 D000045504 Hypoglycemic Agents Physiological Effects of Drugs Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Dipeptidyl-Peptidase IV Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Linagliptin control group Linagliptin patients with schizophrenia CNSDep PsychDr All Hypo Infe Central Nervous System Depressants Psychotropic Drugs All Drugs and Chemicals Hypoglycemic Agents Anti-Infective Agents VEGF M16056 M27110 M445 M9206 M27058 M8941 M8940 M13495 M18761 Antipsychotic Agents Dipeptidyl-Peptidase IV Inhibitors Linagliptin Hypoglycemic Agents Incretins Hormones Hormone Antagonists Protease Inhibitors HIV Protease Inhibitors low low high low low low low low low 12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment. D000069476 Linagliptin Linagliptin Tradjenta Drug",1,10
796,"Biological: Infusion IV of Mesenchymal Stem cells Parallel Assignment Mesenchymal Stem Cell from umbilical cord allogenic from de bank laboratory, will be applied IV to 5 patients con pneumonia bilateral due to COVID 19, complicated with acute respiratory distress syndrome. The clinical, biochemical, inflammatory and immune changes will be described and compare against historical cases treated in the Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán   Treated group Coag All Coagulants All Drugs and Chemicals  M203827 Fibrin fragment D low Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose   Infusion IV of Mesenchymal Stem cells  Biological",1,10
797,Procedure: Bronchoscopy Procedure: Bronchoscopy Parallel Assignment    Valves plus cells Valves plus saline       Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.   Bronchoscopy  Procedure,1,10
798,"Biological: mesenchymal stem cells Single Group Assignment    mesenchymal stem cells       Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.   mesenchymal stem cells  Biological",1,10
799,Single Group Assignment           Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)   Homeo-GH  Drug,1,10
800,Biological: Autologous Mesenchymal Stem Cells Single Group Assignment    Autologous Mesenchymal Stem Cells          Autologous Mesenchymal Stem Cells Mesenchymal Stem Cells Stromal Cells Stem Cells Cell Therapy Biological,1,10
801,Genetic: TYF-ADA gene-modified autologous stem cells Single Group Assignment    TYF-ADA-modified autologous stem cells AnArAg VaDiAg Analg All Anti-Arrhythmia Agents Vasodilator Agents Analgesics All Drugs and Chemicals  M2747 Adenosine low Infusion of TYF-ADA-modified autologous stem cells at 1~10x10^6 gene-modified cells per kg body weight; or more infusions depending on the circumstances   TYF-ADA gene-modified autologous stem cells  Genetic,1,10
802,Biological: Exosomes (sEVs) Single Group Assignment    Experimental group - sEVs       Exosomes 3-5x10e11 particles/dose   Exosomes (sEVs)  Biological,1,10
803,Biological: autologous bone marrow derived mesenchymal stromal cells Single Group Assignment    cells       Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.   autologous bone marrow derived mesenchymal stromal cells  Biological,1,10
804,"Procedure: ASCs injection Device: ASCs injection Device: Closure of fistula tract. Single Group Assignment    ASCs injection ASCs injection ASCs injection CNSDep All PhSol VaCoAg Resp Central Nervous System Depressants All Drugs and Chemicals Pharmaceutical Solutions Vasoconstrictor Agents Respiratory System Agents  M3259 M21013 M7144 M29524 M211051 Anesthetics Pharmaceutical Solutions Epinephrine Racepinephrine Epinephryl borate low low low low low In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.  The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.  The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.  Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue. In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS. A SALVECOLL-E paste will be injected into the fistula tract.   ASCs injection ASCs injection Closure of fistula tract. LIPOGEMS system SALVECOLL-E paste Procedure Device Device",1,10
805,"Biological: Human umbilical cord-derived MSCs Parallel Assignment    Human umbilical cord-derived MSCs and DMARDs Infe ANeo All ARhu Derm Repr Infl Analg Gast Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Antirheumatic Agents Dermatologic Agents Reproductive Control Agents Anti-Inflammatory Agents Analgesics Gastrointestinal Agents  M15711 M10855 M14432 Thalidomide Methotrexate Sulfasalazine low low low 1.0E+6 MSC/kg, IV drop and repeat repeated after three months   Human umbilical cord-derived MSCs  Biological",1,10
806,"Single Group Assignment           1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)   allogeneic mesenchymal stem cell transplantation  Genetic",1,10
807,Biological: mesenchymal cell and fibroblast injection Biological: mesenchymal cell transplantation Parallel Assignment    mesenchymal cell transplantaion mesenchymal cell and fibroblast transplantaion       Mesenchymal cell transplantation in patients with Crohn's disease. Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.   mesenchymal cell transplantation mesenchymal cell and fibroblast injection  Biological Biological,1,10
808,Biological: Mesenchymal stromal cells Single Group Assignment    Mesenchymal stromal cells          Mesenchymal stromal cells  Biological,1,10
809,"Biological: MSCTC-0010 Dose Escalation Sequential Assignment    MSCTC-0010 Dose Escalation       Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)  Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD   MSCTC-0010 Dose Escalation MSCTC-0010 Biological",1,10
810,Biological: Mesenchymal Stem Cells Single Group Assignment    Mesenchymal Stem Cells       Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)   Mesenchymal Stem Cells Allogenic Bone Marrow MSCs Biological,1,10
811,Biological: Injection of Umbilical cord derived MSCs Biological: Injection of Umbilical cord derived MSCs Single Group Assignment    Injection of MSCs differentiated into neural stem cells NSCs Injection of Umbilical cord derived MSCs       Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients   Injection of Umbilical cord derived MSCs injection of Umbilical cord derived MSCs differentiated into neural stem cells NSCs. Biological,1,10
812,Other: Exosomes derived from mesenchymal stromal cells (MSCs) Parallel Assignment Participants (ELBW infants GA 25/0-27/6 week) are randomized to one of two groups in parallel for the duration of the study. The first group (exosome treatment group) will receive intranasal administration of exosomes and the second (control group) will not receive exosomes. Patients in both groups will receive standard basic therapy   Intranasal exosomes administration       Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants   Exosomes derived from mesenchymal stromal cells (MSCs)  Other,1,10
813,"Other: tissue engineered group Procedure: autogenous bone graft group Parallel Assignment    tissue engineered group autogenous bone graft group       cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)   tissue engineered group autogenous bone graft group BM-MSCs on collagen matrix (Osteovit) Other Procedure",1,10
814,"Biological: mesenchymal cells Single Group Assignment single arm due to not alternative treatment exist   treatment with mesenchymal stem cells AnCoag All Anticoagulants All Drugs and Chemicals  M3396 Anticoagulants low Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration   mesenchymal cells  Biological",1,10
815,Genetic: Gene-modified autologous stem cells Single Group Assignment    Gene-modified autologous stem cells       Infusion for 5x10^6~1x10^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances   Gene-modified autologous stem cells  Genetic,1,10
816,Procedure: Autologous BMSCs Drug: bone marrow-derived mesenchymal stem cells Single Group Assignment    Autologous BMSCs Autologous BMSCs Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Cultured autologous bone marrow-derived mesenchymal stem cells   Autologous BMSCs bone marrow-derived mesenchymal stem cells BMSC Procedure Drug,1,10
817,Genetic: Mesenchymal stem cells Single Group Assignment    Intervention arm       60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)   Mesenchymal stem cells  Genetic,1,10
818,"Biological: Autologous, Adipose derived Mesenchymal Stem Cells Single Group Assignment    Phase I       The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.   Autologous, Adipose derived Mesenchymal Stem Cells  Biological",1,10
819,Biological: Autologous adipose-derived mesenchymal stem cells Other: Standard treatment according to the Clinical protocols Other: Standard treatment according to the Clinical protocols Parallel Assignment    mesenchymal stem cells control mesenchymal stem cells PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Autologous adipose-derived mesenchymal stem cells mixed with collagen solution Standard treatment according to the Clinical protocols   Autologous adipose-derived mesenchymal stem cells Standard treatment according to the Clinical protocols  Biological Other,1,10
820,"Other: MSC Single Group Assignment    MSC       mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks   MSC  Other",1,10
821,"Biological: Autologous mesenchymal stem cell Factorial Assignment    Mesenchymal stem cell       Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.   Autologous mesenchymal stem cell Autologous adipose tissue derived mesenchymal stem cell Biological",1,10
822,Procedure: MSCs injection Single Group Assignment    MSCs injection       MSCs cells will be injected in two aliquots of 10 ml by catheterism   MSCs injection  Procedure,1,10
823,Combination Product: adipose-derived messenchymal stem cell Single Group Assignment    Adipose-derived messenchymal stem cell (AD-MSC)       Collaborative research program between Vinmec Research Institute of Stem Cell and Gene Technology with the National Yang-Ming University in Taiwan The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors who have screened for infectious diseases and then multiplied in large numbers. These products were produced following the GMP laboratory system and approved by Taiwan FDA for preclinical and clinical trials with completed certificates   adipose-derived messenchymal stem cell  Combination Product,1,10
824,Other: Intramuscular injection of a suspension of adult mesenchymal stem cells derived Single Group Assignment    Autologous mesenchymal stem cells       Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients   Intramuscular injection of a suspension of adult mesenchymal stem cells derived  Other,1,10
825,"Drug: AGLE-102 Single Group Assignment    AGLE-102       In this protocol, 2nd degree burn wounds will receive direct application of EVs derived from bone marrow MSCs. We have observed success with this type of approach in the past using bone marrow stem cells including MSCs. We have evidence that EVs derived from MSCs are responsible for many of the healing effects produced by MSCs and may be a safer, more reliable alternative to allogeneic cell therapy. This protocol is designed to develop a safe and ideal method of administering bone marrow cell Extracellular Vesicles to wounds.   AGLE-102  Drug",1,10
826,"Biological: Mesenchymal Stem Cells Single Group Assignment A phase I/II, open-label, single-arm, single-center intervention study in the NICU at the Wilhelmina children's Hospital / University Medical Centre in Utrecht of (near-)term newborns ≥36 weeks of gestation within the first week of onset of presenting clinical symptoms.   Mesenchymal Stem Cells HB All Herbal and Botanical All Drugs and Chemicals  T248 Passionflower low One dose of 50x10^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.   Mesenchymal Stem Cells Bone Marrow-derived Allogeneic Mesenchymal Cells Biological",1,10
827,"Biological: Human umbilical cord blood-derived mesenchymal stem cells Biological: Human umbilical cord blood-derived mesenchymal stem cells Parallel Assignment    1 2       1x1,000,000 hMSC/kg, IV after unrelated HSCT 5x1,000,000 hMSC/kg, IV after unrelated HSCT   Human umbilical cord blood-derived mesenchymal stem cells Human umbilical cord blood-derived mesenchymal stem cells PROMOSTEM PROMOSTEM Biological Biological",1,10
828,"Biological: Implantation of autologous mesenchymal stem cells (CSM) expanded ""in vitro"" and administered directly into the lung suture line Single Group Assignment    Prolonged postoperative air leaks in risk patients.       Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro   Implantation of autologous mesenchymal stem cells (CSM) expanded ""in vitro"" and administered directly into the lung suture line  Biological",1,10
829,Drug: Adipose-derived expanded stem cells Single Group Assignment    Autologous expanded stem cells       Intralesional application ASC   Adipose-derived expanded stem cells  Drug,1,10
830,Biological: Autologous mesenchymal cells transplantation Single Group Assignment    Single group       All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.   Autologous mesenchymal cells transplantation  Biological,1,10
831,"Drug: Suspension of human autologous MSC 3P in 1.5 ml Single Group Assignment    Human AMSC (passage 3) 3P in 1.5 mL       During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.   Suspension of human autologous MSC 3P in 1.5 ml hAMSC Drug",1,10
832,Procedure: Bone marrow aspiration Single Group Assignment    Mesenchymal stem cells       Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy   Bone marrow aspiration  Procedure,1,10
833,"Genetic: mesenchymal stem cells Single Group Assignment    mesenchymal stem cells Infe All Anti-Infective Agents All Drugs and Chemicals  M12469 M3154 M255364 M11052 M15249 Penicillins Amphotericin B Liposomal amphotericin B Mitogens Streptomycin low low low low low collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient   mesenchymal stem cells  Genetic",1,10
834,Biological: Cellgram-CKD Single Group Assignment    Cellgram-CKD PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease   Cellgram-CKD  Biological,1,10
835,"Procedure: umbilical cord blood stem cell implantation for osteoarthritis treatment Single Group Assignment    Osteoarthritic knee patients All CNSDep All Drugs and Chemicals Central Nervous System Depressants  M9030 M3259 Hyaluronic Acid Anesthetics low low The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.  Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface.   umbilical cord blood stem cell implantation for osteoarthritis treatment  Procedure",1,10
836,"Drug: mesenchymal stem cell Single Group Assignment    Mesenchymal stem cell All All Drugs and Chemicals  M28485 Phosphodiesterase 5 Inhibitors low Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.   mesenchymal stem cell Cellgram-ED Drug",1,10
837,"Drug: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy Single Group Assignment Staggered enrollment for subjects 1 to 3, followed by conditioned open enrollment for subjects 4 to 10.   BM-MSC injections for low back pain       Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy   Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy  Drug",1,10
838,Other: no Intervention     Mesenchymal stem cell       no Intervention   no Intervention  Other,1,10
839,Biological: Intravenous injection Biological: Intravenous injection Parallel Assignment    AD-MSC Placebo       Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .   Intravenous injection  Biological,1,10
840,Biological: UCMSC Single Group Assignment    UCMSC treatment       UCMSC: umbilical cord mesenchymal stem cells 3-5*10^7/5 ml   UCMSC  Biological,1,10
841,"Biological: Cellgram™ (Bone marrow-derived MSCs) Single Group Assignment A single-dose injection of autologous bone marrow-derived mesenchymal stem cells (Cellgram™) will be administered to the patient by an experienced interventional radiologist.   Cellgram™ (Bone marrow-derived MSCs) CNSDep All Hemat Central Nervous System Depressants All Drugs and Chemicals Hematinics  M3259 M10262 Anesthetics Liver Extracts low low Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).   Cellgram™ (Bone marrow-derived MSCs)  Biological",1,10
842,Biological: Longeveron Mesenchymal Stem Cells Biological: Longeveron Mesenchymal Stem Cells Parallel Assignment Phase 1: 10 patient safety run-in: all patients treated with LMSCs during Stage II surgery.  Phase 2: 20 patients randomized 1:1 to receive either LMSCs or no cells (controls) during Stage II surgery.   Cohort A - Phase 1 (Open Label) Cohort B - Phase 2 Treatment Group       Allogeneic bone marrow-derived mesenchymal stem cell   Longeveron Mesenchymal Stem Cells LMSCs Biological,1,10
843,"Biological: mesenchymal stem cells Single Group Assignment    mesenchymal stem cells       Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.  Intravenous infusion of umbilical cord derived mesenchymal stem cells   mesenchymal stem cells  Biological",1,10
844,Biological: Adult Autologous Mesenchymal Bone Marrow Cell Single Group Assignment    Autologous Mesenchymal Bone Marrow Cell       Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.   Adult Autologous Mesenchymal Bone Marrow Cell  Biological,1,10
845,Drug: AstroStem-V Single Group Assignment    AstroStem-V       Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)   AstroStem-V  Drug,1,10
846,Biological: Umbilical Cord Mesenchymal Stem Cell Single Group Assignment    Umbilical Cord Mesenchymal Stem Cell          Umbilical Cord Mesenchymal Stem Cell umbilical cord mesenchymal stem cells Biological,1,10
847,Biological: Autologous bone marrow-derived mesenchymal stem cells. Single Group Assignment    Safety       Intrathecal infusion of a single dose of ex vivo expanded MSC.   Autologous bone marrow-derived mesenchymal stem cells.  Biological,1,10
848,Biological: Umbilical Cord Mesenchymal Stem Cell Therapy Single Group Assignment    Treatment group       Umbilical Cord Mesenchymal Stem Cell Therapy   Umbilical Cord Mesenchymal Stem Cell Therapy  Biological,1,10
849,"Genetic: Mesenchymal stromal cells Single Group Assignment    Mesenchymal Stromal Cells (MSC)       Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).   Mesenchymal stromal cells  Genetic",1,10
850,Biological: mesenchymal stem cells Other: standard treatment Other: standard treatment Parallel Assignment    mesenchymal stem cells mesenchymal stem cells standard treatment       autologous mesenchymal stem cells standard treatment according to clinical protocols   mesenchymal stem cells standard treatment  Biological Other,1,10
851,take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth   flow cytomery  Device,1,10
852,Procedure: MSC Treatment Single Group Assignment    MSC Treatment Derm All Dermatologic Agents All Drugs and Chemicals  M5415 Coal Tar low Intravenous administration of up to 2x10^6 autologous MSCs per kg   MSC Treatment Mesenchymal Stem Cells Multipotent Mesenchymal Stem Cells Multipotent Mesenchymal Stromal Cells Procedure,1,10
853,"Drug: ExoFlo Drug: ExoFlo Parallel Assignment    15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46 15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46       A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle product, for the treatment of medically refractory ulcerative colitis   ExoFlo  Drug",1,10
854,Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell Single Group Assignment    Ambulatory Patients Non-Ambulatory Patients          Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell  Drug,1,10
855,"Drug: Exosome ointment Single Group Assignment Single-center, single-arm, open-label study   Exosome Ointment       100 µg MSC exosomes/g ointment   Exosome ointment  Drug",1,10
856,"Genetic: Intervention on primary cultured cells     Kabuki syndrome/ unaffected parents       The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells   Intervention on primary cultured cells  Genetic",1,8
857,"Drug: Adipose tissue-derived mesenchymal stem cells Single Group Assignment    Adipose tissue-derived mesenchymal stem cells       CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre   Adipose tissue-derived mesenchymal stem cells  Drug",1,7
858,Biological: allogenic bone marrow derived mesenchymal stem cells Single Group Assignment    CS20AT04       Step -1 dose : 1.0x10^6cells/kg Step 1 dose : 2.0x10^6cells/kg Step 2 dose : 3.0x10^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days   allogenic bone marrow derived mesenchymal stem cells CS20AT04 Biological,1,7
859,Drug: autologous bone marrow derived stem cells Single Group Assignment    autologous bone marrow stem cells       intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume   autologous bone marrow derived stem cells  Drug,1,1
860,"Biological: Allogeneic bone marrow-derived mesenchymal stromal cells Single Group Assignment    Mesenchymal Stromal Cells (MSCs)       This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; <18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : >34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.   Allogeneic bone marrow-derived mesenchymal stromal cells  Biological",1,1
861,Drug: Mesenchymal stem cell injection Single Group Assignment    Mesenchymal stem cell injection       Aspirated bone marrow then separation for Mesenchymal stem cell   Mesenchymal stem cell injection  Drug,1,1
862,"Biological: autologous adipose-derived mesenchymal stem cells Single Group Assignment    Mesenchymal stem cells treatment       Patients will receive five infusions, one month apart, each comprising 5-7x10^7 cells of autologous adipose-derived mesenchymal stem cells.   autologous adipose-derived mesenchymal stem cells  Biological",1,1
863,Biological: Umbilical Cord Mesenchymal Stem Cells Single Group Assignment    Mesenchymal Stem Cells          Umbilical Cord Mesenchymal Stem Cells  Biological,1,1
864,Single Group Assignment           single intrathecal dose of 10x6 cells by lumbar puncture.   autologous mesenchymal stem cells  Biological,1,1
865,"Drug: Mesenchymal Stem Cell Antigen-1, Human Drug: Mesenchymal Stem Cell Antigen-1, Human Drug: Mesenchymal Stem Cell Antigen-1, Human     stem cell application; Group I disease 0-7. days, stem cell application; Group II; 8-14 days of the disease. days stem cell application; Group III; those applied on the 15th day and after.       Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies   Mesenchymal Stem Cell Antigen-1, Human Human umblical cord deriveted Mesenchymal Stem Cell Drug",1,1
866,"Biological: MSC Single Group Assignment    1       MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.   MSC  Biological",1,1
867,Drug: Allo-hMSCs Drug: Placebo Drug: Allo-hMSCs Parallel Assignment    Allogeneic hMSCs Pilot - Allogeneic hMSCs Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M85407 Plasma-lyte 148 low a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A   Allo-hMSCs Placebo Allogeneic Human Mesenchymal Stem Cells Stem Cells Drug Drug,1,1
868,Biological: Allogeneic stem cells implantation Single Group Assignment    Stem cells implantation          Allogeneic stem cells implantation  Biological,1,1
869,Biological: Pooled mesenchymal stem cell Other: Standard treatment according to the Clinical protocols Other: Standard treatment according to the Clinical protocols Parallel Assignment    SLE patients MSC treatment SLE patients MSC treatment SLE patients standard treatment       Pooled allogenic mesenchymal stem cell derived from olfactory mucosa Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus   Pooled mesenchymal stem cell Standard treatment according to the Clinical protocols  Biological Other,1,7
870,"Drug: Mesenchymal stem cells Drug: Suspension media Crossover Assignment    Mesenchymal stem cells Suspension media       After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs. injection suspension media   Mesenchymal stem cells Suspension media  Drug Drug",1,1
871,"Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells Sequential Assignment    20×10^6 AD-MSCs 5×10^6 AD-MSCs Derm All Dermatologic Agents All Drugs and Chemicals  M5415 Coal Tar low Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).   Autologous Adipose-Derived Mesenchymal Stromal Cells AMSCs Drug",1,1
872,Procedure: Cellular transplantation Single Group Assignment    A       600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.   Cellular transplantation  Procedure,1,1
873,"Biological: Placenta Derived Mesenchymal Stem Cell Drug: Sodium Hyaluronate Parallel Assignment A Randomized, Double Blind, Phase-II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients with Osteoarthritis of Knee D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Placenta Derived Mesenchymal Stem Cell sodium hyaluronate All All Drugs and Chemicals PCOS M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low 1ml 1*10^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once Sodium hyaluronate administered into the knee joint once D000006820 Hyaluronic Acid Placenta Derived Mesenchymal Stem Cell Sodium Hyaluronate Mesenchymal Stromal Cells (MSCs) hyaluronate Biological Drug",1,1
874,Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19 Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19 Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19 Other: Placebo Sequential Assignment    RAPA-501 cells Single agent RAPA-501 cells (dose level 1) Single agent RAPA-501 cells (dose level 2) Placebo-control Cohort       Allogeneic off-the-shelf RAPA-501 cells RAPA-501-Allo cell placebo   RAPA-501-Allo off-the-shelf Therapy of COVID-19 Placebo RAPA-501-Allo cells Biological Other,1,1
875,Biological: ASTROSTEM Single Group Assignment    Astrostem       Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10^7cells/5mL 15kg ~ 25kg : 1x10^8cells/10mL 25kg over : 1.5x10^8cells/15mL   ASTROSTEM Autologous Adipose Tissue Derived Mesenchymal Stem Cells Biological,1,1
876,Biological: Trophic factors from umbilical cord mesenchymal stem cells Biological: Trophic factors from umbilical cord mesenchymal stem cells Single Group Assignment    Intra-articular knee injection of MTF Subcutaneous injection of MTF          Trophic factors from umbilical cord mesenchymal stem cells  Biological,1,0
877,Drug: XCEL-MT-OSTEO-BETA Procedure: Surgical treatment Procedure: Surgical treatment Parallel Assignment    XCEL-MT-OSTEO-BETA Standard treatment XCEL-MT-OSTEO-BETA Coag All Coagulants All Drugs and Chemicals  M17443 Fibrin Tissue Adhesive low XCEL-MT-OSTEO-BETA followed by endomedullary nailing Isolated endomedullary nailing   XCEL-MT-OSTEO-BETA Surgical treatment  Drug Procedure,1,0
878,Biological: Mesenchymal Stem Cells Single Group Assignment    Mesenchymal stem cells       Mesenchymal Stem Cell Infusions   Mesenchymal Stem Cells  Biological,1,2
879,"Biological: Autologous adipose derived mesenchymal cells Single Group Assignment    Adipose derived mesenchymal cells       Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.   Autologous adipose derived mesenchymal cells ADSC, mesenchymal cells, stromal cells Biological",1,2
880,Other: Intestinal biopsies during colonoscopy Other: Biopsies taken on surgical specimen Other: Intestinal biopsies during colonoscopy Other: Biopsies taken on surgical specimen Other: Intestinal biopsies during colonoscopy Other: Biopsies taken on surgical specimen Parallel Assignment    Control group Crohn's disease patient group Ulcerative colitis patient group Control group Crohn's disease patient group Ulcerative colitis patient group HB All Herbal and Botanical All Drugs and Chemicals  T120 Cola low Intestinal biopsies during colonoscopy biopsies taken on surgical specimen after intestinal resection   Intestinal biopsies during colonoscopy Biopsies taken on surgical specimen  Other Other,1,2
881,Drug: MSC Fistula Plug Single Group Assignment    MSC Fistula plug: Single Treatment Group       Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.   MSC Fistula Plug mesenchymal stromal cell coated fistula plug Drug,1,2
882,Procedure: Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells Single Group Assignment    Tracheal Replacement       The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.   Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells  Procedure,1,4
883,"Single Group Assignment This clinical trial is a Phase 1/2a, open and researcher-led clinical trial. Subjects will be enrolled in succession, signed informed consent, and administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3 to each eligible subject meeting all selection criteria.          Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.   administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3  Biological",1,4
884,"Biological: ALLO-ASC-DFU     ALLO-ASC-DFU treatment Infl All Anti-Inflammatory Agents All Drugs and Chemicals  M3369 M11052 M17833 Anti-Inflammatory Agents Mitogens Endothelial Growth Factors low low low ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.  This study is a follow-up study without intervention.   ALLO-ASC-DFU Allogenic adipose-derived mesenchymal stem cells Biological",1,4
885,Biological: adipose tissue derived stromal cells dosage Single Group Assignment    adipose tissue derived stromal cells Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization   adipose tissue derived stromal cells dosage  Biological,1,4
886,"Biological: autologous mesenchymal stem cells Single Group Assignment    autologous mesenchymal stem cells       Patients will be injected with autologous mesenchymal stem cells, intracavernously   autologous mesenchymal stem cells  Biological",1,4
887,"Biological: Autologous Mesenchymal stem cells (MSCs) Single Group Assignment    Autologous Mesenchymal stem cells       2 intrathecal autologous MSCs infusions (1x10^8 cells) will be performed, escalated from 30 days apart   Autologous Mesenchymal stem cells (MSCs)  Biological",1,3
888,Procedure: Bone marrow aspirate Single Group Assignment    Bone Marrow Aspirate       A single bone marrow aspirate procedure is planned.   Bone marrow aspirate bone marrow-derived MSC Procedure,1,3
889,"Drug: MR-MC-01 Single Group Assignment    Stem cell group       Submucosal injection of 2.0 x 10,000,000/5ml (1mL * 5 sites)   MR-MC-01  Drug",1,3
890,"Biological: hMSCs Biological: hMSCs Sequential Assignment a first group of 3 patients will receive a lower dose of 20 million hMSCs, followed by a second group of 3 patients to receive a dose of 100 million hMSCs   Group receiving 100 million hMSCs Group receiving 20 million hMSCs       intravenous infusion of bone marrow-derived allogeneic stem cells   hMSCs allogeneic mesenchymal stem cell Biological",1,3
891,Biological: Cell injection Single Group Assignment    Cirrhotic Patients Hemat All Hypo Hematinics All Drugs and Chemicals Hypoglycemic Agents  M10262 M1693 Liver Extracts Pioglitazone low low MSCs introduced into portal vein   Cell injection  Biological,1,3
892,"Other: Ex vivo expanded cord blood cells Single Group Assignment    Expanded All All Drugs and Chemicals  M247314 Flt3 ligand protein low Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.   Ex vivo expanded cord blood cells  Other",1,3
893,Procedure: bone marrow aspirate Single Group Assignment    Mesenchymal Stem Cell          bone marrow aspirate  Procedure,1,3
894,Biological: autologous mesenchymal stromal cell Parallel Assignment    autologous mesenchymal stromal cell       Islet transplantation patients will receive autologous MSCs following islets infusion   autologous mesenchymal stromal cell  Biological,1,3
895,Biological: UNEX-42 Biological: UNEX-42 Biological: UNEX-42 Biological: Phosphate-buffered saline Sequential Assignment    20 pmol phospholipid/kg body weight 200 pmol phospholipid/kg body weight 60 pmol phospholipid/kg body weight Placebo       UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline. Phosphate-buffered saline   UNEX-42 Phosphate-buffered saline Placebo Biological Biological,1,3
896,Procedure: Intravitreal transplantation of mesenchymal stem cell Biological: Culture and isolation of autologous bone-marrow mesenchymal stem cells Single Group Assignment    MSC transplantion MSC transplantion CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low    Intravitreal transplantation of mesenchymal stem cell Culture and isolation of autologous bone-marrow mesenchymal stem cells  Procedure Biological,1,2
897,"Biological: Human umbilical cord mesenchymal stem cells Parallel Assignment    hUC-MSC treatment       A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.   Human umbilical cord mesenchymal stem cells  Biological",1,2
898,Biological: mesenchymal stromal cells Single Group Assignment unblinded single arm intervention   mesenchymal stromal cells       mesenchymal stromal cells in a collagen scaffold   mesenchymal stromal cells  Biological,1,2
899,"Biological: ARM 1: AdMSC: adipose stem cells Other: ARM 2: Placebo Crossover Assignment  D000051056 D000007166 D000007155 D000045505 Complement Inactivating Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs ARM 1: AdMSC: adipose stem cells ARM 2 Placebo All All Drugs and Chemicals A 30- M5544 M18692 M9364 M9353 Complement System Proteins Complement Factor H Immunosuppressive Agents Immunologic Factors low high low low Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm. D000017242 Complement Factor H ARM 1: AdMSC: adipose stem cells ARM 2: Placebo ARM 1: AdMSC: Adipose derived mesenchymal stem cells ARM 2 Placebo Biological Other",1,0
900,Drug: Only 1 arm: treatment with MSC-AFP Single Group Assignment    Only 1 arm: treatment with MSC-AFP       Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.   Only 1 arm: treatment with MSC-AFP mesenchymal stromal cells Drug,1,0
901,"Drug: Cellgram-CLI Single Group Assignment    2-time injection group : Cellgram-CLI       Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip  Main ingredient: Autologous bone marrow-derived mesenchymal stem cells  Dosage: 50,000,000 cells/10ml, 2-time injection  Storage: An airtight container, 20~25℃  Injection Method: Intramuscular   Cellgram-CLI Autologous bone marrow derived Mesenchymal Stem Cells Drug",1,0
902,Drug: Stem Cell Product Drug: Stem Cell Product Parallel Assignment Double-blind placebo-controlled   ASC Placebo       100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline   Stem Cell Product  Drug,1,0
903,Biological: bone marrow-derived mesenchymal stem cells Drug: Placebo Parallel Assignment    mesenchymal stem cells Placebo       bone marrow-derived mesenchymal stem cells Placebo   bone marrow-derived mesenchymal stem cells Placebo  Biological Drug,1,0
904,Biological: mesenchymal stem cell Single Group Assignment    mesenchymal stem cell       intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline   mesenchymal stem cell  Biological,1,0
905,"Biological: UC-MSCs Other: Placebo Parallel Assignment    UC-MSCs treatment group Control group       0.5*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7 100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7   UC-MSCs Placebo  Biological Other",1,0
906,Biological: HUCMSC injection Biological: collagen scaffolds/HUCMSC injection Parallel Assignment    HUCMSC injection collagen scaffolds/HUCMSC injection       The subjects will receive intracavernous injection of HUCMSC.' The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'   HUCMSC injection collagen scaffolds/HUCMSC injection  Biological Biological,1,0
907,"Other: Autologous bone marrow mesenchymal stem cells Single Group Assignment    MSV autologous transplantation       Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.   Autologous bone marrow mesenchymal stem cells MSV, mesenchymal stem cells by IBGM-Valladolid protocol. Other",1,0
908,Biological: Ex vivo cultured adult allogenic MSCs Other: Plasmalyte-A Parallel Assignment  D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions Ex vivo cultured adult allogenic MSCs Plasmalyte-A PhSol All Pharmaceutical Solutions All Drugs and Chemicals CAB M85407 M21013 M11966 Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions high low low Single IV dose of allogenic MSCs Single IV dose of Plasmalyte-A C000012499 Plasma-lyte 148 Ex vivo cultured adult allogenic MSCs Plasmalyte-A  Biological Other,1,0
909,"D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 D000000020 D000000019 D000012102 D000000964 D000000963 D000003879 D000004791 D000005493 D000019384 D000000935 D000000890 D000065095 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents Antimetabolites, Antineoplastic Antimetabolites Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors Antifungal Agents Anti-Infective Agents Calcineurin Inhibitors  Infe ARhu Derm All ANeo Repr Micro Hemat Vi Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Antineoplastic Agents Reproductive Control Agents Micronutrients Hematinics Vitamins Impact Impact Off Tablet Into M18113 M5882 M4488 M5879 M10855 M9364 M9353 M19757 M20095 M2972 M3433 M6226 M7770 M16698 M7771 M3406 M5404 M10948 M3366 M29605 T447 T446 T448 T475 Cyclosporine Cyclosporins Busulfan Cyclophosphamide Methotrexate Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Antimetabolites Dermatologic Agents Folic Acid Vitamin B Complex Folic Acid Antagonists Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Calcineurin Inhibitors Folinic Acid Folic Acid Folate Vitamin B9 high high high high high low low low low low low low low low low low low low low low low low low low  D000016572 D000003520 D000002066 D000008727 D000003524 Cyclosporine Cyclophosphamide Busulfan Methotrexate Cyclosporins autologous expanded mesenchymal stem cells OTI-010 busulfan cyclophosphamide cyclosporine methotrexate peripheral blood stem cell transplantation radiation therapy  Biological Drug Drug Drug Drug Procedure Radiation",1,0
910,Biological: COVI-MSC Biological: COVI-MSC Parallel Assignment    COVI-MSC 1 vial COVI-MSC 2 vials       COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells   COVI-MSC  Biological,1,0
911,Biological: Human umbilical cord tissue-derived mesenchymal stem cells Biological: Human umbilical cord tissue-derived mesenchymal stem cells Parallel Assignment    IV injection of UC-MSC Intra-articular knee injection of UC-MSC          Human umbilical cord tissue-derived mesenchymal stem cells  Biological,1,0
912,"Biological: Mesenchymal stem cells Other: Reference therapy: 400 mL of 0.9% NaCl solution Parallel Assignment    MSC group Control Group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution   Mesenchymal stem cells Reference therapy: 400 mL of 0.9% NaCl solution  Biological Other",1,0
913,"Biological: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs) Single Group Assignment    hCT-MSC infusion PhSol All ANeo Pharmaceutical Solutions All Drugs and Chemicals Antineoplastic Agents  M85407 M8814 Plasma-lyte 148 Altretamine low low Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):  hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10^6 cells/kg (up to a maximum dose of 100x10^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL.   Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)  Biological",1,0
914,"Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection Parallel Assignment    arthroscopy with removal of calcified cartilage arthroscopy without removal of calcified cartilage       Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)   arthroscopy of the affected knee/ Bone Marrow Concentrate Injection Injection of bone marrow aspirate concentrate harvested from the patient's iliac crest (produced using the Harvest/Terumo BCT system) Procedure",1,0
915,"Biological: Mesenchymal stromal cells Single Group Assignment    Mesenchymal stromal cell treatment CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 M3261 Anesthetics Anesthetics, Local low low Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.   Mesenchymal stromal cells  Biological",1,0
916,Biological: Intraventricular injection Single Group Assignment    stem cell recipient       intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS   Intraventricular injection intraventricular injection of mesenchymal stem cell by stereotaxis Biological,1,0
917,"Drug: Placebo Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs) Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs) Drug: Placebo Parallel Assignment    Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Group 1 - Placebo Group B - Placebo PhSol All AnArAg ChanBlk CNSDep Infl Resp Pharmaceutical Solutions All Drugs and Chemicals Anti-Arrhythmia Agents Channel Blockers Central Nervous System Depressants Anti-Inflammatory Agents Respiratory System Agents  M21013 M10166 M4061 M4062 M229281 M259082 M248671 Pharmaceutical Solutions Lidocaine Betamethasone Betamethasone Valerate Betamethasone-17,21-dipropionate Betamethasone benzoate Betamethasone sodium phosphate low low low low low low low A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.   Allogeneic Human Mesenchymal Stem Cells (hMSCs) Placebo allo-hMSCs stem cells Biological Drug",1,0
918,"Biological: HB-adMSCs Single Group Assignment    HB-adMSCs       Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;   HB-adMSCs  Biological",1,0
919,Drug: mesenchymal stem cells (MSCs) Single Group Assignment    mesenchymal stem cells (MSCs)       Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch   mesenchymal stem cells (MSCs) Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Drug,1,0
920,"Biological: Stromal Cells Injection Biological: Stromal Cells Injection Biological: Stromal Cells Injection Biological: Stromal Cells Injection Parallel Assignment It is a randomized, prospective, double-blind, placebo-controlled clinical study.  Eligible patients will be randomly divided into 4 groups (one control group and 3 active treatment groups): 10 PATIENTS EACH ARM Control Group - saline injection Low dose group (BD) - hASC injection (1x106 / kg body weight) Intermediate dose group (DI) - injection of hASC (2x106 / kg body weight) High dose group (AD) - hASC injection (4x106 / kg body weight)   High dose group Intermediate Dose Low dose group PLACEBO GROUP PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Adipose stromal cell   Stromal Cells Injection  Biological",1,0
921,"Drug: placebo Biological: autologous bone marrow mononuclear cell transfusion Biological: marrow stromal cells Parallel Assignment    autologous mononuclear cells autologous marrow stromal cells Placebo       a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight) a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow   autologous bone marrow mononuclear cell transfusion marrow stromal cells placebo mononuclear cells mesenchymal stromal cells Biological Biological Drug",1,0
922,"Biological: Mesenchymal stromal cell infusion Single Group Assignment    Cell therapy ANeo All Antineoplastic Agents All Drugs and Chemicals  M5334 Cisplatin low The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.   Mesenchymal stromal cell infusion  Biological",1,0
923,Biological: Allo-hMSCs Biological: Allo-hMSCs Biological: Allo-hMSCs Biological: Allo-hMSCs Biological: Placebo Parallel Assignment Safety run-in phase will have 3 subjects with 2 treatment groups Randomized phase will have 15 subjects with 3 treatment groups   Randomized: Cohort 1 Allo-hMSCs Randomized: Cohort 2 Allo-hMSCs Safety Run-In: Treatment 1 Allo-hMSCs Safety Run-In: Treatment 2 Allo-hMSCs Randomized: Cohort 3 Allo-hMSCs PhSol All ANeo Pharmaceutical Solutions All Drugs and Chemicals Antineoplastic Agents  M85407 M8814 Plasma-lyte 148 Altretamine low low 1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs) 1 peripheral intravenous infusion   Allo-hMSCs Placebo Stem cells Biological Biological,1,0
924,"Biological: UCMSCs Other: Placebo Parallel Assignment    Group 1: (UCMSCs) Group 2: (Placebo) PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 M85407 Pharmaceutical Solutions Plasma-lyte 148 low low 100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion. Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion   UCMSCs Placebo  Biological Other",1,0
925,Biological: Stem cells Biological: Stem cells Parallel Assignment    Control Stem Cells PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Allogeneic mesenchymal stem cells   Stem cells  Biological,1,0
926,Biological: MSC Infusion Biological: Placebo Comparator Parallel Assignment    MSC infusion SHAM infusion       Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset Normal saline   MSC Infusion Placebo Comparator  Biological Biological,1,0
927,Biological: Mesenchymal cells Drug: Standard of care Parallel Assignment    Mesenchymal cells Standard of care       1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue Best treatment option for COVID-19 according to investigator criteria   Mesenchymal cells Standard of care  Biological Drug,1,0
928,Drug: MSC Treatment group 1 (low dose) Drug: MSC Treatment group 2 (high dose) Other: Healthy Control (no treatment) Parallel Assignment 24 participants will be equally randomized into two groups; 12 Healthy controls subjects & 12 treatment subjects. The treatment group will then be sub-divided and randomized into 6 subjects receiving a low dosage treatment and 6 subjects receiving a high dosage treatment   MSC treatment group 1 MSC treatment group 2 Healthy Control (no treatment) PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution Comparative analysis of psychometric and morphometric based data   MSC Treatment group 1 (low dose) MSC Treatment group 2 (high dose) Healthy Control (no treatment)  Drug Drug Other,1,0
929,Biological: Human allogeneic mesenchymal bone marrow derived stem cells Biological: Human allogeneic mesenchymal bone marrow derived stem cells Biological: Human allogeneic mesenchymal bone marrow derived stem cells Sequential Assignment    Group 1 Group 2 Group 3       Intraarticular administration of 20x10^6 MSCs   Human allogeneic mesenchymal bone marrow derived stem cells  Biological,1,0
930,Biological: Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells Single Group Assignment    IV and IT UC-MSC and BMMC          Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells  Biological,1,0
931,Biological: Mesenchymal stem cell Biological: Placebo Parallel Assignment    mesenchymal stem cell placebo       intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation Patients with knee joint osteoarthritis who underwent intra articular placebo injection   Mesenchymal stem cell Placebo  Biological Biological,1,0
932,Biological: Mesenchymal Stem Cells Single Group Assignment    Mesenchymal Stem Cell          Mesenchymal Stem Cells  Biological,1,0
933,Biological: Mesenchymal Stem Cells Other: Culture medium without MSC. Parallel Assignment    Mesenchymal Stem Cells Culture medium without MSC. CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed. 2 ml of culture medium.   Mesenchymal Stem Cells Culture medium without MSC. MSC Biological Other,1,0
934,Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) Single Group Assignment    Pilot       Peri-fistula injections   Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) allo-hMSCs Drug,1,0
935,Procedure: Autologous Adipose Tissue derived MSCs Transplantation Single Group Assignment    AdMSC       Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL   Autologous Adipose Tissue derived MSCs Transplantation  Procedure,1,0
936,Drug: Autologous hMSCs Device: Biosense Webster MyoStar NOGA Injection Catheter System Drug: Autologous Human C-Kit CSCs II Device: Biosense Webster MyoStar NOGA Injection Catheter System Drug: Placebo Device: Biosense Webster MyoStar NOGA Injection Catheter System Parallel Assignment    Group A - Autologous hMSCs Group B - Autologous Human C-Kit CSCs II Placebo Group A - Autologous hMSCs Group B - Autologous Human C-Kit CSCs II Placebo ANeo All Antineoplastic Agents All Drugs and Chemicals  M8814 Altretamine low Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs. Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs. Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]). Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug   Autologous hMSCs Autologous Human C-Kit CSCs II Placebo Biosense Webster MyoStar NOGA Injection Catheter System Autologous Human Mesenchymal Stem Cells (hMSCs) Autologous Human C-Kit Cardiac Stem Cells (CSCs) II NOGA Drug Drug Drug Device,1,0
937,"Procedure: PLF with autograft Biological: PLF with NeoFuse Biological: PLF with NeoFuse Biological: PLF with NeoFuse Parallel Assignment Subjects will be randomized to one of four (4) parallel treatment arms; autograft standard of care control, or one of three (3) doses of mesenchymal precursor cells (MPCs) combined with MasterGraft Granules. Subjects randomized to receive investigational product will be treated with one of the following three doses of allogeneic MPCs in 4 milliliters (mLs) per posterolateral lumbar fusion (PLF) level (204 mLs per side): 25 million (M), 50M or 75M MPCs per PLF level (or a total dose of 50 million, 100 million or 150 million MPCs if subject undergoes fusion at two levels). Each of the four treatment groups will include six (6) evaluable subjects.   1 2 3 4       6 subjects 6 subjects low dose 6 subjects medium dose 6 subjects high dose   PLF with autograft PLF with NeoFuse PLF with NeoFuse PLF with NeoFuse spinal fusion spinal fusion stem cell spinal fusion stem cell spinal fusion stem cell Procedure Biological Biological Biological",1,0
938,"Drug: Autologous mesenchymal stem cells Single Group Assignment    autologous mesenchymal stem cells       After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.   Autologous mesenchymal stem cells MSC Drug",1,0
939,Biological: Stempeucel(R) Single Group Assignment    Stem cells       Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells   Stempeucel(R)  Biological,1,0
940,"Drug: COVI-MSC Drug: Placebo Parallel Assignment    COVI-MSC Placebo       1 x 10^6 MSCs/kg or 1.5 x 10^6 MSCs/kg, depending on CRP level Equivalent volume of placebo will be administered   COVI-MSC Placebo  Drug Drug",1,0
941,"Biological: Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil Drug: Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil Parallel Assignment  D000004791 D000045504 D000007166 D000007155 D000045505 D000000935 D000000890 D000003879 D000018501 D000065095 D000000903 D000000970 D000000904 D000000995 D000000900 D000000893 D000000932 D000001337 D000018373 D000005765 D000005938 D000006728 D000006730 D000018696 D000020011 D000018931 Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Antibiotics, Antineoplastic Antineoplastic Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Neuroprotective Agents Protective Agents Antineoplastic Agents, Hormonal 1 2 Infe ARhu Derm All ANeo Infl AnEm NeuroAg Gast Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Antineoplastic Agents Anti-Inflammatory Agents Antiemetics Neuroprotective Agents Gastrointestinal Agents Impact Impact Bolus Neck Neck Neck Neck Neck Neck Neck Genotype 1 Stockings M18113 M5882 M11280 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M9364 M1830 M255749 M9353 M3406 M5404 M10948 M3366 M6226 M19757 M29605 M3374 M3376 M3463 M3369 M3403 M8033 M8199 M8941 M8940 M19926 M21022 M20119 Cyclosporine Cyclosporins Mycophenolic Acid Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Immunosuppressive Agents Basiliximab Thymoglobulin Immunologic Factors Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Inflammatory Agents Antiemetics Gastrointestinal Agents Glucocorticoids Hormones Hormone Antagonists Neuroprotective Agents Protective Agents Antineoplastic Agents, Hormonal high high high high high high high high high high low high high low low low low low low low low low low low low low low low low low low low low Cell therapy  Mesenchymal cells infusion.  Induction therapy:  Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).  Maintenance therapy:  Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx). Routine immunosuppressive therapy  Induction therapy:  Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).  Maintenance therapy:  Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx). D000016572 D000009173 D000008775 D000077555 D000008776 D000011239 C000009935 D000003524 D000077552 C000512542 C000021322 C000009022 Cyclosporine Mycophenolic Acid Methylprednisolone Methylprednisolone Acetate Methylprednisolone Hemisuccinate Prednisolone Prednisolone acetate Cyclosporins Basiliximab Thymoglobulin Prednisolone hemisuccinate Prednisolone phosphate Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil  Biological Drug",1,4
942,Other: MSC transplantation Sequential Assignment comparison with historic control   MSC transplantation All All Drugs and Chemicals  M9336 M3377 Immunoglobulins Antibodies low low MSC transplantation: patients with ABMR treated with MSC transplantation   MSC transplantation  Other,1,4
943,Biological: HYNR-CS inj. Single Group Assignment    Single arm       Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.   HYNR-CS inj.  Biological,1,4
944,Biological: cell and RPR injection Single Group Assignment    cell and RPR recepients       mesenchymal cells and Plasma reach Protein are injected to the callus center   cell and RPR injection cell therapy Biological,1,6
945,Biological: UMC119-06-05 Sequential Assignment Cohort 1: Low dose of UMC119-06-05 Cohort 1: High dose of UMC119-06-05   UMC119-06-05       Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05   UMC119-06-05  Biological,1,6
946,Biological: Mesenchymal Stromal Cells Single Group Assignment    Mesenchymal Stromal Cells          Mesenchymal Stromal Cells  Biological,1,6
947,"Biological: Mesenchymal stem cell Single Group Assignment    Mesenchymal stem cell       1*10^8 cells are administered once a week, total four times intravenously.   Mesenchymal stem cell  Biological",1,6
948,Biological: cell injection Single Group Assignment    bone cyst       injection of mesenchymal cells to bone cyst defect   cell injection cell transplantation Biological,1,6
949,Biological: Bone marrow derived mesenchymal stem cells Single Group Assignment    Bone marrow mesenchymal stem cells       Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells   Bone marrow derived mesenchymal stem cells  Biological,1,6
950,Drug: Arterial infusion of autologous mesenchymal stem cells Single Group Assignment    infusion of autologous mesenchymal stem cells          Arterial infusion of autologous mesenchymal stem cells MSC Drug,1,6
951,Biological: mesenchymal stem cell Single Group Assignment    stem cell recipient       intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis   mesenchymal stem cell stem cell transplantation Biological,1,6
952,Biological: ADRC transplantation in autoimmune refractory epilepsy Single Group Assignment Experimental clinical treatment   Experimental group All All Drugs and Chemicals  M9336 M3377 Immunoglobulins Antibodies low low    ADRC transplantation in autoimmune refractory epilepsy  Biological,1,6
953,"Procedure: BMAC/PRP Injection Procedure: Cortisone Injection Parallel Assignment randomized control trial D000000893 Anti-Inflammatory Agents BMAC/PRP Injection Group Cortisone Injection Group CNSDep All Infl ANeo AnEm NeuroAg Gast Central Nervous System Depressants All Drugs and Chemicals Anti-Inflammatory Agents Antineoplastic Agents Antiemetics Neuroprotective Agents Gastrointestinal Agents 450 M3259 M13272 M1833 M10901 M10902 M229437 M211896 M248768 M4467 M5721 M3369 Anesthetics Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Bupivacaine Cortisone Anti-Inflammatory Agents low low low low low low low low low high low Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound. An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound. D000003348 Cortisone BMAC/PRP Injection Cortisone Injection  Procedure Procedure",1,6
954,Other: 103024-F     103024-F       mesenchymal stem cell isolation   103024-F  Other,1,6
955,Drug: PLX-PAD Drug: PLX-PAD Drug: PLX-PAD Single Group Assignment    0.5 M PLX-PAD 1 M PLX-PAD 2 M PLX-PAD       intravenous administration of a single dose of PLX-PAD cells   PLX-PAD allogeneic Mesenchymal-like Adherent Stromal Cells (ASCs) Drug,1,6
956,Biological: hMSCs Biological: hMSCs Single Group Assignment    Group 1 Group 2       intravenous infusion of bone marrow-derived allogeneic stem cells   hMSCs allogeneic mesenchymal stem cell Biological,1,6
957,"Biological: Approximately 100 million cells allogeneic hMSC Single Group Assignment    hMSC Treatment group       Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.   Approximately 100 million cells allogeneic hMSC  Biological",1,6
958,"Biological: mesenchymal stem cells Drug: cyclophosphamide administration Single Group Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Mesenchymal Stem Cell in Haplo-SCT Mesenchymal Stem Cell in Haplo-SCT ANeo ARhu All Antineoplastic Agents Antirheumatic Agents All Drugs and Chemicals Tablet M5879 M9364 M9353 M19757 M20095 M2972 Cyclophosphamide Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents high low low low low low After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused. After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. D000003520 Cyclophosphamide mesenchymal stem cells cyclophosphamide administration  Biological Drug",1,6
959,"Biological: UMC119-06-05 Device: Hyaluronic acid Sequential Assignment Cohort 1 : Low does UMC119-06-05 + Hyaluronic acid； Cohort 2 : High does UMC119-06-05 + Hyaluronic acid D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents UMC119-06-05 UMC119-06-05 All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.  Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05 IA injection of hyaluronic acid. D000006820 Hyaluronic Acid UMC119-06-05 Hyaluronic acid  Biological Device",1,6
960,Biological: adipose tissue derived stromal cells dosage Single Group Assignment    adipose tissue derived stromal cells       intra-coronary administration of autologous adipose tissue derived stroma cells   adipose tissue derived stromal cells dosage  Biological,1,6
961,"Procedure: Bone marrow transplantation Biological: Mesenchymal Stromal Cells Single Group Assignment    Mesenchymal stromal cells Mesenchymal stromal cells       Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.   Bone marrow transplantation Mesenchymal Stromal Cells  Procedure Biological",1,6
962,Biological: Intravenous injection autologous mesenchymal stem cells Single Group Assignment    mesenchymal stem cell transplantation       Intravenous injection of mesenchymal stem cell in patients with PKD   Intravenous injection autologous mesenchymal stem cells  Biological,1,6
963,"Biological: Autologous adipose derived stem cells(low dose group) Biological: Autologous adipose derived stem cells(high dose group)     Low dose group High dose group       low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage. high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.   Autologous adipose derived stem cells(low dose group) Autologous adipose derived stem cells(high dose group) mesenchymal stem cell, ANTG-ASC, adipose derived stem cell Group 1: low dose group mesenchymal stem cell, ANTG-ASC, adipose derived stem cell Group 2: high dose group Biological Biological",1,6
964,Biological: adipose tissue derived stromal cells Single Group Assignment    adipose tissue derived stromal cells Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low dosage   adipose tissue derived stromal cells  Biological,1,6
965,Biological: intra venous injection of stem cell Single Group Assignment    stem cell reciepient       Intra venous injection of mesenchymal stem cell   intra venous injection of stem cell Stem cell transplantation Biological,1,6
966,Biological: injection of autologous stromal vascular fraction Single Group Assignment    Stromal vascular fraction injection       Acquiring autologous stromal vascular fraction (SVF) from liposuction purifying SVF from lipoaspirates and making syringe filled with SVF SVF injection - Inject SVF on fingers subcutaneously.   injection of autologous stromal vascular fraction  Biological,1,7
967,Biological: Allogeneic adult adipose-derived mesenchymal stem cells Single Group Assignment    Mesenchymal stem cells(MSC) treatment       Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells   Allogeneic adult adipose-derived mesenchymal stem cells  Biological,1,7
968,Other: Laboratory Biomarker Analysis Other: Standard of Care Drug: Mesenchymal Stem Cell Transplantation Other: Laboratory Biomarker Analysis Other: Standard of Care Drug: Mesenchymal Stem Cell Transplantation Parallel Assignment    Arm I (hMSCs) Arm II (standard of care drugs) Arm I (hMSCs) Arm II (standard of care drugs) Arm I (hMSCs) Arm II (standard of care drugs)       Correlative studies Undergo mesenchymal stem cell infusion Undergo mesenchymal stem cell infusion   Laboratory Biomarker Analysis Standard of Care Mesenchymal Stem Cell Transplantation  Other Other Drug,1,7
969,Biological: adipose-derived multipotent mesenchymal stem cells Single Group Assignment    AD-MSCs group       AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.   adipose-derived multipotent mesenchymal stem cells AD-MSCs Biological,1,7
970,"Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 Single Group Assignment This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS).   Mesenchymal Stromal Stem Cell Treatment       Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).   Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Drug",1,7
971,"Biological: Mesenchymal Stem Cells Single Group Assignment    Treatment with Mesenchymal Stem Cells Hemat All Hematinics All Drugs and Chemicals  M10262 M18102 M9364 M1830 Liver Extracts Tacrolimus Immunosuppressive Agents Basiliximab low low low low Donor-specific, bone marrow derived mesenchymal stem (stromal) cells   Mesenchymal Stem Cells  Biological",1,7
972,Drug: MSC-AFP Single Group Assignment    MSC-AFP Single Treatment Group       Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.   MSC-AFP mesenchymal stromal cell coated fistula plug Drug,1,7
973,"Other: Human amniotic mesenchymal stem cells Single Group Assignment    Uremic Calciphylaxis Patients       Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance). Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).   Human amniotic mesenchymal stem cells  Other",1,7
974,Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs) Sequential Assignment First dose is125 million cells and only proceed to second dose of 150 million cells for patients clinically not recovered after 24 weeks from first dose.   Human umbilical cord mesenchymal stem cells (UC-MSCs)       All patients to receive 1st dose of 125 million UC-MSCs and the 2nd dose of 150 million UC-MSCs only if patients have no clinical improvement post 24 weeks after 1st dose   Human umbilical cord mesenchymal stem cells (UC-MSCs)  Biological,1,7
975,"During bone marrow harvest, an additional 10 mL sample will be collected for the study.   bone marrow harvest  Other",1,7
976,"Biological: Autologous mesenchymal stem cells Single Group Assignment Open-label phase 1, single-center, pre-post comparison study   Open label single arm study       IV therapy with autologous bone-marrow derived mesenchymal stem cells   Autologous mesenchymal stem cells  Biological",1,7
977,Biological: Intravenous injection Single Group Assignment    MSC recipient       Intravenous injection of bone marrow derived MSC in patients with CKD.   Intravenous injection Intravenous transplantation Biological,1,7
978,"Biological: Allogeneic Human Mesenchymal Stem Cells Single Group Assignment    Allogeneic Human Mesenchymal Stem Cells       This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV 4 days prior to undergoing a planned prostatectomy.  The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy.   Allogeneic Human Mesenchymal Stem Cells  Biological",1,7
979,"Biological: Donor-derived Mesenchymal Stromal Cells Drug: alemtuzumab Drug: belatacept Drug: sirolimus Drug: mycophenolate mofetil Drug: mycophenolate acid Drug: prednisone Biological: Donor-derived Mesenchymal Stromal Cells Drug: alemtuzumab Drug: belatacept Drug: sirolimus Drug: mycophenolate mofetil Drug: mycophenolate acid Drug: prednisone Biological: Donor-derived Mesenchymal Stromal Cells Drug: alemtuzumab Drug: belatacept Drug: sirolimus Drug: mycophenolate mofetil Drug: mycophenolate acid Drug: prednisone Parallel Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000018931 D000000970 D000000903 D000000904 D000000995 D000000900 D000000890 D000004791 D000045504 D000000935 D000007166 D000007155 D000074322 D000082082 D000018501 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antifungal Agents Immunosuppressive Agents Immunologic Factors Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors Antirheumatic Agents MSCs 10^4 cells/kg+anti-rejection drugs MSCs 10^5 cells/kg+anti-rejection drugs MSCs 10^6 cells/kg+anti-rejection drugs MSCs 10^4 cells/kg+anti-rejection drugs MSCs 10^5 cells/kg+anti-rejection drugs MSCs 10^6 cells/kg+anti-rejection drugs MSCs 10^4 cells/kg+anti-rejection drugs MSCs 10^5 cells/kg+anti-rejection drugs MSCs 10^6 cells/kg+anti-rejection drugs MSCs 10^4 cells/kg+anti-rejection drugs MSCs 10^5 cells/kg+anti-rejection drugs MSCs 10^6 cells/kg+anti-rejection drugs MSCs 10^4 cells/kg+anti-rejection drugs MSCs 10^5 cells/kg+anti-rejection drugs MSCs 10^6 cells/kg+anti-rejection drugs MSCs 10^4 cells/kg+anti-rejection drugs MSCs 10^5 cells/kg+anti-rejection drugs MSCs 10^6 cells/kg+anti-rejection drugs MSCs 10^4 cells/kg+anti-rejection drugs MSCs 10^5 cells/kg+anti-rejection drugs MSCs 10^6 cells/kg+anti-rejection drugs Infe ANeo All CNSDep ARhu Infl Ot Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Central Nervous System Depressants Antirheumatic Agents Anti-Inflammatory Agents Other Dietary Supplements Laparoscopic Scan Fusion Protein Emission Until M21113 M11280 M4006 M483 M1347 M13273 M3369 M8199 M8941 M8940 M20119 M3374 M3376 M3463 M3366 M3406 M5404 M10948 M9364 M9353 M1346 M2343 M19757 T433 Sirolimus Mycophenolic Acid Benzocaine Abatacept Alemtuzumab Prednisone Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Antineoplastic Agents, Hormonal Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Infective Agents Antifungal Agents Clotrimazole Miconazole Immunosuppressive Agents Immunologic Factors Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors Antirheumatic Agents Tannic Acid high high low high high high low low low low low low low low low low low low low low low low low low These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile. Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept. Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation. Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction. Per protocol, and, only permitted in cases of sirolimus intolerance. Per protocol, and, only permitted in cases of sirolimus intolerance. Per protocol, and, only permitted in cases of sirolimus intolerance. D000009173 D000020123 D000011241 D000074323 D000069594 Mycophenolic Acid Sirolimus Prednisone Alemtuzumab Abatacept Donor-derived Mesenchymal Stromal Cells alemtuzumab belatacept sirolimus mycophenolate mofetil mycophenolate acid prednisone Donor-derived MSCs human bone marrow derived MSCs hBM-MSC EPIC-MSC-ITN2015-IVF-0X Campath® Lemtrada® Nulojix® LEA29Y Rapamune® CellCept® Myfortic® corticosteroid Biological Drug Drug Drug Drug Drug Drug",1,6
980,"Drug: Low Dose Mesenchymal Stem Cells (MSCs) Single Group Assignment    Drug: Low Dose Mesenchymal Stem Cells ( MSCs) PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 M85407 Pharmaceutical Solutions Plasma-lyte 148 low low Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.   Low Dose Mesenchymal Stem Cells (MSCs)  Drug",1,6
981,Biological: ALLO-ASC-SHEET Other: Vehicle Control Parallel Assignment    ALLO-ASC-SHEET Conventional Therapy       Weekly administration Weekly administration   ALLO-ASC-SHEET Vehicle Control  Biological Other,1,6
982,Biological: Mesenchymal Injection Single Group Assignment    Mesenchymal Injection       Intra Articular Injection of Mesenchymal cells to the knee joint   Mesenchymal Injection Cell Injection Biological,1,6
983,"Biological: Infusion of hCT-MSC Biological: Infusion of hCT-MSC Parallel Assignment The first cohort of three patients will receive a single dose in the first 48 postnatal hours. If there are no safety concerns, the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.   First cohort of 3 subjects enrolled Second cohort of 3 subjects enrolled       Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.   Infusion of hCT-MSC  Biological",1,6
984,Drug: YB-1113 Drug: YB-1113 Sequential Assignment    High-dose Low-dose       Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)   YB-1113  Drug,1,6
985,"Biological: Mesenchymal Stem Cells Biological: Mesenchymal Stem Cells Parallel Assignment    Intracoronary Group Intravenous Group       The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.   Mesenchymal Stem Cells  Biological",1,4
986,Procedure: maxillary alveolar graft by tissue engineering Procedure: Bone tissue engineering using mesenchymal stem cells Single Group Assignment    cleft lip and palate cleft lip and palate       Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells; Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.   maxillary alveolar graft by tissue engineering Bone tissue engineering using mesenchymal stem cells alveolar bone graft bone tissue engineering bone tissue engineering using mesenchymal stem cells Procedure Procedure,1,5
987,"Drug: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells Single Group Assignment    FURESTEM-CD Inj       3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks   Human Umbilical Cord Blood-derived Mesenchymal Stem Cells hUCB-MSCs FURESTEM-CD Inj Drug",1,5
988,Biological: ALLO-ASC-DFU Single Group Assignment    ALLO-ASC-DFU          ALLO-ASC-DFU  Biological,1,5
989,"Biological: WJ-MSCs Single Group Assignment Patients positively diagnosed with COVID-19   WJ-MSCs PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.  WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.   WJ-MSCs  Biological",1,5
990,Other: Allogeneic mesenchymal stem cells Device: Polyurethene Film Parallel Assignment    ALLO-ASC-DFU Conventional Therapy       Dressing for Dystrophic Epidermolysis Bullosa wound. Dressing for Dystrophic Epidermolysis Bullosa wound.   Allogeneic mesenchymal stem cells Polyurethene Film ALLO-ASC-DFU Other Device,1,5
991,"Biological: GD2 CAR modified Tri-virus specific cytotoxic t-cells Single Group Assignment    GD2 CAR modified Tri-virus CTL infusion       This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation   GD2 CAR modified Tri-virus specific cytotoxic t-cells  Biological",1,5
992,Other: Mesenchymal stem cell transplantation Single Group Assignment Tomography-guided mesenchymal stem cells injection.   Mesenchymal stem cell transplantation       Mesenchymal stem cell transplantation through percutaneous injection.   Mesenchymal stem cell transplantation  Other,1,5
993,"Drug: Infusion of MSC Drug: Infusion of placebo Parallel Assignment Phase 1: uncontrolled, single arm biosafety evaluation (n=5) Phase 2: placebo-controlled, randomized, evaluation (n=10)   Mesenchymal stem cells Placebo       Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20). Infusion of placebo (weeks 0-4-8-20)   Infusion of MSC Infusion of placebo Placebo Drug Drug",1,5
994,Drug: MSC-AFP Single Group Assignment    MSC-AFP Single Treatment Group       Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.   MSC-AFP • mesenchymal stromal cell coated fistula plug Drug,1,5
995,Genetic: MSC-INFβ Behavioral: Questionnaires Single Group Assignment  D000000970 D000000998 D000000890 D000007155 D000045505 Antineoplastic Agents Antiviral Agents Anti-Infective Agents Immunologic Factors Physiological Effects of Drugs Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ) Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ) Infe ANeo All Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Inhibitor Vivo M9559 M18396 M3466 M3366 M9353 Interferons Interferon-beta Antiviral Agents Anti-Infective Agents Immunologic Factors high high low low low MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.  Starting dose: 10^5 MSC/kg once a week for 4 treatments. Symptom questionnaire completed once a week for 4 weeks. D000007372 D000016899 Interferons Interferon-beta MSC-INFβ Questionnaires Mesenchymal stem cells with interferon beta Surveys Genetic Behavioral,1,5
996,Biological: Umbilical cord mesenchymal stem cells Single Group Assignment    UCMSCs group       Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.   Umbilical cord mesenchymal stem cells UCMSCs Biological,1,5
997,"Biological: allo-APZ2-ACLF Single Group Assignment    allo-APZ2-ACLF PhSol All Hemat Pharmaceutical Solutions All Drugs and Chemicals Hematinics  M21013 M10262 Pharmaceutical Solutions Liver Extracts low low Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.   allo-APZ2-ACLF Skin-derived ABCB5-positive mesenchymal stem cells Biological",1,5
998,Genetic: Stem Cell Genetic: Stem Cell Genetic: Stem Cell Single Group Assignment    Conventional standard therapy and MSCs Standard therapy and control saline spray standard therapy and fibrin spray          Stem Cell  Genetic,1,5
999,"Drug: Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant Single Group Assignment    Stemcell          Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant  Drug",1,5
1000,"Procedure: sampling mesenchymal stem cells Single Group Assignment    Children with cleft CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft   sampling mesenchymal stem cells  Procedure",1,5
1001,"Biological: MSC-PLGA Single Group Assignment    MSC-PLGA       Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.   MSC-PLGA  Biological",1,4
1002,Biological: Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) Other: Placebo Parallel Assignment    Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg 1.5 mL/kg Lactated Ringer's Solution   Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) Placebo  Biological Other,1,4
1003,Drug: Adipose-Derived Mesenchymal Stem Cells Single Group Assignment    ADMSCs          Adipose-Derived Mesenchymal Stem Cells  Drug,1,4
1004,Biological: exosome Single Group Assignment    exosome or vesicle       allogenic mesenchymal stem cells derived exosome enriched by miR-124   exosome  Biological,1,5
1005,"Combination Product: CD 34 and MSC infusion Drug: Standard of care for Cirrhosis management Parallel Assignment    Combination MSC and HSC Standard of care for Cirrhosis management All Gast All Drugs and Chemicals Gastrointestinal Agents  M6563 M9962 Diuretics Lactulose low low Combination of stem cells Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose   CD 34 and MSC infusion Standard of care for Cirrhosis management Stem cell infusion Combination Product Drug",1,5
1006,Biological: cell injection Single Group Assignment    non union       Injection of mesenchymal cells in fractured zone   cell injection Cell transplantation Biological,1,6
1007,Other: BPF-001 Single Group Assignment    Treatment Arm       Expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold   BPF-001  Other,1,5
1008,Biological: stem cell injection Single Group Assignment    hip osteoarthritis       intra articular inection of mesenchymal stem cell   stem cell injection  Biological,1,6
1009,"Drug: cyclophosphamide Drug: fludarabine phosphate Radiation: total-body irradiation Drug: cyclosporine Drug: mycophenolate mofetil Procedure: umbilical cord blood transplantation Procedure: mesenchymal stem cell transplantation Single Group Assignment  D000007166 D000007155 D000045505 D000018501 D000018906 D000000477 D000045504 D000000970 D000019653 D000000964 D000000963 D000004791 D000000935 D000000890 D000003879 D000065095 D000000903 D000000904 D000000995 D000000900 Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antimetabolites, Antineoplastic Antimetabolites Enzyme Inhibitors Antifungal Agents Anti-Infective Agents Dermatologic Agents Calcineurin Inhibitors Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Treatment (intra-osseous UCB with hMSC co-transplant) Treatment (intra-osseous UCB with hMSC co-transplant) Treatment (intra-osseous UCB with hMSC co-transplant) Treatment (intra-osseous UCB with hMSC co-transplant) Treatment (intra-osseous UCB with hMSC co-transplant) Treatment (intra-osseous UCB with hMSC co-transplant) Treatment (intra-osseous UCB with hMSC co-transplant) Infe ARhu Derm All ANeo Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Antineoplastic Agents Impact Impact Bolus Under Tablet Interview M18113 M5882 M11280 M283219 M5879 M10693 M6457 M225481 M1945 M9364 M9353 M19757 M20095 M2972 M3433 M3406 M5404 M10948 M3366 M6226 M29605 M3374 M3376 M3463 Cyclosporine Cyclosporins Mycophenolic Acid Fludarabine Cyclophosphamide Melphalan Dimethyl Sulfoxide Fludarabine phosphate Lenograstim Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Antimetabolites Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Dermatologic Agents Calcineurin Inhibitors Anti-Bacterial Agents Antibiotics, Antitubercular Antitubercular Agents high high high high high low low high low low low low low low low low low low low low low low low low All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6 Given by IV during prep at 40mg/m2 for 5 days Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1 Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100 Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated. Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant. The total dosage of hMSC will be 2x10^6cells/kg (+/-20%). D000016572 D000009173 D000003520 C000024352 C000042382 D000003524 Cyclosporine Mycophenolic Acid Cyclophosphamide Fludarabine Fludarabine phosphate Cyclosporins cyclophosphamide fludarabine phosphate total-body irradiation cyclosporine mycophenolate mofetil umbilical cord blood transplantation mesenchymal stem cell transplantation CPM CTX Cytoxan Endoxan Endoxana 2-F-ara-AMP Beneflur Fludara TBI ciclosporin cyclosporin cyclosporin A CYSP Sandimmune Cellcept MMF cord blood transplantation transplantation, umbilical cord blood UCB transplantation hMSC transplantation Drug Drug Radiation Drug Drug Procedure Procedure",1,6
1010,"Combination Product: EB-CMF Single Group Assignment    EB-CMF Implant       Autologous, anatomically shaped bone graft   EB-CMF  Combination Product",1,6
1011,Drug: Allo-hMSCs Drug: Placebo Parallel Assignment 20 patients and 10 patients will be controls with a total of 30 HLHS patients.   Group A - Allo-hMSCs Group B       Allogeneic Human Mesenchymal Stem Cells Placebo   Allo-hMSCs Placebo stem cells; Allogeneic Human Mesenchymal Stem Cells Placebo comparator Drug Drug,1,5
1012,Drug: MSC-AFP Single Group Assignment    MSC-AFP       Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.   MSC-AFP mesenchymal stromal cell coated anal fistula plug Drug,1,5
1013,"Drug: Mesenchymal Stem Cell Single Group Assignment    UC-Mesenchymal Stem Cell       Mesenchymal Stem Cell + NaCl 0,9% 2ml   Mesenchymal Stem Cell  Drug",1,5
1014,"Infl All Anti-Inflammatory Agents All Drugs and Chemicals  M3369 M11052 M17833 Anti-Inflammatory Agents Mitogens Endothelial Growth Factors low low low ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.  This study is a follow-up study without intervention.  Other Names:  Allogenic adipose-derived mesenchymal stem cells   ALLO-ASC-DFU  Biological",1,5
1015,Biological: ALLO-ASC-DFU Single Group Assignment    ALLO-ASC-DFU       Dressing for second-degree burn wound.   ALLO-ASC-DFU  Biological,1,5
1016,Biological: Intravenous injection Single Group Assignment    AD-MSC       Intravenous injection of AD-MSC to the patients with FSGS   Intravenous injection  Biological,1,5
1017,Combination Product: USPIO labeled MSC injection Single Group Assignment    USPIO labeled MSC injection Micro All Micronutrients All Drugs and Chemicals  M9685 Iron low USPIO labeled MSC injection   USPIO labeled MSC injection  Combination Product,1,5
1018,Procedure: Autologous Bone marrow derived stem cells transplant Single Group Assignment    Therapy for Parkinson's disease CaAg All Cardiotonic Agents All Drugs and Chemicals  M6625 Dopamine low Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.   Autologous Bone marrow derived stem cells transplant stem cells cell therapy for Parkinson's disease Procedure,1,5
1019,"Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis Single Group Assignment PRP clot loaded of BM-MSC in order to regenerate dental pulp tissue, placed in the root canal of an immature tooth from a patient with pulp necrosis and chronic apical periodontitis   Allogenic transplant of BM-MSCs Coag All Coagulants All Drugs and Chemicals  M15828 Thrombin low The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis   Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis  Biological",1,5
1020,"Biological: ALLO-ASC-DFU     ALLO-ASC-DFU treatment Infl All Anti-Inflammatory Agents All Drugs and Chemicals  M3369 M11052 M17833 Anti-Inflammatory Agents Mitogens Endothelial Growth Factors low low low ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.  This tudy is a follow-up study without intervention.  Other Names:  Allogenic adipose-derived mesenchymal stem cells   ALLO-ASC-DFU  Biological",1,5
1021,Single Group Assignment           Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml   Autologous Adipose Tissue derived MSCs Transplantation  Procedure,1,5
1022,"Biological: Mesenchymal Stem Cells Single Group Assignment    stem cells group Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low 1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)   Mesenchymal Stem Cells  Biological",1,5
1023,Procedure: intravitreal injection of MSV Single Group Assignment    Mesenchymal stem from valladolid (MSV)       A unique intravitreal injection of MSV in acute fase of NAION   intravitreal injection of MSV  Procedure,1,5
1024,Biological: Mesenchymal Stromal Cells Biological: Mesenchymal Stromal Cells Parallel Assignment    Stratum A Stratum B       Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow   Mesenchymal Stromal Cells ex-vivo expanded MSCs Biological,1,5
1025,Procedure: Repair of cranial defects by tissue engineering Single Group Assignment    Repair of cranial defect       Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates   Repair of cranial defects by tissue engineering  Procedure,1,10
1026,"Biological: MSC construct for Osteonecrosis Single Group Assignment    MSC construct for Osteonecrosis       30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).  Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.  The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures.   MSC construct for Osteonecrosis  Biological",1,10
1027,Biological: Injection of autologous bone marrow derived mesenchymal stem cells Single Group Assignment    Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously       60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously   Injection of autologous bone marrow derived mesenchymal stem cells Mesenchymal stem cells of bone marrow Biological,1,24
1028,"Biological: MSC Drug: Control Parallel Assignment    MSC transfusion Control Infe All Analg Infl AnCoag Anti-Infective Agents All Drugs and Chemicals Analgesics Anti-Inflammatory Agents Anticoagulants  M3374 M3184 M3369 M3396 M3376 Anti-Bacterial Agents Analgesics Anti-Inflammatory Agents Anticoagulants Antibiotics, Antitubercular low low low low low Two intravenous infusion of 1*10E6 adipose tissue derived-MSCs /kg body weight reach Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.   MSC Control  Biological Drug",1,20
1029,Biological: Autologous Mesenchymal Stem Cells Crossover Assignment    Autologous Mesenchymal Stem Cells       Single dose of 1-2 x 1000000 cells/Kg body weight   Autologous Mesenchymal Stem Cells  Biological,1,20
1030,Biological: mesenchymal stem cell Single Group Assignment    2       Autologous MSC transplantation   mesenchymal stem cell  Biological,1,20
1031,"Biological: CELYVIR Single Group Assignment    CELYVIR          CELYVIR Bone marrow-derived autologous mesenchymal stem cells infected with ICOVIR5, an oncolytic adenovirus. Biological",1,20
1032,"Biological: Biological: mesenchymal stem cell Drug: ursodeoxycholic acid Parallel Assignment  D000002756 D000005765 Cholagogues and Choleretics Gastrointestinal Agents allogenic mesenchymal stem cells (MSCs) ursodeoxycholic acid (UDCA) Gast All Gastrointestinal Agents All Drugs and Chemicals Ester M16481 M8033 Ursodeoxycholic Acid Gastrointestinal Agents high low Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition 13-15 mg/kg/day, to the end of the study D000014580 Ursodeoxycholic Acid Biological: mesenchymal stem cell ursodeoxycholic acid regenerative medicine:MSCs UDCA Biological Drug",1,20
1033,"Biological: intrathecal administration of autologous MSC-NP Single Group Assignment    autologous MSC-NP       Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.   intrathecal administration of autologous MSC-NP  Biological",1,20
1034,Drug: MSC-AFP Single Group Assignment    1          MSC-AFP  Drug,1,20
1035,"Biological: mesenchymal stem cell conditioned medium-derived pleiotropic factor Parallel Assignment    experimental group Derm All Dermatologic Agents All Drugs and Chemicals  M12637 M11021 Petrolatum Mineral Oil low low After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.   mesenchymal stem cell conditioned medium-derived pleiotropic factor  Biological",1,20
1036,Biological: bone marrow derived mesenchymal stem cells Single Group Assignment    MSC       Intravenous administration of up to 1x10^6 MSCs per kg; intrathecal administration of up to 1x10^6 MSCs per kg.   bone marrow derived mesenchymal stem cells Mesenchymal Stem Cells Multipotent Mesenchymal Stem Cells Multipotent Mesenchymal Stromal Cells Biological,1,20
1037,"Other: Mesenchymal stromal cell-based therapy Other: Mesenchymal stromal cell-based therapy Other: Mesenchymal stromal cell-based therapy Parallel Assignment    MSC - high dose (10x10ˆ7) MSC - intermediate dose (5x10ˆ7) MSC - low dose (2.5x10ˆ7)       Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)   Mesenchymal stromal cell-based therapy  Other",1,20
1038,"Drug: cellgram-spine Single Group Assignment posterior cervical laminectomy and Mesenchymal stem cells(cellgram-spine) tranplantation.  After laminectomy, 1.6X107 and 3.2 X107 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively   cellgram-spine       Mesenchymal stem cells transplantation   cellgram-spine Mesenchymal stem cells Drug",1,20
1039,"Biological: Human umbilical cord mesenchymal stem cells Single Group Assignment    hUC-MSC treatment       A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.   Human umbilical cord mesenchymal stem cells  Biological",1,20
1040,Biological: Adipose mesenchymal cells with bone marrow mononuclear cells Biological: Adipose mesenchymal cells with bone marrow mononuclear cells Parallel Assignment    Dose 1 mil/kg Dose 10 mil/kg       Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.   Adipose mesenchymal cells with bone marrow mononuclear cells  Biological,1,20
1041,Procedure: fetal blood transfusion Parallel Assignment    fetal blood Infl ARhu Analg All Anti-Inflammatory Agents Antirheumatic Agents Analgesics All Drugs and Chemicals  M207490 Chrysarobin low transfusion of fetal blood   fetal blood transfusion  Procedure,1,20
1042,"Drug: Mesenchymal stem cells Other: Placebo Parallel Assignment    Mesenchymal stem cells Placebo       1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care 100 ml of normal saline will be given intravenously to control arm   Mesenchymal stem cells Placebo MSCs Drug Other",1,20
1043,Procedure: Microfracture Device: Arthroscopic synovial brushing Parallel Assignment    Intervention group Control group       The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects. Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.   Arthroscopic synovial brushing Microfracture Marrow-stimulation Device Procedure,1,20
1044,Biological: Mesenchymal stem cells Single Group Assignment    Mesenchymal stem cells       10-20 x 10^6 cells/20mL   Mesenchymal stem cells  Biological,1,20
1045,Biological: conventional therapy plus low dose hUC-MSCs treatment Biological: conventional therapy plus medium dose hUC-MSCs treatment Biological: conventional therapy plus high dose hUC-MSCs treatment Parallel Assignment    Conventional plus hUC-MSCs treatment (low dose) conventional therapy plus hUC-MSCs treatment （medium dose） conventional therapy plus hUC-MSCs treatment （high dose） Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low patients will receive the conventional therapy plus low dose hUC-MSCs treatment patients will receive conventional therapy plus medium dose hUC-MSCs treatment patients will receive conventional therapy plus high dose hUC-MSCs treatment   conventional therapy plus low dose hUC-MSCs treatment conventional therapy plus medium dose hUC-MSCs treatment conventional therapy plus high dose hUC-MSCs treatment  Biological Biological Biological,1,20
1046,Other: human umbilical cord mesenchymal stem cells Single Group Assignment    Human Umbilical Cord Mesenchymal Stem Cells       Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.   human umbilical cord mesenchymal stem cells  Other,1,20
1047,"Biological: Collection and expansion of BM-MSC Diagnostic Test: VI-SCI evaluation and patients' follow up Biological: Collection and expansion of BM-MSC Diagnostic Test: VI-SCI evaluation and patients' follow up Parallel Assignment Patients with complete transection of the spinal cord. Each group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI.   patients with SCI without total transaction. patients with complete transection of the spinal cord patients with SCI without total transaction. patients with complete transection of the spinal cord CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method. At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline. The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities. Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection.   Collection and expansion of BM-MSC VI-SCI evaluation and patients' follow up  Biological Diagnostic Test",1,20
1048,Biological: Mesenchymal stem cells (MSC) Single Group Assignment Single center open label study   Repeated MSCs treatment in ALS patients       Intrathecal injections of autologous bone marrow derived mesenchymal stem cells   Mesenchymal stem cells (MSC) stem cells Stromal cells Biological,1,20
1049,Biological: Allogeneic MSC (AlloMSC) Single Group Assignment    1 ANeo ARhu All Antineoplastic Agents Antirheumatic Agents All Drugs and Chemicals  M5879 Cyclophosphamide low Intervention:  Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.  Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight   Allogeneic MSC (AlloMSC)  Biological,1,20
1050,"Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial) Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial) Sequential Assignment Phase 1 is conducted to evaluate the tolerability of the IP Subjects receive the IP once and are checked for adverse events. Subjects are evaluated for adverse events after the administration of the IP by registering 3 subjects each at the dosing phase.  If the maximum tolerated dose (MTD) is determined with the test group 2 (high dose) in the Phase 1, the Phase 2a clinical trial will be conducted. However, if 1 adverse events occur, the test group 2 will be considered as the maximum tolerated dose (MTD), or but only the test group 1 will proceed to Phase 2a.  If 2 adverse events occur, a dose smaller than test group 1 (low dose) is determined to be the maximum tolerated dose. The Phase 2a clinical trial will not proceed and the clinical trial will end.  If tolerability and safety are secured, subjects meeting the final inclusion criteria are assigned to Phase 2a, admitted by the same procedure, and administered the IP once. Safety and efficacy assessments are performed.   Test Group 1 (Low Dose) Test Group 2 (High Dose) CNSDep All PhSol Central Nervous System Depressants All Drugs and Chemicals Pharmaceutical Solutions  M3259 M21013 Anesthetics Pharmaceutical Solutions low low Dose: 1 x 10^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells) Dose: 1 x 10^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)   Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial) Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)  Biological Biological",1,20
1051,"Biological: Mesenchymal stem cell Single Group Assignment    Mesenchymal stem cell Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow & umbilical cord , IN 6 divided doses , at interval of 1 week .   Mesenchymal stem cell  Biological",1,20
1052,Biological: mesenchymal stem cell Single Group Assignment    1 All All Drugs and Chemicals  M18102 Tacrolimus low transplantation of mesenchymal stem cell   mesenchymal stem cell MMF FK506 Biological,1,20
1053,Biological: BM-MSCs Biological: Placebo Parallel Assignment    Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) Placebo       Participants will receive conventional treatment plus BM-MSCs(1*10E6 /kg body weight intravenously at Day 1). Placebo   BM-MSCs Placebo  Biological Biological,1,20
1054,"Drug: Adipose derived allogenic mesenchymal stem cells (adAMSC) Single Group Assignment    Single Dose       adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure   Adipose derived allogenic mesenchymal stem cells (adAMSC)  Drug",1,20
1055,"Drug: Single Dose Drug: Double Dose Sequential Assignment 2 consecutive cohorts will be included in order of recruitment. the first 10 patients will receive 1 single dose and the second 10 patients will receive 2 doses separated by 15 days   Single dose Allogenic Adiposse derived mesenchimal stem cells Double dose Allogenic Adiposse derived mesenchimal stem cells       Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection. Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.   Single Dose Double Dose  Drug Drug",1,20
1056,Biological: human umbilical cord mesenchymal stem cells Single Group Assignment    Human umbilical cord mesenchymal stem cells transplantation       Participants will be given hUC-MSCs transplantation.   human umbilical cord mesenchymal stem cells Intervention Group Biological,1,20
1057,"Combination Product: Mesenchymal Stem cell + Nacl 0.9% Combination Product: NaCl 0.9% Single Group Assignment    MSC Group MSC Group       Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml   Mesenchymal Stem cell + Nacl 0.9% NaCl 0.9%  Combination Product Combination Product",1,20
1058,Biological: human umbilical cord mesenchymal stem cells Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells Drug: Conventional therapy Parallel Assignment    Group1 :Conventional plus hUCMSCs treatment Group 2: Conventional plus hCBMNCs and hUCMSCs therapy Group 3:Conventional therapy       Participants will be given conventional therapy plus hUCMSCs transplantation. Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation. Participants will be given conventional therapy only.   human umbilical cord mesenchymal stem cells human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells Conventional therapy  Biological Biological Drug,1,20
1059,"Procedure: Control group Procedure: SVF group Parallel Assignment    Control group SVF group       Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula   Control group SVF group  Procedure Procedure",1,20
1060,Biological: Human umbilical cord-derived mesenchymal stem cell infusion Single Group Assignment    human umbilical cord-derived mesenchymal stem cell transplantation for patients with liver cirrhosis Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis   Human umbilical cord-derived mesenchymal stem cell infusion  Biological,1,20
1061,"Procedure: β TCP bone substitute only Procedure: GF+GMSCs carried on β TCP Parallel Assignment    GroupII GroupI PhSol All Infl ARhu Analg Pharmaceutical Solutions All Drugs and Chemicals Anti-Inflammatory Agents Antirheumatic Agents Analgesics  M21013 M9254 Pharmaceutical Solutions Ibuprofen low low surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).  Ibuprofen surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen   GF+GMSCs carried on β TCP β TCP bone substitute only  Procedure Procedure",1,20
1062,Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment Single Group Assignment    No SAE attributable to IP in clinical investigational use to date. All All Drugs and Chemicals  M9364 Immunosuppressive Agents low Intravenous Infusion over 60 minutes   Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment ExoFlo Biological,1,20
1063,Biological: Mesenchymal stem cells Parallel Assignment    Mesenchymal stem cells       Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.   Mesenchymal stem cells  Biological,1,20
1064,Drug: XCEL-M-ALPHA and standard rehabilitation Other: Rehabilitation Parallel Assignment    XCEL-M-ALPHA and standard rehabilitation standard rehabilitation       Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank) Standard rehabilitation program   XCEL-M-ALPHA and standard rehabilitation Rehabilitation XCEL-M-ALPHA Drug Other,1,20
1065,Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC) Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC) Sequential Assignment    Dose Arm 1 Dose Arm 2       Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10^6 cells at day 0 and day 84 Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10^6 cells at day 0   Allogeneic adipose-derived mesenchymal stem cells (MSC) Allogeneic adipose-derived mesenchymal stem cells (MSC)  Drug Drug,1,20
1066,Single Group Assignment           An allogeneic Mesenchymal Stem Cell product.   Descartes-25  Drug,1,20
1067,Drug: Mesenchymal stem cells Drug: Placebo Parallel Assignment    Mesenchymal stem cell arm Placebo          Mesenchymal stem cells Placebo Intravenous saline infusion will be designated as placebo. Drug Drug,1,20
1068,Other: cord blood transplantation Single Group Assignment    cord blood transplant       One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen   cord blood transplantation  Other,1,20
1069,"Biological: Human umbilical cord mesenchymal stem cells Single Group Assignment    hUC-MSC treatment       A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.   Human umbilical cord mesenchymal stem cells hUC-MSC Biological",1,20
1070,Single Group Assignment           Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 ~3x10e8 cells   Autologous Adipose Tissue derived MSCs Transplantation  Procedure,1,20
1071,"Procedure: mesenchymal stem cells Procedure: Pure platelet-rich plasma Parallel Assignment    mesenchymal stem cells Pure platelet-rich plasma AnCoag All Anticoagulants All Drugs and Chemicals  M3396 Anticoagulants low Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.  The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.  The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%.   mesenchymal stem cells Pure platelet-rich plasma  Procedure Procedure",1,20
1072,"Biological: MSC exosomes. Single Group Assignment    Exosomes All All Drugs and Chemicals  M18746 Annexin A5 low Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase   MSC exosomes. Extacellular vesicles Microvesicles Biological",1,20
1073,"Biological: Intravenous Infusions of Stem Cells Parallel Assignment Group 1 (15 subjects) Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10^5 (per Kg body weight) UCMSCs delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).  Group 2 (5 subjects) Five (5) subjects will be treated under SOC. From two subjects in group 1 will not be treated 24hrs apart. Patients will be randomized in a 1:3 ratio (SOC: UCMSC).   Group 1 : Treatment       Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30   Intravenous Infusions of Stem Cells  Biological",1,20
1074,"Other: stem cell transplantation Single Group Assignment    Stem cell transplantation       The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).   stem cell transplantation Cell therapy. Other",1,20
1075,"Biological: UCMSC group Single Group Assignment    UCMSC group       Human umbilical cord MSCs are transplanted by intravenous infusion(5×10^5/kg) once a day,a total of three times.   UCMSC group  Biological",1,20
1076,Biological: Trophic factors from umbilical cord mesenchymal stem cells Single Group Assignment    Intra-nasal infusion of MTF          Trophic factors from umbilical cord mesenchymal stem cells  Biological,1,20
1077,"Drug: UCMSC Drug: UDCA Drug: UDCA Parallel Assignment    UCMSC UCMSC UDCA Gast All Gastrointestinal Agents All Drugs and Chemicals  M16481 Ursodeoxycholic Acid low infusion of aUCMSC at day 0, 7, 14, and 21 oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d   UCMSC UDCA  Drug Drug",1,20
1078,Biological: Olfactory mucosa-derived mesenchymal stem cells Other: Patients treated according to current clinical protocols Other: Patients treated according to current clinical protocols Parallel Assignment    Patients with tracheal/laryngeal stenosis receiving standard treatment and stem cells Patients with tracheal/laryngeal stenosis receiving standard treatment Patients with tracheal/laryngeal stenosis receiving standard treatment and stem cells       Autologous olfactory mucosa-derived mesenchymal stem cells Patients treated according to current clinical protocols   Olfactory mucosa-derived mesenchymal stem cells Patients treated according to current clinical protocols  Biological Other,1,20
1079,"Biological: 2 million hMSC/kg Biological: placebo Biological: 4 million hMSC/kg Biological: placebo Biological: 6 million hMSC/kg Biological: placebo Sequential Assignment This is a dose escalation study using three groups (or cohorts) of patients randomly assigned within treatment groups to MSCs or placebo. The first group will consist of 5 patients who receive MSCs and one patient who receives placebo, the second and third group will consist of five patients each who receive MSCs and two patients who receive placebo. The three doses are 2 million hMSCs/kg (Cohort 1), 4 million hMSCs/kg (Cohort 2), and 6 million hMSCs/kg (Cohort 3) and placebo control of normal saline.   Cohort 1 Cohort 2 Cohort 3 Cohort 1 Cohort 2 Cohort 3       2 million hMSCs/kg infusion 4 million hMSC/kg infusion 6 million hMSC/kg infusion placebo infusion   2 million hMSC/kg 4 million hMSC/kg 6 million hMSC/kg placebo  Biological Biological Biological Biological",1,20
1080,Biological: Mesenchymal stem cells enriched by extracellular vesicles Other: Standard treatment of bone defects Other: Standard treatment of bone defects Parallel Assignment    Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles Patients with bone defects receiving standard treatment Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles       Mesenchymal stem cells enriched by extracellular vesicles Standard surgical treatment of bone defects   Mesenchymal stem cells enriched by extracellular vesicles Standard treatment of bone defects  Biological Other,1,20
1081,Genetic: Autologous BMSCs transplantation Genetic: Autologous EPCs transplantation Genetic: IV infusion of placebo Parallel Assignment    BMSCs group EPCs group Control group       The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.  The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting. The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.  The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting. IV infusion of saline plus 5% autologous serum.   Autologous BMSCs transplantation Autologous EPCs transplantation IV infusion of placebo Autologous Bone marrow stromal cells transplantation Autologous Mesenchymal stem cells transplantation Autologous endothelial progenitor cells transplantation Placebo control group Genetic Genetic Genetic,1,20
1082,"Biological: UC-MSCs Gel group Other: Gel group Parallel Assignment    UC-MSCs Gel group Gel group       This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter. This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.   UC-MSCs Gel group Gel group  Biological Other",1,20
1083,"Biological: Mesenchymal stromal cells Single Group Assignment This study is a monocentric prospective phase I/II clinical trial, aiming at evaluating the safety and efficacy of 3 intravenous administrations of BM-MSC in 20 patients with severe to critical COVID-19 pneumonia.   MSC therapy for severe COVID-19 infection       Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.   Mesenchymal stromal cells MSC Biological",1,20
1084,Biological: Peripheral iv Parallel Assignment    Treatment Group       6*10^7 cells   Peripheral iv  Biological,1,20
1085,"Biological: Biocomplex: aBM-MSCs/fibrin glue/collagen fleece Procedure: Two-stage surgical implant placement Parallel Assignment Prospective, randomised, single blind, control clinical trial D000006490 D000003029 Hemostatics Coagulants Group-A Control Group-B Coag All Coagulants All Drugs and Chemicals Isoflurane M17443 M8728 M5411 Fibrin Tissue Adhesive Hemostatics Coagulants high low low Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece. Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives. D000015718 Fibrin Tissue Adhesive Biocomplex: aBM-MSCs/fibrin glue/collagen fleece Two-stage surgical implant placement  Biological Procedure",1,20
1086,"Biological: ALLO-ASCs Parallel Assignment    ALLO-ASCs Infe All Anti-Infective Agents All Drugs and Chemicals  M3374 M3376 Anti-Bacterial Agents Antibiotics, Antitubercular low low 1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.   ALLO-ASCs Allogeneic adipose-derived stem cells Biological",1,20
1087,"Procedure: Autologous Fat Grafting Single Group Assignment    Patients with critic limb ischemia CNSDep All PhSol Central Nervous System Depressants All Drugs and Chemicals Pharmaceutical Solutions  M3259 M21013 Anesthetics Pharmaceutical Solutions low low The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.   Autologous Fat Grafting adipose tissue transplantation Procedure",1,20
1088,Other: injection the mesenchymal stem cell in non union site Single Group Assignment    mesenchymal stem cell CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low    injection the mesenchymal stem cell in non union site  Other,1,19
1089,Biological: 3D-Tissue Engineered Bone Equivalent Single Group Assignment    3D-Tissue Engineered Bone Equivalent       Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent   3D-Tissue Engineered Bone Equivalent Tissue-engineered bone-like construct transplantation Biological,1,20
1090,Biological: Stemchymal® Sequential Assignment    Stemchymal® Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low ALF/ ACLF patients will receive Stemchymal® through intravenous infusion   Stemchymal®  Biological,1,20
1091,Biological: human umbilical cord mesenchymal stem cells Single Group Assignment    Human umbilical cord mesenchymal stem cells transplantation       Participants will be given hUC-MSCs transplantation.   human umbilical cord mesenchymal stem cells  Biological,1,20
1092,"Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Other: Intravenous saline injection (Placebo) Parallel Assignment    hDPSCs group Control group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19 Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19   allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Intravenous saline injection (Placebo)  Biological Other",1,20
1093,Drug: MSC+ATG Single Group Assignment    MSC+ATG       MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.   MSC+ATG Mesenchymal Stem Cells (Umbilical Cord Derived) Drug,1,20
1094,Drug: Mesenchymal stromal cells Other: Placebo Parallel Assignment    MSC injections Placebo injections       8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon). 8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).   Mesenchymal stromal cells Placebo  Drug Other,1,20
1095,"Biological: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome Biological: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome Biological: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome Biological: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome Parallel Assignment    Arthroscopy + Booster Arthroscopy + Pre-Conditioning Non Arthroscopy + Booster Non Arthroscopy + Pre-Conditioning       After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular. After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular. Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular. Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.   Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome Secretome Biological Biological Biological Biological",1,20
1096,Biological: Wharton Jelly Mesenchymal stem cells Single Group Assignment    Wharton Jelly Mesenchymal stem cells PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Wharton Jelly Mesenchymal stem cells will be injected intravenously   Wharton Jelly Mesenchymal stem cells  Biological,1,20
1097,Single Group Assignment     CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.   MSC administration (intraosseal)  Biological,1,20
1098,"Biological: mesenchymal stem cells Single Group Assignment    mesenchymal stem cells       Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.   mesenchymal stem cells  Biological",1,20
1099,Biological: Wharton Jelly Mesenchymal stem cells Single Group Assignment    Wharton Jelly Mesenchymal stem cells       Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma   Wharton Jelly Mesenchymal stem cells  Biological,1,20
1100,Drug: Transplantation of hUC-MSCs Drug: No transplantation of hUC-MSCs Parallel Assignment    Transplantation of hUC-MSCs No transplantation of hUC-MSCs       Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs   Transplantation of hUC-MSCs No transplantation of hUC-MSCs Intravenous infusion of hUC-MSCs No intravenous infusion of hUC-MSCs Drug Drug,1,20
1101,"Drug: Adipose derived, autologous mesenchymal stem cells Single Group Assignment    Autologous mesenchymal stem cells       Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.   Adipose derived, autologous mesenchymal stem cells AD-MSC Drug",1,20
1102,"Biological: UC-MSCs Biological: Saline solution Parallel Assignment    Experimental Comparator PhSol All Infe Pharmaceutical Solutions All Drugs and Chemicals Anti-Infective Agents  M21013 M3466 Pharmaceutical Solutions Antiviral Agents low low Usage: The stem cell preparation in this study is used intravenously in the elbow.  Dose: The dose of stem cell injection in this clinical study is set at 1×10^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively   UC-MSCs Saline solution  Biological Biological",1,20
1103,"Biological: Autologous Adipose MSC's Sequential Assignment This is an Interventional, Prospective, Open label (Voluntary Assignment), single to multiple center expansion, unmatched controlled, Sequentially Interim analysis tested Trial   Autologous Adipose Derived Mesenchymal Cells       Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV   Autologous Adipose MSC's  Biological",1,20
1104,"Biological: Application of autologous mesenchymal stem cells Parallel Assignment    Fractures with Mesenchymal Stem Cells       within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12   Application of autologous mesenchymal stem cells  Biological",1,20
1105,"Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) Sequential Assignment    Bone marrow-derived MSC transplantation (1 x 10 6 MSC/kg) Bone marrow-derived MSC transplantation (3 x 10 6 MSC/kg) Bone marrow-derived MSC transplantation (6 x 10 6 MSC/kg) Bone marrow-derived MSC transplantation (10 x 10 6 MSC/kg)       Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD). Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD). Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD). Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).   Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)  Biological Biological Biological Biological",1,20
1106,"Drug: Stem cell infusion Drug: Stem cell infusion Drug: Stem cell infusion Drug: Stem cell infusion Parallel Assignment    Autologous endothelial stem cell from the bone marrow Autologous mesenchymal stem cells from the adiposite tissue Autologous mononuclear stem cell from the bone marrow Current medication for the disease Hypo All Hypoglycemic Agents All Drugs and Chemicals  M9517 M172956 Insulin Insulin, Globin Zinc low low Unique stem cell infusion of the randomized group   Stem cell infusion  Drug",1,20
1107,Biological: Cellular therapy Single Group Assignment    Cellular therapy Cellular therapy Coag All Coagulants All Drugs and Chemicals  M7464 Factor VIII low bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen   Cellular therapy cellular therapy hepatocyte-like MSC Biological Biological,1,20
1108,Drug: Ossium vBM-MSC Other: Placebo Crossover Assignment Crossover Assignment   Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC) Placebo       Vertebral bone marrow derived mesenchymal stem cells Normal Saline   Ossium vBM-MSC Placebo Ossium Vertebral Bone Marrow Derived Mesenchymal Stem Cells Drug Other,1,20
1109,Biological: NurOwn (MSC-NTF cells) Single Group Assignment Open label   NurOwn (MSC-NTF cells)       Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors   NurOwn (MSC-NTF cells)  Biological,1,20
1110,Drug: EV-Pure™ and WJ-Pure™ Drug: Placebo Parallel Assignment    Experimental/treatment arm Placebo       The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care Cryopreservation media plus standard care   EV-Pure™ and WJ-Pure™ Placebo  Drug Drug,1,20
1111,Single Group Assignment           1-2X10^6 MSC per kg   MSC transplantation  Procedure,1,20
1112,"Other: Cord-blood mesenchymal stromal cells Single Group Assignment    MSC PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 M9364 Pharmaceutical Solutions Immunosuppressive Agents low low The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.   Cord-blood mesenchymal stromal cells  Other",1,11
1113,"Drug: ProTrans: Allogeneic transplantation with WJMSCs Drug: Placebos Parallel Assignment    Allogeneic transplantation with WJMSCs Sham transplantation (placebo) Hypo All Hypoglycemic Agents All Drugs and Chemicals  M9517 M172956 Insulin Insulin, Globin Zinc low low The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue. Placebo treatment   ProTrans: Allogeneic transplantation with WJMSCs Placebos  Drug Drug",1,24
1114,"Biological: Mesenchymal stem cell suspension Biological: PRP Biological: PRP Parallel Assignment    Mesenchymal stem cell, PRP Mesenchymal stem cell, PRP platelet rich plasma AnCoag All Coag Ot Anticoagulants All Drugs and Chemicals Coagulants Other Dietary Supplements  M20473 M1837 M3396 M5411 T382 Citric Acid Sodium Citrate Anticoagulants Coagulants Citrate low low low low low About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use. Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.   Mesenchymal stem cell suspension PRP MSC Platelet gel Biological Biological",1,24
1115,"Biological: Mesenchymal Stem Cells (MSC) Single Group Assignment Single Center, Open phase study   Repeated MSCs treatment in MS patients       Repeated intrathecal and intravenous injection of autologous mesenchymal stem cells (1 million cells per Kg of body weight) at 6 months intervals.   Mesenchymal Stem Cells (MSC) MSC Biological",1,24
1116,"Biological: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium Biological: Conditioned Medium Biological: Conditioned Medium Biological: Triamcinolone Acetonide Parallel Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000007166 D000007155 D000004791 D000045504 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action UC-MSCs + CM CM + CM UC-MSCs + CM Triamcinolon acetonide Infl All Anti-Inflammatory Agents All Drugs and Chemicals Pulse Periodontal Periodontal Periodontal M16126 M16127 M237968 M209570 M3369 M8199 M8941 M8940 M9364 M9353 Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Immunosuppressive Agents Immunologic Factors high high high high low low low low low low Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm. Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm. Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm. D000014221 D000014222 C000005900 C000030262 Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium Conditioned Medium Triamcinolone Acetonide Secretome Biological Biological Biological",1,24
1117,"Biological: CYP-001 Parallel Assignment    CYP-001       The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.   CYP-001 Cymerus MSCs Biological",1,24
1118,"Procedure: Tendon repair procedure Procedure: Tendon repair augmented with AAdMSC-HAM composite Parallel Assignment    Control group (Tendon repair) Experimental group (Tendon repair augmented with AAdMSC-HAM composite)       Tendon repair procedure:  Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon. Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity. Then, double suturing of the supraspinatus tendon is performed. After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.   Tendon repair procedure Tendon repair augmented with AAdMSC-HAM composite  Procedure Procedure",1,24
1119,The osteochondral explants isolated from arthroplasty patients will be induced to an OA phenotype and treated with ASC secretome (either complete conditioned medium or extracellular vesicles) in order to investigate its therapeutic potential.   ASC secretome  Biological,1,24
1120,Drug: Remestemcel-L Drug: Remestemcel-L Other: Placebo Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents remestemcel-L (150 million cells) remestemcel-L (300 million cells) Placebo Infe Infl All HB Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals Herbal and Botanical 1440 M186752 M3369 M3466 M3366 T120 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Cola high low low low low adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis Normal saline C000711674 Remestemcel-l Remestemcel-L Remestemcel-L Placebo  Drug Drug Other,1,24
1121,Biological: 1X level of MSCs-Exo Biological: 2X level of MSCs-Exo Biological: 4X level of MSCs-Exo Biological: 6X level of MSCs-Exo Biological: 8X level of MSCs-Exo Parallel Assignment MSCs-exosomes   1X level 2X level 4X level 6X level 8X level       Once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml) Once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml) Once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml) Once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml) Once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)   1X level of MSCs-Exo 2X level of MSCs-Exo 4X level of MSCs-Exo 6X level of MSCs-Exo 8X level of MSCs-Exo  Biological Biological Biological Biological Biological,1,24
1122,"Procedure: Nerve transfer procedure Procedure: Nerve transfer with HAM-AdMSC composite wrapping Parallel Assignment    Control group (Nerve transfer procedure) Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)       Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle. Donor nerve is checked for its viability with an electric stimulator during surgery Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis. When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)   Nerve transfer procedure Nerve transfer with HAM-AdMSC composite wrapping  Procedure Procedure",1,24
1123,"Biological: Human umbilical cord mesenchymal stem cells Single Group Assignment    hUC-MSC treatment       A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.   Human umbilical cord mesenchymal stem cells hUC-MSC Biological",1,20
1124,Parallel Assignment              autologous mesenchymal stem cells implantation  Procedure,1,24
1125,"Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. Other: Vehicle + Heparin along with best supportive care Parallel Assignment The trial has two groups, each with 12 subjects (n=24). All eligible subjects will be randomized to either the treatment group or standard of care, and randomization will be stratified by ARDS severity. D000000925 D000005343 D000050299 D000045504 Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action UC-MSCs Group Control Group FiAg AnCoag All BDCA Fibrinolytic Agents Anticoagulants All Drugs and Chemicals Bone Density Conservation Agents Who are Who are M8731 M45326 M3396 M4533 M4550 M7625 Heparin Calcium heparin Anticoagulants Calcium Calcium, Dietary Fibrinolytic Agents high high low low low low UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment. Best supportive care treatment per the treating hospital protocol. D000006493 C000006871 Heparin Calcium heparin Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. Vehicle + Heparin along with best supportive care  Biological Other",1,24
1126,"Biological: allo-APZ2-DFU Single Group Assignment Single Group Assignment Interventional, single arm, multicenter, phase I/IIa clinical trial   Experimental: allo-APZ2-DFU       Suspension of ABCB5-positive mesenchymal stem cells   allo-APZ2-DFU  Biological",1,23
1127,Biological: PLX-PAD Parallel Assignment    PLX-PAD Treatment       PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells   PLX-PAD  Biological,1,23
1128,"Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) Drug: Lactated Ringer's Solution Crossover Assignment    Experimental: Human (aMBMC) Placebo:Lactated Ringer's Solution (LRS) PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg. One time infusion 1.5mL/kg   Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) Lactated Ringer's Solution Mesenchymal Stem Cells, (MSC) Marrow Stromal Cells. (LRS) Drug Drug",1,23
1129,Biological: XCEL-MT-OSTEO-ALPHA Procedure: Standard treatment Parallel Assignment    XCEL-MT-OSTEO-ALPHA Standard Treatment       Core decompression plus XCEL-MT-OSTEO-ALPHA Isolated core decompression   XCEL-MT-OSTEO-ALPHA Standard treatment  Biological Procedure,1,23
1130,Biological: HUC-MSCs Transplantation Biological: HUC-MSCs with Injectable Collagen Scaffold Transplantation Parallel Assignment    HUC-MSCs Transplantation HUC-MSCs with Injectable Collagen Scaffold Transplantation       The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs. The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.   HUC-MSCs Transplantation HUC-MSCs with Injectable Collagen Scaffold Transplantation  Biological Biological,1,23
1131,Biological: SBI-101 Biological: SBI-101 Parallel Assignment    High dose cohort Low dose cohort       SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.   SBI-101  Biological,1,22
1132,Biological: Stem cells Single Group Assignment    Treatment          Stem cells FURESTEM-CD Inj. Biological,1,24
1133,Drug: Remestemcel-L Drug: Remestemcel-L Other: Placebo Parallel Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Remestemcel-L (150 million cells) Remestemcel-L (300 million cells) Placebo Infe Infl All HB Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals Herbal and Botanical 1440 M186752 M3369 M3466 M3366 T120 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Cola high low low low low An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis Normal saline C000711674 Remestemcel-l Remestemcel-L Remestemcel-L Placebo  Drug Drug Other,1,24
1134,"Biological: HB-adMSCs Other: Placebo Biological: HB-adMSCs Other: Placebo Parallel Assignment A parallel study is a type of clinical study where two groups of treatments, A (HB-adMSCs) and B (Placebo), are given so that one group receives only A while another group receives only B.   HB-adMSCs Placebo HB-adMSCs Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low HB-adMSCs will be administered intravenously to study participants who qualify. Placebo will be administered intravenously to study participants who qualify.   HB-adMSCs Placebo Autologous Hope Biosciences adipose derived mesenchymal stem cells. Sterile Saline Solution 0.9% Biological Other",1,24
1135,"Biological: HB-adMSCs Single Group Assignment Single arm, non-randomized study to determine safety and treatment effect of three infusions of HB-adMSC (2 x 10^8 total cells per dose) in adult patients with sub-acute or chronic neurological injury   HB-adMSC       Hope Biosciences autologous adipose-derived mesenchymal stem cells   HB-adMSCs  Biological",1,24
1136,"Biological: MSCs-derived exosomes Single Group Assignment    MSCs-derived Exosomes Treatment Group       5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).   MSCs-derived exosomes  Biological",1,24
1137,"Biological: allogenic adipose stem cell injection Biological: fibrin glue/normal saline injection Biological: normal saline injection Parallel Assignment  D000006490 D000003029 Hemostatics Coagulants Mesenchymal stem cell group Active control (fibrin glue) group Control (normal saline )group Coag All Coagulants All Drugs and Chemicals Isoflurane M17443 M8728 M5411 Fibrin Tissue Adhesive Hemostatics Coagulants high low low Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise. Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise Total 1cc of normal saline injection and range of motion exercise D000015718 Fibrin Tissue Adhesive allogenic adipose stem cell injection fibrin glue/normal saline injection normal saline injection experimental group active control group placebo group Biological Biological Biological",1,24
1138,Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion Other: Normal Saline (Placebo) Infusion Parallel Assignment    Mesenchymal Stromal Stem Cells Infusion Placebo Infusion CNSDep All Infe ANeo Ot Central Nervous System Depressants All Drugs and Chemicals Anti-Infective Agents Antineoplastic Agents Other Dietary Supplements  M3259 M11280 M4006 M18102 M1830 T433 Anesthetics Mycophenolic Acid Benzocaine Tacrolimus Basiliximab Tannic Acid low low low low low low Investigational infusion bag containing autologous mesenchymal stromal cells wrapped to cover contents to maintain the blind.  Mesenchymal Stromal Stem Cells Infusion. Matching infusion containing normal saline wrapped to cover contents to maintain the blind.  Normal Saline (Placebo) Infusion.   Mesenchymal Stromal Stem Cells (MSCs) Infusion Normal Saline (Placebo) Infusion Investigational autologous biological product Matching placebo infusion bag Biological Other,1,24
1139,Biological: Trinity multipotent stem cells Biological: Demineralized bone matrix(DBM) Single Group Assignment    Trinity Demineralized bone matrix       Enough to fill voids which vary in size Enough DBM to fill a bone void defect   Trinity multipotent stem cells Demineralized bone matrix(DBM) Grafton Biological Biological,1,0
1140,"Drug: TH-SC01 Single Group Assignment    TH-SC01       Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)   TH-SC01  Drug",1,24
1141,"Single Group Assignment     Gast All Gastrointestinal Agents All Drugs and Chemicals  M21707 M12266 Pancrelipase Pancreatin low low First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.   autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells  Biological",1,24
1142,Biological: umbilical cord derived-mesenchymal stromal cells Biological: umbilical cord derived-mesenchymal stromal cells Biological: umbilical cord derived-mesenchymal stromal cells Parallel Assignment    CLT high-dose CLT low-dose CLT medium-dose       Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells   umbilical cord derived-mesenchymal stromal cells  Biological,1,24
1143,Biological: Catholic MASTER cell Other: Saline Parallel Assignment    MASTER cell Saline       Injection of CATHOLIC MASTER cells 1 x 10^8 cells/DMEM 5cc into knee of patents with osteoarthritis Injection of saline 5cc into knee of patents with osteoarthritis   Catholic MASTER cell Saline  Biological Other,1,24
1144,"Drug: Autologous Adipose Derived Mesenchymal Stromal Cells Drug: Autologous Adipose Derived Mesenchymal Stromal Cells Parallel Assignment    Single Injection Two Injections       Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices   Autologous Adipose Derived Mesenchymal Stromal Cells ASCLEPIOS Drug",1,24
1145,IV infusion   stem cells FURESTEM-CD Inj. Biological,1,24
1146,"Drug: Dexamethasone Device: Lipogems Parallel Assignment  D000000893 D000000932 D000001337 D000018373 D000045505 D000005765 D000005938 D000006728 D000006730 D000018931 D000000970 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Micro-Fragmented Adipose Tissue Corticosteroid Infl ANeo AnEm Gast All Anti-Inflammatory Agents Antineoplastic Agents Antiemetics Gastrointestinal Agents All Drugs and Chemicals Test M6254 M16126 M16127 M237968 M209570 M235540 M3369 M3403 M8033 M8199 M8941 M8940 M20119 Dexamethasone Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate Dexamethasone acetate Anti-Inflammatory Agents Antiemetics Gastrointestinal Agents Glucocorticoids Hormones Hormone Antagonists Antineoplastic Agents, Hormonal high low low low low low low low low low low low low The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications. Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance. D000003907 Dexamethasone Lipogems Dexamethasone Micro-fragmented Adipose Tissue Corticosteroid Device Drug",1,24
1147,"Biological: hUCMSCs Biological: hUCMSCs Biological: hUCMSCs Sequential Assignment We allocate 24 participants into 3 group, low-dose, medium-dose and high-dose group. It is going to proceeded sequential from low-dose group to high-dose group. Next group is allowed to be started only the last group has been finished.  Low-dose group: 100mL human umbilical cord mesenchymal stem cell preparation, containing 2.5×10^7 cells; medium-dose group: 100mL human umbilical cord mesenchymal stem cell preparation, containing 5.0×10^7 cells; High-dose group: 100mL human umbilical cord mesenchymal stem cell preparation, containing 1.0×10^8 cells   High-dose group Low-dose group medium-dose group       Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells   hUCMSCs  Biological",1,24
1148,"Biological: Dental pulp mesenchymal stem cells Single Group Assignment Dental pulp mesenchymal stem cells were injected intravenously   Pulp mesenchymal stem cells       On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.   Dental pulp mesenchymal stem cells  Biological",1,24
1149,"Biological: SBI-101 Biological: SBI-101 Device: Sham Parallel Assignment    High dose cohort Low dose cohort Control       SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue. The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.   SBI-101 Sham  Biological Device",1,24
1150,"Drug: Ruxolitinib Other: Cellular Therapy Drug: Ruxolitinib Other: Cellular Therapy Drug: Ruxolitinib Parallel Assignment  D000047428 D000004791 D000045504 Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Arm 2 (ruxolitinib, lower dose ds-MSCs) Arm 3 (ruxolitinib, higher dose ds-MSCs) Arm 1 (ruxolitinib) Arm 2 (ruxolitinib, lower dose ds-MSCs) Arm 3 (ruxolitinib, higher dose ds-MSCs) All All Drugs and Chemicals Definity M1474 M24973 Janus Kinase Inhibitors Protein Kinase Inhibitors high low Given ds-MSCs IV Given PO D000075242 Janus Kinase Inhibitors Cellular Therapy Ruxolitinib Cell Therapy INCB-18424 INCB18424 Jakafi Oral JAK Inhibitor INCB18424 Other Drug",1,24
1151,Parallel Assignment           Intramyocardial Injection of BMSCs   Cell Therapy  Other,1,24
1152,Biological: human umbilical cord mesenchymal stem cell complex collagen Biological: human umbilical cord mesenchymal stem cell complex collagen Procedure: intrauterine injection Parallel Assignment    control group stem cell and collagen transplantation group control group       1 * 10^7 cells (2ml) intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time   human umbilical cord mesenchymal stem cell complex collagen intrauterine injection  Biological Procedure,1,24
1153,"Drug: infusion of BMMSCs Drug: infusion BMMNCs Drug: insulin Drug: infusion BMMNCs Drug: insulin Drug: insulin Parallel Assignment  D000007004 D000045505 Hypoglycemic Agents Physiological Effects of Drugs BMMSC+BMMNC BMMNC BMMSC+BMMNC BMMNC BMMSC+BMMNC Insulin Hypo All Hypoglycemic Agents All Drugs and Chemicals Cycle M9517 M172956 M9206 Insulin Insulin, Globin Zinc Hypoglycemic Agents high low low infusion of BMMSCs infusion of BMMNCs intensive insulin care D000007328 Insulin infusion of BMMSCs infusion BMMNCs insulin  Drug Drug Drug",1,22
1154,Biological: ALLO-ASC-DFU Device: Conventional Therapy Parallel Assignment    ALLO-ASC-DFU Conventional Therapy       Dressing for Second Deep degree Burn injury Typical therapy conducted for burn injury patients   ALLO-ASC-DFU Conventional Therapy Allogeneic mesenchymal stem cells Biological Device,1,22
1155,"Drug: Umbilical Cord Lining Stem Cells Sequential Assignment Study Participants will be assigned to one of 3 doses of stem cells depending on when the subject is enrolled. The first three patients will be assigned to the low dose group, the next three patients will be assigned the intermediate dose group and last three patients will receive the high dose of ULSC's. An independent review group will evaluate the response to therapy to each dose group before moving to the next dose. The groups and doses are described below:  A low dose group receives an IV infusion of 50 million stem cells.  An intermediate dose group receives an IV infusion of 100 million stem cells.  A high dose group receives an IV infusion of 200 million stem cells.   Treatment Arm       An IV infusion of ULSCs will be administered.   Umbilical Cord Lining Stem Cells  Drug",1,22
1156,Biological: Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction Other: Standard treatment according to the clinical protocols Other: Standard treatment according to the clinical protocols Parallel Assignment    Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC Standard treatment according to the clinical protocols       Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols   Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction Standard treatment according to the clinical protocols  Biological Other,1,20
1157,"Procedure: UC-MSCs therapy Single Group Assignment    UC-MSCs therapy All All Drugs and Chemicals  M8941 Hormones low After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.   UC-MSCs therapy collagen scaffold Procedure",1,20
1158,Biological: Mesenchymal Stromal Cells Parallel Assignment    Mesenchymal Stromal Cells (MSC) Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low    Mesenchymal Stromal Cells  Biological,1,20
1159,Biological: Umbilical cord mesenchymal stem cells Single Group Assignment    Umbilical cord mesenchymal stem cells ARhu All Antirheumatic Agents All Drugs and Chemicals  M19757 Antirheumatic Agents low    Umbilical cord mesenchymal stem cells  Biological,1,20
1160,Biological: Mesenchymal Stem Cells (MSCs) Single Group Assignment    Mesenchymal Stem Cells PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 M85407 Pharmaceutical Solutions Plasma-lyte 148 low low Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1.   Mesenchymal Stem Cells (MSCs)  Biological,1,20
1161,Drug: Stem cell Drug: Plasmalyte A Parallel Assignment  D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions stem cells Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals CAB M85407 M21013 M11966 Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions high low low IV infusion of stem cells IV infusion C000012499 Plasma-lyte 148 Stem cell Plasmalyte A  Drug Drug,1,20
1162,Biological: Stem Cells Single Group Assignment    Stem Cells       Transplantation of purified autologous bone marrow-derived stem cells.   Stem Cells  Biological,1,20
1163,"Biological: Mesenchymal stem cell Biological: Placebo Parallel Assignment    Mesenchymal stem cell Placebo       1*10^8 cells are administered once a week, total four times intravenously. Commercially available saline.   Mesenchymal stem cell Placebo  Biological Biological",1,20
1164,Behavioral: Active Behavioral: Sedentary     Active Sedentary       No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels. No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.   Active Sedentary  Behavioral Behavioral,1,20
1165,"Biological: MSCs Parallel Assignment    MSCs Treatment Group       3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).   MSCs  Biological",1,20
1166,"Biological: Mesenchymal stromal cells Other: Placebo Parallel Assignment    Mesenchymal Stromal cells Control group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Administration of one single dose of allogenic Mesenchymal stromal cells Administration of placebo (solution identical to experimental treatment, without the MSC)   Mesenchymal stromal cells Placebo  Biological Other",1,20
1167,Drug: Bone marrow mesenchymal stem cells Drug: Placebo Parallel Assignment    MSCs placebo       Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline intravenous infusion of 400 mL saline   Bone marrow mesenchymal stem cells Placebo  Drug Drug,1,20
1168,"Biological: Adipose derived stem cells Single Group Assignment    Treatment       Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.   Adipose derived stem cells Adipose derived stem cells and platelet rich plasma ADSC and PRP Biological",1,20
1169,"Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells Parallel Assignment    CABG with hUC-MSC treatment group CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low In CABG with hUC-MSC treatment group, 1×10^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG   Allogeneic Human Umbilical Cord Mesenchymal Stem Cells  Biological",1,20
1170,"Biological: Autologous Mesenchymal Stem Cells Treatment (MSCs) Drug: Hyaluronic acid (HA) Parallel Assignment Prospective Randomized Controlled Trial D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Autologous Mesenchymal Stem Cells Treatment (MSCs) Hyaluronic acid (HA) All All Drugs and Chemicals Compression M9030 M250495 M2780 M9353 M27448 M21022 Hyaluronic Acid Hylan Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low low The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee. The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) D000006820 Hyaluronic Acid Autologous Mesenchymal Stem Cells Treatment (MSCs) Hyaluronic acid (HA)  Biological Drug",1,20
1171,Drug: Mesenchymal stem cells isolated from Wharton's jelly Single Group Assignment    Treatment arm       Intrathecal administration of mesenchymal stem cells   Mesenchymal stem cells isolated from Wharton's jelly  Drug,1,20
1172,"Biological: umbilical cord mesenchymal stem cells Device: Hyaluronic acid Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Mesenchymal stem cell treatment Hyaluronic acid treatment All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low  D000006820 Hyaluronic Acid umbilical cord mesenchymal stem cells Hyaluronic acid UCMSC Biological Device",1,20
1173,Biological: MSCs Single Group Assignment    MSCs       The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects   MSCs  Biological,1,20
1174,"Biological: bone marrow derived mesenchymal stem cells Single Group Assignment    MSC       Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks   bone marrow derived mesenchymal stem cells Mesenchymal Stem Cells Multipotent Mesenchymal Stem Cells Multipotent Mesenchymal Stromal Cells Biological",1,20
1175,"Biological: Intravenous Injection of autologous mesenchymal stem cells Other: Intravenous injection of placebo Crossover Assignment    Mesenchymal Stem Cells Transplantation Placebo       Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 & 3 Intravenous injection of normal saline (sodium chloride 0.9%)   Intravenous Injection of autologous mesenchymal stem cells Intravenous injection of placebo  Biological Other",1,20
1176,Biological: Mesenchymal progenitor cells Biological: Mesenchymal progenitor cells Biological: Mesenchymal progenitor cells Parallel Assignment    Mesenchymal progenitor cells Dosage 1 Mesenchymal progenitor cells Dosage 2 Mesenchymal progenitor cells Dosage 3       Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use   Mesenchymal progenitor cells  Biological,1,22
1177,"Drug: 50 Adipose Derived Stem Cell Infusion Drug: 150 Adipose Derived Stem Cell Infusion Drug: 300 Adipose Derived Stem Cell Infusion Drug: Placebo Infusion Parallel Assignment The proposed study is a single-site, double-blinded, placebo-controlled study involving a single administration of either individual, autologous ATCell™ lines suspended in 5% dextrose lactated Ringer's solution or a vehicle (5% dextrose lactated Ringer's solution) not containing cells. Each ATCell™ cell line will be created from cells grown from the stromal vascular fraction (SVF) of a participant's own adipose tissue collected by liposuction, and each treated participant will only receive their own cells.   50 million cell infusion 150 million cell infusion 300 million cell infusion Placebo       Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.   50 Adipose Derived Stem Cell Infusion 150 Adipose Derived Stem Cell Infusion 300 Adipose Derived Stem Cell Infusion Placebo Infusion Autologous Adipose Derived Mesenchymal Stem Cells ADSC Infusion Therapy 50 Autologous Adipose Derived Mesenchymal Stem Cells ADSC Infusion Therapy 150 Autologous Adipose Derived Mesenchymal Stem Cells ADSC Infusion Therapy 300 ADSC Infusion Therapy Placebo Drug Drug Drug Drug",1,20
1178,Biological: Mesenchymal Stromal Cells Parallel Assignment    Mesenchymal Stromal Cells (MSC)          Mesenchymal Stromal Cells  Biological,1,22
1179,Drug: Normal saline Drug: Pneumostem Parallel Assignment    MSC group Control       direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap direct intracerebroventricular injection of normal saline via ventricular tap   Pneumostem Normal saline Umbilical cord blood derived mesenchymal stem cells Drug Drug,1,22
1180,Biological: injection of cell free media Biological: intravenous injection of mesenchymal stem cells Parallel Assignment    mesenchymal stem cell reciepiants cell free media       15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.   intravenous injection of mesenchymal stem cells injection of cell free media stem cell transplantation control group Biological Biological,1,22
1181,Drug: Mesenchymal stromal cells (MSC) for infusion Single Group Assignment    Mesenchymal stromal cells       MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks   Mesenchymal stromal cells (MSC) for infusion No other names Drug,1,21
1182,Drug: AstroStem Other: Placebo-Control Parallel Assignment    AstroStem Placebo-Control       Autologous adipose tissue derived mesenchymal stem cells (AdMSC) Saline with 30% auto-serum   AstroStem Placebo-Control  Drug Other,1,21
1183,Drug: Mesenchymal stem cells Drug: Placebo Crossover Assignment    mesenchymal stem cells Placebo       1.0-2.0 million cells/kg body weight Placebo   Mesenchymal stem cells Placebo Mesenchymal stromal cells Sham Drug Drug,1,21
1184,"Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.   Mesenchymal Stem Cell ADR-001 Drug",1,21
1185,"Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection. Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. Parallel Assignment    Control group Cohort 1 Cohort 2 Cohort 3       Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs. Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs   Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection. Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.  Procedure Procedure",1,21
1186,"Biological: GEM00220 Biological: GEM00220 Biological: GEM00220 Sequential Assignment A dose-escalation study evaluating GEM00220 cell therapy in 3 cohorts with 3 subjects per cohort. Study will proceed from lower dose to next higher dose if no safety concerns are observed in each cohort. If no safety issues are identified, we will continue to the Phase 1b trial.  Phase 1b: A single-arm, open-label extension of the Phase 1a trial to assess early signs of efficacy (major morbidity and mortality). The Phase 1b trial will enroll up to 12 participants.   Treatment Arm - Low Dose Treatment arm - High dose Treatment arm - Mid dose       Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion   GEM00220  Biological",1,21
1187,"Biological: JOINTSTEM Drug: Saline Parallel Assignment    JOINTSTEM Saline       JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10^8cells/(saline), 1 time injection under ultrasonic guided saline, 1 time injection under ultrasonic guided   JOINTSTEM Saline Autologous Adipose Tissue derived MSCs Biological Drug",1,21
1188,"Other: Mesenchymal stem cells Other: Mesenchymal stem cells Other: Mesenchymal stem cells Parallel Assignment Coronavirus Disease 2019 (COVID-19) patients with pneumonia  1.group: Intubated without comorbidity, 2.group: Intubated with comorbidity, 3.group: No intubated   Group 1 Group 2 Group 3       Intravenous infusion of Mesenchymal stem cells   Mesenchymal stem cells  Other",1,21
1189,Biological: ALLO-ASC injection Drug: Placebo Parallel Assignment  D000006490 D000003029 Hemostatics Coagulants ALLO-ASC group Normal saline group Coag All Coagulants All Drugs and Chemicals Isoflurane M17443 M8728 M5411 Fibrin Tissue Adhesive Hemostatics Coagulants high low low Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence 0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence D000015718 Fibrin Tissue Adhesive ALLO-ASC injection Placebo ALLO-ASC Normal saline with fibrin glue injection Biological Drug,1,21
1190,Biological: Intramuscular injection Single Group Assignment    Stem cell recipient       Intramuscular injection of stem cells in patients with FSHD.   Intramuscular injection Intramuscular cell transplantation Biological,1,21
1191,Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS Single Group Assignment    INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS ANeo ARhu All Antineoplastic Agents Antirheumatic Agents All Drugs and Chemicals  M5879 Cyclophosphamide low    INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS  Biological,1,20
1192,Drug: mesenchymal stem cells Drug: Plasmalyte A Parallel Assignment  D000009883 D000019999 Ophthalmic Solutions Pharmaceutical Solutions mesenchymal stem cells Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals CAB M85407 M21013 M11966 Plasma-lyte 148 Pharmaceutical Solutions Ophthalmic Solutions high low low Intramuscular injection Intramuscular injection C000012499 Plasma-lyte 148 mesenchymal stem cells Plasmalyte A  Drug Drug,1,20
1193,Biological: Stem Cells Biological: Stem Cells Parallel Assignment    stromal vascular fraction cells application group umbilical cord derived mesenchymal stem cells transplantation group       ATMP   Stem Cells  Biological,1,20
1194,"Procedure: Maxillary sinus floor elevation grafting with synthetic bone substitute. Procedure: Maxillary sinus floor elevation grafting with synthetic bone substitute. Parallel Assignment Double-blind, randomized controlled clinical trial, intra-individual (split-mouth design).   Control (conventional graft procedure), bone substitute and saline solution. Test (modified graft), bone substitute and concentrated culture medium (CM) PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Bone augmentation at the floor of the maxillary sinus with bone substitutes.   Maxillary sinus floor elevation grafting with synthetic bone substitute. Maxillary sinus lift bone grafting Procedure",1,20
1195,Biological: mesenchymal stem cells Single Group Assignment    Stem cell       mesenchymal stem cells injection via peripheral vein.   mesenchymal stem cells  Biological,1,19
1196,Drug: Placebo Drug: Allogenic mesenchymal stem cells from adipose tissue Parallel Assignment    Allogeneic stem cells from adipose tissue Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low    Allogenic mesenchymal stem cells from adipose tissue Placebo  Drug Drug,1,19
1197,Biological: MPC; rexlemestrocel-L Parallel Assignment    Treatment Arm       MPCs will be injected into the patient's myocardium during planned surgical procedures.   MPC; rexlemestrocel-L Allogeneic Mesenchymal Precursor Cell Biological,1,19
1198,"Biological: SMUP-IA-01(low-dose) Biological: SMUP-IA-01(mid-dose) Biological: SMUP-IA-01(high-dose) Parallel Assignment    SMUP-IA-01(low-dose) SMUP-IA-01(mid-dose) SMUP-IA-01(high-dose) All All Drugs and Chemicals  M9030 Hyaluronic Acid low A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL) A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL) A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10^7 cells/2mL)   SMUP-IA-01(low-dose) SMUP-IA-01(mid-dose) SMUP-IA-01(high-dose) Human umbilical cord blood-derived mesenchymal stem cells Human umbilical cord blood-derived mesenchymal stem cells Human umbilical cord blood-derived mesenchymal stem cells Biological Biological Biological",1,12
1199,Biological: UCMSCs Biological: UCMSCs Biological: BMMSCs Biological: BMMSCs Biological: UCMSCs Biological: BMMSCs Other: Placebo Parallel Assignment    Group A (UCMSCs - 100 million) Pilot Phase: Group 1 (UCMSCs - 20 million) Pilot Phase: Group 3 (UCMSCs - 100 million) Group B (BMMSCs - 100 million) Pilot Phase: Group 2 (BMMSCs - 20 million) Pilot Phase: Group 4 (BMMSCs -100 million) Group C (Placebo)       Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs) Bone Marrow derived Mesenchymal Stem Cells (BMMSCs) a single administration of placebo delivered via peripheral intravenous infusion.   UCMSCs BMMSCs Placebo  Biological Biological Other,1,14
1200,"Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University. Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University. Other: Placebo Sequential Assignment    Open Label infusion of hCT-MSC Randomized infusion of hCT-MSC Randomized infusion of Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M85407 Plasma-lyte 148 low Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami. Placebo will be comprised of 40-80 mL of Plasmalyte-A + 1% Human Serum Albumin (HAS) prepared in an identical container to the one used for cell administration. The placebo product will undergo the same process of sterility testing including release inspection, transport and product custodian.   Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University. Placebo hCT-MSC Biological Other",1,14
1201,Drug: ADSTEM Inj. (Adult human mesenchymal stem cells) Single Group Assignment    intervention: Biological: ADSTEM Inj.       Comparison of different dosages of the drug in the aspect of safety and efficacy.   ADSTEM Inj. (Adult human mesenchymal stem cells) ADSTEM Inj. Drug,1,13
1202,Biological: Autologous Mesenchymal Stem Cells Biological: Autologous Mesenchymal Stem Cells Parallel Assignment    mesenchymal cells&platelet lysate mesenchymal stem cells       Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate   Autologous Mesenchymal Stem Cells  Biological,1,13
1203,"Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells Single Group Assignment    arm treated with MSC VaDiAg Urol All Vasodilator Agents Urological Agents All Drugs and Chemicals  M292 M279 Sildenafil Citrate Tadalafil low low Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination & Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores & Pharmaco-Doppler   Autologous Bone Marrow derived Mesenchymal Stem Cells  Drug",1,13
1204,"Biological: Mesenchymal Stem Cells (MSC) Single Group Assignment    MSC       MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart   Mesenchymal Stem Cells (MSC)  Biological",1,13
1205,"Drug: BCP with autologous mesenchymal stem cells (MSC). Single Group Assignment    Augmentation of new alveolar bone All BDCA All Drugs and Chemicals Bone Density Conservation Agents  M4533 M4550 Calcium Calcium, Dietary low low Augmentation of narrow alveolar ridge with BCP and MSC   BCP with autologous mesenchymal stem cells (MSC). MSC and BCP Drug",1,13
1206,Biological: Autologous Mesenchymal Stem Cells Single Group Assignment    MSCs injection          Autologous Mesenchymal Stem Cells  Biological,1,13
1207,"Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Single Group Assignment The study model is considered as a single group assignment since all the participants are being administered with the same treatment.   intravenous injection of UC-MSC Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low All research samples will be treated by Intravenous injection of allogeneic mesenchymal stem cells and hemodynamic observation will be done for 24 hours after treated. Periodic post-treatment observation will be done on 1st month, 3rd month, and 6th month after therapy. The Independent variable in this research is Child-Pugh B Cirrhosis caused by Hepatitis B, while the dependent variable is the degree of liver function damage consisting of an examination of liver function, Child-Pugh score, and MELD score.   Allogeneic Umbilical Cord Mesenchymal Stem Cell  Biological",1,12
1208,Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Parallel Assignment    Conventional treatment plus high dose: 3x10e6 cells / Kg. Conventional treatment plus low dose: 1x10e6 cells / Kg Conventional treatment plus high dose: 3x10e6 cells / Kg. Conventional treatment plus low dose: 1x10e6 cells / Kg Infe ARhu Derm All Infl ANeo Anti-Infective Agents Antirheumatic Agents Dermatologic Agents All Drugs and Chemicals Anti-Inflammatory Agents Antineoplastic Agents  M18113 M5882 M18102 M13273 Cyclosporine Cyclosporins Tacrolimus Prednisone low low low low Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.  Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin. Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.  Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.   Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.  Other Other,1,19
1209,"Other: placebo Biological: stem cells Parallel Assignment    Stem Cell Group Control group PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Using umbilical cord stem cells 15x10^6 cells in 2 cc saline/NaCl 0,9% solution using 2 cc saline/NaCl 0,9% solution   stem cells placebo  Biological Other",1,12
1210,"Biological: hCT-MSC infusion Single Group Assignment    hCT-MSC infusion       This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).   hCT-MSC infusion  Biological",1,12
1211,"Biological: mesenchymal stem cell injection Single Group Assignment    MSC injection Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.   mesenchymal stem cell injection  Biological",1,12
1212,Biological: Mesenchymal stromal cell therapy Single Group Assignment    Mesenchymal stromal cell therapy       Stem cells administration locally   Mesenchymal stromal cell therapy BMMSCs= Bone Marrow Mesenchymal Stem Cells Biological,1,12
1213,Drug: injection of microfat and plasma rich platelet PRP Device: MRI Single Group Assignment    Intra-articular injection Intra-articular injection       intra-articular injections MRI 3T   injection of microfat and plasma rich platelet PRP MRI  Drug Device,1,12
1214,Biological: Allogeneic mesenchymal stromal cells (MSCs) Biological: Extracorporeal photopheresis (ECP) Single Group Assignment    MSCs + ECP MSCs + ECP       Treatment dose 2 x10^6 cells/kg (+/- 20%) Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant   Allogeneic mesenchymal stromal cells (MSCs) Extracorporeal photopheresis (ECP)  Biological Biological,1,12
1215,Biological: CARTISTEM® Single Group Assignment    CARTISTEM® All All Drugs and Chemicals  M9030 Hyaluronic Acid low    CARTISTEM® human umbilical cord blood-derived mesenchymal stem cells Biological,1,12
1216,Procedure: Lipoaspiration Procedure: Transplantation Procedure: Lipoaspiration Procedure: Transplantation Procedure: Lipoaspiration Procedure: Transplantation Parallel Assignment    GROUP I GROUP II GROUP III GROUP I GROUP II GROUP III       The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained. The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient   Lipoaspiration Transplantation  Procedure Procedure,1,12
1217,Procedure: Stem Cell Transplantation Single Group Assignment Mesenchymal stem cell transplantation.   Stem Cell Transplantation       All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.   Stem Cell Transplantation BMMSC - Bone Marrow Mesenchymal Stem Cells. Procedure,1,14
1218,Drug: Darvadstrocel     patients with Crohn's disease and complex perianal fistula       Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract   Darvadstrocel Alofisel Drug,1,14
1219,"Biological: Mesenchymal Stem Cells Single Group Assignment    Human Allogeneic Mesenchymal Stem Cells All Infe All Drugs and Chemicals Anti-Infective Agents  M9336 M3377 M1804 Immunoglobulins Antibodies Carbamide Peroxide low low low A single dose, one time infusion (in the vein) of one of the following doses of hMSCs: 1 x 10^6, 3 x 10^6 or 5 x 10^6 hMSCs/kg body weight during Visit 2. A traditional 3+3 design will be utilized.  Allogeneic MSCs will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common CFTR mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of CF lung infection and inflammation.   Mesenchymal Stem Cells MSCs Biological",1,14
1220,"Biological: NEUROSTEM®-AD     NEUROSTEM®-AD NootAg All AnDyAg NeuroAg Nootropic Agents All Drugs and Chemicals Anti-Dyskinesia Agents Neuroprotective Agents  M1721 M10694 M317 M19927 M7972 Donepezil Memantine Rivastigmine Nootropic Agents Galantamine low low low low low NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.   NEUROSTEM®-AD human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) Biological",1,14
1221,Drug: Allogeneic adipose derived mesenchymal stem cells Drug: Allogeneic adipose derived mesenchymal stem cells Drug: Allogeneic adipose derived mesenchymal stem cells Parallel Assignment    Intra parenchymal injection Intra parenchymal injection & Intra-arterial infusion Intra-arterial infusion       Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft   Allogeneic adipose derived mesenchymal stem cells  Drug,1,15
1222,"Procedure: Instrumented posterolateral arthrodesis Single Group Assignment    MSC seeded onto a phosphate ceramic All BDCA All Drugs and Chemicals Bone Density Conservation Agents  M4533 M4550 Calcium Calcium, Dietary low low Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.  They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.  Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery.   Instrumented posterolateral arthrodesis  Procedure",1,15
1223,Drug: Adipose Derived Mesenchymal Stem Cells Single Group Assignment    Adipose Derived Mesenchymal Stem Cells PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution   Adipose Derived Mesenchymal Stem Cells AMSC Drug,1,15
1224,Biological: human umbilical cord mesenchymal stem cells Single Group Assignment    Intervention Group       rehabilitation therapy plus human umbilical cord mesenchymal stem cells   human umbilical cord mesenchymal stem cells  Biological,1,15
1225,Biological: MSC and PRP Single Group Assignment    MSC and PRP       MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.   MSC and PRP  Biological,1,15
1226,Procedure: Autologous Adipose Tissue derived MSCs Transplantation Single Group Assignment    Autologous Adipose Tissue derived MSCs       Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL   Autologous Adipose Tissue derived MSCs Transplantation  Procedure,1,15
1227,Biological: mesenchymal stem cell infusion Biological: bone marrow mononuclear cell infusion Single Group Assignment    stem cell stem cell          mesenchymal stem cell infusion bone marrow mononuclear cell infusion MSC infusion BMMNC infusion Biological Biological,1,15
1228,Factorial Assignment           autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1&2   autologous adipose tissue derived mesenchymal stem cells  Drug,1,15
1229,"Other: Autologous MSC knee implantation Single Group Assignment    Autologous MSC knee implantation       Isolation and ""Ex-Vivo"" expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection.   Autologous MSC knee implantation Xcel-m-condro-alpha Other",1,15
1230,"Biological: Allogeneic (MSC's) Application to the Burn Wounds Single Group Assignment    Allogeneic (MSC's) Application to the Burn Wounds       Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose  Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.  Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.   Allogeneic (MSC's) Application to the Burn Wounds Stem Cells Application to the Burn Wounds Biological",1,15
1231,Other: BM-MSC Single Group Assignment    BM-MSC PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.   BM-MSC  Other,1,14
1232,"Drug: JOINTSTEM Single Group Assignment    Long Term Follow-up after Jointstem Transplantation       JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.   JOINTSTEM autologous adipose-derived mesenchymal stem cells Drug",1,14
1233,"Biological: UMSC01 Single Group Assignment    UMSC01 FiAg All Fibrinolytic Agents All Drugs and Chemicals  M13001 Tissue Plasminogen Activator low There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.   UMSC01  Biological",1,14
1234,"Biological: Autologous Mesenchymal Stem Cells Biological: Autologous Mesenchymal Stem Cells Parallel Assignment    Recipient of AT-MSC Recipient of BM-MSC       Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.   Autologous Mesenchymal Stem Cells  Biological",1,14
1235,"Biological: Mesenchymal Stem Cells from adipose Biological: Hyaluronic Acid Parallel Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents Mesenchymal Stem Cells from adipose hyaluronic acid All All Drugs and Chemicals Compression M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low inject mesenchymal Stem Cells from adipose inject hyaluronic acid D000006820 Hyaluronic Acid Mesenchymal Stem Cells from adipose Hyaluronic Acid  Biological Biological",1,14
1236,Biological: Mesenchymal cell therapy Single Group Assignment    Mesenchymal cell therapy       Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow  Registry Type: autologous Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France). Route of administration: endomyocardial injection Dose administered: 120-140 x106 MSC (mesenchymal stem cells)   Mesenchymal cell therapy  Biological,1,14
1237,"Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF Single Group Assignment    MSC-NTF          MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF  Biological",1,14
1238,Drug: ET-STEM Single Group Assignment Single Group   Treatment Arm Infe Lipd All Anti-Infective Agents Lipid Regulating Agents All Drugs and Chemicals  M7300 Ethionamide low mesenchymal stem cells preconditioned with ethionamide   ET-STEM  Drug,1,12
1239,"Biological: 1 x 10^6 MSCs Biological: 10 x 10^6 MSCs Biological: 50 x 10^6 MSCs Single Group Assignment    Cohort 1 Cohort 2 Cohort 3       Autologous, bone-marrow derived MSCs Autologous, bone-marrow derived MSCs Autologous, bone-marrow derived MSCs   1 x 10^6 MSCs 10 x 10^6 MSCs 50 x 10^6 MSCs Mesenchymal Stromal Cells (MSCs) Mesenchymal Stromal Cells (MSCs) Mesenchymal Stromal Cells (MSCs) Biological Biological Biological",1,12
1240,"Biological: MSC-NTF cells transplantation (IM) Biological: MSC-NTF cells transplantation (IT) Parallel Assignment    MSC-NTF cells IM MSC-NTF cells IT CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.   MSC-NTF cells transplantation (IM) MSC-NTF cells transplantation (IT)  Biological Biological",1,12
1241,Drug: Bone marrow-derived mesenchymal stromal cells (MSCs) Single Group Assignment    Children with OI receiving Bone marrow-derived MSCs infusion       Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.   Bone marrow-derived mesenchymal stromal cells (MSCs) MSC infusions Drug,1,12
1242,"Procedure: Bone Marrow Aspiration Diagnostic Test: Ultrasound Imaging of Salivary Glands Other: Salivary Assay Other: Quality of Life Instruments Single Group Assignment    Participants with Xerostomia Participants with Xerostomia Participants with Xerostomia Participants with Xerostomia       collection of approximately 40 mL of bone marrow aspirate Salivary gland size will be measured by ultrasound. Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.   Bone Marrow Aspiration Ultrasound Imaging of Salivary Glands Salivary Assay Quality of Life Instruments Bone Marrow Collection sialometry Procedure Diagnostic Test Other Other",1,12
1243,Biological: autologous bone marrow mesenchymal stem cells Single Group Assignment    IPF patients       intravenous infusion   autologous bone marrow mesenchymal stem cells  Biological,1,12
1244,Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells Single Group Assignment    PNEUMOSTEM®       Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:  Dose A: 10 million cells per kg / Dose B: 20 million cells per kg   Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells PNEUMOSTEM® Biological,1,12
1245,"Biological: Mesenchymal Stem Cells Single Group Assignment    Mesenchymal Stem Cells       After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.   Mesenchymal Stem Cells Human Umbilical Cord-derived Mesenchymal Stem Cells Biological",1,12
1246,Drug: 20 million hMSCs Drug: 40 million hMSCs Drug: 80 million hMSCs Sequential Assignment Advanced Therapeutic Medicinal Product ( ATMP) Bone Marrow Derived Mesenchymal Stem Cells   low dose cohort mid dose cohort high dose cohort          20 million hMSCs 40 million hMSCs 80 million hMSCs 20 million hMSCs intramuscularly 40 million hMSCs intramuscularly 80 million hMSCs intramuscularly Drug Drug Drug,1,12
1247,Other: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment) Single Group Assignment Cell therapy   Experimental       A single application in the context of a single surgical intervention.   HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)  Other,1,12
1248,"Drug: Albuterol Sulfate Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs) Drug: Prednisone Single Group Assignment  D000000893 D000005938 D000006728 D000006730 D000045505 D000018931 D000000970 D000000998 D000000890 D000001993 D000001337 D000018373 D000018927 D000019141 D000015149 D000012102 D000058666 D000000318 D000000322 D000018663 D000018377 D000045504 Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiviral Agents Anti-Infective Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Tocolytic Agents Reproductive Control Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Infusion of γMSCs Infusion of γMSCs Infusion of γMSCs Repr Resp All Infe ANeo Infl Reproductive Control Agents Respiratory System Agents All Drugs and Chemicals Anti-Infective Agents Antineoplastic Agents Anti-Inflammatory Agents Affecting Inhibitor Until Details M2919 M9559 M13273 M9558 M3369 M8199 M8941 M8940 M20119 M3466 M3366 M4421 M20116 M20290 M17021 M19899 M2822 M2825 M19657 Albuterol Interferons Prednisone Interferon-gamma Anti-Inflammatory Agents Glucocorticoids Hormones Hormone Antagonists Antineoplastic Agents, Hormonal Antiviral Agents Anti-Infective Agents Bronchodilator Agents Anti-Asthmatic Agents Respiratory System Agents Tocolytic Agents Adrenergic Agents Adrenergic beta-Agonists Adrenergic Agonists Neurotransmitter Agents high high high high low low low low low low low low low low low low low low low Participants who experience symptoms of cough, dyspnea, chest tightness or wheezing will initiate use of albuterol (2 inhalations, 90 mcg/actuation) by metered dose inhaler (MDI) every 20 minutes for up to 1 hour and then every 4 hours if necessary. IFNγ-primed bone marrow MSCs at a dose level of 2x106 cells/kg and a dose level of 5x106 cells/kg Prednisone is recommended if the participant uses more than 12 inhalations of albuterol in 24 hours (excluding preventive use before exercise), or if the patient has ongoing symptoms for 48 hours or longer. The recommended prednisone dose for acute exacerbations is 2 mg/kg/day (maximum 60 mg) as a single dose for two days followed by 1 mg/kg/day (maximum 30 mg) as a single dose for two days. All administered doses will be rounded down to the nearest 10 mg. D000007372 D000007371 D000011241 D000000420 Interferons Interferon-gamma Prednisone Albuterol Albuterol Sulfate Interferon gamma-primed mesenchymal stromal cells (MSCs) Prednisone Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells Drug Drug Drug",1,12
1249,Biological: Olfactory mucosa-derived mesenchymal stem cells Parallel Assignment    Mesenchymal stem cell treated group       Olfactory mucosa-derived mesenchymal stem cells   Olfactory mucosa-derived mesenchymal stem cells  Biological,1,12
1250,Drug: EN001 Drug: EN001 Parallel Assignment    Dose group A (Low dose) Dose group B (High dose)       EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.  Dose group A (Low dose): 5.0x10^5 cells/kg EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.  Dose group B (High dose): 2.5x10^6 cells/kg   EN001 EN001 EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) Drug Drug,1,12
1251,"Biological: RegStem Single Group Assignment    RegStem       RegStem, 1.5 ml, one injection   RegStem MSC Biological",1,12
1252,"Drug: Jointstem Single Group Assignment    Long Term Follow-up after Jointstem Transplantation       JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.   Jointstem autologous adipose-derived mesenchymal stem cells Drug",1,11
1253,Biological: Autologous mesenchymal stromal cells (MSCs) Biological: Autologous mesenchymal stromal cells (MSCs) Biological: Autologous mesenchymal stromal cells (MSCs) Parallel Assignment    Dose Level 1: Infusion of MSCs Dose Level 2: Infusion of MSCs Dose Level 3: Infusion of MSCs       Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.   Autologous mesenchymal stromal cells (MSCs)  Biological,1,11
1254,Drug: Prochymal® Single Group Assignment  D000000893 D000000998 D000000890 Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents Prochymal® Infe Infl All Anti-Infective Agents Anti-Inflammatory Agents All Drugs and Chemicals 1440 M186752 M3369 M3466 M3366 Remestemcel-l Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents high low low low Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells C000711674 Remestemcel-l Prochymal® Remestemcel-L Drug,1,11
1255,"Biological: autologous adipose tissue derived stromal vascular fraction (SVF) Single Group Assignment retrospective study to report the outcome in patients treated with fluoroscopic guided per cutaneous injection of Adipose tissue derived stromal vascular fraction (SVF) at the site of fracture as an outpatient procedure between November 2012 to August 2018.  The indication for this procedure was established atrophic non-union with no evidence of infection with maximum gap between the fragments to be<5 mm and duration not later than one year between the fracture and the procedure.  Healing at the injury site was evaluated using clinical and radio logical examination at 1,2,6, and 12 months post-treatment.Anterior-posterior radio graphs   Patients with nonunion of long bones       liquid and solid portion of lipo-aspirate after non enzymatic processing yields SVF.  This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ ,  , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC, 20%), plus a wide number of CD34+ hematopoietic cells (40%).   autologous adipose tissue derived stromal vascular fraction (SVF)  Biological",1,11
1256,"Biological: MSV treatment Single Group Assignment MSV-H autologous transplantation: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal   MSV treatment       Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)   MSV treatment H-MSV, Human Mesenchymal Stem Cells from Valladolid Biological",1,11
1257,Procedure: Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP). Single Group Assignment    Stem cells implantation       Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).   Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).  Procedure,1,11
1258,"Biological: Mesenchymal stromal cells Single Group Assignment    Mesenchymal stromal cell treatment       Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.   Mesenchymal stromal cells  Biological",1,11
1259,"Biological: hCT-MSC Single Group Assignment    hCT-MSC infusion AnCoag BlSubst All PhSol ANeo Anticoagulants Blood Substitutes All Drugs and Chemicals Pharmaceutical Solutions Antineoplastic Agents  M6258 M85407 M8814 Dextrans Plasma-lyte 148 Altretamine low low low 2x10^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump   hCT-MSC  Biological",1,12
1260,Biological: OSSM-001 Biological: OSSM-001 Biological: OSSM-001 Biological: OSSM-001 Single Group Assignment    12M cells/kg 24M cells/kg 2M cells/kg 6M cells/kg       Direct IV infusion of OSSM-001   OSSM-001  Biological,1,12
1261,"Biological: hCT-MSC infusion Biological: hCT-MSC infusion Biological: hCT-MSC infusion Sequential Assignment    Single hCT-MSC infusion Three hCT-MSC infusions Two hCT-MSC infusions       hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.   hCT-MSC infusion  Biological",1,12
1262,Drug: EN001 Drug: EN001 Sequential Assignment    Dose group A (Low dose) Dose group B (High dose) Antipy Analg All AnEm CNSDep PsychDr Derm Gast Infl AAll AntiConv Antipyretics Analgesics All Drugs and Chemicals Antiemetics Central Nervous System Depressants Psychotropic Drugs Dermatologic Agents Gastrointestinal Agents Anti-Inflammatory Agents Anti-Allergic Agents Anticonvulsants  M2341 M18740 M9064 M155022 M228602 M263157 M5137 M10292 Acetaminophen Ondansetron Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Chlorpheniramine Lorazepam low low low low low low low low EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.  Dose group A (Low dose): 5.0x10^5 cells/kg EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.  Dose group B (High dose): 2.5x10^6 cells/kg   EN001 EN001 EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) Drug Drug,1,12
1263,"Other: Autologous bone marrow mesenchymal stem cells (MSV) Single Group Assignment    MSV autologous transplantation       Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.   Autologous bone marrow mesenchymal stem cells (MSV) MSV, mesenchymal stem cells by IBGM-Valladolid protocol. Other",1,12
1264,Drug: Mesenchymal Stromal Cell (MSC) injections Single Group Assignment    Mesenchymal Stromal Cell (MSC)       12 patients suffering of PRD (LENT-SOMA scale>2) will receive Mesenchymal Stromal Cell (MSC) injections   Mesenchymal Stromal Cell (MSC) injections Cell therapy Drug,1,12
1265,Drug: Transplantation of mesenchymal stem cell Drug: No transplantation of mesenchymal stem cell Parallel Assignment    Transplantation of Mesenchymal Stem Cell No Transplantation of Mesenchymal Stem Cell       Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.  Dose A - 1 million cells per kg Dose B - 5 million cells per kg Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.   Transplantation of mesenchymal stem cell No transplantation of mesenchymal stem cell Intravenous infusion of mesenchymal stem cell No intravenous infusion of mesenchymal stem cell Drug Drug,1,12
1266,Biological: ABMD-MSC Single Group Assignment    ABDM-MSC       10-20 x 10^6 cells/20mL   ABMD-MSC  Biological,1,12
1267,Biological: hucMSCs Biological: hucMSCs Biological: hucMSCs Parallel Assignment    High dose group Low dose group Medium dose group       Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion   hucMSCs  Biological,1,12
1268,"Biological: SMUP-IA-01(low-dose) Biological: SMUP-IA-01(mid-dose) Biological: SMUP-IA-01(high-dose) Parallel Assignment    SMUP-IA-01(low-dose) SMUP-IA-01(mid-dose) SMUP-IA-01(high-dose) All All Drugs and Chemicals  M9030 Hyaluronic Acid low A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL) A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL) A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10^7 cells/2mL)   SMUP-IA-01(low-dose) SMUP-IA-01(mid-dose) SMUP-IA-01(high-dose) Human umbilical cord blood-derived mesenchymal stem cells Human umbilical cord blood-derived mesenchymal stem cells Biological Biological Biological",1,12
1269,"Biological: Autologous MSCs transplantation Single Group Assignment    Autologous MSCs transplantation       Autologous mesenchymal stem cells derived bone marrow, bronchoscopy   Autologous MSCs transplantation  Biological",1,12
1270,Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection Parallel Assignment    1 million cells/ml of ALLO-ASC 10 million cells/ml of ALLO-ASC          ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection  Biological,1,12
1271,"Biological: Collagen membrane + HUC-MSCs Single Group Assignment    Collagen membrane + HUC-MSCs Infe All Anti-Infective Agents All Drugs and Chemicals  M3374 M3376 Anti-Bacterial Agents Antibiotics, Antitubercular low low After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.   Collagen membrane + HUC-MSCs  Biological",1,12
1272,Biological: PLX-PAD Biological: PLX-PAD Factorial Assignment    PLX-PAD high dose PLX-PAD low dose       IM injection   PLX-PAD  Biological,1,12
1273,"Biological: AloCELYVIR Single Group Assignment Open, non-randomized, single-center Phase I clinical trial.   AloCELYVIR       Mesenchymal allogenic cells + ICOVIR-5: 500.000 cells/kg   AloCELYVIR  Biological",1,12
1274,"Biological: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells Single Group Assignment single-center, open-label, non-randomized, non-placebo controlled, single-group assignment, pilot study D000000970 D000000998 D000000890 Antineoplastic Agents Antiviral Agents Anti-Infective Agents Treatment with MSCs Infe ANeo All Anti-Infective Agents Antineoplastic Agents All Drugs and Chemicals Inhibitor Details M9559 M9558 M3466 M3366 Interferons Interferon-gamma Antiviral Agents Anti-Infective Agents high high low low Single dose, starting at  Dose Level 0: 10 x 10^6 injected into one submandibular gland on Day 1 D000007372 D000007371 Interferons Interferon-gamma Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells  Biological",1,12
1275,Biological: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC) Biological: High dose adipose tissue derived mesenchymal stromal cells (A-MSC) Single Group Assignment    Low Dose Group High Dose Group All All Drugs and Chemicals  M9336 M3377 Immunoglobulins Antibodies low low Single intra-arterial infusion of 1 x 10^5 cells/kg Single intra-arterial infusion of 5 x 10^5 cells/kg infused over 5 minutes   Low dose adipose tissue derived mesenchymal stromal cells (A-MSC) High dose adipose tissue derived mesenchymal stromal cells (A-MSC)  Biological Biological,1,12
1276,"Biological: XSTEM-VLU Other: Vehicle Parallel Assignment    XSTEM-VLU Vehicle       XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers. CryoStor CS10 cryomedium   XSTEM-VLU Vehicle  Biological Other",1,12
1277,"Combination Product: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix. Procedure: Surgery by sternotomy Parallel Assignment - Experimental group: The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.  In addition, the matrix-cell construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.  - Control group: The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed.   Experimental group Control group       A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.   PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix. Surgery by sternotomy  Combination Product Procedure",1,12
1278,Procedure: Oral mucosa biopsy Procedure: Sinus lift with implantation of tissue engineered construction Device: Dental implant Single Group Assignment    Tissue engineered construction implantation Tissue engineered construction implantation Tissue engineered construction implantation          Oral mucosa biopsy Sinus lift with implantation of tissue engineered construction Dental implant  Procedure Procedure Device,1,12
1279,Other: stem cells Single Group Assignment    hAMSCs injection       hAMSCs injection via venous in the dorsum of hand   stem cells  Other,1,12
1280,"Biological: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC Biological: Intravenous Infusion of UC-MSC Parallel Assignment 5 subjects receive BM-MNC and 10 subjects receive UC-MSC   BM-MNC experimental UC-MSC Gast All Gastrointestinal Agents All Drugs and Chemicals  M21707 M12266 Pancrelipase Pancreatin low low Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10^5 - 1 x 10^6 CD34 cells/kgBW Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10^6 cells/kgBW, twice, with three months interval   Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC Intravenous Infusion of UC-MSC  Biological Biological",1,15
1281,Drug: MSC-AFP Single Group Assignment    MSC-AFP       Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.   MSC-AFP mesenchymal stromal cell coated fistula plug Drug,1,15
1282,"Biological: Mesenchymal Stem Cells(MSCs) Single Group Assignment    The MSCs group Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Six doses of 1*10^6/kg body weight MSCs are given, intravenously.   Mesenchymal Stem Cells(MSCs)  Biological",1,15
1283,Biological: Stem cells Single Group Assignment    Stem cells therapy CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.   Stem cells  Biological,1,18
1284,Biological: Autologous Adipose Tissue Derived MSCs Transplantation Single Group Assignment    Autologous Adipose Tissue derived MSCs Autologous Adipose Tissue derived MSCs Autologous Adipose Tissue derived MSCs       Study drugs: Autologous adipose tissue derived MSCs  Injection dosage and volume of the study drugs:  Low dose: 1x10e7 cells/3mL Number of injections : only once during the study period Device: Ultrasound Injection technique: Injection into the lesion by investigator Study drugs: Autologous adipose tissue derived MSCs  Injection dosage and volume of the study drugs:  Mid dose: 5x10e7 cells/3mL Number of injections : only once during the study period Device: Ultrasound Injection technique: Injection into the lesion by investigator Study drugs: Autologous adipose tissue derived MSCs  Injection dosage and volume of the study drugs:  High dose: 1x10e8 cells/3mL Number of injections : only once during the study period Device: Ultrasound Injection technique: Injection into the lesion by investigator   Autologous Adipose Tissue Derived MSCs Transplantation Autologous Adipose Tissue Derived MSCs Transplantation Autologous Adipose Tissue Derived MSCs Transplantation  Biological Biological Biological,1,18
1285,Genetic: surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold Single Group Assignment    mesenchymal stem cell CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low    surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold  Genetic,1,18
1286,Biological: Autologous adipose derived stem cells administrated for intra-articular use Biological: Autologous adipose derived stem cells administrated for intra-articular use Biological: Autologous adipose derived stem cells administrated for intra-articular use Parallel Assignment    Group 2 Group 3 Group 1       Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.   Autologous adipose derived stem cells administrated for intra-articular use Autologous adipose derived stem cells administrated for intra-articular use  Biological Biological,1,18
1287,"Dietary Supplement: Antioxidative supplementation Single Group Assignment Each participant enrolled in the study will be part of the supplementation and control condition group in a non-randomized order   Antioxidative Supplementation       Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation   Antioxidative supplementation  Dietary Supplement",1,18
1288,"Drug: WJ-MSC (XCEL-UMC-BETA) Drug: Placebo Parallel Assignment Double-blind, randomized, placebo-controlled, 2-arms, multicenter clinical trial   WJ-MSC (XCEL-UMC-BETA) Placebo PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months   WJ-MSC (XCEL-UMC-BETA) Placebo Tested product Drug Drug",1,18
1289,Biological: UCMSC Biological: UCMSC Other: Placebo Parallel Assignment    One infusion of UCMSC Two infusions of UCMSC Placebo infusions PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M85407 Plasma-lyte 148 low Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A. Each infusion will consist of 50 mL of PlasmaLyte A.   UCMSC Placebo umbilical cord derived mesenchymal stromal cells Biological Other,1,18
1290,Biological: Endobronchial infusion of adult mesenchymal stem cells Biological: Autologous mesenchymal stem cells derived from bone marrow Single Group Assignment    MSC endobronchial infusion MSC endobronchial infusion          Endobronchial infusion of adult mesenchymal stem cells Autologous mesenchymal stem cells derived from bone marrow  Biological Biological,1,17
1291,"Biological: HMB002 Single Group Assignment ATIMP   HMB002 PhSol All Hemat Pharmaceutical Solutions All Drugs and Chemicals Hematinics  M21013 M10262 Pharmaceutical Solutions Liver Extracts low low The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.   HMB002  Biological",1,17
1292,"Biological: Umbilical Cord Lining Stem Cells (ULSC) Biological: Umbilical Cord Lining Stem Cells (ULSC) Other: Placebo (carrier control) Parallel Assignment    ULSC in Phase 1 Open Label ULSC in Phase 2a Randomized Placebo in Phase 2a Randomized       IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection IV infusion of carrier control consisting of sterile saline for injection   Umbilical Cord Lining Stem Cells (ULSC) Placebo (carrier control) Umbilical Cord Lining Stem Cells (ULSC), type of mesenchymal stem cells (MSC) derived from single donor umbilical cord tissue for allogeneic use Biological Other",1,17
1293,"Biological: SUPERCELL GLUE Biological: PRFM ALONE Parallel Assignment The study will be a Double Blinded Randomized controlled clinical trial with a split mouth design.   SUPERCELL GLUE(STEM CELLS AND PRFM) PRFM ALONE CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method) Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)   SUPERCELL GLUE PRFM ALONE  Biological Biological",1,17
1294,Biological: Mesenchymal Stem Cells Biological: Mesenchymal Stem Cells Parallel Assignment    Allogeniec Mesenchymal Stem Cells Autologus Mesenchymal Stem Cells       These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.   Mesenchymal Stem Cells Mesenchymal Stromal Cells Biological,1,17
1295,"Biological: Autologous Mesenchymal Stem Cells Biological: Autologous Mesenchymal Stem Cells Parallel Assignment Prospective, single-center phase I pilot study to evaluate the safety and tolerability of a single intra-articular injection of autologous bone marrow-derived MSCs in 16 subjects, 8 who have knee osteoarthritis and 8 who have a focal chondral defect in the knee.   Cartilage Osteoarthritis       Bone marrow will be harvested from each individual patient's iliac crest, followed by stem cell isolation, expansion and preparation. Stem cell will be injected approximately 3-4 weeks after bone marrow harvest, injecting 50x10^6 MSCs in the knee via a medial parapatellar approach under sterile technique in 8 patients with generalized knee OA or focal chondral defects.   Autologous Mesenchymal Stem Cells Stem Cell Injection Biological",1,16
1296,Biological: UCMSCs Biological: Placebo Parallel Assignment    UCMSCs Placebo       Biological: Human UCMSCs 20 million cells per subject (0.5×10^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks) Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)   UCMSCs Placebo Human Umbilical Cord Derived Mesenchymal Biological Biological,1,16
1297,Drug: PSORI-CM01 formula Biological: adipose-derived multipotent mesenchymal stem cells Drug: Gu Ben Hua Yu formula Biological: adipose-derived multipotent mesenchymal stem cells Parallel Assignment    PSORI-CM01 group Gu Ben Hua Yu group Gu Ben Hua Yu group PSORI-CM01 group       PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg   PSORI-CM01 formula Gu Ben Hua Yu formula adipose-derived multipotent mesenchymal stem cells Chinese Herbal Medicine Chinese Herbal Medicine stem cells AD-MSCs Drug Drug Biological,1,16
1298,Biological: OSSM-001 Biological: OSSM-001 Other: Placebo Parallel Assignment    100M of OSSM-001 300M of OSSM-001 Placebo       Single injection of OSSM-001 at dose of 100M or 300M cells Single injection of placebo (saline)   OSSM-001 Placebo  Biological Other,1,16
1299,Biological: Allogeneic bone marrow derived mesenchymal stem cells Parallel Assignment    Active/Treatment Group CNSDep All Central Nervous System Depressants All Drugs and Chemicals  M3259 Anesthetics low Injection of HLA-A2+ and/or gender mismatched allogeneic MSCs above the site of amputation and into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective lower extremity major amputation at 7 days before amputation.   Allogeneic bone marrow derived mesenchymal stem cells cBMA MSCs Biological,1,16
1300,Biological: hUC-MSC suspension Biological: Placebo Parallel Assignment    hUC-MSC treatment Placebo control PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low Patients will be treated at dose of 0.75×10^6 cells/kg of body weight (Cohort 1) or 1.5×10^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit. Placebo contains the same cell suspension as BX-U001 but without cells.   hUC-MSC suspension Placebo BX-U001 Biological Biological,1,16
1301,Biological: Allogeneic MSC Biological: Allogeneic MSC Biological: Allogeneic MSC Sequential Assignment A longitudinal assessment using a classic dose-escalation study design to assess the safety of locally delivered allogenic mesenchymal stromal cells for promoting corneal repair.   High dose of allogeneic MSC Low dose of allogeneic MSC Medium dose of allogeneic MSC       Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells   Allogeneic MSC  Biological,1,18
1302,"Single Group Assignment           Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL   Autologous Adipose Tissue derived MSCs Transplantation RNL-JointStem® Procedure",1,18
1303,Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium Parallel Assignment    composite group conditioned medium group control group stem cells group Coag All Coagulants All Drugs and Chemicals  M17443 Fibrin Tissue Adhesive low rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium   adypose mesenchymal conditioned medium and ligament derived conditioned medium  Biological,1,16
1304,Biological: Mesenchymal stem cells low-dose group Biological: Mesenchymal stem cells mid-dose group Biological: Mesenchymal stem cells high-dose group Single Group Assignment    Mesenchymal stem cells low-dose group Mesenchymal stem cells mid-dose group Mesenchymal stem cells high-dose group       Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use   Mesenchymal stem cells low-dose group Mesenchymal stem cells mid-dose group Mesenchymal stem cells high-dose group Adipose tissue derived mesenchymal stem cells Adipose tissue derived mesenchymal stem cells Adipose tissue derived mesenchymal stem cells Biological Biological Biological,1,18
1305,Biological: Cordstem-ST Biological: Placebo Biological: Cordstem-ST Biological: Placebo Parallel Assignment    Cohort 1 Cohort 2 Cohort 1 Cohort 2          Cordstem-ST Placebo  Biological Biological,1,19
1306,"Drug: XCEL-MT-OSTEO-ALPHA Procedure: Surgery Other: autologous iliac crest Procedure: Surgery Parallel Assignment    XCEL-MT-OSTEO-ALPHA and surgery Autologous iliac crest and surgery Autologous iliac crest and surgery XCEL-MT-OSTEO-ALPHA and surgery       ""ex-vivo"" expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery Autologous iliac crest in association with surgery Standard surgery for non-union fractures   XCEL-MT-OSTEO-ALPHA autologous iliac crest Surgery  Drug Other Procedure",1,19
1307,Biological: Mesenchymal stem cell 0.5 Biological: Mesenchymal stem cell 1.0 Biological: Mesenchymal stem cell 1.0 Single Group Assignment    Mesenchymal Stem cells Booster Mesenchymal Stem Cells Mesenchymal Stem cells       0.5 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours. 1 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.   Mesenchymal stem cell 0.5 Mesenchymal stem cell 1.0  Biological Biological,1,19
1308,"Biological: Chondrochymal® Biological: Chondrochymal® Biological: Chondrochymal® Sequential Assignment The treatment protocol consists of two stages: the first stage is a traditional 3+3 dose-escalation open study design with three cohorts. At the second stage, a total of 6 patients with knee OA will be treated by the cell products of the maximum tolerance dose (MTD) as determined by the results of the first stage.   Chondrochymal® 1 x 10^7 cells Chondrochymal® 10 x 10^7 cells Chondrochymal® 5 x 10^7 cells       Allogeneic Bone Marrow Derived Mesenchymal Stem Cells   Chondrochymal®  Biological",1,18
1309,Biological: BOOST cells Biological: BOOST cells Parallel Assignment    Postnatal Prenatal Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.   BOOST cells  Biological,1,18
1310,Biological: Wharton jelly derived mesenchymal stem cell Device: Repetitive electromagnetic stimulation Device: Repetitive electromagnetic stimulation Biological: Wharton jelly derived mesenchymal stem cell Parallel Assignment The cases were divided into 3 groups according to their similar demographic characteristics. Prospective open label   Only WJ-MSC WJ-MSC combine witf rEMS Only rEMS WJ-MSC combine witf rEMS       WJ-MSC rEMS   Wharton jelly derived mesenchymal stem cell Repetitive electromagnetic stimulation CordoSight Magnovision Biological Device,1,18
1311,Drug: Allogenic MSC Drug: Allogenic MSC Drug: Normal saline Single Group Assignment    High Dose Allogenic MSC Low Dose Allogenic MSC Placebo       Hypoxia-cultured human bone marrow derived mesenchymal stem cells   Allogenic MSC Normal saline Biochymal Drug Drug,1,18
1312,Biological: hESC derived MSC like cell Single Group Assignment    Meniscus Injured patients       Different dosage of hESC derived MSC like cell for the meniscus injured patients   hESC derived MSC like cell  Biological,1,18
1313,"Biological: PN-101 Biological: PN-101 Biological: PN-101 Sequential Assignment    High dose group Intermediate dose group Low dose group       PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.  3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose.   PN-101  Biological",1,18
1314,"Biological: Low dose UCMSCs Biological: Moderate dose UCMSCs Biological: High dose UCMSCs Sequential Assignment    Low dose UCMSCs Moderate dose UCMSCs High dose UCMSCs       Receive one course of treatment with a single injection : 0.5×10^6 cells/kg, with a total volume of 100 ml UCMSCs; Receive one course of treatment with a single injection : 1.0×10^6 cells/kg, with a total volume of 100 ml UCMSCs; Receive one course of treatment with a single injection : 2.0×10^6 cells/kg, with a total volume of 100 ml UCMSCs;   Low dose UCMSCs Moderate dose UCMSCs High dose UCMSCs  Biological Biological Biological",1,18
1315,"Drug: umbilical cord mesenchymal stem cells combined with collagen scaffold Single Group Assignment    stem cell therapy       3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.   umbilical cord mesenchymal stem cells combined with collagen scaffold  Drug",1,18
1316,"Other: MSCs Drug: Saline Other: MSCs Drug: Saline Crossover Assignment Prospective, randomized, placebo-controlled, cross-over study   Arm A - Crossover with MSCs at baseline and placebo at 6 months Arm B - Crossover with placebo at baseline and MSCs at 6 months Arm A - Crossover with MSCs at baseline and placebo at 6 months Arm B - Crossover with placebo at baseline and MSCs at 6 months       Autologous bone-marrow derived mesenchymal stem cells Isotonic saline   MSCs Saline Mesenchymal stem cells Other Drug",1,18
1317,Biological: Conditioned Medium (CM) Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC) Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC) Biological: Conditioned Medium (CM) Parallel Assignment    UC-MSC + NaCl UC-MSC+CM Conditioned Medium (CM) UC-MSC+CM       Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar Conditioned Medium (CM) injected by peribulbar   Umbilical Cord Mesenchymal Stem Cell (UC-MSC) Conditioned Medium (CM)  Biological Biological,1,18
1318,Biological: MSC Secretome Eye Drops Biological: MSC Secretome Eye Drops Biological: MSC Secretome Eye Drops Sequential Assignment A longitudinal assessment using a classic dose-escalation study design to evaluate the safety and maximal tolerated dose of topical MSC Secretome eye drops D000019999 Pharmaceutical Solutions High dose of allogenic MSC drops Low dose of allogenic MSC drops Medium dose of allogenic MSC drops PhSol All Pharmaceutical Solutions All Drugs and Chemicals Spray M11966 M21013 Ophthalmic Solutions Pharmaceutical Solutions high low MSC Secretome eye drop will be dispensed. D000009883 Ophthalmic Solutions MSC Secretome Eye Drops  Biological,1,18
1319,Biological: Platelet Rich Plasma Other: Normal Saline Parallel Assignment    Platelet Rich Plasma Normal Saline       Platelet rich plasma injection into knee versus placebo (saline) injection. Platelet rich plasma injection into knee versus placebo (saline) injection.   Platelet Rich Plasma Normal Saline Platelet Concentrate Biological Other,1,18
1320,"Drug: Human umbilical cord mesenchymal stem cell injection Single Group Assignment    Dose escalation       Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.   Human umbilical cord mesenchymal stem cell injection  Drug",1,18
1321,Biological: Autologous adipose-derived mesenchymal stem cells Single Group Assignment Patients with trophic ulcers received standard treatment and mesenchymal stem cells   MSC       Autologous adipose-derived mesenchymal stem cells   Autologous adipose-derived mesenchymal stem cells  Biological,1,18
1322,Drug: Adult Allogeneic Mesenchymal cells from adipose tissue. Single Group Assignment    Allogeneic Mesenchymal Cells       Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.  Subjects will receive four sequential IV dose of Mesenchymal stem cells.  Sequential doses:  Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg   Adult Allogeneic Mesenchymal cells from adipose tissue. MSC for the treatment of graft -versus -host disease Drug,1,16
1323,Procedure: Peripheral blood stem cell mobilisation and collection Drug: High-dose chemotherapy Drug: Bone marrow derived allogeneic MMSCs infusion Procedure: Autologous peripheral blood stem cells infusion Single Group Assignment    allogeneic MMSCs infusion allogeneic MMSCs infusion allogeneic MMSCs infusion allogeneic MMSCs infusion       High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)   Peripheral blood stem cell mobilisation and collection High-dose chemotherapy Bone marrow derived allogeneic MMSCs infusion Autologous peripheral blood stem cells infusion  Procedure Drug Drug Procedure,1,16
1324,"Genetic: Allogenic Mesenchymal Stem Cell Single Group Assignment    Allogenic Mesenchymal Stem Cell       Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, ""Agencia Española de Medicamentos y Productos Sanitarios"" with number 06-076)   Allogenic Mesenchymal Stem Cell  Genetic",1,15
1325,"Biological: MSC-KI-PL-204 Single Group Assignment This is a phase I/IIa open, single-arm clinical study evaluating the safety and tolerability as well as the influence on VF function, of local injection of the autologous MSC product KI-MSC-PL-204, in patients suffering from chronic VF dysfunction.   Single arm: MSC administration to vocal fold scar       Autologous MSC product   MSC-KI-PL-204  Biological",1,15
1326,"Combination Product: Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier Single Group Assignment  D000006490 D000003029 Hemostatics Coagulants CartiLage Auto/Allo IMplantation for Focal Hip Cartilage Defects Coag All Coagulants All Drugs and Chemicals Isoflurane M17443 M11052 M8728 M5411 Fibrin Tissue Adhesive Mitogens Hemostatics Coagulants high low low low Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed. D000015718 Fibrin Tissue Adhesive Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier  Combination Product",1,15
1327,"Biological: Autologous cultured adipose derived stem cells(low dose group) Biological: Autologous cultured adipose derived stem cells(high dose group) Parallel Assignment    Group 1 Group 2       low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage. high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.   Autologous cultured adipose derived stem cells(low dose group) Autologous cultured adipose derived stem cells(high dose group) mesenchymal stem cell, ANTG-ASC, adipose derived stem cell Group1: low dose group mesenchymal stem cell, ANTG-ASC, adipose derived stem cell Group2: high dose group Biological Biological",1,15
1328,Biological: Autologous mesenchymal stem cells Biological: Autologous mesenchymal stem cells Parallel Assignment    Autologous mesenchymal stem cells group Control group AnEm Gast All Infl AAll Derm Antiemetics Gastrointestinal Agents All Drugs and Chemicals Anti-Inflammatory Agents Anti-Allergic Agents Dermatologic Agents  M10912 M9064 M155022 M228602 M263157 M5137 Metoclopramide Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Chlorpheniramine low low low low low low Autologous mesenchymal stem cells   Autologous mesenchymal stem cells MSC Biological,1,15
1329,Biological: PLX-PAD IM injection Biological: PLX-PAD IM injection Biological: PLX-PAD IM injection Factorial Assignment    PLX-PAD high dose PLX-PAD intermediate dose PLX-PAD low dose       Single treatment; multiple injections   PLX-PAD IM injection  Biological,1,15
1330,Single Group Assignment              Mesenchymal stem cell (MSC)  Procedure,1,15
1331,Biological: Autologous mesenchymal stem cells Single Group Assignment    Refractory rheumatoid arthritis patients       A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)   Autologous mesenchymal stem cells  Biological,1,15
1332,Biological: Dental Implant with PRFM Biological: Dental Implant with PRFM and PBMSCs Parallel Assignment The selected sites would be randomly (coin toss method) assigned into an edentulous area allowing for the placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM and (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.   Dental Implant with PRFM Dental Implant with PRFM and PBMSCs       placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.   Dental Implant with PRFM Dental Implant with PRFM and PBMSCs  Biological Biological,1,15
1333,"Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded ""in vitro"" Single Group Assignment    Patients with cytopenia after allo-HSCT          Sequential infusion of allogeneic mesenchymal stem cells expanded ""in vitro""  Biological",1,15
1334,"Biological: Autologous Adipose Mesenchymal Stem Cell Implantation Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation Parallel Assignment    Autologous Adipose MSC Group Allogeneic Umbilical Cord MSC Group Allogeneic Umbilical Cord MSC and Adipose Secretome Group CNSDep All Ot Central Nervous System Depressants All Drugs and Chemicals Other Dietary Supplements  M4006 M20124 T433 Benzocaine Hepatitis C Antibodies Tannic Acid low low low Before taking adipose tissue, each subject was screened including HbSAg, Anti HbS, Anti HCV, HIC, MCV and syphilis tests.  Adipose tissue was taken through 5 grams of subcutaneous fat biopsy from the abdomen of each subject and put into a transport medium and then sent to the RSCM-FKUI cGMP IPT Stem Cells Laboratory for immediate isolation of mesenchymal stem cells.  MSC that has been isolated will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.  The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.  The MSC to be injected into the subject will be prepared in 2cc physiological NaCl transport medium just before implantation.  The adipose secretion used is prepared in whole form as much as 10cc in a 10cc syringe. Before taking the umbilical cord tissue, a pregnant woman's donor was screened including HbSAg, Anti HbS, Anti HCV, HIC, MCV and syphilis tests.  Immediately after delivery, the umbilical cord was collected and stored in a sterile specimen plate containing 0.9% NaCl at 4⁰C.  The umbilical cord is transported to the GMP standard culture laboratory at the UPT TK Stem Cells RSCM-FKUI for isolation process of mesenchymal stem cells. Sample processing was carried out within 8 hours of delivery to maintain cell viability.  MSC that has been isolated will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.  The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.  The MSC to be injected into the subject will be prepared in a suitable transport medium just prior to implantation. Before taking adipose and umbilical cord tissue, each subject was screened. -For Adipose tissue : The adipose secretion used is prepared in whole form as much as 10cc in a 10cc syringe.  -Uc-MSC : Immediately after delivery, the umbilical cord was collected and stored in a sterile specimen plate containing 0.9% NaCl at 4⁰C.  The umbilical cord is transported to the GMP standard culture laboratory to have isolation process of mesenchymal stem cells. Sample processing was carried out within 8 hours of delivery to maintain cell viability.  Later it will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.   Autologous Adipose Mesenchymal Stem Cell Implantation Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation  Biological Biological Biological",1,15
1335,"Drug: Human umbilical cord mesenchymal stem cells Single Group Assignment    Human umbilical cord mesenchymal stem cells       Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times   Human umbilical cord mesenchymal stem cells  Drug",1,15
1336,Drug: Adipose derived stromal cells intravenously injected Single Group Assignment    Adipose derived stromal cells intravenously injected       2×10^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).   Adipose derived stromal cells intravenously injected  Drug,1,15
1337,Biological: Autologous mesenchymal stem cells Biological: Autologous mesenchymal stem cells Crossover Assignment    Delayed treatment with mesenchymal stem cells Early treatment with mesenchymal stem cells          Autologous mesenchymal stem cells  Biological,1,15
1338,"Biological: Mesenchymal Stem Cells Single Group Assignment    Subjects with Advanced Chronic Obstructive Pulmonary Disease       0.5- 2 million cells/kg, intravenously once   Mesenchymal Stem Cells  Biological",1,15
1339,"Biological: Conditioned Medium Biological: Umbilical Cord Mesenchymal Stem Cells Biological: Umbilical Cord Mesenchymal Stem Cells Procedure: Neurologic and Neutrophic Drugs Factorial Assignment    Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment Umbilical cord mesenchymal stem cells treatment Standard treatment (control) PlAggInh All NootAg NeuroAg Platelet Aggregation Inhibitors All Drugs and Chemicals Nootropic Agents Neuroprotective Agents  M1669 M5923 M12932 Clopidogrel Cytidine Diphosphate Choline Piracetam low low low Intranasal of 3 cc of conditioned medium each, for 3 days in a row Intra-parenchymal transplantation of 20x10^6 UC-MSCs Such as clopidogrel, piracetam, citicoline   Conditioned Medium Umbilical Cord Mesenchymal Stem Cells Neurologic and Neutrophic Drugs Secretome Mesenchymal stromal cells Biological Biological Procedure",1,15
1340,Procedure: Autologous Adipose Tissue derived MSCs Transplantation Single Group Assignment    Autologous Adipose Tissue Derived MSCs       Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL   Autologous Adipose Tissue derived MSCs Transplantation  Procedure,1,15
1341,Biological: MSCTC-0010 Biological: MSCTC-0010 Biological: MSCTC-0010 Single Group Assignment    High Dose MSCTC-0010 Low Dose MSCTC-0010 Medium Dose MSCTC-0010       MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).   MSCTC-0010  Biological,1,15
1342,"Procedure: Implantation Procedure: Lipoaspiration Procedure: Implantation Procedure: Implantation Procedure: Lipoaspiration Parallel Assignment In this study, 15 evaluable patients affected by corneal stromal dystrophies of any type (particularly keratoconus) will be included in 3 different groups. Ten patients will be included in the two experimental groups and five in the control group with cell-free treatment (5 patients per group and a total of 3 groups)   ADASCs Group ADASCs recellularized laminas group Acellular laminas group ADASCs Group ADASCs recellularized laminas group       Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.  Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient   Implantation Lipoaspiration corneal implantation corneal implantation Procedure Procedure",1,15
1343,"Biological: Administration of ERC Single Group Assignment    Intramuscular injection of ERC       Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.   Administration of ERC  Biological",1,15
1344,Biological: HB-adMSCs Single Group Assignment A single IV infusion of autologous adipose-derived mesenchymal stem cells (HB-adMSCs) in subjects with clinical diagnosis of RA.   Treatment Arm       Hope Biosciences autologous adipose-derived mesenchymal stem cells   HB-adMSCs  Biological,1,15
1345,"Biological: aMSC Biological: aMSC+hyaluronan gel Single Group Assignment  D000000276 D000007155 D000045505 D000055675 D000020011 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents aMSC with and without hyaluronan gel aMSC with and without hyaluronan gel All All Drugs and Chemicals Placebo administration M9030 M2780 M9353 M27448 M21022 Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Viscosupplements Protective Agents high low low low low aMSC injected into the vocal fold of the patient aMSC+ hyaluronan gel is injected into the patients vocal fold D000006820 Hyaluronic Acid aMSC aMSC+hyaluronan gel  Biological Biological",1,16
1346,"Other: Autologous mesenchymal stem cells Single Group Assignment    Autologous mesenchymal stem cells       The trial is divided in three phases:  I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.  II.- Treatment phase includes:  Liposuction procedure to obtain adipose tissue. Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs) ASCs implant  III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant.   Autologous mesenchymal stem cells Implant of ASCs. Other",1,15
1347,"Biological: Mesenchymoangioblast-derived mesenchymal stem cells Biological: Mesenchymoangioblast-derived mesenchymal stem cells Sequential Assignment    Cohort A Cohort B       The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.   Mesenchymoangioblast-derived mesenchymal stem cells CYP-001 Biological",1,16
1348,"Biological: UC-MSCs Single Group Assignment reaching the criteria of pneumonia according to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4)   pneumonia       After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.   UC-MSCs  Biological",1,16
1349,Drug: Corlicyte Drug: Corlicyte Drug: Corlicyte Sequential Assignment    Dose 1 Dose 2 Dose 3       expanded umbilical cord lining mesenchymal stem cells   Corlicyte  Drug,1,16
1350,Drug: Infusion of mesenchymal stem cells from adipose tissue Other: Infusion of placebo Parallel Assignment    Mesenchymal stem cells Ringer lactate solution PhSol All Pharmaceutical Solutions All Drugs and Chemicals  M21013 Pharmaceutical Solutions low    Infusion of mesenchymal stem cells from adipose tissue Infusion of placebo  Drug Other,1,16
1351,"Other: human bone marrow MSC Single Group Assignment    human bone marrow MSC       The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.   human bone marrow MSC  Other",1,16
1352,Drug: 20 million Allogeneic Mesenchymal Human Stem Cells Drug: 100 million Allogeneic Mesenchymal Human Stem Cells Drug: 20 million Allogeneic Mesenchymal Human Stem Cells Drug: 100 million Allogeneic Mesenchymal Human Stem Cells Parallel Assignment    Pilot Phase 20 million allogeneic hMSCs Randomized Phase 20 million allogeneic hMSCs Pilot Phase 100 million hMSCs Randomized Phase 100 million allogeneic hMSCs       1 single intravenous infusion 1 single intravenous infusion   20 million Allogeneic Mesenchymal Human Stem Cells 100 million Allogeneic Mesenchymal Human Stem Cells allo-hMSCs stem cells allo-hMSCs stem cells Drug Drug,1,16
1353,Biological: autologous mesenchymal stromal cell Single Group Assignment    autologous mesenchymal stromal cells          autologous mesenchymal stromal cell  Biological,1,16
1354,"Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) Parallel Assignment 3 parallel group with different doses of UC-MSC   high dose low dose middle dose Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4*10^5 cells/kg/each time, and medium dose: 8*10^5 cells/kg/each time, high dose 12*10^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.   Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)  Genetic",1,16
1355,"Drug: human amniotic mesenchymal stem cell Parallel Assignment    human amniotic mesenchymal stem cell treatment group       human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).   human amniotic mesenchymal stem cell  Drug",1,16
1356,Biological: allo-APZ2-EB Single Group Assignment    allo-APZ2-EB       intravenous infusion of allo-APZ2-EB   allo-APZ2-EB allogeneic ABCB5-positive mesenchymal stem cells Biological,1,16
1357,"Other: saline Biological: human umbilical cord-derived mesenchymal stem cells Parallel Assignment    MSCs injection control       In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery. In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.   human umbilical cord-derived mesenchymal stem cells saline  Biological Other",1,16
1358,Biological: RNL-Vascostem® Single Group Assignment    RNL-Vascostem®          RNL-Vascostem® Autologous adipose tissue derived mesenchymal stem cells Biological,1,15
1359,"Single Group Assignment           MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.   Mesenchymal stem cell infusion Bone marrow derived mesenchymal stem cells. Procedure",1,15
1360,"Drug: ProTrans Drug: ProTrans Drug: ProTrans Single Group Assignment    High dose Low dose Medium dose Hypo All Hypoglycemic Agents All Drugs and Chemicals  M9517 M172956 Insulin Insulin, Globin Zinc low low ProTrans is an pooled allogenic mesenchymal stromal cell treatment   ProTrans  Drug",1,15
1361,"Other: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) Single Group Assignment    15 refractory ITP patients       This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.   Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)  Other",1,15
1362,"Biological: Mesenchymal Stromal Cells Biological: Mesenchymal Stromal Cells Biological: Mesenchymal Stromal Cells Sequential Assignment CIRCA-1901 is is a dose-escalating and safety trial using a 3+3+3 design to determine the safety, and maximum feasible tolerated dose (MFTD) of intravenously (IV) delivered umbilical cord derived MSCs (UC-MSCs). If no safety issues are identified, we will continue to the Phase 2a trial.  CIRCA-1902 is a single-arm, open-label extension of the CIRCA-1901 trial to assess early signs of efficacy (major morbidity and mortality). The Phase 2a trial (CIRCA-1902) will enroll 12 patients to assess early signals of benefit on mortality and major morbidity in a high risk, high mortality population.   Panel 1 Panel 2 Panel 3       The Mesenchymal Stromal Cells will be administered intravenously   Mesenchymal Stromal Cells  Biological",1,15
1363,Biological: BOOST cells Parallel Assignment Historical and Untreated prospective control and Treatment group   Treatment Hemat All Hematinics All Drugs and Chemicals  M10262 Liver Extracts low Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.   BOOST cells  Biological,1,15
1364,"Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.   Allogeneic human mesenchymal stem cells (Allo-hMSCs)  Drug",1,0
